

September 2026

Volume 33

Editors:

Kaye Wilson, Doris Chong, Teresa Tay
email: enquiry@pharmac.govt.nz
Telephone +64 4 460 4990
Level 9, 40 Mercer Street
PO Box 10 254 Wellington

Freephone Information Line

0800 66 00 50 (9am – 5pm weekdays)

Circulation

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month by subscribing at pharmac.govt.nz/subscribe.

Production


Typeset automatically from XML and T_EX.
XML version of the Schedule available from schedule.pharmac.govt.nz/pub/schedule

Programmers

Anrik Drenth

email: texschedule@pharmac.govt.nz

©Pharmaceutical Management Agency



ISSN 1179-3686

This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to Pharmac and abide by the other licence terms. To view a copy of this licence, visit: creativecommons.org/licenses/by/4.0/.

Attribution to Pharmac should be in written form and not by reproduction of the Pharmac logo. While care has been taken in compiling this Schedule, Pharmac takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Introducing Pharmac 2

Section A General Rules 5

Section B Alimentary Tract & Metabolism 6

Blood & Blood Forming Organs 36

Cardiovascular System 47

Dermatologicals 69

Genito Urinary System 79

Hormone Preparations – Systemic 85

Infections – Agents For Systemic Use 96

Musculoskeletal System 121

Nervous System 126

Oncology Agents & Immunosuppressants 158

Respiratory System & Allergies 268

Sensory Organs 280

Various 285

Section C Extemporaneous Compounds (ECPs) 287

Section D Special Foods 289

Section E Ambulance List 312

Section I National Immunisation Schedule 313

Index 329

Introducing Pharmac

The Pharmaceutical Management Agency (Pharmac) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. Pharmac negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list.

Pharmac's role:

"to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided."

Pae Ora (Healthy Futures) Act 2022

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about Pharmac and the way we make funding decisions can be found on the Pharmac website at <https://pharmac.govt.nz/about>.

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in Health NZ Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in Health NZ Hospitals for which national prices have been negotiated by Pharmac.

The Schedule does not show the final cost to Government of subsidising each Community Pharmaceutical or to Health NZ Hospitals in purchasing each Pharmaceutical, since that will depend on any rebate and other arrangements Pharmac has with the supplier and, for Pharmaceuticals used in Health NZ Hospitals, on any logistics arrangements put in place.

This book contains sections A to D and Section I of the Pharmaceutical Schedule and lists the Pharmaceuticals funded for use in the community, including vaccines, as well as haemophilia and cancer treatments given in Health NZ Hospitals. Section H lists the Pharmaceuticals that can be used in Health NZ Hospitals and is a separate publication.

The Pharmaceuticals in this book are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. The listings are displayed alphabetically under each heading.

The index lists both chemical entities and product brand names.

Explaining pharmaceutical entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the subsidy, the supplier's price and the access conditions that may apply.

Example

ANATOMICAL HEADING			
THERAPEUTIC HEADING			
CHEMICAL			
Presentation, form and strength			
10.00	100	Brand A	Brand B
15.00	50	Brand C	
18.00	250 ml	Brand D	
a) Prescriptions must be written by a paediatrician or paediatric cardiologist; or			
b) on the recommendation of a paediatrician or a paediatric cardiologist			
CHEMICAL			
26.53	100	Brand E	
(35.27)			
Sole Supply/Principal Supply			
Fully Subsidised			

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Practitioner's Supply Order

Conditions of and restrictions on prescribing (including Special Authority where it applies)

Three months or six months, as applicable, dispensed at one time

Brand or manufacturer's name

Sole Subsidised Supply product or Principal Supply Status

Fully subsidised product

Original Pack - Subsidy is rounded up to a multiple of whole packs

Quantity the Subsidy applies to

Subsidy paid on a product before mark-ups and GST

Manufacturer's Price if different from Subsidy

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Glossary

Units of Measure

gram	g	microgram.....	mcg	millimole.....	mmol
kilogram.....	kg	milligram	mg	unit.....	u
international unit.....	iu	millilitre.....	ml		

Abbreviations

Ampoule	Amp	Gelatinous	Gel	Solution.....	Soln
Capsule	Cap	Granules	Gran	Suppository.....	Supp
Cream.....	Crm	Infusion	Inf	Tablet.....	Tab
Device.....	Dev	Injection	Inj	Tincture.....	Tinc
Dispersible.....	Disp	Liquid.....	Liq	Trans Dermal Delivery	
Effervescent.....	Eff	Long Acting.....	LA	System.....	TDDS
Emulsion.....	Emul	Ointment.....	Oint		
Enteric Coated.....	EC	Sachet	Sach		

Read the [General Rules](https://pharmac.govt.nz/section-a) : <https://pharmac.govt.nz/section-a>.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Antacids and Antiflatulents

Antacids and Reflux Barrier Agents

ALGINIC ACID

Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet	8.06	30	✓	Gaviscon Infant
--	------	----	---	-----------------

SODIUM ALGINATE

* Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour.....	1.80 (19.05)	60		Gaviscon Extra Strength
* Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml.....	1.50 (7.50)	500 ml		Acidex

(Gaviscon Extra Strength Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour to be delisted 1 July 2027)

Phosphate Binding Agents

ALUMINIUM HYDROXIDE

* Tab 600 mg	12.56	100	✓	Alu-Tab
--------------------	-------	-----	---	---------

CALCIUM CARBONATE

Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) –				
Subsidy by endorsement	39.00	500 ml	✓	Roxane
	47.30	473 ml	✓	Calcium carbonate PAI ^{S29}

Only when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate and the prescription is endorsed accordingly.

Antidiarrhoeals

Agents Which Reduce Motility

LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a PSO

* Tab 2 mg	10.75	400	✓	Nodia
* Cap 2 mg	12.00	400	✓	Diamide Relief

Rectal and Colonic Anti-inflammatories

BUDESONIDE

Cap modified-release 3 mg – Special Authority see SA2535 below – Retail pharmacy	33.38	90	✓	Budesonide Te Arai
---	-------	----	---	--------------------

► [SA2535](#) Special Authority for Subsidy

Initial application — (Crohn's disease) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

2 Any of the following:

- 2.1 Diabetes; or
- 2.2 Cushingoid habitus; or
- 2.3 Osteoporosis where there is significant risk of fracture; or
- 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
- 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
- 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
- 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogeneic bone marrow transplantation*.

Note: Indication marked with * is an unapproved indication.

Initial application — (non-cirrhotic autoimmune hepatitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has autoimmune hepatitis*; and
- 2 Patient does not have cirrhosis; and
- 3 Any of the following:
 - 3.1 Diabetes; or
 - 3.2 Cushingoid habitus; or
 - 3.3 Osteoporosis where there is significant risk of fracture; or
 - 3.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 3.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 3.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
 - 3.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated); or
 - 3.8 Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth) .

Note: Indication marked with * is an unapproved indication.

Renewal — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (non-cirrhotic autoimmune hepatitis) from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC-Free (14 applications).....57.09 15 g OP ✓ **Colifoam**

HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE

Topical aerosol foam, 1% with pramoxine hydrochloride 1%.....26.55 10 g OP ✓ **Proctofoam** S29

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MESALAZINE				
Tab 400 mg	49.50	100	✓	Asacol
	71.00	90	✓	Octasa ^{\$29}
Tab long-acting 500 mg	56.10	100	✓	Pentasa
Tab 800 mg	85.50	90	✓	Asacol
			✓	Asacol ^{\$29} ^{\$29}
Tab 1,600 mg	85.50	60	✓	Asacol ^{\$29}
Modified release granules, 1 g	118.10	100 OP	✓	Pentasa
Enema 1 g per 100 ml	41.30	7	✓	Pentasa
Suppos 500 mg	22.80	20	✓	Asacol
Suppos 1 g	50.96	28	✓	Pentasa
OLSALAZINE				
Tab 500 mg	56.02	60	✓	Atnahs
				Olsalazine ^{\$29}
	93.37	100	✓	Dipentum
Cap 250 mg	53.00	100	✓	Dipentum
SODIUM CROMOGLICATE				
Cap 100 mg	44.50	20	✓	Nalcrom ^{\$29}
	113.35	100	✓	Ralicrom
	125.70		✓	Allergoval ^{\$29}
	365.00		✓	Somex ^{\$29}
SULFASALAZINE				
* Tab 500 mg	19.49	100	✓	Salazopyrin
* Tab EC 500 mg	20.54	100	✓	Salazopyrin EN

Local preparations for Anal and Rectal Disorders

Antihæmorrhoidal Preparations

FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE

Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g	13.05	30 g OP	✓	Ultraproct
Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg	8.61	12	✓	Ultraproct

HYDROCORTISONE WITH CINCHOCAINE

Oint 5 mg with cinchocaine hydrochloride 5 mg per g	17.03	30 g OP	✓	Proctosedyl
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g	11.24	12	✓	Proctosedyl

PREDNISOLONE HEXANOATE WITH CINCHOCAINE HYDROCHLORIDE

Suppos 1.3 mg with cinchocaine hydrochloride 1 mg per g	8.61	12	✓	Scheriproct ^{\$29}
---	------	----	---	------------------------------------

Management of Anal Fissures

GLYCERYL TRINITRATE – Special Authority see [SA1329 below](#) – Retail pharmacy

* Oint 0.2%	22.00	30 g OP	✓	Rectogesic
-------------------	-------	---------	---	-------------------

► **SA1329** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has a chronic anal fissure that has persisted for longer than three weeks.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Antispasmodics and Other Agents Altering Gut Motility

GLYCOPYRRONIUM BROMIDE

Inj 200 mcg per ml, 1 ml ampoule – Up to 10 inj available on a

PSO	11.99	10	✓ <u>Glycopyrronium- AFT</u>
-----------	-------	----	----------------------------------

HYOSCINE BUTYLBROMIDE

* Tab 10 mg	2.25	20	✓ <u>Hyoscine Butylbromide (Adiramedita)</u>
-------------------	------	----	--

* Inj 20 mg, 1 ml ampoule – Up to 5 inj available on a PSO	5.54	5	✓ <u>Spazmol</u>
--	------	---	------------------

MEBEVERINE HYDROCHLORIDE

* Tab 135 mg	8.00	90	✓ <u>Colofac</u>
--------------------	------	----	------------------

Colofac to be Principal Supply on 1 December 2026

Antilucerants

Antisecretory and Cytoprotective

MISOPROSTOL – Wastage claimable

* Tab 200 mcg – Up to 120 tab available on a PSO	47.73	120	✓ <u>Cytotec</u>
--	-------	-----	------------------

Helicobacter Pylori Eradication

CLARITHROMYCIN

Tab 500 mg – Subsidy by endorsement.....	14.58	14	✓ <u>Klacid</u>
--	-------	----	-----------------

a) Maximum of 28 tab per prescription

b) Subsidised only if prescribed for helicobacter pylori eradication and prescription is endorsed accordingly.

Note: the prescription is considered endorsed if clarithromycin is prescribed in conjunction with a proton pump inhibitor and either amoxicillin or metronidazole.

H2 Antagonists

FAMOTIDINE – Only on a prescription

* Tab 20 mg	4.86	100	✓ <u>Famotidine Hovid</u> ^{\$29}
* Tab 40 mg	10.27	100	✓ <u>Famotidine Hovid MY</u> ^{\$29}
* Inj 10 mg per ml, 4 ml – Subsidy by endorsement	CBS	10	✓ <u>Mylan</u> ^{\$29}

Subsidy by endorsement – Subsidised for patients receiving treatment as part of palliative care.

Proton Pump Inhibitors

LANSOPRAZOLE

* Tab orodispersible 30 mg	5.43	100	✓ <u>Lansoprazole (Viatris)</u> ^{\$29}
* Cap 15 mg	1.21	30	✓ <u>Lanzol Relief</u>
	4.04	100	✓ <u>Lanzol Relief</u>
* Cap 30 mg	5.43	100	✓ <u>Lanzol Relief</u>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
OMEPRAZOLE				
For omeprazole suspension refer Standard Formulae, page 287				
* Cap 10 mg.....	2.06	90	✓	Omeprazole Teva ✓ Omeprazole actavis 10
* Cap 20 mg.....	2.02	90	✓	Omeprazole Teva ✓ Omeprazole actavis 20
* Cap 40 mg.....	3.18	90	✓	Omeprazole Teva ✓ Omeprazole actavis 40
* Powder – Only in combination.....	52.00	5 g	✓	Midwest
Only in extemporaneously compounded omeprazole suspension.				
* Inj 40 mg ampoule with diluent.....	37.38	5	✓	Dr Reddy's Omeprazole ✓ Ocicure ^{\$29}
PANTOPRAZOLE				
* Tab EC 20 mg.....	1.81	90	✓	Panzop Relief
* Tab EC 40 mg.....	2.70	90	✓	Panzop Relief

Site Protective Agents

COLLOIDAL BISMUTH SUBCITRATE				
Tab 120 mg.....	14.51	50	✓	Gastrodenol ^{\$29}
SUCRALFATE				
Tab 1 g.....	35.50 (48.28)	120		Carafate

Bile and Liver Therapy

RIFAXIMIN – Special Authority see SA1461 below – Retail pharmacy				
Tab 550 mg.....	625.00	56	✓	Xifaxan

➔SA1461 Special Authority for Subsidy

Initial application only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid for 6 months where the patient has hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

Renewal only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Diabetes

Hyperglycaemic Agents

DIAZOXIDE – Special Authority see SA1320 on the next page – Retail pharmacy				
Cap 25 mg.....	110.00	100	✓	Proglidem ^{\$29}
Cap 100 mg.....	280.00	100	✓	Proglidem ^{\$29}
Oral liq 50 mg per ml.....	620.00	30 ml OP	✓	e5 Pharma ^{\$29}

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
►SA1320 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals valid for 12 months where used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism.			
Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.			
GLUCAGON HYDROCHLORIDE			
Inj 1 mg syringe kit – Up to 5 kit available on a PSO.....	32.00	1	✓ Glucagen Hypokit
GLUCOSE [DEXTROSE]			
Oral soln 15 g per 80 ml sachet.....	75.00	50	✓ HypoPak Glucose
Insulin - Short-acting Preparations			
INSULIN NEUTRAL			
▲ Inj human 100 u per ml, 3 ml.....	42.66	5	✓ Actrapid Penfill ✓ Humulin R
▲ Inj human 100 u per ml, 10 ml vial.....	25.26	1 OP	✓ Actrapid ✓ Humulin R
Insulin - Intermediate-acting Preparations			
INSULIN ASPART WITH INSULIN ASPART PROTAMINE			
▲ Inj 100 iu per ml, 3 ml prefilled pen.....	52.15	5	✓ NovoMix 30 FlexPen
INSULIN DEGLUDEC WITH INSULIN ASPART			
▲ Inj degludec 70 u with insulin aspart 30 u, 100 u per ml, 3 ml.....	80.00	5	✓ Ryzodeg 70/30 Penfill
INSULIN ISOPHANE			
▲ Inj human 100 u per ml, 3 ml.....	29.86	5	✓ Humulin NPH ✓ Protaphane Penfill
▲ Inj human 100 u per ml, 10 ml vial.....	17.68	1 OP	✓ Humulin NPH ✓ Protaphane
INSULIN ISOPHANE WITH INSULIN NEUTRAL			
▲ Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	✓ Humulin 30/70
▲ Inj human with neutral insulin 100 u per ml, 10 ml vial.....	25.26	1 OP	✓ Humulin 30/70
INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE			
▲ Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml.....	42.66	5	✓ Humalog Mix 25
▲ Inj lispro 50% with insulin lispro protamine 50% 100 u per ml, 3 ml.....	42.66	5	✓ Humalog Mix 50
Insulin - Long-acting Preparations			
INSULIN GLARGINE			
▲ Inj 100 u per ml, 10 ml.....	63.00	1	✓ Lantus
▲ Inj 100 u per ml, 3 ml	94.50	5	✓ Lantus
▲ Inj 100 u per ml, 3 ml disposable pen.....	94.50	5	✓ Lantus SoloStar
Insulin - Rapid Acting Preparations			
INSULIN ASPART			
▲ Inj 100 u per ml, 10 ml.....	30.03	1	✓ NovoRapid
▲ Inj 100 u per ml, 3 ml	51.19	5	✓ NovoRapid Penfill
▲ Inj 100 u per ml, 3 ml syringe	51.19	5	✓ NovoRapid FlexPen

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN GLULISINE				
▲ Inj 100 u per ml, 10 ml.....	27.03	1	✓	Apidra
▲ Inj 100 u per ml, 3 ml.....	46.07	5	✓	Apidra
▲ Inj 100 u per ml, 3 ml disposable pen.....	46.07	5	✓	Apidra SoloStar
INSULIN LISPRO				
▲ Inj 100 u per ml, 3 ml.....	59.52	5	✓	Humalog
▲ Inj 100 u per ml, 10 ml vial.....	34.92	1 OP	✓	Humalog

Alpha Glucosidase Inhibitors

ACARBOSE				
* Tab 50 mg	11.20	90	✓	Accarb
* Tab 100 mg	17.38	90	✓	Accarb

Oral Hypoglycaemic Agents

GLIBENCLAMIDE				
* Tab 5 mg	7.50	100	✓	Daonil
GLICLAZIDE				
* Tab 80 mg	20.10	500	✓	Glizide
GLIPIZIDE				
* Tab 5 mg	6.86	100	✓	Minidiab
METFORMIN HYDROCHLORIDE				
* Tab immediate-release 500 mg.....	14.74	1,000	✓	Metformin Viatris
* Tab immediate-release 850 mg.....	11.28	500	✓	Metformin Viatris
PIOGLITAZONE				
* Tab 15 mg	6.15	90	✓	Vexazone
* Tab 30 mg	7.25	90	✓	Vexazone
* Tab 45 mg	12.00	90	✓	Vexazone
VILDAGLIPTIN				
* Tab 50 mg	35.00	60	✓	Galvus
VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE				
* Tab 50 mg with 1,000 mg metformin hydrochloride	35.00	60	✓	Galvumet
* Tab 50 mg with 850 mg metformin hydrochloride	35.00	60	✓	Galvumet

GLP-1 Agonists

DULAGLUTIDE – Special Authority see [SA2690 below](#) – Retail pharmacy

Note: Not to be given in combination with another funded GLP-1 agonist or empagliflozin / empagliflozin with metformin hydrochloride unless receiving empagliflozin / empagliflozin with metformin hydrochloride for the treatment of heart failure.

Inj 1.5mg per 0.5 ml prefilled pen	115.23	4	✓	Trulicity
--	--------	---	---	------------------

►SA2690 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has type 2 diabetes; and
- 2 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of all of the following blood-glucose lowering agents for a period of at least 6 months, where clinically appropriate: empagliflozin, metformin and vildagliptin; and
- 3 Funded dulaglutide is not to be prescribed in combination with funded empagliflozin/ empagliflozin with metformin unless receiving funded empagliflozin / empagliflozin with metformin hydrochloride for the treatment of heart failure.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

LIRAGLUTIDE – Special Authority see [SA2691 below](#) – Retail pharmacy

- a) No more than 0.1 inj per day
 - b) Note: Not to be given in combination with another funded GLP-1 agonist or empagliflozin / empagliflozin with metformin hydrochloride unless receiving empagliflozin / empagliflozin with metformin hydrochloride for the treatment of heart failure.
- | | | | |
|---|--------|---|------------------|
| Inj 6 mg per ml, 3 ml prefilled pen | 383.72 | 3 | ✓ Victoza |
|---|--------|---|------------------|

► **SA2691** Special Authority for Subsidy

Initial application — (Type 2 Diabetes) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has type 2 diabetes; and
- 2 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of all of the following blood-glucose lowering agents for a period of at least 6 months, where clinically appropriate: empagliflozin, metformin and vildagliptin; and
- 3 Funded liraglutide is not to be prescribed in combination with funded empagliflozin/ empagliflozin with metformin unless receiving funded empagliflozin / empagliflozin with metformin hydrochloride for the treatment of heart failure.

SGLT2 Inhibitors

► **SA2692** Special Authority for Subsidy

Initial application — (heart failure reduced ejection fraction) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has heart failure; and
- 2 Patient is in NYHA functional class II or III or IV; and
- 3 Either:
 - 3.1 Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 40%; or
 - 3.2 An ECHO is not reasonably practicable, and in the opinion of the treating practitioner the patient would benefit from treatment; and
- 4 Patient is receiving concomitant optimal standard funded chronic heart failure treatment.

Initial application — (Type 2 Diabetes) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient has type 2 diabetes; and
 - 1.1.2 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months; or
 - 1.2 Patient has previously had an initial approval for a GLP-1 agonist and is changing funded treatment to an SGLT2i; and
- 2 Funded empagliflozin or empagliflozin with metformin hydrochloride is not to be prescribed in combination with a funded GLP-1 agonist unless for the treatment of heart failure .

EMPAGLIFLOZIN – Special Authority see [SA2692 above](#) – Retail pharmacy

* Tab 10 mg	58.56	30	✓ Jardiance
* Tab 25 mg	58.56	30	✓ Jardiance

EMPAGLIFLOZIN WITH METFORMIN HYDROCHLORIDE – Special Authority see [SA2692 above](#) – Retail pharmacy

* Tab 5 mg with 1,000 mg metformin hydrochloride	58.56	60	✓ Jardiamet
* Tab 5 mg with 500 mg metformin hydrochloride	58.56	60	✓ Jardiamet
* Tab 12.5 mg with 1,000 mg metformin hydrochloride	58.56	60	✓ Jardiamet
* Tab 12.5 mg with 500 mg metformin hydrochloride	58.56	60	✓ Jardiamet

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Diabetes Management

Ketone Testing

BLOOD KETONE DIAGNOSTIC TEST STRIP – Subsidy by endorsement

- a) Not on a BSO
 - b) Maximum of 20 strip per prescription
 - c) Up to 10 strip available on a PSO
 - d) Patient has any of the following:
 - 1) type 1 diabetes; or
 - 2) permanent neonatal diabetes; or
 - 3) undergone a pancreatectomy; or
 - 4) cystic fibrosis-related diabetes; or
 - 5) metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist.
- The prescription must be endorsed accordingly.

Test strips..... 15.50 10 strip OP ✓ KetoSens

Dual Blood Glucose and Blood Ketone Testing

DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER – Subsidy by endorsement

- a) Maximum of 1 pack per prescription
 - b) Up to 1 pack available on a PSO
 - c) A dual blood glucose and blood ketone diagnostic test meter is subsidised for a patient who has:
 - 1) type 1 diabetes; or
 - 2) permanent neonatal diabetes; or
 - 3) undergone a pancreatectomy; or
 - 4) cystic fibrosis-related diabetes; or
 - 5) metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist.
- The prescription must be endorsed accordingly. Only 1 meter per patient will be subsidised (no repeat prescriptions). For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a funded CareSens meter.

Meter with 50 lancets, a lancing device and 10 blood glucose
diagnostic test strips..... 20.00 1 OP ✓ CareSens Dual

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Blood Glucose Testing

BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement

- Maximum of 1 pack per prescription
- Up to 1 pack available on a PSO
- A diagnostic blood glucose test meter is subsidised for a patient who:
 - is receiving insulin or sulphonylurea therapy; or
 - is pregnant with diabetes; or
 - is on home TPN at risk of hypoglycaemia or hyperglycaemia; or
 - has a genetic or an acquired disorder of glucose homeostasis, excluding type 1 or type 2 diabetes and metabolic syndrome.

The prescription must be endorsed accordingly. Only one CareSens meter per patient will be subsidised (no repeat prescriptions). Patients already using the CareSens N POP meter and CareSens N meter are not eligible for a new meter, unless they have:

- type 1 diabetes; or
- permanent neonatal diabetes; or
- undergone a pancreatectomy; or
- cystic fibrosis-related diabetes.

For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a funded CareSens meter.

Meter with 50 lancets, a lancing device and 10 diagnostic test strips.....	10.00	1 OP	✓ CareSens N
	20.00		✓ CareSens N POP
			✓ CareSens N Premier

Note: Only 1 meter available per PSO

BLOOD GLUCOSE DIAGNOSTIC TEST STRIP – Up to 50 test available on a PSO

The number of test strips available on a prescription is restricted to 50 unless:

- Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or
- Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- Prescribed for a pregnant woman with diabetes and endorsed accordingly; or
- Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or
- Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

Test strips.....	10.56	50 test OP	✓ CareSens N
			✓ CareSens PRO

BLOOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED)

The number of test strips available on a prescription is restricted to 50 unless:

- Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or
- Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- Prescribed for a pregnant woman with diabetes and endorsed accordingly; or
- Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or
- Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

Blood glucose test strips.....	33.69	50 test OP	✓ SensoCard
--------------------------------	-------	------------	-------------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Insulin Syringes and Needles				
Subsidy is available for disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or liraglutide or when prescribed for a patient and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or liraglutide.				
INSULIN PEN NEEDLES				
Maximum of 200 dev per three months				
* 29 g x 12.7 mm	10.95	100	✓	B-D Micro-Fine ✓ Embecta Micro-Fine
* 31 g x 5 mm	12.26	100	✓	B-D Micro-Fine ✓ Embecta Micro-Fine
* 31 g x 6 mm	9.50	100	✓	Berpu
* 31 g x 8 mm	10.95	100	✓	B-D Micro-Fine ✓ Embecta Micro-Fine
* 32 g x 4 mm	10.95	100	✓	B-D Micro-Fine ✓ Embecta Micro-Fine
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE				
Maximum of 200 dev per three months				
* Syringe 0.3 ml with 29 g x 12.7 mm needle	13.56	100	✓	B-D Ultra Fine ✓ Embecta Ultra Fine
	1.36 (1.99)	10		B-D Ultra Fine
* Syringe 0.3 ml with 31 g x 8 mm needle	13.56	100	✓	B-D Ultra Fine II ✓ Embecta Ultra Fine
	1.30 (1.99)	10		B-D Ultra Fine II
* Syringe 0.5 ml with 29 g x 12.7 mm needle	13.56	100	✓	B-D Ultra Fine ✓ Embecta Ultra Fine
	1.36 (1.99)	10		B-D Ultra Fine
* Syringe 0.5 ml with 31 g x 8 mm needle	13.56	100	✓	B-D Ultra Fine II ✓ Embecta Ultra Fine
	1.36 (1.99)	10		B-D Ultra Fine II
* Syringe 1 ml with 29 g x 12.7 mm needle	13.56	100	✓	B-D Ultra Fine ✓ Embecta Ultra Fine
	1.36 (1.99)	10		B-D Ultra Fine
* Syringe 1 ml with 31 g x 8 mm needle	13.56	100	✓	B-D Ultra Fine II ✓ Embecta Ultra Fine
	1.36 (1.99)	10		B-D Ultra Fine II

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Insulin Pumps

INSULIN PUMP WITH ALGORITHM – Special Authority see [SA2367 below](#) – Retail pharmacy

a) Maximum of 1 dev per prescription

b) Only on a prescription

c) Maximum of 1 insulin pump per patient each four year period.

Min basal rate 0.02 U/h	8,970.00	1	✓ mylife YpsoPump with CamAPS FX
Min basal rate 0.1 U/h	7,653.00	1	✓ Tandem t:slim X2 with Basal-IQ
			✓ Tandem t:slim X2 with Control-IQ+

►SA2367 Special Authority for Subsidy

Initial application — (type 1 diabetes) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- Any of the following:
 - The patient has type 1 diabetes; or
 - The patient has permanent neonatal diabetes or specific monogenic diabetes subtypes with insulin deficiency, considered by the treating endocrinologist as likely to benefit; or
 - The patient has Type 3c diabetes considered by the treating endocrinologist as likely to benefit (Type 3c diabetes includes insulin deficiency due to pancreatectomy, insulin deficiency secondary to cystic fibrosis or pancreatitis); or
 - The patient has atypical inherited forms of diabetes; and
- Patient has been evaluated by a diabetes multidisciplinary team for their suitability for insulin pump therapy; and
- In the opinion of the treating relevant practitioner the patient would benefit from an Automated Insulin Delivery (AID) system.

Renewal — (type 1 diabetes) from any relevant practitioner. Approvals valid for 6 months where the patient is continuing to derive benefit according to the treatment plan agreed at induction.

Insulin Pump Consumables

►SA2536 Special Authority for Subsidy

Initial application — (type 1 diabetes) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- Any of the following:
 - The patient has type 1 diabetes; or
 - The patient has permanent neonatal diabetes or specific monogenic diabetes subtypes with insulin deficiency, considered by the treating endocrinologist as likely to benefit; or
 - The patient has Type 3c diabetes considered by the treating endocrinologist as likely to benefit (Type 3c diabetes includes insulin deficiency due to pancreatectomy, insulin deficiency secondary to cystic fibrosis or pancreatitis); or
 - The patient has atypical inherited forms of diabetes; and
- Patient has been evaluated by a diabetes multidisciplinary team for their suitability for insulin pump therapy; and
- In the opinion of the treating relevant practitioner the patient would benefit from an Automated Insulin Delivery (AID) system.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN PUMP CARTRIDGE – Special Authority see SA2536 on the previous page – Retail pharmacy				
a) Only on a prescription				
b) Maximum of 190 cartridges will be funded per year.				
c) Maximum of 50 cart per three months				
* Cartridge 300 u, tlock x 10	86.00	10 OP	✓	Tandem Cartridge
INSULIN PUMP INFUSION SET (STEEL CANNULA) – Special Authority see SA2536 on the previous page – Retail pharmacy				
a) Only on a prescription				
b) Maximum of 19 infusion sets will be funded per year.				
c) Maximum of 5 set per three months				
* 6 mm steel needle; 60 cm tubing x 10	219.00	1 OP	✓	MiniMed Sure-T MMT-864A
* 6 mm steel needle; 80 cm tubing x 10	219.00	1 OP	✓	MiniMed Sure-T MMT-866A
* 8 mm steel needle; 60 cm tubing x 10	219.00	1 OP	✓	MiniMed Sure-T MMT-874A
* 8 mm steel needle; 80 cm tubing x 10	219.00	1 OP	✓	MiniMed Sure-T MMT-876A
<i>(MiniMed Sure-T MMT-864A 6 mm steel needle; 60 cm tubing x 10 to be delisted 1 October 2026)</i>				
<i>(MiniMed Sure-T MMT-866A 6 mm steel needle; 80 cm tubing x 10 to be delisted 1 October 2026)</i>				
<i>(MiniMed Sure-T MMT-874A 8 mm steel needle; 60 cm tubing x 10 to be delisted 1 October 2026)</i>				
<i>(MiniMed Sure-T MMT-876A 8 mm steel needle; 80 cm tubing x 10 to be delisted 1 October 2026)</i>				
INSULIN PUMP INFUSION SET (STEEL CANNULA, STRAIGHT INSERTION) – Special Authority see SA2536 on the previous page – Retail pharmacy				
a) Only on a prescription				
b) Maximum of 19 infusion sets will be funded per year.				
c) Maximum of 5 sets per three months				
* 5.5 mm steel cannula; straight insertion; 45 cm line x 10 with 10 needles	136.00	1 OP	✓	mylife Orbit micro
* 5.5 mm steel needle; straight insertion; 60 cm line x 10 with 10 needles	136.00	1 OP	✓	mylife Orbit micro
* 5.5 mm steel needle; straight insertion; 80 cm line x 10 with 10 needles	136.00	1 OP	✓	mylife Orbit micro
* 8.5 mm steel needle; straight insertion; 60 cm line x 10 with 10 needles	136.00	1 OP	✓	mylife Orbit micro
* 8.5 mm steel needle; straight insertion; 80 cm line x 10 with 10 needles	136.00	1 OP	✓	mylife Orbit micro
6 mm steel cannula; straight insertion; 80 cm line x 10 with 10 needles	182.00	1 OP	✓	TruSteel
8 mm steel cannula; straight insertion; 80 cm line x 10 with 10 needles	182.00	1 OP	✓	TruSteel
6 mm steel cannula; straight insertion; 60 cm line x 10 with 10 needles	182.00	1 OP	✓	TruSteel
8 mm steel cannula; straight insertion; 60 cm line x 10 with 10 needles	182.00	1 OP	✓	TruSteel

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA) – Special Authority see SA2536 on page 17 – Retail pharmacy			
a) Only on a prescription			
b) Maximum of 19 infusion sets will be funded per year.			
c) Maximum of 5 set per three months			
* 13 mm teflon needle, 60 cm tubing x 10	219.00	1 OP	✓ MiniMed Silhouette MMT-381A
* 17 mm teflon needle, 110 cm tubing x 10	219.00	1 OP	✓ MiniMed Silhouette MMT-377A
* 17 mm teflon needle, 60 cm tubing x 10	219.00	1 OP	✓ MiniMed Silhouette MMT-378A
* 6 mm teflon needle, 110 cm tubing x 10	219.00	1 OP	✓ MiniMed Quick-Set MMT-398A
* 6 mm teflon needle, 60 cm tubing x 10	219.00	1 OP	✓ MiniMed Quick-Set MMT-399A
* 9 mm teflon needle, 110 cm tubing x 10	219.00	1 OP	✓ MiniMed Quick-Set MMT-396A
* 9 mm teflon needle, 60 cm tubing x 10	219.00	1 OP	✓ MiniMed Quick-Set MMT-397A

(MiniMed Silhouette MMT-381A 13 mm teflon needle, 60 cm tubing x 10 to be delisted 1 October 2026)

(MiniMed Silhouette MMT-377A 17 mm teflon needle, 110 cm tubing x 10 to be delisted 1 October 2026)

(MiniMed Silhouette MMT-378A 17 mm teflon needle, 60 cm tubing x 10 to be delisted 1 October 2026)

(MiniMed Quick-Set MMT-398A 6 mm teflon needle, 110 cm tubing x 10 to be delisted 1 October 2026)

(MiniMed Quick-Set MMT-399A 6 mm teflon needle, 60 cm tubing x 10 to be delisted 1 October 2026)

(MiniMed Quick-Set MMT-396A 9 mm teflon needle, 110 cm tubing x 10 to be delisted 1 October 2026)

(MiniMed Quick-Set MMT-397A 9 mm teflon needle, 60 cm tubing x 10 to be delisted 1 October 2026)

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE INSERTION WITH INSERTION DEVICE) – Special Authority see SA2536 on page 17 – Retail pharmacy				
a) Only on a prescription				
b) Maximum of 19 infusion sets will be funded per year.				
c) Maximum of 5 sets per three months				
* 6 mm teflon cannula; angle insertion; insertion device; 60 cm line x 4 with 4 needles.....	210.00	1 OP	✓	Med Adv Ext Infusion Set MDT-MMT-431AK
* 6 mm teflon cannula; angle insertion; insertion device; 80 cm line x 4 with 4 needles.....	210.00	1 OP	✓	Med Adv Ext Infusion Set MDT-MMT-432AK
* 9 mm teflon cannula; angle insertion; insertion device; 60 cm line x 4 with 4 needles.....	210.00	1 OP	✓	Med Adv Ext Infusion Set MDT-MMT-441AK
* 9 mm teflon cannula; angle insertion; insertion device; 80 cm line x 4 with 4 needles.....	210.00	1 OP	✓	Med Adv Ext Infusion Set MDT-MMT-442AK
* 13 mm teflon cannula; angle insertion; insertion device; 110 cm line x 10 with 10 needles.....	182.00	1 OP	✓	AutoSoft 30
* 13 mm teflon cannula; angle insertion; insertion device; 60 cm line x 10 with 10 needles.....	182.00	1 OP	✓	AutoSoft 30
<i>(Med Adv Ext Infusion Set MDT-MMT-431AK 6 mm teflon cannula; angle insertion; insertion device; 60 cm line x 4 with 4 needles to be delisted 1 October 2026)</i>				
<i>(Med Adv Ext Infusion Set MDT-MMT-432AK 6 mm teflon cannula; angle insertion; insertion device; 80 cm line x 4 with 4 needles to be delisted 1 October 2026)</i>				
<i>(Med Adv Ext Infusion Set MDT-MMT-441AK 9 mm teflon cannula; angle insertion; insertion device; 60 cm line x 4 with 4 needles to be delisted 1 October 2026)</i>				
<i>(Med Adv Ext Infusion Set MDT-MMT-442AK 9 mm teflon cannula; angle insertion; insertion device; 80 cm line x 4 with 4 needles to be delisted 1 October 2026)</i>				
INSULIN PUMP INFUSION SET (TEFLON CANNULA, FLEXIBLE INSERTION WITH INSERTION DEVICE) – Special Authority see SA2536 on page 17 – Retail pharmacy				
a) Only on a prescription				
b) Maximum of 19 infusion sets will be funded per year.				
c) Maximum of 5 set per three months				
* 6 mm teflon cannula; flexible insertion; insertion device; 46 cm line x 10 with 10 needles.....	157.00	1 OP	✓	mylife Inset soft
* 6 mm teflon cannula; flexible insertion; insertion device; 60 cm line with integrated inserter x 10 with 10 needles	157.00	1 OP	✓	mylife Inset soft
* 6 mm teflon cannula; flexible insertion; insertion device; 80 cm line x 10 with 10 needles.....	157.00	1 OP	✓	mylife Inset soft
* 9 mm teflon cannula; flexible insertion; insertion device; 60 cm line x 10 with 10 needles.....	157.00	1 OP	✓	mylife Inset soft
* 9 mm teflon cannula; flexible insertion; insertion device; 80 cm line x 10 with 10 needles.....	157.00	1 OP	✓	mylife Inset soft

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, FLEXIBLE INSERTION) – Special Authority see SA2536 on page 17 –			
Retail pharmacy			
a) Only on a prescription			
b) Maximum of 19 infusion sets will be funded per year.			
c) Maximum of 5 sets per three months			
* 6 mm teflon cannula; flexible insertion; 45 cm line x 10 needles	136.00	1 OP	✓ mylife Orbit soft
* 6 mm teflon cannula; flexible insertion; 60 cm line x 10 needles	136.00	1 OP	✓ mylife Orbit soft
* 6 mm teflon cannula; flexible insertion; 80 cm line x 10 needles	136.00	1 OP	✓ mylife Orbit soft
* 9 mm teflon cannula; flexible insertion; 60 cm line x 10 needles	136.00	1 OP	✓ mylife Orbit soft
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGHT INSERTION WITH INSERTION DEVICE) – Special Authority see SA2536 on page 17 – Retail pharmacy			
a) Brand switch fee payable (Pharmacode 2733498) - see page 285 for details			
b) Only on a prescription			
c) Maximum of 19 infusion sets will be funded per year.			
d) Maximum of 5 sets per three months			
* 6 mm teflon cannula; straight insertion; insertion device; 110 cm line x 10 with 10 needles	182.00	1 OP	✓ AutoSoft 90
* 6 mm teflon cannula; straight insertion; insertion device; 60 cm line x 10 with 10 needles	182.00	1 OP	✓ AutoSoft 90
* 9 mm teflon cannula; straight insertion; insertion device; 110 cm line x 10 with 10 needles	182.00	1 OP	✓ AutoSoft 90
* 9 mm teflon cannula; straight insertion; insertion device; 60 cm line x 10 with 10 needles	182.00	1 OP	✓ AutoSoft 90
INSULIN PUMP INFUSION SET (TEFLON CANNULA, VARIABLE INSERTION) – Special Authority see SA2536 on page 17 –			
Retail pharmacy			
a) Only on a prescription			
b) Maximum of 19 infusion sets will be funded per year.			
c) Maximum of 5 set per three months			
* 13 mm teflon cannula; variable insertion; 60 cm line x 10 with 10 needles	182.00	1 OP	✓ VariSoft
INSULIN PUMP RESERVOIR – Special Authority see SA2536 on page 17 – Retail pharmacy			
a) Only on a prescription			
b) Maximum of 360 reservoirs will be funded per year.			
c) Maximum of 90 cart per three months			
* 10 x 1.6 ml glass reservoir for YpsoPump	50.00	10 OP	✓ mylife YpsoPump Reservoir
* 10 x luer lock conversion cartridges 1.8 ml for paradigm pumps	50.00	10 OP	✓ ADR Cartridge 1.8
* Cartridge for 7 series pump; 3.0 ml x 10	98.00	10 OP	✓ MiniMed 3.0 Reservoir MMT-332A
* Cartridge for 7 series pump; 3.0 ml x 5	102.00	5 OP	✓ MiniMed 3.0 Ext Reservoir MDT-MMT-342G

(ADR Cartridge 1.8 10 x luer lock conversion cartridges 1.8 ml for paradigm pumps to be delisted 1 October 2026)

(MiniMed 3.0 Reservoir MMT-332A Cartridge for 7 series pump; 3.0 ml x 10 to be delisted 1 October 2026)

(MiniMed 3.0 Ext Reservoir MDT-MMT-342G Cartridge for 7 series pump; 3.0 ml x 5 to be delisted 1 October 2026)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Continuous Glucose Monitor

CONTINUOUS GLUCOSE MONITOR (INTEROPERABLE) – Special Authority see [SA2537 below](#) – Retail pharmacy

Only on a prescription

* Sensor (9) and transmitter (Dexcom G6)	990.00	1 OP	✓	Dexcom G6
a) Maximum of 5 dev will be funded per year.				
b) Maximum of 1 dev per three months				
* Sensor (Dexcom G7)	110.00	1	✓	Dexcom G7
a) Maximum of 40 dev will be funded per year.				
b) Maximum of 9 dev per three months				
* Sensor (Freestyle Libre 3 Plus)	99.46	1	✓	Freestyle Libre 3 Plus
a) Maximum of 28 dev will be funded per year.				
b) Maximum of 6 dev per three months				

►SA2537 Special Authority for Subsidy

Initial application — (type 1 diabetes) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- Any of the following:
 - The patient has type 1 diabetes; or
 - The patient has permanent neonatal diabetes or specific monogenic diabetes subtypes with insulin deficiency, considered by the treating endocrinologist or relevant secondary health care professional as practicable, as likely to benefit; or
 - The patient has Type 3c diabetes considered by the treating endocrinologist or relevant secondary health care professional as practicable, as likely to benefit (Type 3c diabetes includes insulin deficiency due to pancreatectomy, insulin deficiency secondary to cystic fibrosis or pancreatitis); or
 - The patient has atypical inherited forms of diabetes; and
- In the opinion of the treating relevant practitioner the patient would benefit from an Automated Insulin Delivery (AID) system.

CONTINUOUS GLUCOSE MONITOR (STANDALONE) – Special Authority see [SA2538 below](#) – Retail pharmacy

Only on a prescription

* Sensor (Dexcom ONE+)	81.00	1	✓	Dexcom ONE+
a) Maximum of 40 dev will be funded per year.				
b) Maximum of 9 dev per three months				
* Sensor (Freestyle Libre 2 Plus)	99.46	1	✓	Freestyle Libre 2 Plus
a) Maximum of 28 dev will be funded per year.				
b) Maximum of 6 dev per three months				

►SA2538 Special Authority for Subsidy

Initial application — (type 1 diabetes) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- The patient has type 1 diabetes; or
- The patient has permanent neonatal diabetes or specific monogenic diabetes subtypes with insulin deficiency, considered by the treating endocrinologist or relevant secondary health care professional as practicable, as likely to benefit; or
- The patient has Type 3c diabetes considered by the treating endocrinologist or relevant secondary health care professional as practicable, as likely to benefit (Type 3c diabetes includes insulin deficiency due to pancreatectomy, insulin deficiency secondary to cystic fibrosis or pancreatitis); or
- The patient has atypical inherited forms of diabetes.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Digestives Including Enzymes				
PANCREATIC ENZYME				
Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U)	34.93	100	✓	Creon 10000
Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U)	94.38	100	✓	Creon 25000
Modified release granules pancreatin 60.12 mg (amylase 3,600 Ph Eur U, lipase 5,000 Ph Eur U, protease 200 Ph Eur U)	34.93	20 g OP	✓	Creon Micro
URSODEOXYCHOLIC ACID – Special Authority see SA2448 below – Retail pharmacy				
Cap 250 mg	33.45	100	✓	Ursosan
	62.00		✓	APO- Ursodeoxycholic Acid \$29

► **SA2448** Special Authority for Subsidy

Initial application — (Alagille syndrome or progressive familial intrahepatic cholestasis) from any relevant practitioner.

Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Initial application — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initial application — (Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

Initial application — (Pregnancy) from any relevant practitioner. Approvals valid for 6 months where the patient diagnosed with cholestasis of pregnancy.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogeneic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Initial application — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and
- 2 Liver function has not improved with modifying the TPN composition.

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

continued...

Renewal — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 6 months where the patient continues to benefit from treatment.

Renewal — (Pregnancy/Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months where the paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels.

Initial application — (prevention of sinusoidal obstruction syndrome) from any relevant practitioner. Approvals valid without further renewal unless notified where the individual has leukaemia/lymphoma and requires prophylaxis for medications/therapies with a high risk of sinusoidal obstruction syndrome.

Laxatives

Bulk-forming Agents

ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription

* Powder for oral soln.....	22.10	500 g OP	✓ Konsyl-D
-----------------------------	-------	----------	------------

Faecal Softeners

DOCUSATE SODIUM – Only on a prescription

* Tab 50 mg	3.53	100	✓ Coloxyl
-------------------	------	-----	-----------

* Tab 120 mg	5.65	100	✓ Coloxyl
--------------------	------	-----	-----------

DOCUSATE SODIUM WITH SENNOSIDES

Tab 50 mg with sennosides 8 mg.....	1.50	100	✓ Solax
-------------------------------------	------	-----	---------

POLOXAMER – Only on a prescription

Not funded for use in the ear.

* Oral drops 10%.....	4.38	30 ml OP	✓ Coloxyl
-----------------------	------	----------	-----------

Opioid Receptor Antagonists - Peripheral

METHYLNALTREXONE BROMIDE – Special Authority see [SA1691 below](#) – Retail pharmacy

Inj 12 mg per 0.6 ml vial	36.00	1	✓ Relistor
---------------------------------	-------	---	------------

	246.00	7	✓ Relistor
--	--------	---	------------

» [SA1691](#) Special Authority for Subsidy

Initial application — (Opioid induced constipation) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

1 The patient is receiving palliative care; and

2 Either:

2.1 Oral and rectal treatments for opioid induced constipation are ineffective; or

2.2 Oral and rectal treatments for opioid induced constipation are unable to be tolerated.

Osmotic Laxatives

GLYCEROL

* Suppos 2.8/4.0 g – Only on a prescription	12.39	20	✓ <u>Lax-suppositories</u> <u>Glycerol</u>
---	-------	----	---

LACTULOSE – Only on a prescription

* Oral liq 10 g per 15 ml	6.16	500 ml	✓ <u>Laevolac</u>
---------------------------------	------	--------	-------------------

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE			
Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg.....	10.15	30	✓ Molaxole ✓ Movicol
SODIUM ACID PHOSPHATE – Only on a prescription			
Enema 16% with sodium phosphate 8%.....	3.70	1	✓ Fleet Phosphate Enema
SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription			
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml.....	36.89	50	✓ Micolette

Stimulant Laxatives

BISACODYL – Only on a prescription			
* Tab 5 mg	6.28	200	✓ Bisacodyl-AFT
* Suppos 10 mg	4.14	10	✓ Lax-Suppositories
SENNA – Only on a prescription			
* Tab, standardised.....	2.17 (10.78)	100	Senokot
SODIUM PICOSULFATE – Special Authority see SA2053 below – Retail pharmacy			
Oral soln 7.5 mg per ml	7.40	30 ml OP	✓ Dulcolax SP Drop

►SA2053 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:
Both:

- 1 The patient is a child with problematic constipation despite an adequate trial of other oral pharmacotherapies including macrogol where practicable; and
- 2 The patient would otherwise require a high-volume bowel cleansing preparation or hospital admission.

Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Metabolic Disorder Agents

ALGLUCOSIDASE ALFA – Special Authority see SA1986 below – Retail pharmacy			
Inj 50 mg vial	1,142.60	1	✓ Myozyme

►SA1986 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:
All of the following:

- 1 The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and
- 2 Any of the following:
 - 2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
 - 2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
 - 2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
- 3 Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
- 4 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
- 5 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

Renewal only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
- 3 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 4 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
- 5 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 6 There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
- 7 There is no evidence of new or progressive cardiomyopathy.

ARGININE – Special Authority see [SA2042 below](#) – Retail pharmacy

Tab 1,000 mg	CBS	90	✓ Clinicians
Cap 500 mg	CBS	50	✓ Solgar
Powder	CBS	400 g	✓ Biomed

➔SA2042 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 6 months where patient has a suspected inborn error of metabolism that may respond to arginine supplementation.

Renewal only from a metabolic physician. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to arginine supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

BETAINE – Special Authority see [SA1987 below](#) – Retail pharmacy

Powder for oral soln.....	575.00	180 g OP	✓ Cystadane
---------------------------	--------	----------	-------------

➔SA1987 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a confirmed diagnosis of homocystinuria; and
- 2 Any of the following:
 - 2.1 A cystathionine beta-synthase (CBS) deficiency; or
 - 2.2 A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency; or
 - 2.3 A disorder of intracellular cobalamin metabolism; and
- 3 An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation.

Renewal only from a metabolic physician. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

COENZYME Q10 – Special Authority see [SA2039 on the next page](#) – Retail pharmacy

Cap 120 mg	CBS	30	✓ Solgar
Cap 160 mg	CBS	60	✓ Go Healthy

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

»SA2039 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 6 months where patient has a suspected inborn error of metabolism that may respond to coenzyme Q10 supplementation.

Renewal only from a metabolic physician. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to coenzyme Q10 supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

GALSULFASE – Special Authority see [SA1988 below](#) – Retail pharmacy

Inj 1 mg per ml, 5 ml vial.....	2,234.00	1	✓ Naglazyme
---------------------------------	----------	---	-------------

»SA1988 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has been diagnosed with mucopolysaccharidosis VI; and
- 2 Either:
 - 2.1 Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency by either enzyme activity assay in leukocytes or skin fibroblasts; or
 - 2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.

Renewal only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 3 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
- 4 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

IDURSULFASE – Special Authority see [SA1623 below](#) – Retail pharmacy

Inj 2 mg per ml, 3 ml vial.....	4,608.30	1	✓ Elaprase
---------------------------------	----------	---	------------

»SA1623 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 24 weeks for applications meeting the following criteria:

All of the following:

- 1 The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II); and
- 2 Either:
 - 2.1 Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
 - 2.2 Detection of a disease causing mutation in the iduronate 2-sulfatase gene; and
- 3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant; and
- 4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
- 5 Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.

LARONIDASE – Special Authority see [SA1695 on the next page](#) – Retail pharmacy

Inj 100 U per ml, 5 ml vial.....	1,335.16	1	✓ Aldurazyme
----------------------------------	----------	---	--------------

►SA1695 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 24 weeks for applications meeting the following criteria:
All of the following:

- 1 The patient has been diagnosed with Hurler Syndrome (mucopolysaccharidosis I-H); and
- 2 Either:
 - 2.1 Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
 - 2.2 Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome; and
- 3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be bridging treatment to transplant; and
- 4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
- 5 Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every week.

LEVOCARNITINE – Special Authority see SA2040 below – Retail pharmacy

Tab 500 mg	CBS	30	✓ Solgar
Cap 250 mg	CBS	30	✓ Solgar
Cap 500 mg	CBS	60	✓ Balance
		300	✓ Metabolics
Oral liq 1 g per 10 ml	CBS	118 ml	✓ Lacuna §29
Oral liq 500 mg per 10 ml	CBS	300 ml	✓ Balance

►SA2040 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 6 months where patient has a suspected inborn error of metabolism that may respond to carnitine supplementation.

Renewal only from a metabolic physician. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to carnitine supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

NITISINONE – Special Authority see SA2561 below – Retail pharmacy

Cap 2 mg	676.00	60	✓ Nitisinone LogixX Pharma
Cap 5 mg	1,302.00	60	✓ Nitisinone LogixX Pharma
Cap 10 mg	1,704.00	60	✓ Nitisinone LogixX Pharma

►SA2561 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where patient requires nitisinone for the management of inherited metabolic disorders.

RIBOFLAVIN – Special Authority see SA2041 on the next page – Retail pharmacy

Tab 100 mg	CBS	100	✓ Country Life
			✓ Puritan's Pride Vitamin B-2 100 mg §29
Cap 100 mg	CBS	100	✓ Solgar

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2041 Special Authority for Subsidy

Initial application only from a metabolic physician or neurologist. Approvals valid for 6 months where patient has a suspected inborn error of metabolism that may respond to riboflavin supplementation.

Renewal only from a metabolic physician or neurologist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to riboflavin supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

SAPROPTERIN DIHYDROCHLORIDE – Special Authority see [SA1989 below](#) – Retail pharmacy

Tab soluble 100 mg 1,452.70 30 OP ✓ **Kuvan**

►SA1989 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 1 month for applications meeting the following criteria: All of the following:

- 1 Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant; and
- 2 Treatment with sapropterin is required to support management of PKU during pregnancy; and
- 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

Renewal only from a metabolic physician or any relevant practitioner on the recommendation of a metabolic physician.

Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or
 - 1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and
- 2 Any of the following:
 - 2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or
 - 2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or
 - 2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and
- 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

SODIUM BENZOATE – Special Authority see [SA1599 below](#) – Retail pharmacy

Soln 100 mg per ml CBS 100 ml ✓ **Amzoate** S29

►SA1599 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months where the patient has a diagnosis of a urea cycle disorder.

Renewal only from a metabolic physician. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

SODIUM PHENYLBUTYRATE – Special Authority see [SA1990 on the next page](#) – Retail pharmacy

Grans 483 mg per g 2,016.00 174 g OP ✓ **Pheburane**

►SA1990 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months where the patient has a diagnosis of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.

Renewal only from a metabolic physician. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

TAURINE – Special Authority see [SA2043 below](#) – Retail pharmacy

Cap 500 mg.....	CBS	50	✓ Solgar
Cap 1,000 mg.....	CBS	90	✓ Life Extension
Powder	CBS	300 g	✓ Life Extension

►SA2043 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 6 months where patient has a suspected specific mitochondrial disorder that may respond taurine supplementation.

Renewal only from a metabolic physician. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The patient has confirmed diagnosis of a specific mitochondrial disorder which responds to taurine supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

TRIENTINE – Special Authority see [SA2324 below](#) – Retail pharmacy

Cap 250 mg.....	2,022.00	100	✓ Trientine Waymade
-----------------	----------	-----	---------------------

►SA2324 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Wilson disease; and
- 2 Treatment with D-penicillamine has been trialled and discontinued because the person has experienced intolerable side effects or has not received sufficient benefit; and
- 3 Treatment with zinc has been trialled and discontinued because the person has experienced intolerable side effects or has not received sufficient benefit, or zinc is considered clinically inappropriate as the person has symptomatic liver disease and requires copper chelation.

Gaucher's Disease

TALIGLUCERASE ALFA – Special Authority see [SA2137 below](#) – Retail pharmacy

Inj 200 unit vial.....	1,072.00	1	✓ Elelyso
------------------------	----------	---	-----------

►SA2137 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of symptomatic type 1 or type 3* Gaucher disease confirmed by the demonstration of specific deficiency of glucocerebrosidase in leukocytes or cultured skin fibroblasts, and genotypic analysis; and
- 2 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by enzyme replacement therapy (ERT) or the disease might be reasonably expected to compromise a response to ERT; and
- 3 Any of the following:
 - 3.1 Patient has haematological complications of Gaucher disease; or
 - 3.2 Patient has skeletal complications of Gaucher disease; or
 - 3.3 Patient has significant liver dysfunction or hepatomegaly attributable to Gaucher disease; or
 - 3.4 Patient has reduced vital capacity from clinically significant or progressive pulmonary disease due to Gaucher

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

disease; or

3.5 Patient is a child and has experienced growth failure with significant decrease in percentile linear growth over a 6-12 month period; and

4 Taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units).

Note: Indication marked with * is an unapproved indication

Renewal only from a metabolic physician or any relevant practitioner on the recommendation of a metabolic physician.

Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Patient has demonstrated a symptomatic improvement and has maintained improvements in the main symptom or symptoms for which therapy was started; and
- 2 Patient has demonstrated a clinically objective improvement or no deterioration in haemoglobin levels, platelet counts and liver and spleen size; and
- 3 Radiological (MRI) signs of bone activity performed at two years since initiation of treatment, and five yearly thereafter, demonstrate no deterioration shown by the MRI, compared with MRI taken immediately prior to commencement of therapy or adjusted dose; and
- 4 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 5 Patient is adherent with regular treatment and taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units).

Mouth and Throat

Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE

Soln 0.15% – Higher subsidy of \$22.60 per 500 ml with

Endorsement	9.00	500 ml	
	(22.60)		Difflam

Additional subsidy by endorsement for a patient who has oral mucositis as a result of treatment for cancer, and the prescription is endorsed accordingly.

CARMELLOSE SODIUM WITH GELATIN AND PECTIN

Paste	17.20	56.7 g OP	✓ Stomahesive
Powder	8.48	28 g OP	
	(10.95)		Stomahesive

TRIAMCINOLONE ACETONIDE

Paste 0.1%	3.57	5 g OP	✓ Kenalog in Orabase
Kenalog in Orabase to be Principal Supply on 1 December 2026			

Oropharyngeal Anti-infectives

AMPHOTERICIN B

Lozenges 10 mg	5.86	20	✓ Fungilin
----------------------	------	----	------------

MICONAZOLE

Oral gel 20 mg per g	5.19	40 g OP	✓ Decozol
----------------------------	------	---------	-----------

NYSTATIN

Oral liq 100,000 u per ml	2.73	24 ml OP	✓ Nilstat
---------------------------------	------	----------	-----------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Vitamins				
Vitamin B				
HYDROXOCOBALAMIN				
* Inj 1 mg per ml, 1 ml ampoule – Up to 6 inj available on a PSO	3.95	3	✓	Hydroxocobalamin Panpharma
PYRIDOXINE HYDROCHLORIDE				
a) No more than 100 mg per dose				
b) Only on a prescription				
* Tab 25 mg – No patient co-payment payable.....	3.43	90	✓	Vitamin B6 25
* Tab 50 mg	23.45	500	✓	Pyridoxine multichem
THIAMINE HYDROCHLORIDE – Only on a prescription				
* Tab 50 mg	3.89	100	✓	Thiamine-REX
	4.65		✓	Thiamine multichem
Thiamine-REX to be Principal Supply on 1 December 2026 (Thiamine multichem Tab 50 mg to be delisted 1 December 2026)				
VITAMIN B COMPLEX				
* Tab, strong, BPC	14.30	500	✓	Bplex
Vitamin C				
ASCORBIC ACID				
a) No more than 100 mg per dose				
b) Only on a prescription				
* Tab 100 mg	16.00	500	✓	Cvite
Vitamin D				
ALFACALCIDOL				
* Cap 0.25 mcg	26.32	100	✓	One-Alpha
* Cap 1 mcg	87.98	100	✓	One-Alpha
* Oral drops 2 mcg per ml	60.68	20 ml OP	✓	One-Alpha
CALCITRIOL				
* Cap 0.25 mcg	6.31	100	✓	Calcitriol Devatis
	7.89		✓	Calcitriol XL ^{\$29}
			✓	Calcitriol-AFT
* Cap 0.5 mcg	10.94	100	✓	Calcitriol Devatis
	13.68		✓	Calcitriol XL ^{\$29}
			✓	Calcitriol-AFT
(Calcitriol XL ^{\$29} Cap 0.25 mcg to be delisted 1 February 2027)				
(Calcitriol-AFT Cap 0.25 mcg to be delisted 1 February 2027)				
(Calcitriol XL ^{\$29} Cap 0.5 mcg to be delisted 1 February 2027)				
(Calcitriol-AFT Cap 0.5 mcg to be delisted 1 February 2027)				
COLECALCIFEROL				
* Cap 1.25 mg (50,000 iu)	3.65	12	✓	Vit.D3
Maximum of 12 cap per three months				
* Oral liq 188 mcg per ml (7,500 iu per ml)	9.00	5 ml OP	✓	Clinicians

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

Multivitamin Preparations

MULTIVITAMIN RENAL – Special Authority see [SA1546 below](#) – Retail pharmacy

* Cap 7.28 30 ✓ Clinicians Renal Vit

►SA1546 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or
- 2 The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73 m² body surface area (BSA).

MULTIVITAMINS – Special Authority see [SA1036 below](#) – Retail pharmacy

* Powder 74.88 200 g OP ✓ Paediatric Seravit

►SA1036 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has inborn errors of metabolism.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where patient has had a previous approval for multivitamins.

VITAMINS

* Tab (BPC cap strength) 21.65 1,000 ✓ Mvite

Mvite to be Principal Supply on 1 December 2026

* Cap (fat soluble vitamins A, D, E, K) – Special Authority see
[SA1720 below](#) – Retail pharmacy 23.40 60 ✓ Vitabdeck

►SA1720 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Patient has cystic fibrosis with pancreatic insufficiency; or
- 2 Patient is an infant or child with liver disease or short gut syndrome; or
- 3 Patient has severe malabsorption syndrome.

Minerals

Calcium

CALCIUM CARBONATE

* Tab 1.25 g (500 mg elemental) 7.48 250 ✓ Calci-Tab 500

* Tab eff 1.25 g (500 mg elemental) – Subsidy by endorsement 260.00 100 ✓ Calcium 500 mg

Hexal ^{S29}

Subsidy by endorsement – Only when prescribed for paediatric patients (< 5 years) where calcium carbonate oral liquid is considered unsuitable.

CALCIUM GLUCONATE

* Inj 10%, 10 ml ampoule 32.00 10 ✓ Max Health -
Hameln ^{S29}

Iodine

POTASSIUM IODATE

* Tab 253 mcg (150 mcg elemental iodine) 6.94 90 ✓ NeuroTabs

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Iron				
FERROUS FUMARATE				
* Tab 200 mg (65.7 mg elemental)	3.49	100	✓	Ferro-tab
FERROUS FUMARATE WITH FOLIC ACID				
* Tab 310 mg (100 mg elemental) with folic acid 350 mcg	5.98	100	✓	Ferro-F-Tabs
FERROUS SULFATE				
* Oral liq 30 mg (6 mg elemental) per 1 ml	10.25	250 ml	✓	Ferro-Liquid
IRON (AS FERRIC CARBOXYMALTOSE) – Special Authority see SA2394 below – Retail pharmacy				
Inj 50 mg per ml, 10 ml vial.....	150.00	1	✓	Ferinject

➔SA2394 Special Authority for Subsidy

Initial application — (Anaemia) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with anaemia; and
- 2 Any of the following:
 - 2.1 Serum ferritin level is 20 mcg/L or less; or
 - 2.2 Both:
 - 2.2.1 Serum ferritin is between 20 and 50 mcg/L; and
 - 2.2.2 C-Reactive Protein (CRP) is at least 5 mg/L; or
 - 2.3 Patient has chronic inflammatory disease with symptoms of anaemia despite normal iron levels; and
- 3 Any of the following:
 - 3.1 Oral iron treatment has proven ineffective; or
 - 3.2 Oral iron treatment has resulted in dose-limiting intolerance; or
 - 3.3 Rapid correction of anaemia is required.

Renewal — (Anaemia) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient continues to have anaemia with a serum ferritin level of 20 mcg/L, or less or between 20 and 50 mcg/L with CRP of at least 5 mg/L, or has chronic inflammatory disease with symptoms of anaemia despite normal iron levels; and
- 2 A trial (or re-trial) with oral iron is clinically inappropriate.

Initial application — (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or medical practitioner on the recommendation of a internal medicine physician, obstetrician, gynaecologist or anaesthetist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has been diagnosed with iron-deficiency anaemia; and
- 2 Any of the following:
 - 2.1 Patient has been compliant with oral iron treatment and treatment has proven ineffective; or
 - 2.2 Treatment with oral iron has resulted in dose-limiting intolerance; or
 - 2.3 Patient has symptomatic heart failure, chronic kidney disease stage 3 or more or active inflammatory bowel disease and a trial of oral iron is unlikely to be effective; or
 - 2.4 Rapid correction of anaemia is required.

Renewal — (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or medical practitioner on the recommendation of a internal medicine physician, obstetrician, gynaecologist or anaesthetist.

Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient continues to have iron-deficiency anaemia; and
- 2 A re-trial with oral iron is clinically inappropriate.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
IRON POLYMALTOSE				
* Inj 50 mg per ml, 2 ml ampoule	41.75	5	✓	Ferrosig
Magnesium				
MAGNESIUM HYDROXIDE				
Suspension 8%.....	33.60	355 ml	✓	Phillips Milk of Magnesia \$29
MAGNESIUM SULPHATE				
* Inj 2 mmol per ml, 5 ml ampoule	26.27	10	✓	Martindale
* Inj 2 mmol per ml, 10 ml ampoule	75.06	10	✓	Inresa \$29
Zinc				
ZINC SULPHATE				
* Cap 220 mg (50 mg elemental)	29.14	100	✓	Rugby \$29
* Cap 137.4 mg (50 mg elemental)	11.00	100	✓	Zincaps
			✓	Zincaps S29 \$29

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Antianaemics

Hypoplastic and Haemolytic

►SA2539 Special Authority for Subsidy

Initial application — (chronic renal failure) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin is less than or equal to 100g/L; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; or
 - 3.3 Patient is on haemodialysis or peritoneal dialysis.

Initial application — (myelodysplasia) from any specialist. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS)*; and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication

Renewal — (myelodysplasia) from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication

EPOETIN ALFA – Special Authority see SA2539 above – Retail pharmacy

Wastage claimable

Inj 1,000 iu in 0.5 ml, syringe.....	250.00	6	✓ Binocrit
Inj 2,000 iu in 1 ml, syringe.....	100.00	6	✓ Binocrit
Inj 3,000 iu in 0.3 ml, syringe.....	150.00	6	✓ Binocrit
Inj 4,000 iu in 0.4 ml, syringe.....	96.50	6	✓ Binocrit
Inj 5,000 iu in 0.5 ml, syringe.....	125.00	6	✓ Binocrit
Inj 6,000 iu in 0.6 ml, syringe.....	145.00	6	✓ Binocrit
Inj 8,000 iu in 0.8 ml, syringe.....	175.00	6	✓ Binocrit
Inj 10,000 iu in 1 ml, syringe.....	197.50	6	✓ Binocrit
Inj 40,000 iu in 1 ml, syringe.....	250.00	1	✓ Binocrit

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Megaloblastic				
FOLIC ACID				
* Tab 0.8 mg	26.60	1,000	✓	Folic Acid multichem
* Tab 5 mg	5.82	100	✓	Folic Acid Viatrix
Oral liq 50 mcg per ml	31.77	25 ml OP	✓	Biomed

Antifibrinolytics, Haemostatics and Local Sclerosants

EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpharm]

For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treators Group in conjunction with the National Haemophilia Management group.

Inj 250 iu vial.....	612.50	1	✓	Alprolix
Inj 500 iu vial.....	1,225.00	1	✓	Alprolix
Inj 1,000 iu vial.....	2,450.00	1	✓	Alprolix
Inj 2,000 iu vial.....	4,900.00	1	✓	Alprolix
Inj 3,000 iu vial.....	7,350.00	1	✓	Alprolix
Inj 4,000 iu vial.....	9,800.00	1	✓	Alprolix

ELTROMBOPAG – Special Authority see SA1743 below – Retail pharmacy

Wastage claimable

Tab 25 mg	1,550.00	28	✓	Revolade
Tab 50 mg	3,100.00	28	✓	Revolade

➔SA1743 Special Authority for Subsidy

Initial application — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialed and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
 - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
 - 3.2 Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or
 - 3.3 Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

Initial application — (idiopathic thrombocytopenic purpura - preparation for splenectomy) only from a haematologist.

Approvals valid for 6 weeks where the patient requires eltrombopag treatment as preparation for splenectomy.

Initial application — (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist.

Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and
- 2 Two immunosuppressive therapies have been trialed and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Either:
 - 3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

and significant mucocutaneous bleeding.

Initial application — (severe aplastic anaemia) only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
- 2 Either:
 - 2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Renewal — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 12 months where the patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre.

Renewal — (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient's significant contraindication to splenectomy remains; and
- 2 The patient has obtained a response from treatment during the initial approval period; and
- 3 Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
- 4 Further treatment with eltrombopag is required to maintain response.

Renewal — (severe aplastic anaemia) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
- 2 Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

EMICIZUMAB – [Xpharm] – Special Authority see [SA2272 below](#)

Inj 30 mg in 1 ml vial.....	3,570.00	1	✓ Hemlibra
Inj 60 mg in 0.4 ml vial.....	7,138.00	1	✓ Hemlibra
Inj 105 mg in 0.7 ml vial.....	12,492.00	1	✓ Hemlibra
Inj 150 mg in 1 ml vial.....	17,846.00	1	✓ Hemlibra

➔ [SA2272](#) Special Authority for Subsidy

Initial application — (Severe Haemophilia A with or without FVIII inhibitors) only from a haematologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has severe congenital haemophilia A with a severe bleeding phenotype (endogenous factor VIII activity less than or equal to 2%); and
- 2 Emicizumab is to be administered at a dose of no greater than 3 mg/kg weekly for 4 weeks followed by the equivalent of 1.5 mg/kg weekly.

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – [Xpharm]

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for > 14 days predicted use. Access to funded treatment for > 14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria.

Inj 1 mg syringe	1,178.30	1	✓ NovoSeven RT
Inj 2 mg syringe	2,356.60	1	✓ NovoSeven RT
Inj 5 mg syringe	5,891.50	1	✓ NovoSeven RT
Inj 8 mg syringe	9,426.40	1	✓ NovoSeven RT

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
FACTOR EIGHT INHIBITOR BYPASSING FRACTION – [Xpharm]			
For patients with haemophilia. Preferred Brand of bypassing agent for > 14 days predicted use. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.			
Inj 500 U	1,315.00	1	✓ FEIBA NF
Inj 1,000 U	2,630.00	1	✓ FEIBA NF
Inj 2,500 U	6,575.00	1	✓ FEIBA NF
MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – [Xpharm]			
For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.			
Inj 250 iu prefilled syringe.....	287.50	1	✓ Xyntha
Inj 500 iu prefilled syringe.....	575.00	1	✓ Xyntha
Inj 1,000 iu prefilled syringe.....	1,150.00	1	✓ Xyntha
Inj 2,000 iu prefilled syringe.....	2,300.00	1	✓ Xyntha
Inj 3,000 iu prefilled syringe.....	3,450.00	1	✓ Xyntha
NONACOG GAMMA, [RECOMBINANT FACTOR IX] – [Xpharm]			
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.			
Inj 1,000 iu vial.....	870.00	1	✓ RIXUBIS
Inj 2,000 iu vial.....	1,740.00	1	✓ RIXUBIS
Inj 3,000 iu vial.....	2,610.00	1	✓ RIXUBIS
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – [Xpharm]			
For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.			
Inj 500 iu vial.....	420.00	1	✓ Advate
Inj 1,000 iu vial.....	840.00	1	✓ Advate
Inj 2,000 iu vial.....	1,680.00	1	✓ Advate
Inj 3,000 iu vial.....	2,520.00	1	✓ Advate
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) – [Xpharm]			
For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.			
Inj 250 iu vial.....	237.50	1	✓ Kogenate FS
Inj 500 iu vial.....	475.00	1	✓ Kogenate FS
Inj 1,000 iu vial.....	950.00	1	✓ Kogenate FS
Inj 2,000 iu vial.....	1,900.00	1	✓ Kogenate FS
Inj 3,000 iu vial.....	2,850.00	1	✓ Kogenate FS
RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] – [Xpharm]			
For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management group.			
Inj 1,000 iu vial.....	1,200.00	1	✓ Adynovate
Inj 2,000 iu vial.....	2,400.00	1	✓ Adynovate
SODIUM TETRADECYL SULPHATE			
* Inj 3% 2 ml.....	28.50	5	
	(144.20)		Fibro-vein

BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TRANEXAMIC ACID				
Tab 500 mg	9.93	60	✓	Mercury Pharma
Inj 100 mg per ml, 10 ml ampoule – Subsidy by endorsement.....	7.99	5	✓	Tranexamic-AFT
a) Up to 5 inj available on a PSO				
b) Only on a PSO				
c) Subsidised only for use within a Primary Response in Medical Emergencies (PRIME) service or for the treatment of post-partum haemorrhage (PPH) and the PSO is endorsed accordingly.				

Vitamin K

PHYTOMENADIONE				
Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO.....	8.00	5	✓	Konaktion MM Paediatric
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO	9.21	5	✓	Konaktion MM

Anti-thrombotic Agents

Antiplatelet Agents

ASPIRIN				
* Tab 100 mg	12.65	990	✓	Ethics Aspirin EC
CLOPIDOGREL				
* Tab 75 mg	5.07	84	✓	Arrow - Clopid
DIPYRIDAMOLE				
Note: No new patients to be initiated on dipyridamole.				
Cap modified-release 200 mg	55.13	60	✓	Dipyridamole - Strides S29
TICAGRELOR – Subsidy by endorsement; can be waived by Special Authority see SA2683 below				
Subsidy by endorsement - May be supplied on BSO to Ambulance Service Providers under the provisions in Section E of the Pharmaceutical Schedule and the BSO is endorsed accordingly.				
* Tab 90 mg	20.35	56	✓	Ticagrelor Sandoz
			✓	Ticagrelor Sandoz S29 S29
	23.85		✓	Ticagrelor Mylan S29

►SA2683 Special Authority for Subsidy

Initial application — (acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Renewal — (subsequent acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (thrombosis prevention neurological stenting) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient has had a neurological stenting procedure* in the last 60 days; or
 - 1.2 Patient is about to have a neurological stenting procedure performed*; and
- 2 Either:
 - 2.1 Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor; or
 - 2.2 Either:
 - 2.2.1 Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event; or
 - 2.2.2 Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent.

Renewal — (thrombosis prevention neurological stenting) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient is continuing to benefit from treatment; and
- 2 Treatment continues to be clinically appropriate.

Initial application — (Percutaneous coronary intervention with stent deployment) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic**.

Renewal — (Percutaneous coronary intervention with stent deployment) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic**.

Initial application — (Stent thrombosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Initial application — (acute minor stroke or high-risk transient ischemic attack (TIA)*) from any relevant practitioner.

Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with a minor stroke (NIHSS† score 3 or less), high-risk TIA (ABCD2 score 4 or more) or Crescendo TIA; and
- 2 Either:
 - 2.1 Patient is expected to be a poor metaboliser of clopidogrel, with documented clinical rationale; or
 - 2.2 Patient is allergic to clopidogrel**; and
- 3 Ticagrelor to be prescribed for a maximum of 21 days following minor stroke or TIA.

Renewal — (subsequent minor stroke or TIA, or Crescendo TIA) from any relevant practitioner. Approvals valid for 1 month where patient has been diagnosed with a minor stroke (NIHSS score 3 or less) or high-risk transient ischemic attack (ABCD2 score 4 or more) or Crescendo TIA.

Notes: indications marked with * are unapproved indications.

Note:** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Note:NIHSS† National Institutes of Health Stroke Scale.

Fibrinolytic Agents

TENECTEPLASE – Subsidy by endorsement

- Up to 1 inj available on a PSO
 - Only on a PSO
 - Only for use within a Primary Response in Medical Emergencies (PRIME) service and the PSO is endorsed accordingly.
- Inj 50 mg per vial with diluent.....2,390.00 1 ✓ **Metalyse**

Heparin and Antagonist Preparations

ENOXAPARIN SODIUM – Subsidy by endorsement; can be waived by Special Authority see [SA2628](#) below

Subsidy by Endorsement - enoxaparin 100 mg syringe available on PSO for use within a Primary Response in Medical Emergencies (PRIME) service and the PSO is endorsed accordingly.

Inj 20 mg in 0.2 ml syringe.....	21.90	10	✓ Clexane
Inj 40 mg in 0.4 ml syringe.....	29.74	10	✓ Clexane
Inj 60 mg in 0.6 ml syringe.....	42.47	10	✓ Clexane
Inj 80 mg in 0.8 ml syringe.....	56.62	10	✓ Clexane
Inj 100 mg in 1 ml syringe – Up to 2 inj available on a PSO.....	70.91	10	✓ Clexane
Inj 120 mg in 0.8 ml syringe.....	88.11	10	✓ Clexane Forte
Inj 150 mg in 1 ml syringe.....	100.70	10	✓ Clexane Forte

► [SA2628](#) Special Authority for Subsidy

Initial application — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- Low molecular weight heparin treatment is required during a patients pregnancy; or
- For the treatment of venous thromboembolism where the patient has a malignancy; or
- For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner.

Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
- For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- To be used in association with cardioversion of atrial fibrillation.

Initial application — (Short-term use during treatment of COVID-19 with nirmatrelvir with ritonavir) from any relevant practitioner. Approvals valid for 2 weeks for applications meeting the following criteria:

All of the following:

- Patient is receiving an anticoagulation treatment that has drug/drug interactions with ritonavir that increases risk of bleeding; and
- Patient meets the Access Criteria for COVID-19 antivirals published on the Pharmac website*; and
- Other antiviral treatments for COVID-19 have been considered and are not clinically suitable options.

Renewal — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy; or
- 3 For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

Inj 1,000 iu per ml, 5 ml ampoule	164.40	50	✓ Pfizer
Inj 10 iu per ml, 5 ml ampoule (flushing solution)	19.38	10	✓ Wockhardt ^{S29}
Inj 5,000 iu per ml, 1 ml	70.33	5	✓ Hospira
Inj 5,000 iu per ml, 5 ml ampoule	406.15	50	✓ Pfizer
Inj 25,000 iu per ml, 0.2 ml	25.78	5	✓ Hospira

HEPARINISED SALINE

Inj 10 iu per ml, 5 ml	96.91	50	✓ Pfizer
------------------------------	-------	----	----------

Oral Anticoagulants

DABIGATRAN

Cap 75 mg – No more than 2 cap per day	27.99	60	✓ Pradaxa
Cap 110 mg	27.99	60	✓ Pradaxa
Cap 150 mg	27.99	60	✓ Pradaxa

RIVAROXABAN

Tab 10 mg – No more than 1 tab per day	15.60	30	✓ Xarelto
Tab 15 mg – Up to 14 tab available on a PSO	14.56	28	✓ Xarelto
Tab 20 mg	14.56	28	✓ Xarelto

WARFARIN SODIUM

Note: Marevan and Coumadin are not interchangeable.

* Tab 1 mg	3.46	50	✓ Coumadin
	7.50	100	✓ Marevan
* Tab 2 mg	4.31	50	✓ Coumadin
* Tab 3 mg	12.00	100	✓ Marevan
* Tab 5 mg	5.93	50	✓ Coumadin
	13.50	100	✓ Marevan

Blood Colony-stimulating Factors

FILGRASTIM – Special Authority see [SA2613 below](#) – Retail pharmacy

Inj 300 mcg per 0.5 ml prefilled syringe	86.60	10	✓ Nivestim
Inj 480 mcg per 0.5 ml prefilled syringe	133.72	10	✓ Nivestim

►SA2613 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%); or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 4 Treatment of severe chronic neutropenia ($ANC < 0.5 \times 10^9/L$); or
- 5 Treatment of drug-induced prolonged neutropenia ($ANC < 0.5 \times 10^9/L$).

Note: *Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

PEGFILGRASTIM – Special Authority see [SA2614 below](#) – Retail pharmacy

Inj 6 mg per 0.6 ml syringe	69.50	1	✓ Ziextenzo
-----------------------------------	-------	---	--------------------

➔SA2614 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where used for prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 5%*).

Note: *Febrile neutropenia risk greater than or equal to 5% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Fluids and Electrolytes

Intravenous Administration

GLUCOSE [DEXTROSE]

* Inj 5%, 100 ml bag – Subsidy by endorsement	97.00	50	✓ Fresenius Kabi
a) Up to 50 inj available on a PSO			
b) Only on a PSO			
c) Subsidised only for use within a Primary Response in Medical Emergencies (PRIME) service and the PSO is endorsed accordingly.			
* Inj 10%, 500 ml bag – Subsidy by endorsement	126.00	18	✓ Baxter Glucose 10%
a) Up to 18 inj available on a PSO			
b) Only on a PSO			
c) Subsidised only for use within a Primary Response in Medical Emergencies (PRIME) service and the PSO is endorsed accordingly.			
* Inj 50%, 10 ml ampoule – Up to 5 inj available on a PSO	37.25	5	✓ Biomed
* Inj 50%, 90 ml bottle – Up to 5 inj available on a PSO	19.20	1	✓ Biomed

POTASSIUM CHLORIDE

* Inj 75 mg per ml, 10 ml	65.00	50	✓ Juno ✓ LumaCina ^{S29} ✓ Pfizer ^{S29}
---------------------------------	-------	----	---

SODIUM BICARBONATE

Inj 8.4%, 50 ml	24.70	1	✓ Biomed
a) Up to 5 inj available on a PSO			
b) Not in combination			
Inj 8.4%, 100 ml	25.31	1	✓ Biomed
a) Up to 5 inj available on a PSO			
b) Not in combination			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SODIUM CHLORIDE				
Not funded for use as a nasal drop. Not funded for nebuliser use except when used in conjunction with an antibiotic intended for nebuliser use.				
Inj 23.4% (4 mmol/ml), 20 ml ampoule	40.15	5	✓	Biomed
For Sodium chloride oral liquid formulation refer Standard Formulae, page 287				
Inj 0.9%, 5 ml ampoule – Up to 5 inj available on a PSO	4.12	20	✓	Fresenius Kabi
Inj 0.9%, 10 ml ampoule – Up to 5 inj available on a PSO	7.50	50	✓	Fresenius Kabi
Inj 0.9%, 20 ml ampoule	5.20	20	✓	Fresenius Kabi
Inj 0.9%, 1,000 ml bag – Up to 2 bag available on a PSO	1.58	1	✓	Baxter
Only if prescribed on a prescription for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use. (500 ml and 1,000 ml packs)				
Inj 0.9%, 500 ml bag – Up to 4 bag available on a PSO	1.53	1	✓	Baxter
Only if prescribed on a prescription for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use. (500 ml and 1,000 ml packs)				
TOTAL PARENTERAL NUTRITION (TPN)				
Infusion	CBS	1 OP	✓	TPN
WATER				
1) On a prescription or Practitioner's Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or				
2) On a bulk supply order; or				
3) When used in the extemporaneous compounding of eye drops; or				
4) When used for the dilution of sodium chloride soln 7% for cystic fibrosis patients only.				
Inj 10 ml ampoule – Up to 5 inj available on a PSO	9.50	50	✓	Multichem
Multichem to be Principal Supply on 1 November 2026				
Inj 20 ml ampoule – Up to 5 inj available on a PSO	5.00	20	✓	Fresenius Kabi
	8.40		✓	Multichem
<i>(Fresenius Kabi Inj 20 ml ampoule to be delisted 1 February 2027)</i>				
Oral Administration				
CALCIUM POLYSTYRENE SULPHONATE				
Powder	169.85	300 g OP	✓	Calcium Resonium
			✓	Roma \$29
COMPOUND ELECTROLYTES				
Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A in accordance with the Integrated Community Pharmacy Services Agreement (ICPSA) – Extended Pharmacy Services.				
Powder for oral soln – Up to 5 sach available on a PSO	9.50	50	✓	Electral
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]				
Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A in accordance with the Integrated Community Pharmacy Services Agreement (ICPSA) – Extended Pharmacy Services.				
Soln with electrolytes (2 x 500 ml)	8.45	1 OP	✓	Pedialyte
PHOSPHORUS				
Tab eff 500 mg (16 mmol)	82.50	100	✓	Phosphate Phebra
POTASSIUM CHLORIDE				
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)	5.26 (17.10)	60		Chlorovescent
* Tab long-acting 600 mg (8 mmol)	16.15	200	✓	Span-K
SODIUM BICARBONATE				
Cap 840 mg	8.52	100	✓	Sodibic

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

SODIUM POLYSTYRENE SULPHONATE

Powder	84.65	454 g OP	✓ Resonium-A
--------------	-------	----------	---------------------

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
Alpha-Adrenoceptor Blockers			
Alpha Adrenoceptor Blockers			
DOXAZOSIN			
* Tab 2 mg	17.35	500	✓ Doxazosin Clinect
* Tab 4 mg	20.94	500	✓ Doxazosin Clinect
PHENOXYBENZAMINE HYDROCHLORIDE			
* Cap 10 mg	65.00	30	✓ BNM ^{\$29}
PRAZOSIN			
* Tab 1 mg	5.53	100	✓ Arrotex-Prazosin ^{\$29}
	9.98		✓ Minipress ^{\$29}
* Tab 2 mg	7.00	100	✓ Arrotex-Prazosin ^{\$29}
	13.29		✓ Minipress ^{\$29}
* Tab 5 mg	11.70	100	✓ Arrotex-Prazosin ^{\$29}
	22.00		✓ Minipress ^{\$29}
* Cap 1 mg	15.40	100	✓ Prazosin Mylan ^{\$29}
* Cap 2 mg	15.58	100	✓ Prazosin Mylan ^{\$29}
* Cap 5 mg	23.32	100	✓ Prazosin Mylan ^{\$29}
Agents Affecting the Renin-Angiotensin System			
ACE Inhibitors			
CAPTOPRIL			
* Oral liq 5 mg per ml	98.90	100 ml OP	✓ DP-Captopril
Oral liquid restricted to children under 12 years of age.			
ENALAPRIL MALEATE			
* Tab 5 mg	1.40	90	✓ Ipca-Enalapril
* Tab 10 mg	1.58	90	✓ Ipca-Enalapril
* Tab 20 mg	2.00	90	✓ Ipca-Enalapril
LISINOPRIL			
* Tab 5 mg	12.00	90	✓ Teva Lisinopril
* Tab 10 mg	12.00	90	✓ Teva Lisinopril
* Tab 20 mg	16.00	90	✓ Teva Lisinopril
PERINDOPRIL			
* Tab 2 mg	1.79	30	✓ Coversyl
* Tab 2.5 mg	1.79	30	✓ Coversyl 2.5
* Tab 4 mg	2.44	30	✓ Coversyl
* Tab 5 mg	2.44	30	✓ Coversyl 5
* Tab 8 mg	3.94	30	✓ Coversyl
* Tab 10 mg	3.94	30	✓ Coversyl 10
QUINAPRIL			
* Tab 5 mg	10.24	90	✓ Arrow-Quinapril 5
* Tab 10 mg	12.51	90	✓ Arrow-Quinapril 10
* Tab 20 mg	14.83	90	✓ Arrow-Quinapril 20

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
RAMIPRIL				
* Tab 1.25 mg	5.75	30	✓	Ramipril Viatris ^{\$29}
* Tab 2.5 mg	5.50	30	✓	Ramipril Viatris ^{\$29}
* Tab 5 mg	5.25	28	✓	Ramipril Mylan Generics ^{\$29}
* Tab 10 mg	5.48	28	✓	Ramipril Mylan Generics ^{\$29}
* Cap 1.25 mg	17.25	90	✓	Tryzan
* Cap 2.5 mg	16.50	90	✓	Tryzan
* Cap 5 mg	16.88	90	✓	Tryzan
* Cap 10 mg	17.63	90	✓	Tryzan

Angiotensin II Antagonists

CANDESARTAN CILEXETIL				
Tab 4 mg	2.68	90	✓	Candesartan Viatris
			✓	Candesartan Viatris Sante
	2.92	98	✓	Candestar
	3.53	30	✓	Candesartan Mylan ^{\$29}
Tab 8 mg	1.91	30	✓	Candesartan Sandoz S29 AU ^{\$29}
	2.67	90	✓	Apo- Candesartan ^{\$29}
Tab 16 mg	2.84	30	✓	Candesartan Viatris
			✓	Candestar
	4.22	90	✓	Apo- Candesartan ^{\$29}
Tab 32 mg	3.95	30	✓	Candesartan Viatris
			✓	Candestar
	5.24	90	✓	Apo- Candesartan ^{\$29}
			✓	Candesartan Viatris
			✓	Candestar

LOSARTAN POTASSIUM				
* Tab 12.5 mg	2.00	84	✓	Losartan Actavis
* Tab 25 mg	2.29	84	✓	Losartan Actavis
* Tab 50 mg	2.86	84	✓	Losartan Actavis
* Tab 100 mg	4.57	84	✓	Losartan Actavis

Angiotensin II Antagonists with Diuretics

CANDESARTAN CILEXETIL WITH HYDROCHLOROTHIAZIDE				
* Tab 16 mg with hydrochlorothiazide 12.5 mg	4.10	30	✓	APO-Candesartan HCTZ 16/12.5
* Tab 32 mg with hydrochlorothiazide 12.5 mg	5.25	30	✓	APO-Candesartan HCTZ 32/12.5

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE				
* Tab 50 mg with hydrochlorothiazide 12.5 mg.....	7.25	90	✓	Losartan & Hydrochlorothiazide (Ipc)

Angiotensin II Antagonists with Neprilysin Inhibitors

SACUBITRIL WITH VALSARTAN – Special Authority see [SA2302 below](#) – Retail pharmacy

Tab 24.3 mg with valsartan 25.7 mg	190.00	56	✓	Entresto 24/26
Tab 48.6 mg with valsartan 51.4 mg	190.00	56	✓	Entresto 49/51
Tab 97.2 mg with valsartan 102.8 mg	190.00	56	✓	Entresto 97/103

► [SA2302](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has heart failure; and
- 2 Any of the following:
 - 2.1 Patient is in NYHA/WHO functional class II; or
 - 2.2 Patient is in NYHA/WHO functional class III; or
 - 2.3 Patient is in NYHA/WHO functional class IV; and
- 3 Either:
 - 3.1 Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; or
 - 3.2 An ECHO is not reasonably practical, and in the opinion of the treating practitioner the patient would benefit from treatment; and
- 4 Patient is receiving concomitant optimal standard chronic heart failure treatments.

Antiarrhythmics

For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaesthetics, Local, [page 126](#)

AMIODARONE HYDROCHLORIDE

▲ Tab 100 mg	4.95	30	✓	Aratac
▲ Tab 200 mg	5.86	30	✓	Aratac
Inj 50 mg per ml, 3 ml ampoule – Up to 10 inj available on a PSO	17.96	10	✓	Max Health

ATROPINE SULPHATE

* Inj 600 mcg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	16.10	10	✓	Hikma ^{S29}
			✓	Martindale

DIGOXIN

* Tab 62.5 mcg – Up to 30 tab available on a PSO	8.58	240	✓	Lanoxin PG
* Tab 250 mcg – Up to 30 tab available on a PSO	18.75	240	✓	Lanoxin
* Oral liq 50 mcg per ml	16.60	60 ml	✓	Lanoxin
			✓	Lanoxin S29 ^{S29}

DISOPYRAMIDE PHOSPHATE

▲ Cap 100 mg	55.90	84	✓	Rythmodan - Cheplafarm ^{S29}
			✓	Rythmodan Neon ^{S29}

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
FLECAINIDE ACETATE				
▲ Tab 50 mg	19.95	60	✓	Flecainide BNM
▲ Cap long-acting 100 mg	35.78	90	✓	Flecainide Controlled Release Teva
▲ Cap long-acting 200 mg	54.28	90	✓	Flecainide Controlled Release Teva
Inj 10 mg per ml, 15 ml ampoule	102.79 108.16	5	✓	Almarytm ^{S29}
			✓	Tambocor
			✓	Tambocor German ^{S29}
MEXILETINE HYDROCHLORIDE				
▲ Cap 150 mg	162.00	100	✓	Teva ^{S29}
▲ Cap 250 mg	202.00	100	✓	Teva ^{S29}
PROPAFENONE HYDROCHLORIDE				
▲ Tab 150 mg	40.90	50	✓	Rytmonorm

Antihypotensives

MIDODRINE – Special Authority see [SA1474 below](#) – Retail pharmacy

Tab 2.5 mg	36.68	100	✓	Midodrine Medsurge
Tab 5 mg	58.88	100	✓	Midodrine Medsurge

»SA1474 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years where patient has disabling orthostatic hypotension not due to drugs.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Beta-Adrenoceptor Blockers

Beta Adrenoceptor Blockers

ATENOLOL				
* Tab 50 mg	11.00	500	✓	Viatris
* Tab 100 mg	18.50	500	✓	Atenolol Viatris
* Oral liq 25 mg per 5 ml	49.85	300 ml OP	✓	Atenolol AFT
Restricted to children under 12 years of age.				
BISOPROLOL FUMARATE				
* Tab 2.5 mg	1.36	90	✓	Ipca-Bisoprolol
* Tab 5 mg	2.00	90	✓	Ipca-Bisoprolol
* Tab 10 mg	2.95	90	✓	Ipca-Bisoprolol
CARVEDILOL				
* Tab 6.25 mg	1.97	60	✓	Carvedilol Sandoz
* Tab 12.5 mg	2.03	60	✓	Carvedilol Sandoz
* Tab 25 mg	2.46	60	✓	Carvedilol Sandoz

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LABETALOL				
* Tab 100 mg	14.50	100	✓	Trandate
	49.54		✓	Biocon ^{\$29}
* Tab 200 mg	27.00	100	✓	Trandate
	42.07		✓	Presolol ^{\$29}
* Inj 5 mg per ml, 20 ml ampoule	59.06 (88.60)	5		Trandate
METOPROLOL SUCCINATE				
* Tab long-acting 23.75 mg.....	4.20	90	✓	Myloc CR
* Tab long-acting 47.5 mg.....	3.65	90	✓	Myloc CR
* Tab long-acting 95 mg.....	5.24	90	✓	Myloc CR
* Tab long-acting 190 mg.....	9.76	90	✓	Myloc CR
METOPROLOL TARTRATE				
* Tab 50 mg	5.66	100	✓	IPCA-Metoprolol
* Tab 100 mg	7.55	60	✓	IPCA-Metoprolol
* Tab long-acting 200 mg.....	23.40	28	✓	Slow-Lopresor
* Inj 1 mg per ml, 5 ml vial.....	26.50	5	✓	Metoprolol IV Mylan
			✓	Metoprolol IV Viatris
NADOLOL				
* Tab 40 mg	19.19	100	✓	Nadolol BNM
* Tab 80 mg	30.39	100	✓	Nadolol BNM
PROPRANOLOL				
* Tab 10 mg	7.04	100	✓	Drofate
* Tab 40 mg	8.75	100	✓	IPCA-Propranolol
Cap long-acting 160 mg	18.17 35.15	100	✓	Cardinol LA
			✓	Propranolol LA
				Lupin ^{\$29}
* Oral liq 4 mg per ml – Special Authority see SA1327 below – Retail pharmacy.....	CBS	500 ml	✓	Hikma- Propranolol ^{\$29}
			✓	Roxane- Propranolol ^{\$29}
<i>(Cardinol LA Cap long-acting 160 mg to be delisted 1 January 2027)</i>				
►SA1327 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:				
Either:				
1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or				
2 For the treatment of a child under 12 years with cardiac arrhythmias or congenital cardiac abnormalities.				
Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:				
Either:				
1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or				
2 For the treatment of a child under 12 years with cardiac arrhythmias or congenital cardiac abnormalities.				
SOTALOL				
* Tab 80 mg	40.00	500	✓	Mylan
* Tab 160 mg	20.00	100	✓	Mylan

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

Calcium Channel Blockers

Dihydropyridine Calcium Channel Blockers

AMLODIPINE

* Tab 2.5 mg	2.11	90	✓ Vasorex
* Tab 5 mg	1.54	90	✓ Vasorex
* Tab 10 mg	1.74	90	✓ Vasorex

FELODIPINE

* Tab long-acting 2.5 mg	2.18	30	✓ Plendil ER
* Tab long-acting 5 mg	6.57	90	✓ Felo 5 ER
* Tab long-acting 10 mg	6.95	90	✓ Felo 10 ER

NIFEDIPINE

* Tab long-acting 10 mg – Subsidy by endorsement	19.42	56	✓ Tensipine MR10 ^{\$29}
--	-------	----	----------------------------------

Subsidised for patients who were taking nifedipine tab long-acting 10 mg prior to 1 July 2023 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of nifedipine tab long-acting 10 mg.

* Tab long-acting 20 mg	9.92	56	✓ Valni Retard ^{\$29}
	17.72	100	✓ Nyefax Retard
* Tab long-acting 30 mg	4.78	14	✓ Mylan Italy (24 hr release) ^{\$29}
	34.10	100	✓ Mylan (24 hr release) ^{\$29}
* Tab long-acting 60 mg	52.81	100	✓ Mylan (24 hr release) ^{\$29}

Other Calcium Channel Blockers

DILTIAZEM HYDROCHLORIDE

* Cap long-acting 120 mg	65.35	500	✓ Diltiazem CD Clinect
* Cap long-acting 180 mg	7.00	30	✓ Cardizem CD
* Cap long-acting 240 mg	9.30	30	✓ Cardizem CD

PERHEXILINE MALEATE

* Tab 100 mg	62.90	100	✓ Pexsig
--------------------	-------	-----	----------

VERAPAMIL HYDROCHLORIDE

* Tab 40 mg	7.01	100	✓ Isoptin
* Tab 80 mg	11.74	100	✓ Isoptin
* Tab long-acting 120 mg	36.02	100	✓ Isoptin Retard ^{\$29}
			✓ Isoptin SR
* Tab long-acting 240 mg	15.12	30	✓ Isoptin SR
* Inj 2.5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	25.00	5	✓ Isoptin

Centrally-Acting Agents

CLONIDINE

* Patch 2.5 mg, 100 mcg per day – Only on a prescription	17.64	4	✓ Mylan
* Patch 5 mg, 200 mcg per day – Only on a prescription	20.26	4	✓ Mylan
* Patch 7.5 mg, 300 mcg per day – Only on a prescription	26.49	4	✓ Mylan

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CLONIDINE HYDROCHLORIDE				
* Tab 25 mcg.....	29.74	112	✓	Clonidine Teva
* Tab 150 mcg.....	40.41	100	✓	Catapres
* Inj 150 mcg per ml, 1 ml ampoule	14.10	5	✓	Catapres
METHYLDOPA				
* Tab 250 mg	15.10	100	✓	Methyldopa Viatriis

Diuretics

Loop Diuretics

BUMETANIDE				
* Tab 1 mg	16.36	100	✓	Burinex
* Inj 500 mcg per ml, 4 ml vial.....	7.95	5	✓	Burinex
FUROSEMIDE [FRUSEMIDE]				
* Tab 40 mg – Up to 30 tab available on a PSO	12.80	1,000	✓	IPCA-Frusemide
* Tab 500 mg	25.00	50	✓	Urex Forte
* Oral liq 10 mg per ml	11.20	30 ml OP	✓	Lasix
* Inj 10 mg per ml, 25 ml ampoule	60.65	6	✓	Lasix
* Inj 10 mg per ml, 2 ml ampoule – Up to 10 inj available on a PSO	3.97	10	✓	Furosemide-AFT

Potassium Sparing Diuretics

AMILORIDE HYDROCHLORIDE				
Tab 5 mg	81.07	100	✓	Padagis S29
	171.41	28	✓	Wockhardt S29
Oral liq 1 mg per ml	35.40	25 ml OP	✓	Biomed
EPLERENONE – Special Authority see SA1728 below – Retail pharmacy				
Tab 25 mg	15.84	30	✓	Inspira
Tab 50 mg	25.00	30	✓	Inspira

►SA1728 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has heart failure with ejection fraction less than 40%; and
- 2 Either:
 - 2.1 Patient is intolerant to optimal dosing of spironolactone; or
 - 2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone.

SPIRONOLACTONE				
* Tab 25 mg	4.20	100	✓	Spiractin
* Tab 100 mg	11.40	100	✓	Spiractin
Oral liq 5 mg per ml	35.70	25 ml OP	✓	Biomed

Potassium Sparing Combination Diuretics

AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE				
* Tab 5 mg with furosemide 40 mg	8.63	28	✓	Frumil
AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE				
* Tab 5 mg with hydrochlorothiazide 50 mg	5.00	50	✓	Moduretic

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Thiazide and Related Diuretics				
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]				
* Tab 2.5 mg – Up to 150 tab available on a PSO	51.50	500	✓	Arrow-Bendrofluazide
May be supplied on a PSO for reasons other than emergency.				
* Tab 5 mg	61.00	500	✓	Arrow-Bendrofluazide
CHLOROTHIAZIDE				
Oral liq 50 mg per ml	30.67	25 ml OP	✓	Biomed
CHLORTALIDONE [CHLORTHALIDONE]				
* Tab 25 mg	6.95	50	✓	Hygroton
INDAPAMIDE				
* Tab 2.5 mg	20.85	90	✓	Dapa-Tabs
METOLAZONE				
Tab 5 mg	CBS	50	✓	Zaroxolyn ^{S29}

Vasopressin receptor antagonists

TOLVAPTAN – Special Authority see SA2166 below – Retail pharmacy				
Tab 15 mg	873.50	28 OP	✓	Jinarc
Tab 30 mg	873.50	28 OP	✓	Jinarc
Tab 45 mg + 15 mg	1,747.00	56 OP	✓	Jinarc
Tab 60 mg + 30 mg	1,747.00	56 OP	✓	Jinarc
Tab 90 mg + 30 mg	1,747.00	56 OP	✓	Jinarc

► [SA2166](#) Special Authority for Subsidy

Initial application — (autosomal dominant polycystic kidney disease) only from a renal physician or any relevant practitioner on the recommendation of a renal physician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of autosomal dominant polycystic kidney disease; and
- 2 Patient has an estimated glomerular filtration rate (eGFR) of greater than or equal to 25 mL/min/1.73 m² at treatment initiation; and
- 3 Either:
 - 3.1 Patient's disease is rapidly progressing, with a decline in eGFR of greater than or equal to 5 mL/min/1.73 m² within one-year; or
 - 3.2 Patient's disease is rapidly progressing, with an average decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m² per year over a five-year period.

Renewal — (autosomal dominant polycystic kidney disease) only from a renal physician or any relevant practitioner on the recommendation of a renal physician. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has not developed end-stage renal disease, defined as an eGFR of less than 15 mL/min/1.73 m²; and
- 2 Patient has not undergone a kidney transplant.

Subsidy
(Manufacturer's Price)
\$ Per Fully
Subsidised
✓ Brand or
Generic
Manufacturer

Lipid-Modifying Agents

Fibrates

BEZAFIBRATE

* Tab 200 mg	22.65	90	✓ Bezalip
* Tab long-acting 400 mg.....	21.54	30	✓ Bezalip Retard

Other Lipid-Modifying Agents

ACIPIMOX

* Cap 250 mg	38.19	30	✓ Olbetam
--------------------	-------	----	------------------

Resins

COLESTYRAMINE

Powder for oral suspension 4 g sachet	61.50	50	✓ Colestyramine - Mylan ^{\$29}
			✓ Quantalan sugar free ^{\$29}
			✓ Questran Light (Neon) ^{\$29}

HMG CoA Reductase Inhibitors (Statins)

ATORVASTATIN

* Tab 10 mg	0.31	30	✓ Lorstat
	5.16	500	✓ Lorstat
* Tab 20 mg	8.12	500	✓ Lorstat
* Tab 40 mg	13.79	500	✓ Lorstat
* Tab 80 mg	1.52	30	✓ Lorstat
	25.39	500	✓ Lorstat

PRAVASTATIN

* Tab 20 mg	7.16	100	✓ Clinect
* Tab 40 mg	12.25	100	✓ Clinect

ROSUVASTATIN – Special Authority see [SA2093 on the next page](#) – Retail pharmacy

* Tab 5 mg	1.29	30	✓ Rosuvastatin Mylan
	4.21		✓ Rosuvastatin Viatris
			✓ Rosuvastatin - Sandoz
* Tab 10 mg	1.69	30	✓ Rosuvastatin Mylan
	4.21		✓ Rosuvastatin Viatris
			✓ Rosuvastatin - Sandoz
* Tab 20 mg	2.71	30	✓ Rosuvastatin Mylan
	4.21		✓ Rosuvastatin Viatris
			✓ Rosuvastatin - Sandoz
* Tab 40 mg	4.55	30	✓ Rosuvastatin - Sandoz
			✓ Rosuvastatin Mylan
			✓ Rosuvastatin Viatris

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

►SA2093 Special Authority for Subsidy

Initial application — (cardiovascular disease risk) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient is considered to be at risk of cardiovascular disease; and
 - 1.2 Patient is Māori or any Pacific ethnicity; or
- 2 Both:
 - 2.1 Patient has a calculated risk of cardiovascular disease of at least 15% over 5 years; and
 - 2.2 LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initial application — (familial hypercholesterolemia) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has familial hypercholesterolemia (defined as a Dutch Lipid Criteria score greater than or equal to 6); and
- 2 LDL cholesterol has not reduced to less than 1.8 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initial application — (established cardiovascular disease) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 Patient has proven coronary artery disease (CAD); or
 - 1.2 Patient has proven peripheral artery disease (PAD); or
 - 1.3 Patient has experienced an ischaemic stroke; and
- 2 LDL cholesterol has not reduced to less than 1.4 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

Initial application — (recurrent major cardiovascular events) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has experienced a recurrent major cardiovascular event (defined as myocardial infarction, ischaemic stroke, coronary revascularisation, hospitalisation for unstable angina) in the last 2 years; and
- 2 LDL cholesterol has not reduced to less than 1.0 mmol/litre with treatment with the maximum tolerated dose of atorvastatin and/or simvastatin.

SIMVASTATIN

* Tab 10 mg	1.67	90	✓ Simvastatin Viatris
	1.68		✓ Simvastatin Mylan
Simvastatin Viatris to be Principal Supply on 1 December 2026			
* Tab 20 mg	2.35	90	✓ Simvastatin Viatris
Simvastatin Viatris to be Principal Supply on 1 December 2026			
* Tab 40 mg	3.85	90	✓ Simvastatin Viatris
Simvastatin Viatris to be Principal Supply on 1 December 2026			
* Tab 80 mg	8.75	90	✓ Simvastatin Viatris
Simvastatin Viatris to be Principal Supply on 1 December 2026			

Selective Cholesterol Absorption Inhibitors

EZETIMIBE

* Tab 10 mg	1.44	30	✓ Ezetimibe Sandoz
Ezetimibe Sandoz to be Principal Supply on 1 December 2026			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
EZETIMIBE WITH SIMVASTATIN				
Tab 10 mg with simvastatin 10 mg.....	11.86	30	✓	Zimybe
Tab 10 mg with simvastatin 20 mg.....	12.55	30	✓	Zimybe
Tab 10 mg with simvastatin 40 mg.....	11.55	30	✓	Vytorin ^{\$29}
			✓	Zimybe
Tab 10 mg with simvastatin 80 mg.....	14.27	30	✓	Vytorin ^{\$29}
			✓	Zimybe

Nitrates

GLYCERYL TRINITRATE

* Oral pump spray, 400 mcg per dose – Up to 250 dose available on a PSO.....	7.48	250 dose OP	✓	Nitrolingual Pump Spray
* Patch 25 mg, 5 mg per day	15.73	30	✓	Nitroderm TTS
* Patch 50 mg, 10 mg per day	18.62	30	✓	Nitroderm TTS

ISOSORBIDE MONONITRATE

* Tab 20 mg	22.49	100	✓	Ismo 20
* Tab long-acting 40 mg.....	9.80	30	✓	Ismo 40 Retard
* Tab long-acting 60 mg.....	16.25	90	✓	Duride

Sympathomimetics

ADRENALINE

Inj 1 in 1,000, 1 ml ampoule – Up to 5 inj available on a PSO	4.98	5	✓	Aspen Adrenaline
	17.78		✓	DBL Adrenaline
1) Note: adrenaline inj 1 in 1,000, 1 ml ampoule can be supplied on BSO to a Vaccinator (other than a Pharmacist) under the provisions in Part I of Section A				
2) Note: Direct Provision by a pharmacist of Inj 1 in 1,000, 1 ml ampoule permitted under the provisions in Part I of Section A.				
Inj 1 in 10,000, 10 ml ampoule – Up to 5 inj available on a PSO	36.18	5	✓	DBL Adrenaline
	49.00	10	✓	Aspen Adrenaline

Vasodilators

HYDRALAZINE HYDROCHLORIDE

* Tab 25 mg – Special Authority see SA1321 below – Retail pharmacy.....	CBS	1	✓	Hydralazine
		56	✓	Onelink ^{\$29}
		84	✓	AMDIPHARM ^{\$29}
		100	✓	Camber ^{\$29}
* Inj 20 mg ampoule.....	25.90	5	✓	Apresoline
			✓	Hydrapres ^{\$29}
* Inj 20 mg per ml, 1 ml vial.....	283.00	25	✓	Eugia ^{\$29}

►SA1321 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Either:

- 1 For the treatment of refractory hypertension; or
- 2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.

MINOXIDIL

▲ Tab 10 mg	47.04	60	✓	Minoxidil Roma ^{\$29}
	78.40	100	✓	Loniten

NICORANDIL

▲ Tab 10 mg	27.81	60	✓	Max Health
▲ Tab 20 mg	35.12	60	✓	Max Health

PAPAVERINE HYDROCHLORIDE

* Inj 12 mg per ml, 10 ml ampoule	257.12	5	✓	Hospira
-----------------------------------	--------	---	---	---------

PENTOXIFYLLINE [OXPENTIFYLLINE]

Tab 400 mg	44.37	50	✓	Trental 400
------------	-------	----	---	-------------

Endothelin Receptor Antagonists

AMBRISENTAN – Special Authority see [SA2556 below](#) – Retail pharmacy

Tab 5 mg	200.00	30	✓	Ambrisentan Viatris
Tab 10 mg	200.00	30	✓	Ambrisentan Viatris

► [SA2556](#) Special Authority for Subsidy

Initial application — (PAH monotherapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool^{**}; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and

5 Both:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 5.1 Ambrisentan is to be used as PAH monotherapy; and
- 5.2 Any of the following:
 - 5.2.1 Patient has experienced intolerable side effects with both sildenafil and bosentan; or
 - 5.2.2 Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); or
 - 5.2.3 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease.

Initial application — (PAH dual therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and

5 Both:

- 5.1 Ambrisentan is to be used as PAH dual therapy; and
- 5.2 Any of the following:
 - 5.2.1 Patient has tried bosentan (either as PAH monotherapy, or PAH dual therapy with sildenafil) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; or
 - 5.2.2 Patient has experienced intolerable side effects on bosentan; or
 - 5.2.3 Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); or
 - 5.2.4 Patient is presenting in NYHA/WHO functional class III or IV, and would benefit from initial dual therapy in the opinion of the treating clinician and has an absolute or relative contraindication to bosentan (eg. due to current liver disease or use of a combined oral contraceptive).

Initial application — (PAH triple therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Ambrisentan is to be used as PAH triple therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Both:
 - 5.2.2.1 Patient is presenting in NYHA/WHO functional class IV; and
 - 5.2.2.2 Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**; and
 - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Renewal only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years where the patient is continuing to derive benefit from ambrisentan treatment according to a validated PAH risk stratification tool**.

Note: ** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults.

Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

BOSENTAN – Special Authority see [SA2557 below](#) – Retail pharmacy

Tab 62.5 mg	100.00	60	✓ Bosentan Dr Reddy's
Tab 125 mg	100.00	60	✓ Bosentan Dr Reddy's

►SA2557 Special Authority for Subsidy

Initial application — (PAH monotherapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Bosentan is to be used as PAH monotherapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient has experienced intolerable side effects on sildenafil; or
 - 5.2.2 Patient has an absolute contraindication to sildenafil; or
 - 5.2.3 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease.

Initial application — (PAH dual therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Bosentan is to be used as part of PAH dual therapy; and
- 6 Either:
 - 6.1 Patient has tried a PAH monotherapy (sildenafil) for at least three months and has experienced an inadequate therapeutic response to treatment according to a validated risk stratification tool**; or
 - 6.2 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would likely benefit from initial dual therapy.

Initial application — (PAH triple therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Bosentan is to be used as part of PAH triple therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; and
 - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Renewal only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years where patient is continuing to derive benefit from

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

bosentan treatment according to a validated PAH risk stratification tool**.

Note: ** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults.

Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – Special Authority see [SA2558 below](#) – Retail pharmacy

Tab 25 mg	0.72	4	✓ Vedafil
Tab 50 mg	1.45	4	✓ Sildenafil (Amarox) ^{S29}
Tab 100 mg	11.22	12	✓ Vedafil ✓ Vedafil

►SA2558 Special Authority for Subsidy

Initial application — (Raynaud's Phenomenon*) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has Raynaud's Phenomenon*; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated).

Initial application — (Pulmonary arterial hypertension*) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH is confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) of greater than 20 mmHg; and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) that is less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance (PVR) of at least 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH is non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**;
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

Initial application — (erectile dysfunction due to spinal cord injury) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has a documented history of traumatic or non-traumatic spinal cord injury; and
- 2 Patient has erectile dysfunction secondary to spinal cord injury requiring pharmacological treatment.

Renewal — (erectile dysfunction due to spinal cord injury) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Notes: Indications marked with * are Unapproved Indications.

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

Prostacyclin Analogues

EPOPROSTENOL – Special Authority see [SA2559 below](#) – Retail pharmacy

Inj 500 mcg vial.....	36.61	1	✓ Velettri
Inj 1.5 mg vial	73.21	1	✓ Velettri

► [SA2559](#) Special Authority for Subsidy

Initial application — (PAH dual therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
- 5 All of the following:
 - 5.1 Epoprostenol is to be used as part of PAH dual therapy with either sildenafil or an endothelin receptor antagonist; and
 - 5.2 Patient is presenting in NYHA/WHO functional class IV; and
 - 5.3 Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (PAH triple therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
 - 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
 - 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV; and
 - 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
- 5 Both:
- 5.1 Epoprostenol is to be used as PAH triple therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool; and
 - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Renewal only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years where patient is continuing to derive benefit from iloprost treatment according to a validated PAH risk stratification tool**.

Note: ** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

ILOPROST – Special Authority see [SA2560 below](#) – Retail pharmacy

Nebuliser soln 10 mcg per ml, 2 ml	166.53	30	✓ Veblis
			✓ Veblis S29 S29

►SA2560 Special Authority for Subsidy

Initial application — (PAH monotherapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

continued...

continued...

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
- 5 Both:
 - 5.1 Iloprost is to be used as PAH monotherapy; and
 - 5.2 Either:
 - 5.2.1 Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan); or
 - 5.2.2 Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists.

Initial application — (PAH dual therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
- 5 All of the following:
 - 5.1 Iloprost is to be used as PAH dual therapy with either sildenafil or an endothelin receptor antagonist; and
 - 5.2 Either:
 - 5.2.1 Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil; or
 - 5.2.2 Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist; and
 - 5.3 Either:
 - 5.3.1 Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**; or
 - 5.3.2 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy.

Initial application — (PAH triple therapy) only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
- 5 Both:
 - 5.1 Iloprost is to be used as PAH triple therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or
 - 5.2.3 Both:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; and
- 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Renewal only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years where patient is continuing to derive benefit from iloprost treatment according to a validated PAH risk stratification tool**.

Note: ** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Antiacne Preparations

For systemic antibacterials, refer to INFECTIONS, Antibacterials, [page 96](#)

ADAPALENE – Only on a prescription

Maximum of 30 g per three months

Gel 0.1%.....	22.89	30 g OP	✓ Differin
---------------	-------	---------	------------

ISOTRETINOIN – Special Authority see [SA2584 below](#) – Retail pharmacy

Cap 5 mg.....	11.26	60	✓ Oratane
---------------	-------	----	-----------

Cap 10 mg.....	18.75	120	✓ Oratane
----------------	-------	-----	-----------

Cap 20 mg.....	26.73	120	✓ Oratane
----------------	-------	-----	-----------

►SA2584 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Applicant is a vocationally registered dermatologist, paediatrician, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 3 Any of the following:
 - 3.1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and that they must not become pregnant during treatment and for a period of one month after the completion of treatment; or
 - 3.2 Patient is not of child bearing potential; or
 - 3.3 Patient is a child and it is considered not appropriate to exclude pregnancy or start contraceptives or undertake pregnancy-related isotretinoin counselling.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and that they must not become pregnant during treatment and for a period of one month after the completion of treatment; or
- 2 Patient is not of child bearing potential; or
- 3 Patient is a child and it is considered not appropriate to exclude pregnancy or start contraceptives or undertake pregnancy-related isotretinoin counselling.

Initial application — (Neuroblastoma) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient has neuroblastoma; and
- 2 Any of the following:
 - 2.1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and that they must not become pregnant during treatment and for a period of one month after the completion of treatment; or
 - 2.2 Patient is not of child bearing potential; or
 - 2.3 Patient is a child and it is considered not appropriate to exclude pregnancy or start contraceptives or undertake pregnancy-related isotretinoin counselling.

Renewal — (Neuroblastoma) from any relevant practitioner. Approvals valid for 12 months for applications meeting the

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

following criteria:

Both:

1 The patient has neuroblastoma; and

2 Any of the following:

2.1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and that they must not become pregnant during treatment and for a period of one month after the completion of treatment; or

2.2 Patient is not of child bearing potential; or

2.3 Patient is a child and it is considered not appropriate to exclude pregnancy or start contraceptives or undertake pregnancy-related isotretinoin counselling.

TRETINOIN

Crm 0.5 mg per g..... 16.82 50 g OP ✓ **ReTrieve**
Maximum of 50 g per three months

Antibacterials Topical

For systemic antibacterials, refer to INFECTIONS, Antibacterials, [page 96](#)

HYDROGEN PEROXIDE

* Crm 1%..... 4.89 15 g OP ✓ **Crystaderm**

MUPIROCIN

Oint 2%..... 6.60 15 g OP Bactroban
(13.00)

a) Only on a prescription

b) Not in combination

SODIUM FUSIDATE [FUSIDIC ACID]

Crm 2%..... 1.69 5 g OP ✓ **Foban**

a) Maximum of 5 g per prescription

b) Only on a prescription

c) Not in combination

Oint 2%..... 1.69 5 g OP ✓ **Foban**

a) Maximum of 5 g per prescription

b) Only on a prescription

c) Not in combination

SULFADIAZINE SILVER

Crm 1%..... 10.80 50 g OP ✓ **Flamazine**

a) Up to 250 g available on a PSO

b) Not in combination

Antifungals Topical

For systemic antifungals, refer to INFECTIONS, Antifungals, [page 103](#)

AMOROLFINE

a) Only on a prescription

b) Not in combination

Nail soln 5%..... 21.87 5 ml OP ✓ **MycoNail**

114

Antipruritic Preparations

CALAMINE

- a) Only on a prescription
b) Not in combination

Crēm, aqueous, BP	3.45	100 g	✓ <u>healthE Calamine</u> Aqueous
-------------------------	------	-------	--------------------------------------

CROTAMITON

- a) Only on a prescription
b) Not in combination

Crm 10%.....	3.49	20 g OP	✓ Itch-Soothe
--------------	------	---------	---------------

MENTHOL – Only in combination

- 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain
- 2) With or without other dermatological galenicals.

Crystals.....	12.60	25 g	✓ MidWest
	36.80	100 g	✓ MidWest

*Three months or six months, as applicable, dispensed at one time

Corticosteroids Topical

For systemic corticosteroids, refer to CORTICOSTEROIDS AND RELATED AGENTS, page 86

Corticosteroids - Plain

BETAMETHASONE DIPROPIONATE

Crm 0.05%.....	2.96	15 g OP	✓ Diprosone
	36.00	50 g OP	✓ Diprosone
Oint 0.05%.....	2.96	15 g OP	✓ Diprosone
	36.00	50 g OP	✓ Diprosone
Oint 0.05% in propylene glycol base	4.33	30 g OP	✓ Diprosone OV

BETAMETHASONE VALERATE

* Crm 0.1%.....	5.85	50 g OP	✓ Beta Cream
* Oint 0.1%.....	7.90	50 g OP	✓ Beta Ointment
* Lotn 0.1%.....	30.00	50 ml OP	✓ Betnovate

CLOBETASOL PROPIONATE

* Crm 0.05%.....	3.75	30 g OP	✓ Dermol
* Oint 0.05%.....	3.68	30 g OP	✓ Dermol

CLOBETASONE BUTYRATE

Crm 0.05%.....	5.38	30 g OP	
	(10.00)		Eumovate

HYDROCORTISONE

* Crm 1% – Only on a prescription.....	1.75	30 g OP	✓ Ethics
	20.40	500 g	✓ Noumed
* Powder – Only in combination.....	49.95	25 g	✓ ABM
Up to 5% in a dermatological base (not proprietary Topical Corticosteroid – Plain) with or without other dermatological galenicals			

HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN

Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – Only on a prescription	14.75	250 ml	✓ DP Lotn HC
--	-------	--------	---------------------

HYDROCORTISONE BUTYRATE

Lipocream 0.1%.....	4.85	100 g OP	✓ Locoid Lipocream
Oint 0.1%.....	10.28	100 g OP	✓ Locoid
Milky emul 0.1%	12.33	100 ml OP	✓ Locoid Crelo

METHYLPREDNISOLONE ACEPONATE

Crm 0.1%.....	4.95	15 g OP	✓ Advantan
Advantan to be Principal Supply on 1 December 2026			
Oint 0.1%.....	4.95	15 g OP	✓ Advantan
Advantan to be Principal Supply on 1 December 2026			

MOMETASONE FUROATE

Crm 0.1%.....	2.25	15 g OP	✓ Elocon Alcohol Free
	3.50	50 g OP	✓ Elocon Alcohol Free
Oint 0.1%.....	2.25	15 g OP	✓ Elocon
	3.50	50 g OP	✓ Elocon
Lotn 0.1%	4.99	30 ml OP	✓ Elocon

TRIAMCINOLONE ACETONIDE

Crm 0.02%.....	6.49	100 g OP	✓ Aristocort
Oint 0.02%.....	6.54	100 g OP	✓ Aristocort

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Corticosteroids - Combination				
BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSIDIC ACID] Crm 0.1% with sodium fusidate (fusidic acid) 2%.....	3.49 (10.45)	15 g OP		Fucicort
a) Maximum of 15 g per prescription b) Only on a prescription				
HYDROCORTISONE WITH MICONAZOLE – Only on a prescription * Crm 1% with miconazole nitrate 2%.....	2.85	15 g OP	✓	<u>Micreme H</u>
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – Only on a prescription Oint 1% with natamycin 1% and neomycin sulphate 0.5%.....	4.34	15 g OP	✓	<u>Pimafucort</u>
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g – Only on a prescription	3.49 (9.28)	15 g OP		Viaderm KC
Barrier Creams and Emollients				
Barrier Creams				
DIMETHICONE * Crm 5% pump bottle.....	4.14	460 g OP	✓	<u>Hydralock</u>
* Crm 10% pump bottle.....	4.52	460 g OP	✓	<u>healthE</u> Dimethicone 10%
ZINC AND CASTOR OIL * Oint.....	4.25	500 g	✓	<u>Evara</u>
Emollients				
AQUEOUS CREAM * Crm.....	1.65	500 g	✓	<u>Evara</u>
CETOMACROGOL * Crm BP	2.29	500 g	✓	<u>Cetomacrogol-AFT</u>
CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%.....	1.92 3.25	460 g OP 920 g OP	✓ ✓	<u>Evara</u> <u>Evara</u>
EMULSIFYING OINTMENT * Oint BP	2.95	500 g	✓	<u>Evara Emulsifying</u> <u>Ointment</u>
Evara Emulsifying Ointment to be Principal Supply on 1 December 2026				
OIL IN WATER EMULSION * Crm.....	2.10	500 g	✓	<u>Fatty Emulsion</u> <u>Cream (Evara)</u>
PARAFFIN Oint liquid paraffin 50% with white soft paraffin 50%.....	4.45	500 g OP	✓	<u>EVARA Paraffin</u> <u>Ointment 50/50</u>
UREA * Crm 10%.....	1.37	100 g OP	✓	<u>healthE Urea Cream</u>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
WOOL FAT WITH MINERAL OIL – Only on a prescription				
* Lotn hydrous 3% with mineral oil.....	5.60 (14.96) (20.53)	1,000 ml		DP Lotion Alpha-Keri Lotion
	1.40 (5.87)	250 ml OP		DP Lotion
	5.60 (23.91)	1,000 ml		BK Lotion
	1.40 (7.73)	250 ml OP		BK Lotion

Other Dermatological Bases

PARAFFIN

White soft – Only in combination.....	4.70	450 g	✓	EVARA White Soft Paraffin
	18.00	2,500 g	✓	EVARA White Soft Paraffin

- a) Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain.
b) EVARA White Soft Paraffin to be Principal Supply on 1 December 2026

Minor Skin Infections

POVIDONE IODINE

Oint 10%.....	7.40	65 g OP	✓	Betadine
a) Maximum of 130 g per prescription				
b) Only on a prescription				
Antiseptic Solution 10%.....	4.99	100 ml	✓	Riodine
Antiseptic soln 10%.....	3.83	15 ml	✓	Riodine
	6.99	500 ml	✓	Riodine
Skin preparation, povidone iodine 10% with 30% alcohol.....	1.63 (3.48)	100 ml		Betadine Skin Prep

Parasiticial Preparations

DIMETHICONE

Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A in accordance with the Integrated Community Pharmacy Services Agreement (ICPSA) – Extended Pharmacy Services.

* Lotn 4%	4.60	200 ml OP	✓	healthE Dimethicone 4% Lotion
-----------------	------	-----------	---	--

IVERMECTIN – Special Authority see [SA2511 on the next page](#) – Retail pharmacy

Tab 3 mg – Up to 100 tab available on a PSO.....	17.20	4	✓	Stromectol
--	-------	---	---	-------------------

- 1) PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and a valid Special Authority for patient of that institution.
- 2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution.
- 3) For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or prisons.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

»SA2511 Special Authority for Subsidy

Initial application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:
Either:

- 1 The person has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
- 2 Both:
 - 2.1 The person has a confirmed diagnosis of scabies or is a close contact of a scabies case; and
 - 2.2 Either:
 - 2.2.1 The person is unable to complete topical therapy; or
 - 2.2.2 Previous treatment with topical therapy has been tried and not cleared the infestation.

Initial application — (Other parasitic infections) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:
Any of the following:

- 1 filariasis; or
- 2 cutaneous larva migrans (creeping eruption); or
- 3 strongyloidiasis; or
- 4 The individual has a travel or residence history that requires presumptive parasite treatment.

Renewal — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:
Either:

- 1 The person has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
- 2 Both:
 - 2.1 The person has a confirmed diagnosis of scabies or is a close contact of a scabies case; and
 - 2.2 Either:
 - 2.2.1 The person is unable to complete topical therapy; or
 - 2.2.2 Previous treatment with topical therapy has been tried and not cleared the infestation.

Renewal — (Other parasitic infections) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:
Any of the following:

- 1 filariasis; or
- 2 cutaneous larva migrans (creeping eruption); or
- 3 strongyloidiasis.

PERMETHRIN

Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A in accordance with the Integrated Community Pharmacy Services Agreement (ICPSA) – Extended Pharmacy Services.
Lotn 5% 4.28 30 ml OP ✓ A-Scabies

Psoriasis and Eczema Preparations

ACITRETIN – Special Authority see SA2024 below – Retail pharmacy			
Cap 10 mg.....	30.13	60	✓ Novatretin
Cap 25 mg.....	65.98	60	✓ Novatretin

»SA2024 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:
All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2 Applicant has an up to date knowledge of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:
 - 3.1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and that they must not become pregnant during treatment and for a period of three years after the completion of treatment; or
 - 3.2 Patient is not of child bearing potential.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Either:
- 1 Patient is of child bearing potential and the possibility of pregnancy has been excluded prior to commencement of treatment and patient has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and that they must not become pregnant during treatment and for a period of three years after the completion of treatment; or
 - 2 Patient is not of child bearing potential.

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Foam spray 500 mcg with calcipotriol 50 mcg per g	59.95	60 g OP	✓ Enstilar
Gel 500 mcg with calcipotriol 50 mcg per g	40.92	60 g OP	✓ Daivobet
Oint 500 mcg with calcipotriol 50 mcg per g	14.31	30 g OP	✓ Daivobet

CALCIPOTRIOL

Oint 50 mcg per g	40.00	120 g OP	✓ Daivonex
-------------------------	-------	----------	-------------------

COAL TAR

Soln BP – Only in combination	46.00	200 ml	✓ Midwest
1) Up to 10% only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain			
2) With or without other dermatological galenicals.			

COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULPHUR

Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and allantoin crm 2.5%	6.59 (8.00) 3.43 (4.35)	75 g OP 30 g OP	 Egopsoryl TA Egopsoryl TA
---	----------------------------------	------------------------	--------------------------------------

COAL TAR WITH SALICYLIC ACID AND SULPHUR

Soln 12% with salicylic acid 2% and sulphur 4% oint	7.95	40 g OP	✓ Coco-Scalp
---	------	---------	---------------------

PIMECROLIMUS – Special Authority see SA1970 below – Retail pharmacy

- a) Maximum of 15 g per prescription
 - b) Note: a maximum of 15 g per prescription and no more than one prescription per 12 weeks.
- | | | | |
|----------------|-------|---------|-----------------|
| Cream 1% | 33.00 | 15 g OP | ✓ Elidel |
|----------------|-------|---------|-----------------|

►SA1970 Special Authority for Subsidy

Initial application only from a dermatologist, paediatrician, ophthalmologist or any relevant practitioner on the recommendation of a dermatologist, paediatrician or ophthalmologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has atopic dermatitis on the eyelid; and
- 2 Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy, documented allergy to topical corticosteroids, cataracts, glaucoma, or raised intraocular pressure.

PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCIN – Only on a prescription

* Soln 2.3% with trolamine laurilsulfate and fluorescein sodium	8.99	500 ml	✓ Pinetarsol
---	------	--------	---------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

SALICYLIC ACID

Powder – Only in combination.....	29.00	250 g	✓	Midwest
1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain or collodion flexible				
2) With or without other dermatological galenicals.				

SULPHUR

Precipitated – Only in combination.....	6.35	100 g	✓	Midwest
1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain				
2) With or without other dermatological galenicals.				

(Midwest Precipitated to be delisted 1 October 2028)

TACROLIMUS

Oint 0.1% – Special Authority see SA2074 below – Retail pharmacy.....	33.00	30 g OP	✓	Zematop
a) Maximum of 30 g per prescription				
b) Note: a maximum of 30 g per prescription and no more than one prescription per 12 weeks.				

➤ **SA2074** **Special Authority for Subsidy**

Initial application only from a dermatologist, paediatrician or any relevant practitioner on the recommendation of a dermatologist, paediatrician, . Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has atopic dermatitis on the face; and
- 2 Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy or documented allergy to topical corticosteroids.

Scalp Preparations

BETAMETHASONE VALERATE

* Scalp app 0.1%	12.95	100 ml OP	✓	Beta Scalp
------------------------	-------	-----------	---	-------------------

CLOBETASOL PROPIONATE

* Scalp app 0.05%	6.90	30 ml OP	✓	Dermol
-------------------------	------	----------	---	---------------

HYDROCORTISONE BUTYRATE

Scalp lotn 0.1%.....	6.57	100 ml OP	✓	Locoid
----------------------	------	-----------	---	---------------

KETOCONAZOLE

Shampoo 2%.....	4.09	100 ml OP	✓	Sebizole
a) Maximum of 100 ml per prescription				
b) Only on a prescription				

Sunscreens

SUNSCREENS, PROPRIETARY – Subsidy by endorsement

Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly.

Lotn.....	6.50	200 g OP	✓	Marine Blue Lotion SPF 50+
-----------	------	----------	---	---------------------------------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

Wart Preparations

For salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, [page 75](#)

PODOPHYLLOTOXIN

Soln 0.5%	33.60	3.5 ml OP	✓ Condyline
			✓ Condyline S29 S29

- a) Maximum of 3.5 ml per prescription
- b) Only on a prescription

Other Skin Preparations

Antineoplastics

FLUOROURACIL SODIUM

Crm 5%	5.56	20 g OP	✓ Efudix
--------------	------	---------	-----------------

IMIQUIMOD

Crm 5%, 250 mg sachet	21.72	24	✓ Padagis
			✓ Perrigo
	34.50	12	✓ Aldara S29

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Contraceptives - Non-hormonal				
Condoms				
CONDOMS				
* 49 mm – Up to 144 dev available on a PSO	14.25	144	✓	Moments
* 53 mm.....	1.15	10	✓	Moments
	14.25	144	✓	Moments
a) Maximum of 60 dev per prescription				
b) Up to 60 dev available on a PSO				
* 53 mm, 0.05 mm thickness.....	1.15	10	✓	Moments
	14.25	144	✓	Moments
a) Up to 60 dev available on a PSO				
b) Maximum of 60 dev per prescription				
* 53 mm, chocolate, brown	1.15	10	✓	Moments
	14.25	144	✓	Moments
a) Up to 60 dev available on a PSO				
b) Maximum of 60 dev per prescription				
* 53 mm, strawberry, red.....	1.15	10	✓	Moments
	14.25	144	✓	Moments
a) Up to 60 dev available on a PSO				
b) Maximum of 60 dev per prescription				
* 56 mm.....	1.15	10	✓	Moments
	14.50	144	✓	Moments
a) Maximum of 60 dev per prescription				
b) Up to 60 dev available on a PSO				
* 56 mm, 0.05 mm thickness.....	2.00	12	✓	Gold Knight
	24.10	144	✓	Gold Knight
a) Up to 60 dev available on a PSO				
b) Maximum of 60 dev per prescription				
* 56 mm, 0.05mm thickness (bulk pack)	20.17	144	✓	Gold Knight
a) Maximum of 60 dev per prescription				
b) Up to 60 dev available on a PSO				
* 56 mm, 0.08 mm thickness.....	1.15	10	✓	Moments
	14.25	144	✓	Moments
a) Up to 60 dev available on a PSO				
b) Maximum of 60 dev per prescription				
* 56 mm, 0.08 mm thickness, red	1.15	10	✓	Moments
	14.25	144	✓	Moments
a) Up to 60 dev available on a PSO				
b) Maximum of 60 dev per prescription				
* 56 mm, chocolate	1.79	12	✓	Gold Knight
	21.45	144	✓	Gold Knight
a) Up to 60 dev available on a PSO				
b) Maximum of 60 dev per prescription				
* 56 mm, strawberry.....	1.79	12	✓	Gold Knight
	21.45	144	✓	Gold Knight
a) Up to 60 dev available on a PSO				
b) Maximum of 60 dev per prescription				
* 60 mm.....	1.82	12	✓	Gold Knight XL
	21.89	144	✓	Gold Knight XL
a) Maximum of 60 dev per prescription				
b) Up to 60 dev available on a PSO				
* 60 mm (bulk pack).....	17.38	144	✓	Gold Knight XL

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

- a) Maximum of 60 dev per prescription
b) Up to 60 dev available on a PSO

Contraceptive Devices

INTRA-UTERINE DEVICE

a) Up to 40 dev available on a PSO			
b) Only on a PSO			
* IUD 29.1 mm length x 23.2 mm width	29.80	1	✓ Choice 380 7med Nsha Silver/ copper Short
* IUD 33.6 mm length x 29.9 mm width	26.80	1	✓ TCu 380 Plus Normal
* IUD 35.5 mm length x 19.6 mm width	33.00	1	✓ Cu 375 Standard

Contraceptives - Hormonal

Combined Oral Contraceptives

ETHINYLOESTRADIOL WITH DESOGESTREL

* Tab 20 mcg with desogestrel 150 mcg and 7 inert tab – Up to 84 tab available on a PSO	10.00	84	✓ Mercilon 28
--	-------	----	---------------

ETHINYLOESTRADIOL WITH LEVONORGESTREL

* Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – Up to 84 tab available on a PSO	2.00	84	✓ Lo-Oralcon 20 ED
* Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – Up to 84 tab available on a PSO	2.30	84	✓ Oralcon 30 ED

ETHINYLOESTRADIOL WITH NORETHISTERONE

Tab 35 mcg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO	14.09	84	✓ Brevinor 1/28
Tab 35 mcg with norethisterone 500 mcg and 7 inert tab – Up to 112 tab available on a PSO	23.75	84	✓ Norimin
	29.32	112	✓ Norimin

Progestogen-only Contraceptives

DESOGESTREL

* Tab 75 mcg – Up to 84 tab available on a PSO	24.50	84	✓ Cerazette
--	-------	----	-------------

LEVONORGESTREL

* Tab 30 mcg – Up to 112 tab available on a PSO	22.00	112	✓ Microlut
* Intra-uterine device 52 mg – Up to 25 dev available on a PSO	269.50	1	✓ Mirena
* Intra-uterine device 13.5 mg – Up to 10 dev available on a PSO	215.60	1	✓ Jaydess
* Subdermal implant (2 x 75 mg rods) – Up to 40 impl available on a PSO	106.92	2 OP	✓ Jadelle

MEDROXYPROGESTERONE ACETATE

Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a PSO	10.56	1	✓ Depo-Provera
---	-------	---	----------------

NORETHISTERONE

Tab 350 mcg – Up to 84 tab available on a PSO	12.25	84	✓ Noriday
	13.23		✓ Noriday 28

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Emergency Contraceptives

LEVONORGESTREL

* Tab 1.5 mg	1.31	1	✓	<u>Levonorgestrel -1 (Lupin)</u>
a) Maximum of 2 tab per prescription				
b) Up to 5 tab available on a PSO				
c) Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.				

Antiandrogen Oral Contraceptives

CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL

* Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs – Up to 168 tab available on a PSO	5.08	168	✓	<u>Ginet</u>
---	------	-----	---	--------------

Gynaecological Anti-infectives

ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC ACID

Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator	8.43 (24.87)	100 g OP		Aci-Jel
---	-----------------	----------	--	---------

CLOTRIMAZOLE

* Vaginal crm 1% with applicators.....	4.20	35 g OP	✓	<u>Clomazol</u>
* Vaginal crm 2% with applicators.....	4.60	20 g OP	✓	<u>Clomazol</u>

MICONAZOLE NITRATE

* Vaginal crm 2% with applicator	6.89	40 g OP	✓	<u>Micreme</u>
--	------	---------	---	----------------

NYSTATIN

Vaginal crm 100,000 u per 5 g with applicator(s)	5.87	75 g OP	✓	<u>Niostat</u>
--	------	---------	---	----------------

Myometrial and Vaginal Hormone Preparations

ERGOMETRINE MALEATE

Inj 500 mcg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	160.00	5	✓	<u>DBL Ergometrine</u>
--	--------	---	---	------------------------

OESTRIOL

* Crm 1 mg per g with applicator.....	6.95	15 g OP	✓	<u>Ovestin</u>
* Pessaries 500 mcg	7.55	15	✓	<u>Ovestin</u>

OXYTOCIN – Up to 5 inj available on a PSO

Inj 5 iu per ml, 1 ml ampoule	5.98	5	✓	<u>Oxytocin BNM</u>
Inj 10 iu per ml, 1 ml ampoule	7.18	5	✓	<u>Oxytocin BNM</u>

OXYTOCIN WITH ERGOMETRINE MALEATE – Up to 5 inj available on a PSO

Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule	41.47	5	✓	<u>Syntometrine</u>
---	-------	---	---	---------------------

Pregnancy Tests - hCG Urine

BETA-HCG LOW SENSITIVITY URINE TEST KIT – Up to 15 test available on a PSO

Note: For use in abortion services only.

Midstream.....	17.47	1 test OP	✓	<u>CheckTop</u>
----------------	-------	-----------	---	-----------------

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

PREGNANCY TESTS - HCG URINE

- a) Up to 200 test available on a PSO
- b) Only on a PSO

Cassette	16.00	40 test OP	✓ David One Step Cassette Pregnancy Test
----------------	-------	------------	---

Urinary Agents

For urinary tract Infections refer to INFECTIONS, Antibacterials, [page 117](#)

5-Alpha Reductase Inhibitors

FINASTERIDE – Special Authority see [SA0928 below](#) – Retail pharmacy

* Tab 5 mg	5.11	100	✓ Ricit
------------------	------	-----	----------------

➤ [SA0928](#) **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 Either:
 - 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
 - 2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

Alpha-1A Adrenoreceptor Blockers

TAMSULOSIN HYDROCHLORIDE – Special Authority see [SA1032 below](#) – Retail pharmacy

Cap 400 mcg	28.56	100	✓ Aurobindo Tamsulosin S29 ✓ Tamsulosin-Rex
-------------------	-------	-----	--

➤ [SA1032](#) **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

Other Urinary Agents

OXYBUTYNIN

* Tab 5 mg	5.42	100	✓ Alchemy Oxybutynin
------------------	------	-----	-----------------------------

Alchemy Oxybutynin to be Principal Supply on 1 December 2026

POTASSIUM CITRATE

Oral liq 3 mmol per ml – Special Authority see SA1083 on the next page – Retail pharmacy	37.49	200 ml OP	✓ Biomed
--	-------	-----------	-----------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

►SA1083 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Both:

- 1 The patient has recurrent calcium oxalate urolithiasis; and
- 2 The patient has had more than two renal calculi in the two years prior to the application.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

SODIUM CITRO-TARTRATE

* Grans eff 4 g sachets	3.33	28	✓ Ural
-------------------------------	------	----	--------

Ural to be Principal Supply on 1 December 2026

SOLIFENACIN SUCCINATE

Tab 5 mg	1.95	30	✓ <u>Solifenacin succinate Max Health</u>
Tab 10 mg	3.53	30	✓ <u>Solifenacin succinate Max Health</u>

Detection of Substances in Urine

ORTHO-TOLIDINE

* Compound diagnostic sticks	7.50 (8.25)	50 test OP	Hemastix
------------------------------------	----------------	------------	----------

TETRABROMOPHENOL

* Blue diagnostic strips	13.92	100 test OP	✓ Albustix
--------------------------------	-------	-------------	------------

Obstetric Preparations

Antiprogesterones

MIFEPRISTONE

Tab 200 mg – Up to 15 tab available on a PSO	90.02	1	✓ Mifegyne
	270.06	3	✓ Mifegyne

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

Calcium Homeostasis

CALCITONIN

* Inj 100 iu per ml, 1 ml ampoule	121.00	5	✓ Miacalcic ✓ Miacalcic S29 ^{S29}
-----------------------------------	--------	---	---

(Miacalcic S29 ^{S29} Inj 100 iu per ml, 1 ml ampoule to be delisted 1 October 2026)

CINACALCET – Special Authority see SA2170 below – Retail pharmacy

Tab 30 mg – Wastage claimable	25.24	28	✓ Cinacalcet Devatis
Tab 60 mg – Wastage claimable	50.47	28	✓ Cinacalcet Devatis

►SA2170 Special Authority for Subsidy

Initial application — (parathyroid carcinoma or calciphylaxis) only from a nephrologist or endocrinologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- All of the following:
 - The patient has been diagnosed with a parathyroid carcinoma (see Note); and
 - The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
 - The patient is symptomatic; or
- All of the following:
 - The patient has been diagnosed with calciphylaxis (calcific uraemic arteriopathy); and
 - The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L); and
 - The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.

Renewal — (parathyroid carcinoma or calciphylaxis) only from a nephrologist or endocrinologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- The patient's serum calcium level has fallen to < 3mmol/L; and
- The patient has experienced clinically significant symptom improvement.

Note: This does not include parathyroid adenomas unless these have become malignant.

Initial application — (primary hyperparathyroidism) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- Patient has primary hyperparathyroidism; and
- Either:
 - Patient has hypercalcaemia of more than 3 mmol/L with or without symptoms; or
 - Patient has hypercalcaemia of more than 2.85 mmol/L with symptoms; and
- Surgery is not feasible or has failed; and
- Patient has other comorbidities, severe bone pain, or calciphylaxis.

Initial application — (secondary or tertiary hyperparathyroidism) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- Either:
 - Patient has tertiary hyperparathyroidism and markedly elevated parathyroid hormone (PTH) with hypercalcaemia; or
 - Patient has symptomatic secondary hyperparathyroidism and elevated PTH; and
- Patient is on renal replacement therapy; and

continued...

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

3 Any of the following:

- 3.1 Residual parathyroid tissue has not been localised despite repeat unsuccessful parathyroid explorations; or
- 3.2 Parathyroid tissue is surgically inaccessible; or
- 3.3 Parathyroid surgery is not feasible.

Renewal — (secondary or tertiary hyperparathyroidism) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient has had a kidney transplant, and following a treatment free interval of at least 12 weeks a clinically acceptable parathyroid hormone (PTH) level to support ongoing cessation of treatment has not been reached; or
- 2 The patient has not received a kidney transplant and trial of withdrawal of cinacalcet is clinically inappropriate.

ZOLEDRONIC ACID

Inj 4 mg per 5 ml, vial	15.65	1	✓ Zoledronic acid Injection Mylan ^{S29}
			✓ Zoledronic acid Viatris

(Zoledronic acid Injection Mylan ^{S29} Inj 4 mg per 5 ml, vial to be delisted 1 November 2026)

Corticosteroids and Related Agents for Systemic Use

BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE

* Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml	19.20	5	
	(36.96)		Celestone Chronodose

DEXAMETHASONE

* Tab 0.5 mg – Up to 60 tab available on a PSO	1.80	30	✓ Dexamethasone
* Tab 4 mg – Up to 30 tab available on a PSO	3.18	30	✓ Dexamethasone
Oral liq 1 mg per ml	53.86	25 ml OP	✓ Biomed

DEXAMETHASONE PHOSPHATE

Dexamethasone phosphate injection will not be funded for oral use.

* Inj 4 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	6.88	10	✓ Dexamethasone Medsurge
* Inj 4 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	10.98	10	✓ Dexamethasone Medsurge

FLUDROCORTISONE ACETATE

* Tab 100 mcg	8.05	100	✓ Florinef
---------------------	------	-----	-------------------

HYDROCORTISONE

* Tab 5 mg	8.10	100	✓ Douglas
* Tab 20 mg	20.32	100	✓ Douglas
* Inj 100 mg vial	3.96	1	✓ Solu-Cortef
a) Not on a BSO			
b) Up to 5 inj available on a PSO			

METHYLPREDNISOLONE

* Tab 4 mg	112.00	100	✓ Medrol
* Tab 100 mg	223.10	20	✓ Medrol

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
METHYLPREDNISOLONE (AS SODIUM SUCCINATE)				
Inj 40 mg vial	22.30	1	✓	Solu-Medrol-Act-O-Vial
Inj 125 mg vial	34.10	1	✓	Solu-Medrol-Act-O-Vial
Inj 500 mg vial	43.01	1	✓	Solu-Medrol-Act-O-Vial
Inj 1 g vial	52.54	1	✓	Solu-Medrol
METHYLPREDNISOLONE ACETATE				
Inj 40 mg per ml, 1 ml vial.....	47.06	5	✓	Depo-Medrol
PREDNISOLONE				
* Oral liq 5 mg per ml – Up to 30 ml available on a PSO Restricted to children under 12 years of age.	6.00	30 ml OP	✓	Redipred
PREDNISONE				
* Tab 1 mg	18.58	500	✓	Prednisone Clinect
* Tab 2.5 mg	21.04	500	✓	Prednisone Clinect
* Tab 5 mg – Up to 30 tab available on a PSO	19.30	500	✓	Prednisone Clinect
* Tab 20 mg – Up to 30 tab available on a PSO	50.51	500	✓	Prednisone Clinect
TETRACOSACTRIN				
* Inj 250 mcg per ml, 1 ml ampoule	86.25	1	✓	Synacthen
			✓	UK Synacthen
* Inj 1 mg per ml, 1 ml ampoule	690.00	1	✓	Synacthen Depot
			✓	Synacthene Retard \$29
TRIAMCINOLONE ACETONIDE				
Inj 10 mg per ml, 1 ml ampoule	21.42	5	✓	Kenacort-A 10
Kenacort-A 10 to be Principal Supply on 1 December 2026				
Inj 40 mg per ml, 1 ml ampoule	52.63	5	✓	Kenacort-A 40
Kenacort-A 40 to be Principal Supply on 1 December 2026				

Sex Hormones Non Contraceptive

Androgen Agonists and Antagonists

CYPROTERONE ACETATE				
Tab 50 mg	17.05	50	✓	Siterone
Tab 100 mg	31.00	50	✓	Siterone
TESTOSTERONE				
Gel (transdermal) 16.2 mg per g, 88 g	52.00	60 OP	✓	Testogel
TESTOSTERONE CIPIONATE				
Inj 100 mg per ml, 10 ml vial.....	97.75	1	✓	Depo-Testosterone
TESTOSTERONE ESTERS				
Inj 250 mg per ml, 1 ml	12.98	1	✓	Sustanon Ampoules

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TESTOSTERONE UNDECANOATE				
Cap 40 mg – Subsidy by endorsement	40.80	100	✓	Steril-Gene ^{S29}
Subsidy by endorsement – subsidised for patients who were taking testosterone undecanoate cap 40mg prior to 1 November 2021 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of testosterone undecanoate cap 40 mg in the preceding 12 months.				
Inj 250 mg per ml, 4 ml vial.....	27.50	1	✓	Gonadron
	86.00		✓	Reandron 1000
Gonadron to be Principal Supply on 1 December 2026 (Reandron 1000 Inj 250 mg per ml, 4 ml vial to be delisted 1 December 2026)				

Hormone Replacement Therapy - Systemic

Oestrogens

OESTRADIOL				
* Tab 1 mg	4.12	28 OP		
	(11.10)			Estrofem
* Tab 2 mg	4.12	28 OP		
	(11.10)			Estrofem
* Gel (transdermal) 0.06% (750 mcg/actuation).....	14.25	80 g OP	✓	Estrogel
* Patch 25 mcg per 24 hours – Only on a prescription	8.89	8	✓	Estradiol TDP Mylan
Patch 25 mcg per day.....	16.23	8	✓	Estradot
a) No more than 2 patch per week				
b) Only on a prescription				
* Patch 50 mcg per 24 hours – Only on a prescription	9.26	8	✓	Estradiol TDP Mylan
Patch 50 mcg per day.....	15.79	8	✓	Estradot
a) No more than 2 patch per week				
b) Only on a prescription				
* Patch 75 mcg per 24 hours – Only on a prescription	10.33	8	✓	Estradiol TDP Mylan
Patch 75 mcg per day.....	16.53	8	✓	Estradot
a) No more than 2 patch per week				
b) Only on a prescription				
* Patch 100 mcg per 24 hours – Only on a prescription	10.59	8	✓	Estradiol TDP Mylan
Patch 100 mcg per day.....	16.18	8	✓	Estradot
a) No more than 2 patch per week				
b) Only on a prescription				
OESTRADIOL VALERATE				
* Tab 1 mg	12.36	84	✓	Progynova
* Tab 2 mg	8.24	56	✓	Progynova
	12.36	84	✓	Progynova
OESTROGENS				
* Conjugated, equine tab 300 mcg.....	3.01	28		
	(19.25)			Premarin
* Conjugated, equine tab 625 mcg.....	4.12	28		
	(19.25)			Premarin

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Progestogens				
MEDROXYPROGESTERONE ACETATE				
* Tab 2.5 mg	7.54	30	✓	Provera
	8.75	56	✓	Provera
* Tab 5 mg	9.80	56	✓	Provera
	23.15	100	✓	Provera
* Tab 10 mg	11.10	30	✓	Provera
Progestogen and Oestrogen Combined Preparations				
OESTRADIOL WITH NORETHISTERONE				
* Tab 1 mg with 0.5 mg norethisterone acetate	5.40	28 OP		
	(18.10)			Kliovance
* Tab 2 mg with 1 mg norethisterone acetate	5.40	28 OP		
	(18.10)			Kliogest
* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6).....	5.40	28 OP		
	(18.10)			Trisequens
Other Oestrogen Preparations				
OESTRIOL				
* Tab 2 mg	7.70	30	✓	Ovestin
Other Progestogen Preparations				
MEDROXYPROGESTERONE ACETATE				
Tab 100 mg	153.60	100	✓	Provera HD
NORETHISTERONE				
* Tab 5 mg – Up to 30 tab available on a PSO	5.49	30	✓	Primolut N
PROGESTERONE				
* Cap 100 mg	14.85	30	✓	Utrogestan
Thyroid and Antithyroid Agents				
CARBIMAZOLE				
* Tab 5 mg	7.56	100	✓	Neo-Mercazole
LEVOTHYROXINE				
* Tab 25 mcg.....	5.55	90	✓	Synthroid
* Tab 50 mcg.....	1.71	28	✓	Mercury Pharma
	5.79	90	✓	Synthroid
	64.28	1,000	✓	Eltroxin
* Tablet 50 mcg.....	12.86	200	✓	Eltroxin
* Tab 100 mcg.....	1.78	28	✓	Mercury Pharma
	6.01	90	✓	Synthroid
	66.78	1,000	✓	Eltroxin
* Tablet 100 mcg.....	13.36	200	✓	Eltroxin
PROPYLTHIOURACIL – Special Authority see SA1199 on the next page – Retail pharmacy				
Tab 50 mg	35.00	100	✓	PTU ^{S29}

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

►SA1199 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

Trophic Hormones

Growth Hormones

SOMATROPIN (OMNITROPE) – Special Authority see [SA2032 below](#) – Retail pharmacy

* Inj 5 mg cartridge.....	80.21	1	✓ Omnitrope
* Inj 10 mg cartridge.....	80.21	1	✓ Omnitrope AU \$29
* Inj 15 mg cartridge.....	139.50	1	✓ Omnitrope
			✓ Omnitrope

►SA2032 Special Authority for Subsidy

Initial application — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist.

Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or
- 2 All of the following:
 - 2.1 Height velocity < 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
 - 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
 - 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
 - 2.5 Appropriate imaging of the pituitary gland has been obtained.

Renewal — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

Renewal — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
- 3 A current bone age is 14 years or under; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
- 3 A current bone age is < 14 years or under (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Renewal — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initial application — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:
 - 6.1 The patient has a GFR less than or equal to 30 ml/min/1.73m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l)) × 40 = corrected GFR (ml/min/1.73m²) in a child who may or may not be receiving dialysis; or

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 6.2 The patient has received a renal transplant and has received < 5mg/ m²/day of prednisone or equivalent for at least 6 months..

Renewal — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initial application — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient is aged six months or older; and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 The patient is aged two years or older; and
 - 5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
 - 5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Renewal — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initial application — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

months for applications meeting the following criteria:

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Renewal — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 All of the following:
 - 1.1 The patient has been treated with somatropin for < 12 months; and
 - 1.2 There has been an improvement in Quality of Life defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
 - 1.3 Serum IGF-I levels have been increased within $\pm 1SD$ of the mean of the normal range for age and sex; and
 - 1.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients, or 1 mg per day for female patients; or
- 2 All of the following:
 - 2.1 The patient has been treated with somatropin for more than 12 months; and
 - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
 - 2.3 Serum IGF-I levels have continued to be maintained within $\pm 1SD$ of the mean of the normal range for age and sex (other than for obvious external factors); and
 - 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients; or
- 3 All of the following:
 - 3.1 The patient has had a Special Authority approval for somatropin for childhood deficiency in children and no longer meets the renewal criteria under this indication; and
 - 3.2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
 - 3.3 The patient has severe growth hormone deficiency (see notes); and
 - 3.4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
 - 3.5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

GnRH Analogues

GOSERELIN

Implant 3.6 mg, syringe	66.48	1	✓ Zoladex
Implant 10.8 mg, syringe	138.23	1	✓ Zoladex

LEUPRORELIN

Additional subsidy by endorsement where the patient is a child or adolescent and is unable to tolerate administration of goserelin and the prescription is endorsed accordingly.

Inj 3.75 mg prefilled dual chamber syringe – Higher subsidy of			
\$221.60 per 1 inj with Endorsement	66.48	1	
	(221.60)		Lucrin Depot 1-month
Inj 11.25 mg prefilled dual chamber syringe – Higher subsidy of			
\$591.68 per 1 inj with Endorsement	177.50	1	
	(591.68)		Lucrin Depot 3-month

Vasopressin Agonists

DESMOPRESSIN

Wafer 120 mcg	47.00	30	✓ Minirin Melt
---------------------	-------	----	----------------

DESMOPRESSIN ACETATE

Tab 100 mcg	25.00	30	✓ Minirin
Tab 200 mcg	54.45	30	✓ Minirin
Inj 4 mcg per ml, 1 ml	67.18	10	✓ Minirin
▲ Nasal spray 10 mcg per dose, 6 ml	34.95	60 OP	✓ Desmopressin-PH&T

Other Endocrine Agents

CABERGOLINE

Tab 0.5 mg – Maximum of 2 tab per prescription; can be waived by Special Authority see SA2070 below	4.43	2	✓ Dostinex
	17.94	8	✓ Dostinex

►SA2070 Special Authority for Waiver of Rule

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Hyperprolactinemia; or

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 2 Acromegaly*; or
- 3 Inhibition of lactation.

Renewal — (for patients who have previously been funded under Special Authority form SA1031) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has previously held a valid Special Authority which has expired and the treatment remains appropriate and the patient is benefiting from treatment.

Note: Indication marked with * is an unapproved indication.

CLOMIFENE CITRATE

Tab 50 mg	29.84	10	✓ Mylan Clomiphen ^{S29}
-----------------	-------	----	-------------------------------------

METYRAPONE

Cap 250 mg	558.00	50	✓ Metopirone
------------------	--------	----	--------------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

Anthelmintics

ALBENDAZOLE – Special Authority see [SA2512 below](#) – Retail pharmacy

Tab 400 mg	469.20	60	✓ Eskazole \$29
------------------	--------	----	---------------------------------------

➔ **SA2512** Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:
Either:

- 1 The individual has hydatids; or
- 2 The individual has a travel or residence history that requires presumptive parasite treatment.

Renewal only from an infectious disease specialist or clinical microbiologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefitting from the treatment.

MEBENDAZOLE – Only on a prescription

Tab 100 mg	5.18	6	✓ Vermox
Oral liq 100 mg per 5 ml	2.18	15 ml	
	(7.83)		Vermox

PRAZIQUANTEL

Tab 600 mg	87.68	8	✓ Distoside \$29
------------------	-------	---	--

Antibacterials

- a) For topical antibacterials, refer to DERMATOLOGICALS, [page 70](#)
b) For anti-infective eye preparations, refer to SENSORY ORGANS, [page 280](#)

Cephalosporins and Cephamycins

CEFACTOR MONOHYDRATE

Cap 250 mg	29.73	100	✓ Ranbaxy-Cefaclor
Grans for oral liq 125 mg per 5 ml – Wastage claimable.....	5.83	100 ml	✓ Ranbaxy-Cefaclor

CEFALEXIN

Cap 250 mg	3.90	20	✓ Cefalexin Lupin
Cap 500 mg	3.33	20	✓ Cefalexin Sandoz
Grans for oral liq 25 mg per ml – Wastage claimable.....	5.41	100 ml	✓ Cefalexin Sandoz
	7.88		✓ Flynn

Cefalexin Sandoz to be Principal Supply on 1 December 2026

Grans for oral liq 50 mg per ml – Wastage claimable.....	7.54	100 ml	✓ Cefalexin Sandoz
	10.38		✓ Flynn

Cefalexin Sandoz to be Principal Supply on 1 December 2026

(Flynn Grans for oral liq 25 mg per ml to be delisted 1 December 2026)

(Flynn Grans for oral liq 50 mg per ml to be delisted 1 December 2026)

CEFAZOLIN – Subsidy by endorsement

Only if prescribed for dialysis or cellulitis in accordance with a Health NZ Hospital approved protocol and the prescription is endorsed accordingly.

Inj 500 mg vial	3.48	5	✓ Cefazolin-AFT
Inj 1 g vial	3.59	5	✓ Cefazolin-AFT
Inj 2 g vial	7.09	5	✓ Cefazolin-AFT

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

CEFTRIAXONE – Subsidy by endorsement

- Up to 10 inj available on a PSO
- Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of gonorrhoea, or the treatment of pelvic inflammatory disease, or the treatment of suspected meningococcal disease, and the prescription or PSO is endorsed accordingly.

Inj 500 mg vial	0.94	1	✓ Ceftriaxone-AFT
Inj 1 g vial	3.49	5	✓ Ceftriaxone-AFT

CEFUROXIME AXETIL – Subsidy by endorsement

Only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly.

Tab 250 mg	CBS	20	✓ Ascend- Cefuroxime S29
------------------	-----	----	-------------------------------------

Macrolides

AZITHROMYCIN – Maximum of 5 days treatment per prescription; can be waived by Special Authority see SA1683 below

A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised on Special Authority.

Tab 250 mg	8.19	30	✓ Apo-Azithromycin
Tab 500 mg – Up to 8 tab available on a PSO	2.80	2	✓ Zithromax
Grans for oral liq 200 mg per 5 ml (40 mg per ml) – Wastage claimable	16.97	15 ml	✓ Zithromax

►SA1683 Special Authority for Waiver of Rule

Initial application — (bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- Patient has received a lung transplant, stem cell transplant, or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*; or
- Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*; or
- Patient has cystic fibrosis and has chronic infection with *Pseudomonas aeruginosa* or *Pseudomonas*-related gram negative organisms*; or
- Patient has an atypical *Mycobacterium* infection.

Note: Indications marked with * are unapproved indications.

Initial application — (non-cystic fibrosis bronchiectasis*) only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*; and
- Patient is aged 18 and under; and
- Either:
 - Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
 - Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

Note: Indications marked with * are unapproved indications.

Renewal — (non-cystic fibrosis bronchiectasis*) only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
- Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

3 The patient will not receive more than a total of 24 months' azithromycin cumulative treatment (see note).

The patient must not have had more than 1 prior approval.

Note: No further renewals will be subsidised. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised. Indications marked with * are unapproved indications

CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see [SA1857](#) below

Tab 250 mg	7.31	12	✓ Klaricid ^{S29}
	8.53	14	✓ Klacid
Grans for oral liq 250 mg per 5 ml – Wastage claimable.....	192.00	50 ml	✓ Klacid

►SA1857 Special Authority for Waiver of Rule

Initial application — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician.

Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Atypical mycobacterial infection; or
- 2 Mycobacterium tuberculosis infection where there is drug-resistance or intolerance to standard pharmaceutical agents.

Initial application — (Helicobacter pylori eradication) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 For the eradication of helicobacter pylori in a patient unable to swallow tablets; and
- 2 For use only in combination with omeprazole and amoxicillin as part of a triple therapy regimen.

Initial application — (Prophylaxis of infective endocarditis) from any relevant practitioner. Approvals valid for 3 months where prophylaxis of infective endocarditis associated with surgical or dental procedures if amoxicillin is contra-indicated.

Renewal — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician.

Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

ERYTHROMYCIN (AS LACTOBIONATE)

Inj 500 mg vial	59.95	1	✓ Eritroxex ^{S29}
Inj 1 g vial	10.00	1	✓ Erythrocin IV
	125.95		✓ Amdipharm ^{S29}

ERYTHROMYCIN ETHYL SUCCINATE

Tab 400 mg	35.82	100	✓ E-Myacin
a) Up to 20 tab available on a PSO			
b) Up to 2 x the maximum PSO quantity for RFPP			
Grans for oral liq 200 mg per 5 ml	6.53	100 ml	✓ E-Myacin
a) Up to 300 ml available on a PSO			
b) Up to 2 x the maximum PSO quantity for RFPP			
c) Wastage claimable			
Grans for oral liq 400 mg per 5 ml	9.41	100 ml	✓ E-Myacin
a) Up to 200 ml available on a PSO			
b) Wastage claimable			

ROXITHROMYCIN

Tab 150 mg	13.19	50	✓ Arrow-Roxithromycin
Tab 300 mg	25.00	50	✓ Arrow-Roxithromycin

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Penicillins				
AMOXICILLIN				
Cap 250 mg	54.00	500	✓	Miro-Amoxicillin
a) Up to 30 cap available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP				
Cap 500 mg	1.14	20	✓	Amoxycillin Sandoz
	41.00	500	✓	Miro-Amoxicillin
a) Up to 30 cap available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP				
c) Amoxycillin Sandoz to be Principal Supply on 1 November 2026				
Grans for oral liq 125 mg per 5 ml	2.22	100 ml	✓	Alphamox 125
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq 250 mg per 5 ml	2.81	100 ml	✓	Alphamox 250
a) Up to 300 ml available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP				
c) Wastage claimable				
Inj 250 mg vial	15.97	10	✓	Ibiamox
Inj 500 mg vial	17.43	10	✓	Ibiamox
Inj 1 g vial – Up to 5 inj available on a PSO	21.64	10	✓	Ibiamox
<i>(Miro-Amoxicillin Cap 500 mg to be delisted 1 November 2026)</i>				
AMOXICILLIN WITH CLAVULANIC ACID				
Tab 500 mg with clavulanic acid 125 mg – Up to 30 tab available on a PSO	1.66	10	✓	Curam Duo 500/125
Grans for oral liq amoxicillin 25 mg with clavulanic acid 6.25 mg per ml	8.50	100 ml	✓	Augmentin
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq amoxicillin 50 mg with clavulanic acid 12.5 mg per ml – Up to 200 ml available on a PSO	5.61	100 ml OP	✓	Amoxiclav Devatis Forte
BENZATHINE BENZYL PENICILLIN				
Inj 900 mg (1.2 million units) vial – Up to 5 inj available on a PSO	43.24	1	✓	Benzetacil
Inj 900 mg (1.2 million units) in 2.3 ml syringe – Up to 5 inj available on a PSO	432.37	10	✓	Bicillin LA
BENZYL PENICILLIN SODIUM [PENICILLIN G]				
Inj 600 mg (1 million units) vial – Up to 5 inj available on a PSO	27.43	10	✓	Sandoz

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
FLUCLOXACILLIN				
Cap 250 mg – Up to 30 cap available on a PSO	22.58	250	✓	Staphlex
Cap 500 mg – Up to 30 cap available on a PSO	72.71	500	✓	Staphlex
Grans for oral liq 25 mg per ml	4.89	100 ml	✓	AFT
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq 50 mg per ml	5.89	100 ml	✓	AFT
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Inj 250 mg vial	42.60	10	✓	Flucloxin
Inj 500 mg vial	45.63	10	✓	Flucloxin
Inj 1 g vial – Up to 5 inj available on a PSO	6.00	5	✓	Flucil
PHENOXYMETHYLPENICILLIN (PENICILLIN V)				
Cap 250 mg – Up to 30 cap available on a PSO	7.68	50	✓	Cilicaine VK
Cap 500 mg	13.72	50	✓	Cilicaine VK
a) Up to 20 cap available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP				
Grans for oral liq 125 mg per 5 ml	5.75	100 ml	✓	AFT
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq 250 mg per 5 ml	5.89	100 ml	✓	AFT
a) Up to 300 ml available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP				
c) Wastage claimable				

Tetracyclines

DOXYCYCLINE				
* Tab 100 mg – Up to 30 tab available on a PSO	64.43	500	✓	Doxine
MINOCYCLINE HYDROCHLORIDE				
* Tab 50 mg – Additional subsidy by Special Authority see				
SA1355 below – Retail pharmacy	5.79	60		Mino-tabs
	(12.05)			
* Cap 100 mg	19.32	100		Minomycin
	(52.04)			

►SA1355 Special Authority for Manufacturers Price

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has rosacea.

TETRACYCLINE – Subsidy by endorsement

Subsidised only if prescribed for helicobacter pylori eradication and prescription is endorsed accordingly. Note: the prescription is considered endorsed if tetracycline is prescribed in conjunction with a proton pump inhibitor, bismuth and metronidazole.

Tab 250 mg	68.44	28	✓	Accord ^{S29}
Cap 250 mg	35.90	100	✓	Tetracycline AA ^{S29}

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

Other Antibiotics

For topical antibiotics, refer to DERMATOLOGICALS, [page 70](#)

CIPROFLOXACIN

Recommended for patients with any of the following:

- i) microbiologically confirmed and clinically significant pseudomonas infection; or
- ii) prostatitis; or
- iii) pyelonephritis; or
- iv) gonorrhoea.

Tab 250 mg – Up to 5 tab available on a PSO	1.95	28	✓ Ipca-Ciprofloxacin
Ipca-Ciprofloxacin to be Principal Supply on 1 December 2026			
Tab 500 mg – Up to 5 tab available on a PSO	2.70	28	✓ Ipca-Ciprofloxacin
Ipca-Ciprofloxacin to be Principal Supply on 1 December 2026			
Tab 750 mg	4.80	28	✓ Ipca-Ciprofloxacin
Ipca-Ciprofloxacin to be Principal Supply on 1 December 2026			

CLINDAMYCIN

Cap hydrochloride 150 mg	4.94	24	✓ Dalacin C
Inj 150 mg per ml, 4 ml ampoule	48.78	10	✓ Dalacin C

COLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – Subsidy by endorsement

Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.

Inj 2 million iu, 10 ml vial	216.67	10	✓ Colomycin ^{S29}
------------------------------------	--------	----	----------------------------

GENTAMICIN SULPHATE

Inj 40 mg per ml, 2 ml vial – Subsidy by endorsement	36.70	5	✓ Cidomycin P/Free ^{S29}
--	-------	---	--------------------------------------

Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.

Inj 10 mg per ml, 1 ml ampoule – Subsidy by endorsement	102.60	5	✓ DBL Gentamicin
Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.			
Inj 40 mg per ml, 2 ml ampoule – Subsidy by endorsement	18.38	10	✓ Pfizer
Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.			

MOXIFLOXACIN – Special Authority see [SA1740 below](#) – Retail pharmacy

No patient co-payment payable			
Tab 400 mg	25.98	5	✓ Moximed
	42.00		✓ Avelox

Moximed to be Principal Supply on 1 December 2026

(Avelox Tab 400 mg to be delisted 1 December 2026)

➔SA1740 Special Authority for Subsidy

Initial application — (Tuberculosis) only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Active tuberculosis*; and
 - 1.2 Any of the following:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1.2.1 Documented resistance to one or more first-line medications; or
- 1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
- 1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
- 1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
- 1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or

2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*; or

3 Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.

Note: Indications marked with * are unapproved indications.

Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Mycoplasma genitalium) only from a sexual health specialist or Practitioner on the recommendation of a sexual health specialist. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium* and is symptomatic; and
- 2 Either:
 - 2.1 Has tried and failed to clear infection using azithromycin; or
 - 2.2 Has laboratory confirmed azithromycin resistance; and
- 3 Treatment is only for 7 days.

Initial application — (Penetrating eye injury) only from an ophthalmologist. Approvals valid for 1 month where the patient requires prophylaxis following a penetrating eye injury and treatment is for 5 days only.

Note: Indications marked with * are unapproved indications.

PAROMOMYCIN – Special Authority see [SA1689 below](#) – Retail pharmacy

Cap 250 mg	126.00	16	✓ Humatin ^{\$29}
------------------	--------	----	---------------------------

➔ **SA1689** Special Authority for Subsidy

Initial application only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Either:

- 1 Patient has confirmed cryptosporidium infection; or
- 2 For the eradication of Entamoeba histolytica carriage.

Renewal only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Either:

- 1 Patient has confirmed cryptosporidium infection; or
- 2 For the eradication of Entamoeba histolytica carriage.

SODIUM FUSIDATE [FUSIDIC ACID]

Tab 250 mg	135.70	36	✓ Fucidin
------------------	--------	----	-----------

SULFADIAZINE SODIUM – Special Authority see [SA1331 below](#) – Retail pharmacy

Tab 500 mg	150.70	100	✓ Sulfadiazin-Heyl ^{\$29}
------------------	--------	-----	------------------------------------

➔ **SA1331** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or
- 2 For pregnant patients for the term of the pregnancy; or
- 3 For infants with congenital toxoplasmosis until 12 months of age.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TOBRAMYCIN				
Inj 40 mg per ml, 2 ml vial – Subsidy by endorsement.....	15.50	5	✓	Tobramycin (Viatris)
Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
Solution for inhalation 60 mg per ml, 5 ml – Subsidy by endorsement.....	395.00	56 dose	✓	Tobramycin BNM
a) Wastage claimable				
b) Only if prescribed for a cystic fibrosis patient and the prescription is endorsed accordingly.				
TRIMETHOPRIM				
Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A in accordance with the Integrated Community Pharmacy Services Agreement (ICPSA) – Extended Pharmacy Services.				
* Tab 300 mg – Up to 30 tab available on a PSO.....	27.83	50	✓	TMP
TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]				
* Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – Up to 30 tab available on a PSO.....	115.74	500	✓	Trisul
* Oral liq 8 mg sulphamethoxazole 40 mg per ml – Up to 200 ml available on a PSO.....	4.95	100 ml	✓	Deprim
VANCOMYCIN – Subsidy by endorsement				
Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis or for treatment of Clostridium difficile following metronidazole failure and the prescription is endorsed accordingly.				
Inj 500 mg vial	28.50	10	✓	Vancomycin Viatris

Antifungals

- a) For topical antifungals refer to DERMATOLOGICALS, [page 70](#)
b) For topical antifungals refer to GENITO URINARY, [page 82](#)

FLUCONAZOLE				
Cap 50 mg.....	4.10	28	✓	Mylan
Cap 150 mg.....	0.45	1	✓	Flucazole
Cap 200 mg.....	8.90	28	✓	Mylan
Powder for oral suspension 10 mg per ml – Special Authority see SA1359 below – Retail pharmacy.....	129.02	35 ml	✓	Diflucan
Wastage claimable				

►SA1359 Special Authority for Subsidy

Initial application — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

Initial application — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient is at moderate to high risk of invasive fungal infection; and
- 3 Patient is unable to swallow capsules.

Renewal — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

continued...

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

Renewal — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient remains immunocompromised; and
- 2 Patient remains at moderate to high risk of invasive fungal infection; and
- 3 Patient is unable to swallow capsules.

ITRACONAZOLE

Cap 100 mg.....	6.83	15	✓ Itraconazole Crescent ^{\$29}
			✓ Itrazole
Oral liq 10 mg per ml – Special Authority see SA1322 below – Retail pharmacy.....	141.80	150 ml OP	✓ Itraconazole Kent ^{\$29}

► [SA1322](#) Special Authority for Subsidy

Initial application only from an infectious disease specialist, clinical microbiologist, clinical immunologist or any relevant practitioner on the recommendation of a infectious disease physician, clinical microbiologist or clinical immunologist. Approvals valid for 6 months where the patient has a congenital immune deficiency.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefitting from the treatment.

KETOCONAZOLE

Tab 200 mg – PCT	CBS	30	✓ Burel ^{\$29}
		100	✓ Strides Shasun ^{\$29}
			✓ Taro ^{\$29}
			✓ Teva- Ketoconazole ^{\$29}

NYSTATIN

Tab 500,000 u	14.16 (17.09)	50	
Cap 500,000 u	12.81 (15.47)	50	Nilstat Nilstat

POSACONAZOLE – Special Authority see [SA2383 below](#) – Retail pharmacy

Tab modified-release 100 mg.....	123.60	24	✓ Posaconazole Juno
Oral liq 40 mg per ml	308.26	105 ml OP	✓ Devatis

► [SA2383](#) Special Authority for Subsidy

Initial application only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

Renewal only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment.

Note: * Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (1 mg or greater per kilogram of body weight per day for patients with acute GVHD or 0.8 mg or greater per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.

Initial application — (Invasive fungal infection prophylaxis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient is at risk of invasive fungal infection; and
- 2 Either:
 - 2.1 Posaconazole is prescribed by, or recommended by a haematologist, transplant physician, infectious disease specialist, paediatric haematologist or paediatric oncologist; or
 - 2.2 Prescribing posaconazole is in accordance with a protocol or guideline that has been endorsed by the Health New Zealand - Te Whatu Ora Hospital in the specific settings where there is a greater than 10% risk of invasive fungal infection (IFI).

Renewal — (Invasive fungal infection prophylaxis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient is at risk of invasive fungal infection; and
- 2 Either:
 - 2.1 Posaconazole is prescribed by, or recommended by a haematologist, transplant physician, infectious disease specialist, paediatric haematologist or paediatric oncologist; or
 - 2.2 Prescribing posaconazole is in accordance with a protocol or guideline that has been endorsed by the Health New Zealand - Te Whatu Ora Hospital in the specific settings where there is a greater than 10% risk of invasive fungal infection (IFI).

TERBINAFINE

* Tab 250 mg 12.53 84 ✓ **Deolate**

VORICONAZOLE – Special Authority see [SA2384 below](#) – Retail pharmacy

Tab 50 mg 71.00 56 ✓ **Vttack**

Tab 200 mg 263.00 56 ✓ **Vttack**

Powder for oral suspension 40 mg per ml – Wastage

claimable 1,523.22 70 ml ✓ **Vfend**

► [SA2384](#) **Special Authority for Subsidy**

Initial application — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 3.1 Patient has proven or probable invasive aspergillus infection; or
- 3.2 Patient has possible invasive aspergillus infection; or
- 3.3 Patient has fluconazole resistant candidiasis; or
- 3.4 Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp.

Renewal — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist.

Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient continues to require treatment for proven or probable invasive aspergillus infection; or
 - 3.2 Patient continues to require treatment for possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp.

Initial application — (Invasive fungal infection prophylaxis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient is at risk of invasive fungal infection; and
- 2 Either:
 - 2.1 Voriconazole is prescribed by, or recommended by a haematologist, transplant physician, infectious disease specialist, paediatric haematologist or paediatric oncologist; or
 - 2.2 Prescribing voriconazole is in accordance with a protocol or guideline that has been endorsed by the Health New Zealand - Te Whatu Ora Hospital in the specific settings where there is a greater than 10% risk of invasive fungal infection (IFI).

Renewal — (Invasive fungal infection prophylaxis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient is at risk of invasive fungal infection; and
- 2 Either:
 - 2.1 Voriconazole is prescribed by, or recommended by a haematologist, transplant physician, infectious disease specialist, paediatric haematologist or paediatric oncologist; or
 - 2.2 Prescribing voriconazole is in accordance with a protocol or guideline that has been endorsed by the Health New Zealand - Te Whatu Ora Hospital in the specific settings where there is a greater than 10% risk of invasive fungal infection (IFI).

Antimalarials

PRIMAQUINE – Special Authority see [SA1684 below](#) – Retail pharmacy

Tab 15 mg	395.00	100	✓ Bayshore ^{S29}
	550.00		✓ Sanofi
			Primaquine ^{S29}

►SA1684 Special Authority for Subsidy

Initial application only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 The patient has vivax or ovale malaria; and
- 2 Primaquine is to be given for a maximum of 21 days.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

Renewal only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 The patient has relapsed vivax or ovale malaria; and
- 2 Primaquine is to be given for a maximum of 21 days.

Antitrichomonal Agents

METRONIDAZOLE

Tab 200 mg – Up to 30 tab available on a PSO	25.86	250	✓ Metronidamed
Tab 400 mg – Up to 15 tab available on a PSO	4.29	21	✓ Metronidamed
Oral liq benzoate 200 mg per 5 ml	25.00	100 ml	✓ Flagyl-S
Suppos 500 mg	24.48	10	✓ Flagyl

ORNIDAZOLE

Tab 500 mg	36.52	10	✓ Arrow-Ornidazole
------------------	-------	----	--------------------

Antituberculotics and Antileprotics

Note: There is no co-payment charge for all pharmaceuticals listed in the Antituberculotics and Antileprotics group regardless of immigration status.

BEDAQUILINE – Special Authority see [SA2244](#) below – Retail pharmacy

No patient co-payment payable

Tab 100mg	3,084.51	24 OP	✓ Sirturo
-----------------	----------	-------	-----------

► [SA2244](#) Special Authority for Subsidy

Initial application — (multi-drug resistant tuberculosis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The person has multi-drug resistant tuberculosis (MDR-TB); and
- 2 Ministry of Health's Tuberculosis Clinical Network has reviewed the individual case and recommends bedaquiline as part of the treatment regimen.

CLOFAZIMINE – Retail pharmacy-Specialist

- a) No patient co-payment payable
- b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist.

* Cap 50 mg	442.00	100	✓ Lamprene ^{\$29}
-------------------	--------	-----	----------------------------

CYCLOSERINE – Retail pharmacy-Specialist

- a) No patient co-payment payable
- b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician.

Cap 250 mg	344.00	60	✓ Cyclostin ^{\$29}
------------------	--------	----	-----------------------------

DAPSONE – Retail pharmacy-Specialist

- a) No patient co-payment payable
- b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist

Tab 25 mg	227.00	100	✓ Dapsone (Rising) ^{\$29}
	268.50		✓ Dapsone
Tab 100 mg	329.50	100	✓ Dapsone

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ETHAMBUTOL HYDROCHLORIDE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician				
Tab 100 mg	85.73	100	✓	EMB Fato1 \$29
Tab 400 mg	49.34	56	✓	Myambutol \$29
ISONIAZID – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician				
* Tab 100 mg	94.50	100	✓	Isoniazid Teva \$29
	327.41		✓	Noumed Isoniazid
ISONIAZID WITH RIFAMPICIN – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician				
* Tab 100 mg with rifampicin 150 mg.....	89.82	100	✓	Rifinah
* Tab 150 mg with rifampicin 300 mg.....	179.13	100	✓	Rifinah
* Cap 100 mg with rifampicin 150 mg	199.00	100	✓	Rifamazid \$29
LINEZOLID – Special Authority see SA2234 below – Retail pharmacy				
No patient co-payment payable				
Tab 600 mg	194.60	10	✓	Zyvox
Oral liq 20 mg per ml	1,879.00	150 ml	✓	Zyvox
➔SA2234 Special Authority for Subsidy				
Initial application — (multi-drug resistant tuberculosis) from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria:				
Both:				
1 The person has multi-drug resistant tuberculosis (MDR-TB); and				
2 Ministry of Health's Tuberculosis Clinical Network has reviewed the individual case and recommends linezolid as part of the treatment regimen.				
PARA-AMINO SALICYLIC ACID – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease specialist, clinical microbiologist or respiratory physician				
Grans for oral liq 4 g sachet	280.00	30	✓	Paser \$29
PROTIONAMIDE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease specialist, clinical microbiologist or respiratory physician				
Tab 250 mg	305.00	100	✓	Peteha \$29
PYRAZINAMIDE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician				
* Tab 500 mg	64.95	100	✓	AFT-Pyrazinamide

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
RIFABUTIN – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, respiratory physician or gastroenterologist				
* Cap 150 mg	353.71	30	✓	Mycobutin
RIFAMPICIN – Subsidy by endorsement				
a) No patient co-payment payable				
b) For confirmed recurrent Staphylococcus aureus infection in combination with other effective anti-staphylococcal antimicrobial based on susceptibilities and the prescription is endorsed accordingly; can be waived by endorsement - Retail pharmacy - Specialist. Specialist must be an internal medicine physician, clinical microbiologist, dermatologist, paediatrician, or public health physician.				
* Cap 150 mg	58.54	100	✓	Rifadin
* Cap 300 mg	122.06	100	✓	Rifadin
			✓	Rifadin Sanofi
* Oral liq 100 mg per 5 ml	12.60	60 ml	✓	Rifadin

Antivirals

For eye preparations refer to Eye Preparations, Anti-Infective Preparations, [page 280](#)

Hepatitis B Treatment

ENTECAVIR				
* Tab 0.5 mg	12.04	30	✓	Entecavir (Rex)
LAMIVUDINE – Special Authority see SA1685 below – Retail pharmacy				
* Tab 100 mg	15.00	28	✓	Zetlam
* Oral liq 5 mg per ml	270.00	240 ml OP	✓	Zeffix
►SA1685 Special Authority for Subsidy				
Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.				
Approvals valid for 1 year where used for the treatment or prevention of hepatitis B.				
Renewal from any relevant practitioner. Approvals valid for 2 years where used for the treatment or prevention of hepatitis B.				
TENOFOVIR DISOPROXIL				
Tenofovir disoproxil prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA2139., page 114				
* Tab 245 mg (300 mg as a maleate)	13.80	30	✓	Tenofovir Disoproxil Viatris
* Tab 245 mg (300 mg as a fumarate)	13.80	30	✓	Ricovir ^{S29}

Herpesvirus Treatments

ACICLOVIR				
* Tab dispersible 200 mg	2.05	25	✓	Lovir
* Tab dispersible 400 mg	7.55	56	✓	Lovir
* Tab dispersible 800 mg	7.43	35	✓	Lovir
LETERMOVIR – Special Authority see SA2635 on the next page – Retail pharmacy				
Wastage claimable				
Tab 240 mg	6,664.00	28	✓	Prevymis

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

►SA2635 Special Authority for Subsidy

Initial application — (CMV prophylaxis - post HSCT) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone an allogeneic haematopoietic stem cell transplant; and
- 2 The patient has confirmed presence of cytomegalovirus-specific antibodies; and
- 3 Treatment to commence within 28 days of an allogeneic haematopoietic stem cell transplant; and
- 4 Maximum treatment duration of 100 days post-transplant.

Renewal — (CMV prophylaxis – second or subsequent HSCT) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone an allogeneic haematopoietic stem cell transplant; and
- 2 The patient has confirmed presence of cytomegalovirus-specific antibodies; and
- 3 Treatment to commence within 28 days of an allogeneic haematopoietic stem cell transplant; and
- 4 Maximum treatment duration of 100 days post-transplant.

Initial application — (CMV prophylaxis - severe immunosuppression*) only from an infectious disease specialist, clinical microbiologist or any relevant practitioner on the recommendation of a infectious disease specialist or clinical microbiologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has severe immunosuppression requiring prophylaxis of CMV; and
- 2 Either:
 - 2.1 Patient is contraindicated to all other funded CMV active oral antiviral agents; or
 - 2.2 Patient's CMV is resistant to all other funded CMV active oral antiviral agents.

Renewal — (CMV prophylaxis - severe immunosuppression*) only from an infectious disease specialist, clinical microbiologist or any relevant practitioner on the recommendation of a infectious disease specialist or clinical microbiologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has severe immunosuppression requiring prophylaxis of CMV; and
- 2 Either:
 - 2.1 Patient is contraindicated to all other funded CMV active oral antiviral agents; or
 - 2.2 Patient's CMV is resistant to all other funded CMV active oral antiviral agents.

Note: Indications marked with * are unapproved indications.

VALACICLOVIR

Tab 500 mg	9.64	30	✓ <u>Vaclovir</u>
	13.50	42	✓ <u>Valaciclovir</u> <u>Viatris</u> ^{\$29}
Tab 1,000 mg	12.45	21	✓ <u>Valaciclovir</u> <u>Mylan</u> ^{\$29}
			✓ <u>Valaciclovir</u> <u>Viatris</u> ^{\$29}
	17.78	30	✓ <u>Vaclovir</u>

VALGANCICLOVIR – Special Authority see [SA2514 on the next page](#) – Retail pharmacy

Tab 450 mg	140.89	60	✓ <u>Valganciclovir</u> <u>Viatris</u>
------------------	--------	----	---

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2514 Special Authority for Subsidy

Initial application — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Renewal — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
 - 1.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or
- 2 Both:
 - 2.1 Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy for CMV prophylaxis; and
 - 2.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone.

Initial application — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and
- 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Renewal — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Initial application — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive; and
- 3 Patient has a high risk of CMV disease.

Renewal — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone a lung re-transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive; and
- 3 Patient has a high risk of CMV disease.

Initial application — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

Renewal — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

Hepatitis C Treatment

GLECAPREVIR WITH PIBRENTASVIR – [Xpharm]

Note the supply of treatment is via Pharmac's approved direct distribution supply. Further details can be found on Pharmac's website <https://pharmac.govt.nz/maviret>

Tab 100 mg with pibrentasvir 40 mg	24,750.00	84 OP	✓ Maviret
--	-----------	-------	-----------

LEDIPASVIR WITH SOFOSBUVIR – [Xpharm] – Special Authority see [SA1605 below](#)

No patient co-payment payable

Tab 90 mg with sofosbuvir 400 mg.....	24,363.46	28	✓ Harvoni
---------------------------------------	-----------	----	-----------

►SA1605 Special Authority for Subsidy

Special Authority approved by the Hepatitis C Treatment Panel (HepCTP)

Notes: By application to the Hepatitis C Treatment Panel (HepCTP).

Applications will be considered by HepCTP and approved subject to confirmation of eligibility.

Application details may be obtained from Pharmac's website <http://www.pharmac.govt.nz/harvoni> or:

The Coordinator, Hepatitis C Treatment Panel

Pharmac, PO Box 10-254, WELLINGTON Tel: (04) 460 4990,

Email: hepcpanel@pharmac.govt.nz

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Subsidy by endorsement; can be waived by Special Authority see [SA2520](#) below

- Funding for emtricitabine with tenofovir disoproxil for use as PrEP or PEP, should be applied using Special Authority SA2520.
- Endorsement for treatment of conditions approved via Special Authority SA2139 (antiretrovirals for confirmed HIV, prevention of maternal transmission, post-exposure prophylaxis following exposure to HIV (when co-prescribed with other antiretrovirals) and percutaneous exposure): Prescription is deemed to be endorsed if emtricitabine with tenofovir disoproxil is co-prescribed with another antiretroviral subsidised under Special Authority SA2139 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Emtricitabine with tenofovir disoproxil prescribed under endorsement, for treatment of conditions approved via Special Authority SA2139 (antiretrovirals for confirmed HIV, prevention of maternal transmission, post-exposure prophylaxis following exposure to HIV and percutaneous exposure), is included in the count of up to 4 subsidised antiretrovirals, and counts as two antiretroviral medications, for the purposes of Special Authority SA2139, [page 114](#)

There is an approval process to become a named specialist to prescribe antiretroviral therapy in New Zealand. Further information is available on the Pharmac website.

* Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a fumarate).....	13.45	30	✓ Tenofovir Disoproxil Emtricitabine Mylan \$29
* Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate).....	13.45	30	✓ Tenofovir Disoproxil Emtricitabine Viatr

➔ [SA2520](#) Special Authority for Subsidy

Initial application — (Pre-exposure prophylaxis) from any relevant practitioner. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion; and
- 2 The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate.

Notes: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines:

<https://ashm.org.au/HIV/PrEP/>

Renewal — (Pre-exposure prophylaxis) from any relevant practitioner. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion; and
- 2 The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate.

Notes: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines:

<https://ashm.org.au/HIV/PrEP/>

Initial application — (post-exposure prophylaxis following exposure to HIV) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- with an unknown or detectable viral load greater than 200 copies per ml; or
- 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
- 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is appropriate; or
- 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashm.org.au/hiv/hiv-management/pep/>).

Renewal — (second or subsequent post-exposure prophylaxis) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is appropriate; or
 - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

COVID-19 Treatments

NIRMATRELVIR WITH RITONAVIR – PCT – Subsidy by endorsement

Subsidised for patients meeting access criteria for oral COVID-19 antiviral treatments (as on [Pharmac's website](#)) and where the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed when supplying by Direct Provision under the provisions in Part I of Section A of the Pharmaceutical Schedule.

Tab 150 mg with ritonavir 100 mg 1,274.00 30 OP ✓ Paxlovid

REMEDSIVIR – PCT only

Note: Subsidised for patients meeting access criteria for oral antiviral treatments (as on [Pharmac's website](#)).

Inj 100 mg vial 615.23 1 ✓ Veklury

Antiretrovirals

➡SA2139 Special Authority for Subsidy

Initial application — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the patient has confirmed HIV infection.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following exposure to HIV) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
 - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashm.org.au/hiv/hiv-management/pep/>).

Renewal — (second or subsequent post-exposure prophylaxis) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
 - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

Note: No new patients to be initiated on efavirenz.

* Tab 600 mg	65.38	30	✓ Efavirenz Milpharm ^{S29}
--------------------	-------	----	--

(Efavirenz Milpharm ^{S29} Tab 600 mg to be delisted 1 November 2026)

ETRAVIRINE – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Tab 200 mg	770.00	60	✓ Intencele
--------------------	--------	----	--------------------

NEVIRAPINE – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Tab 200 mg	198.25	60	✓ Nevirapine Viatris
* Oral suspension 10 mg per ml	203.55	240 ml OP	✓ Viramune Suspension

Nucleosides Reverse Transcriptase Inhibitors

ABACAIR SULPHATE – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Tab 300 mg	180.00	60	✓ Ziagen
--------------------	--------	----	-----------------

ABACAIR SULPHATE WITH LAMIVUDINE – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

Note: abacavir with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.

* Tab 600 mg with lamivudine 300 mg	35.00	30	✓ Abacavir/ Lamivudine Viatris
---	-------	----	---

EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

Note: Efavirenz with emtricitabine and tenofovir disoproxil counts as three anti-retroviral medications for the purposes of the anti-retroviral Special Authority

* Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate)	106.88	30	✓ TEEVIR ^{S29} ✓ TEEVIR (India) ^{S29} ✓ Tenofovir Efavirenz Emtricitabine (-Mylan) ^{S29}
--	--------	----	--

* Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate)	106.88	30	✓ Viatris
---	--------	----	------------------

EMTRICITABINE – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Cap 200 mg	307.20	30	✓ Emtriva
--------------------	--------	----	------------------

LAMIVUDINE – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Tab 150 mg	150.00	60	✓ Lamivudine Viatris
* Oral liq 10 mg per ml	102.50	240 ml OP	✓ 3TC

ZIDOVUDINE – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Cap 100 mg	152.25	100	✓ Retrovir
* Oral liq 10 mg per ml	30.45	200 ml OP	✓ Retrovir

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓	

ZIDOVUDINE WITH LAMIVUDINE – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

Note: zidovudine [AZT] with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.

* Tab 300 mg with lamivudine 150 mg.....	92.40	60	✓ Lamivudine/ Zidovudine Viatris
--	-------	----	---

Protease Inhibitors

ATAZANAVIR SULPHATE – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Cap 150 mg.....	102.50	60	✓ Atazanavir Viatris
* Cap 200 mg.....	152.30	60	✓ Atazanavir Viatris

DARUNAVIR – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Tab 400 mg.....	115.00	60	✓ Darunavir Viatris
Darunavir Viatris to be Principal Supply on 1 December 2026			
* Tab 600 mg.....	130.00	60	✓ Darunavir Viatris
Darunavir Viatris to be Principal Supply on 1 December 2026			

LOPINAVIR WITH RITONAVIR – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Tab 200 mg with ritonavir 50 mg.....	875.00	120	✓ Lopinavir/Ritonavir Mylan
--	--------	-----	--

RITONAVIR – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Tab 100 mg.....	43.31	30	✓ Norvir
-------------------	-------	----	-----------------

Strand Transfer Inhibitors

DOLUTEGRAVIR – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Tab 50 mg.....	1,090.00	30	✓ Tivicay
------------------	----------	----	------------------

DOLUTEGRAVIR WITH LAMIVUDINE – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Tab 50 mg with lamivudine 300 mg.....	1,090.00	30	✓ Dovato
---	----------	----	-----------------

RALTEGRAVIR POTASSIUM – Special Authority see [SA2139 on page 114](#) – Retail pharmacy

* Tab 400 mg.....	1,090.00	60	✓ Isentress
* Tab 600 mg.....	1,090.00	60	✓ Isentress HD

Immune Modulators

PEGYLATED INTERFERON ALFA-2A – Special Authority see [SA2034 below](#) – Retail pharmacy

Note: Pharmac will consider funding ribavirin for the small group of patients who have a clinical need for ribavirin and meet Special Authority criteria. Please contact the Hepatitis C Coordinator at Pharmac on 0800-023-588 option 4.

Inj 135 mcg prefilled syringe.....	887.35	1	✓ Pegasys (S29) ^{S29}
Inj 180 mcg prefilled syringe.....	1,074.79	4	✓ Pegasys
	1,355.71		✓ Pegasys S29 ^{S29}

➤SA2034 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or
 - 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2 Maximum of 48 weeks therapy.

Renewal — (Chronic hepatitis C - genotype 1 infection) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist.

Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naïve; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log₁₀ IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (Metavir Stage F2 or greater or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Initial application — (myeloproliferative disorder or cutaneous T cell lymphoma) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Any of the following:

- 1 Patient has a cutaneous T cell lymphoma*; or
- 2 All of the following:
 - 2.1 Patient has a myeloproliferative disorder*; and
 - 2.2 Patient is intolerant of hydroxyurea; and
 - 2.3 Treatment with anagrelide and busulfan is not clinically appropriate; or
- 3 Both:
 - 3.1 Patient has a myeloproliferative disorder; and
 - 3.2 Patient is pregnant, planning pregnancy or lactating.

Renewal — (myeloproliferative disorder or cutaneous T cell lymphoma) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment; and
- 3 Either:
 - 3.1 Patient has a cutaneous T cell lymphoma*; or
 - 3.2 Both:
 - 3.2.1 Patient has a myeloproliferative disorder*; and
 - 3.2.2 Either:
 - 3.2.2.1 Remains intolerant of hydroxyurea and treatment with anagrelide and busulfan remains clinically inappropriate; or
 - 3.2.2.2 Patient is pregnant, planning pregnancy or lactating.

Note: Indications marked with * are unapproved indications.

Initial application — (post-allogenic bone marrow transplant) from any relevant practitioner. Approvals valid for 3 months where patient has received an allogeneic bone marrow transplant* and has evidence of disease relapse.

Renewal — (post-allogenic bone marrow transplant) from any relevant practitioner. Approvals valid for 3 months where patient is responding and ongoing treatment remains appropriate.

Note: Indications marked with * are unapproved indications.

Urinary Tract Infections

FOSFOMYCIN – Special Authority see [SA2406 below](#) – Retail pharmacy

Powder for oral solution, 3 g sachet 18.70 1 ✓ **UroFos**

►SA2406 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

Both:

- 1 Patient has an acute, symptomatic, bacteriologically-proven uncomplicated urinary tract infection (UTI)/cystitis with Escherichia Coli; and
- 2 Either:
 - 2.1 Microbiological testing confirms the pathogen is resistant to all of: trimethoprim, nitrofurantoin, amoxicillin, cefaclor, cefalexin, amoxicillin with clavulanic acid, and norfloxacin; or
 - 2.2 The patient has a contraindication or intolerance to all of: trimethoprim, nitrofurantoin, amoxicillin, cefaclor, cefalexin, amoxicillin with clavulanic acid, and norfloxacin that the pathogen is susceptible to.

Renewal from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

Both:

- 1 Patient has an acute, symptomatic, bacteriologically-proven uncomplicated urinary tract infection (UTI)/cystitis with Escherichia Coli; and

continued...

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
2 Either:				
2.1 Microbiological testing confirms the pathogen is resistant to all of: trimethoprim, nitrofurantoin, amoxicillin, cefaclor, cefalexin, amoxicillin with clavulanic acid, and norfloxacin; or				
2.2 The patient has a contraindication or intolerance to all of: trimethoprim, nitrofurantoin, amoxicillin, cefaclor, cefalexin, amoxicillin with clavulanic acid, and norfloxacin that the pathogen is susceptible to.				
METHENAMINE (HEXAMINE) HIPPURATE				
* Tab 1 g	19.95	100	✓	Hiprex
NITROFURANTOIN				
* Tab 50 mg – Up to 30 tab available on a PSO	22.20	100	✓	Nifuran
			✓	Nitrofurantoin Clinect
* Tab 100 mg	37.50	100	✓	Nifuran
* Cap modified-release 100 mg – Up to 15 cap available on a PSO	81.20	100	✓	Macrobid
Note: Direct Provision of Nitrofurantoin cap modified-release 100 mg by a pharmacist permitted under the provisions in Part I of Section A in accordance with the Integrated Community Pharmacy Services Agreement (ICPSA) – Extended Pharmacy Services.				
(Nifuran Tab 50 mg to be delisted 1 November 2026)				
(Nifuran Tab 100 mg to be delisted 1 November 2026)				
NORFLOXACIN				
Tab 400 mg – Subsidy by endorsement.....	245.00	100	✓	Arrow-Norfloxacin
Only if prescribed for a patient with an uncomplicated urinary tract infection that is unresponsive to a first line agent or with proven resistance to first line agents and the prescription is endorsed accordingly.				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

Anticholinesterases

NEOSTIGMINE METILSULFATE

Inj 2.5 mg per ml, 1 ml ampoule 48.25 10 ✓ Max Health

PYRIDOSTIGMINE BROMIDE

▲ Tab 60 mg 50.28 100 ✓ Mestinon

Non-Steroidal Anti-Inflammatory Drugs

DICLOFENAC SODIUM

* Tab EC 25 mg 2.19 50 ✓ Diclofenac Sandoz
 * Tab 50 mg dispersible 1.50 20 ✓ Voltaren D
 * Tab EC 50 mg 2.19 50 ✓ Diclofenac Sandoz
 * Tab long-acting 75 mg 10.00 100 ✓ Voltaren SR
 * Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO 13.20 5 ✓ Voltaren
 * Suppos 12.5 mg 2.04 10 ✓ Voltaren
 * Suppos 25 mg 2.44 10 ✓ Voltaren
 * Suppos 50 mg – Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren
 * Suppos 100 mg 7.00 10 ✓ Voltaren

IBUPROFEN

* Tab 200 mg 21.40 1,000 ✓ Relieve
 * Tab long-acting 800 mg 3.65 30 ✓ Ibuprofen SR BNM
 * Oral liq 20 mg per ml 2.85 200 ml ✓ Ethics

Note: Direct Provision of Ibuprofen oral liq 20 mg per ml by a pharmacist permitted under the provisions in Part I of Section A in accordance with the Integrated Community Pharmacy Services Agreement (ICPSA) – Extended Pharmacy Services.

KETOPROFEN

* Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR
(Oruvail SR Cap long-acting 200 mg to be delisted 1 October 2026)

MEFENAMIC ACID

* Cap 250 mg 1.25 50
 (10.82)
 0.50 20 Ponstan
 (7.50) Ponstan

NAPROXEN

* Tab 250 mg 3.92 50 ✓ Inza
 7.06 90 ✓ Noflam 250
 39.23 500 ✓ Noflam 250
 * Tab 500 mg 6.89 50 ✓ Inza
 34.45 250 ✓ Noflam 500
 * Tab long-acting 750 mg 10.40 28 ✓ Naprosyn SR 750
 * Tab long-acting 1 g 11.50 28 ✓ Naprosyn SR 1000

TENOXICAM

* Tab 20 mg 23.50 100 ✓ Tilcotil
 * Inj 20 mg vial 9.95 1 ✓ AFT

NSAIDs Other

CELECOXIB

Cap 100 mg 3.60 60 ✓ Celebrex
 Cap 200 mg 2.55 30 ✓ Celostea

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

Topical Products for Joint and Muscular Pain

CAPSAICIN

Crm 0.025% – Special Authority see SA1289 below – Retail pharmacy.....	9.75	45 g OP	✓ Zo-Rub Osteo ✓ Zostrix
--	------	---------	---

» [SA1289](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

Antirheumatoid Agents

HYDROXYCHLOROQUINE SULPHATE

* Tab 200 mg	7.80	100	✓ Ipca-Hydroxychloroquine
--------------------	------	-----	----------------------------------

LEFLUNOMIDE

* Tab 10 mg	6.00	30	✓ Arava
* Tab 20 mg	6.00	30	✓ Arava

PENICILLAMINE

Tab 125 mg	67.23	100	✓ D-Penamine
Tab 250 mg	110.12	100	✓ D-Penamine

Drugs Affecting Bone Metabolism

Alendronate for Osteoporosis

ALENDRONATE SODIUM

* Tab 70 mg	3.10	4	✓ Fosamax
-------------------	------	---	------------------

ALENDRONATE SODIUM WITH COLECALCIFEROL

* Tab 70 mg with colecalciferol 5,600 iu	1.99	4	✓ Fosamax Plus
--	------	---	-----------------------

Other Treatments

DENOSUMAB – Special Authority see [SA2441 below](#) – Retail pharmacy

Note: Denosumab inj 60 mg per 1 ml pre-filled syringe is Medsafe approved for use in osteoporosis. Denosumab inj 120 mg per 1.7 ml vial is Medsafe approved for use in hypercalcaemia of malignancy.

Inj 120 mg per 1.7 ml vial	375.00	1	✓ Xgeva
Inj 60 mg per 1 ml prefilled syringe.....	187.50	1	✓ Prolia

» [SA2441](#) Special Authority for Subsidy

Initial application — (Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 The patient has established osteoporosis; and
- 2 Any of the following:
 - 2.1 History of one significant osteoporotic fracture demonstrated radiologically, with a documented T-Score less than or equal to -2.5, that incorporates BMD measured using dual-energy x-ray absorptiometry (DEXA); or
 - 2.2 History of one significant osteoporotic fracture, demonstrated radiologically, and either the patient is elderly, or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- densitometry scanning cannot be performed because of logistical, technical or pathophysiological reasons; or
- 2.3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 2.4 Documented T-Score less than or equal to -3.0; or
- 2.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm that incorporates BMD measured using DEXA; and

3 Any of the following:

- 3.1 Bisphosphonates are contraindicated because the patient's creatinine clearance or eGFR is less than 35 mL/min; or
- 3.2 The patient has experienced at least two symptomatic new fractures or a BMD loss greater than 2% per year, after at least 12 months' continuous therapy with a funded antiresorptive agent; or
- 3.3 Bisphosphonates result in intolerable side effects; or
- 3.4 Intravenous bisphosphonates cannot be administered due to logistical or technical reasons.

Initial application — (Hypercalcaemia) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has hypercalcaemia of malignancy; and
- 2 Patient has severe renal impairment.

PAMIDRONATE DISODIUM

Inj 3 mg per ml, 10 ml vial.....	32.49	1	✓ Pamisol
Inj 6 mg per ml, 10 ml vial.....	88.11	1	✓ Pamisol
Inj 9 mg per ml, 10 ml vial.....	94.34	1	✓ Pamisol

RISEDRONATE SODIUM

Tab 35 mg	3.00	4	✓ Risedronate Sandoz
-----------------	------	---	-----------------------------

TERIPARATIDE – Special Authority see SA1139 below – Retail pharmacy

Inj 250 mcg per ml, 2.4 ml	200.27	1	✓ Teriparatide - Teva ✓ Teriparatide Teva S29 S29
	490.00		✓ Forteo S29

► **SA1139 Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ZOLEDRONIC ACID				
Inj 0.05 mg per ml, 100 ml, bag.....	19.45	1	✓	Zoledronic Acid Viartis

Hyperuricaemia and Antigout

ALLOPURINOL				
* Tab 100 mg	17.99	1,000	✓	Ipca-Allopurinol
* Tab 300 mg	22.50	500	✓	Ipca-Allopurinol
BENZBROMARONE – Special Authority see SA1963 below – Retail pharmacy				
Tab 50 mg	32.00	100	✓	Narcaricin mite ^{S29}

► [SA1963](#) Special Authority for Subsidy

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefitting from the treatment; and
- 2 There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests.

COLCHICINE				
* Tab 500 mcg.....	3.15	100	✓	Colchicine Indoco
	6.30		✓	Colgout

Colchicine Indoco to be Principal Supply on 1 December 2026

(Colgout Tab 500 mcg to be delisted 1 December 2026)

FEBOXOSTAT – Special Authority see SA2555 below – Retail pharmacy				
Tab 80 mg	4.66	28	✓	Febuxostat (Teva)
Febuxostat (Teva) to be Principal Supply on 1 December 2026				
Tab 120 mg	11.67	28	✓	Febuxostat (Teva)
Febuxostat (Teva) to be Principal Supply on 1 December 2026				

► [SA2555](#) Special Authority for Subsidy

Initial application — (Gout) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol; or
 - 2.4 The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout..

Initial application — (Tumour lysis syndrome) only from a haematologist or oncologist. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient is scheduled to receive cancer therapy carrying an intermediate or high risk of tumour lysis syndrome; and
- 2 Patient has a documented history of allopurinol intolerance.

Renewal — (Tumour lysis syndrome) only from a haematologist or oncologist. Approvals valid for 6 weeks where the treatment remains appropriate and the patient is benefitting from treatment.

PROBENECID				
* Tab 500 mg	66.95	100	✓	Probenecid-AFT

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
Muscle Relaxants			
BACLOFEN			
* Tab 10 mg	3.70	100	✓ <u>Pacifen</u>
Inj 0.05 mg per ml, 1 ml ampoule – Subsidy by endorsement.....	11.55	1	✓ <u>Lioresal Intrathecal</u>
Subsidised only for use in a programmable pump in patients where oral antispastic agents have been ineffective or have caused intolerable side effects and the prescription is endorsed accordingly.			
Inj 2 mg per ml, 5 ml ampoule – Subsidy by endorsement.....	490.91	10	✓ <u>Sintetica Baclofen Intrathecal</u>
Subsidised only for use in a programmable pump in patients where oral antispastic agents have been ineffective or have caused intolerable side effects and the prescription is endorsed accordingly.			
DANTROLENE			
Cap 25 mg	145.77	100	✓ <u>Dantrium S29</u> S29
Cap 50 mg	77.00	100	✓ <u>Dantrium</u>
ORPHENADRINE CITRATE			
Tab 100 mg	23.25	100	✓ <u>Norflex</u>

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

Agents for Parkinsonism and Related Disorders

Dopamine Agonists and Related Agents

AMANTADINE HYDROCHLORIDE

▲ Cap 100 mg	38.24	60	✓ Symmetrel
	63.73	100	✓ Symmetrel

APOMORPHINE HYDROCHLORIDE

▲ Inj 10 mg per ml, 2 ml ampoule	59.50	5	✓ Movapo
▲ Inj 10 mg per ml, 5 ml ampoule	121.84	5	✓ Movapo

ENTACAPONE

▲ Tab 200 mg	13.73	100	✓ <u>Entacapone Viatris</u>
--------------------	-------	-----	-----------------------------

LEVODOPA WITH BENSERAZIDE

* Tab dispersible 50 mg with benserazide 12.5 mg	13.25	100	✓ Madopar Rapid
* Cap 50 mg with benserazide 12.5 mg	13.75	100	✓ Madopar 62.5
* Cap 100 mg with benserazide 25 mg	15.80	100	✓ Madopar 125
* Cap long-acting 100 mg with benserazide 25 mg	22.85	100	✓ Madopar HBS
* Cap 200 mg with benserazide 50 mg	26.25	100	✓ Madopar 250

LEVODOPA WITH CARBIDOPA

* Tab 100 mg with carbidopa 25 mg	26.49	100	✓ <u>Sinemet</u>
* Tab long-acting 200 mg with carbidopa 50 mg	44.99	100	✓ <u>Sinemet CR</u>
* Tab 250 mg with carbidopa 25 mg	39.49	100	✓ <u>Sinemet</u>

LEVODOPA WITH CARBIDOPA AND ENTACAPONE

* Tab 50 mg with carbidopa 12.5 mg and entacapone 200 mg	27.01	100	✓ <u>Stalevo</u>
* Tab 100 mg with carbidopa 25 mg and entacapone 200 mg	34.18	100	✓ <u>Stalevo</u>
* Tab 150 mg with carbidopa 37.5 mg and entacapone 200 mg	44.96	100	✓ <u>Stalevo</u>
* Tab 200 mg with carbidopa 50 mg and entacapone 200 mg	51.23	100	✓ <u>Stalevo</u>

PRAMIPEXOLE HYDROCHLORIDE

▲ Tab 0.25 mg	5.23	100	✓ <u>Ramipex</u>
▲ Tab 1 mg	17.73	100	✓ <u>Ramipex</u>

RASAGILINE

* Tab 1 mg	53.50	30	✓ <u>Azilect</u> \$29
------------------	-------	----	--------------------------------------

ROPINIROLE HYDROCHLORIDE

▲ Tab 0.25 mg	8.83	84	✓ Ropin
▲ Tab 1 mg	10.09	84	✓ Ropin
▲ Tab 2 mg	12.29	84	✓ Ropin
▲ Tab 5 mg	25.94	84	✓ Ropin

TOLCAPONE

▲ Tab 100 mg	152.38	100	✓ Tasmar
--------------------	--------	-----	----------

Anticholinergics

BENZATROPINE MESYLATE

Tab 2 mg	10.99	60	✓ Benztrop
Inj 1 mg per ml, 2 ml	95.00	5	✓ Phebra
a) Up to 10 inj available on a PSO			
b) Only on a PSO			

PROCYCLIDINE HYDROCHLORIDE

Tab 5 mg	15.00	100	✓ Kemadrin
----------------	-------	-----	------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

Agents for Essential Tremor, Chorea and Related Disorders

RILUZOLE – Special Authority see [SA1403 below](#) – Retail pharmacy

Wastage claimable

Tab 50 mg	117.00	56	✓ Rilutek
-----------------	--------	----	------------------

»SA1403 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
 - 5.1 The patient is ambulatory; or
 - 5.2 The patient is able to use upper limbs; or
 - 5.3 The patient is able to swallow.

Renewal from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and
- 3 Any of the following:
 - 3.1 The patient is ambulatory; or
 - 3.2 The patient is able to use upper limbs; or
 - 3.3 The patient is able to swallow.

TETRABENAZINE

Tab 25 mg	126.02	112	✓ Motetis
-----------------	--------	-----	------------------

Anaesthetics

Local

LIDOCAINE [LIGNOCAINE]

Gel 2%, tube – Subsidy by endorsement	14.50	30 ml	✓ Xylocaine 2% Jelly
---	-------	-------	-----------------------------

a) Up to 150 ml available on a PSO

b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.

Gel 2%, 11 ml urethral syringe – Subsidy by endorsement.....	65.45	10	✓ Instillagel Lido
--	-------	----	---------------------------

a) Up to 5 each available on a PSO

b) Subsidised only if prescribed for urethral, cervical or rectal administration and the prescription is endorsed accordingly.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE				
Oral (gel) soln 2%.....	30.80	200 ml	✓	Xylocaine Viscous
Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO.....	15.00	25	✓	Lidocaine-Baxter
	17.50	50		
	(35.00)			Xylocaine
Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO.....	27.50	25	✓	Lidocaine-Baxter
Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO.....	12.00	5		
	(20.00)			Xylocaine
Inj 1%, 20 ml vial – Up to 5 inj available on a PSO.....	19.50	5	✓	Lidocaine-Baxter
Inj 2%, 20 ml vial – Up to 5 inj available on a PSO.....	14.00	5	✓	Lidocaine-Baxter
Inj 10%, 5 ml ampoule – Subsidy by endorsement.....	CBS	10	✓	Xylocard 500 ^{\$29}
Subsidised only for people receiving palliative care services where other analgesic agents haven't been effective.				

Topical Local Anaesthetics

➔SA0906 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years where the patient is a child with a chronic medical condition requiring frequent injections or venepuncture.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

LIDOCAINE [LIGNOCAINE] – Special Authority see [SA0906 above](#) – Retail pharmacy

Crm 4%.....	7.60	5 g OP	✓	LMX4
	30.00	30 g OP	✓	LMX4

LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE – Special Authority see [SA0906 above](#) – Retail pharmacy

Crm 2.5% with prilocaine 2.5%.....	45.00	30 g OP	✓	EMLA
Crm 2.5% with prilocaine 2.5% (5 g tubes).....	45.00	5	✓	EMLA

General Anaesthetics

KETAMINE – Subsidy by endorsement

- Up to 5 inj available on a PSO
- Subsidised only for use within a Primary Response in Medical Emergencies (PRIME) service or to treat intractable pain in palliative care* and the prescription or PSO is endorsed accordingly. Note: Indication marked with * is an unapproved indication.

Inj 100 mg per ml, 2 ml vial.....	91.98	5	✓	Ketalar
-----------------------------------	-------	---	---	----------------

Analgesics

For Anti-inflammatory NSAIDs refer to MUSCULOSKELETAL, [page 121](#)

Non-opioid Analgesics

ASPIRIN

* Tab dispersible 300 mg – Up to 30 tab available on a PSO.....	5.65	100	✓	Ethics Aspirin
---	------	-----	---	-----------------------

CAPSAICIN – Subsidy by endorsement

Subsidised only if prescribed for post-herpetic neuralgia or diabetic peripheral neuropathy and the prescription is endorsed accordingly.

Crm 0.075%.....	11.95	45 g OP	✓	Zo-Rub HP
			✓	Zostrix HP

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
METHOXYFLURANE – Subsidy by endorsement			
a) Only on a PSO			
b) Subsidised only for use within a Primary Response in Medical Emergencies (PRIME) service and the PSO is endorsed accordingly.			
Soln for inhalation 999.9 mg per g, 3 ml bottle – Up to 10 btl available on a PSO	276.00	10	✓ Penthrox
Soln for inhalation 999.9 mg per g, 3 ml bottle with inhaler device and activated carbon chamber – Up to 2 pack available on a PSO	54.00	1 OP	✓ Penthrox
NEFOPAM HYDROCHLORIDE			
Tab 30 mg	23.40	90	✓ Acupan

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PARACETAMOL				
Tab 500 mg - blister pack	12.06	1,000	✓	Pacimol
a) Maximum of 300 tab per prescription; can be waived by endorsement b) Up to 30 tab available on a PSO c) 1) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater, and the prescription is annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition. 2) Maximum of 100 tab per dispensing for non-endorsed patients. If quantities prescribed for more than 100 tabs (for non-endorsed patients), then dispense in repeat dispensings not exceeding 100 tab per dispensing. 3) Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A in accordance with the Integrated Community Pharmacy Services Agreement (ICPSA) – Extended Pharmacy Services. d) Pacimol to be Principal Supply on 1 December 2026				
Tab 500 mg - bottle pack – Maximum of 300 tab per prescription; can be waived by endorsement	17.92	1,000	✓	Noumed Paracetamol
1) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater, and the prescription is annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition. 2) Maximum of 100 tab per dispensing for non-endorsed patients. If quantities prescribed for more than 100 tabs (for non-endorsed patients), then dispense in repeat dispensings not exceeding 100 tab per dispensing.				
Oral liq 120 mg per 5 ml	3.18 3.98	200 ml	✓ ✓	Noumed Paracetamol (Ethics)
a) Maximum of 600 ml per prescription; can be waived by endorsement b) Up to 200 ml available on a PSO c) Not in combination d) 1) Maximum of 200 ml per dispensing for non-endorsed patients. If quantities prescribed exceed 200 ml (for non-endorsed patients), then dispense in repeat dispensing not exceeding 200 ml per dispensing. 2) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater and the prescription is endorsed or annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition. 3) Note: 200 ml presentations of paracetamol oral liquid may be supplied on BSO to a Vaccinator (other than a Pharmacist) under the provisions in Part I of Section A 4) Note: Direct Provision by a pharmacist of up to 200 ml permitted under the provisions in Part I of Section A in conjunction with immunisation of a child under 2 years of age with meningococcal B multicomponent vaccine, and otherwise in accordance with the Integrated Community Pharmacy Services Agreement (ICPSA) – Extended Pharmacy Services. e) Noumed to be Principal Supply on 1 November 2026				
Oral liq 250 mg per 5 ml	3.18	200 ml	✓	Pamol

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
a) Maximum of 600 ml per prescription; can be waived by endorsement			
b) Up to 200 ml available on a PSO			
c) Not in combination			
d)			
1) Maximum of 200 ml per dispensing for non-endorsed patients. If quantities prescribed exceed 200 ml (for non-endorsed patients), then dispense in repeat dispensing not exceeding 200 ml per dispensing.			
2) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater and the prescription is endorsed or annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition.			
3) Note: 200 ml presentations of paracetamol oral liquid may be supplied on BSO to a Vaccinator (other than a Pharmacist) under the provisions in Part I of Section A			
4) Note: Direct Provision by a pharmacist of up to 200 ml permitted under the provisions in Part I of Section A in conjunction with immunisation of a child under 2 years of age with meningococcal B multicomponent vaccine, and otherwise in accordance with the Integrated Community Pharmacy Services Agreement (ICPSA) – Extended Pharmacy Services.			
* Suppos 125 mg	4.93	10	✓ Gacet
* Suppos 250 mg	6.20	10	✓ Gacet
* Suppos 500 mg	18.00	50	✓ Gacet
<i>(Paracetamol (Ethics) Oral liq 120 mg per 5 ml to be delisted 1 November 2026)</i>			

Opioid Analgesics

CODEINE PHOSPHATE – Safety medicine; prescriber may determine dispensing frequency

Tab 15 mg	5.82	100	✓ Noumed
Tab 30 mg	6.88	100	✓ Noumed
Tab 60 mg	13.89	100	✓ Noumed

DIHYDROCODEINE TARTRATE

Tab long-acting 60 mg	9.20	60	✓ DHC Continus
-----------------------------	------	----	-----------------------

FENTANYL

a) Only on a controlled drug form			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensing frequency			
Inj 50 mcg per ml, 2 ml ampoule	4.25	10	✓ Boucher and Muir
Inj 50 mcg per ml, 10 ml ampoule	9.41	10	✓ Boucher and Muir
Patch 12 mcg per hour	6.02	5	✓ Fentanyl Sandoz
Patch 25 mcg per hour	6.91	5	✓ Fentanyl Sandoz
Patch 50 mcg per hour	9.28	5	✓ Fentanyl Sandoz
Patch 75 mcg per hour	15.50	5	✓ Fentanyl Sandoz
Patch 100 mcg per hour	16.37	5	✓ Fentanyl Sandoz

METHADONE HYDROCHLORIDE

a) Only on a controlled drug form			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensing frequency			
Tab 5 mg	1.38	10	✓ Methadone BNM
Oral liq 2 mg per ml	7.80	200 ml	✓ Biodone
Oral liq 5 mg per ml	7.80	200 ml	✓ Biodone Forte
Oral liq 10 mg per ml	9.65	200 ml	✓ Biodone Extra Forte
Inj 10 mg per ml, 1 ml	72.99	10	✓ AFT

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MORPHINE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Oral liq 1 mg per ml	19.00	200 ml	✓	RA-Morph
Oral liq 2 mg per ml	23.55	200 ml	✓	RA-Morph
Oral liq 5 mg per ml	28.20	200 ml	✓	RA-Morph
Oral liq 10 mg per ml	40.25	200 ml	✓	RA-Morph
MORPHINE SULPHATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Tab immediate-release 10 mg	2.80	10	✓	Sevredol
Tab immediate-release 20 mg	5.52	10	✓	Sevredol
Cap long-acting 10 mg	4.10	10	✓	m-Eslon
Cap long-acting 30 mg	6.05	10	✓	m-Eslon
Cap long-acting 60 mg	12.10	10	✓	m-Eslon
Cap long-acting 100 mg	14.50	10	✓	m-Eslon
Oral liq 2 mg per ml	16.31	100 ml	✓	Wockhardt S29
	29.80		✓	Oramorph
			✓	Oramorph CDC
				S29 S29
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	5.96	5	✓	Medsurge
Inj 10 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	4.99	5	✓	Medsurge
Inj 15 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	6.93	5	✓	Medsurge
Inj 30 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	7.28	5	✓	Medsurge
OXYCODONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Tab controlled-release 5 mg	2.49	20	✓	Oxycodone Sandoz
Tab immediate-release 5 mg	13.77	100	✓	Oxycodone Amneal
Tab controlled-release 10 mg	2.49	20	✓	Oxycodone Sandoz
Tab immediate-release 10 mg	18.77	100	✓	Oxycodone Amneal
Tab controlled-release 20 mg	3.41	20	✓	Oxycodone Sandoz
Tab immediate-release 20 mg	26.77	100	✓	Oxycodone Amneal
Tab controlled-release 40 mg	6.67	20	✓	Oxycodone Sandoz
Tab controlled-release 80 mg	12.99	20	✓	Oxycodone Sandoz
Oral liq 1 mg per ml	37.08	250 ml	✓	Rosemont
Inj 10 mg per ml, 1 ml ampoule	4.37	5	✓	Hameln
Inj 10 mg per ml, 2 ml ampoule	8.62	5	✓	Hameln
Inj 50 mg per ml, 1 ml ampoule	14.90	5	✓	Hameln
PARACETAMOL WITH CODEINE – Safety medicine; prescriber may determine dispensing frequency				
* Tab paracetamol 500 mg with codeine phosphate 8 mg	31.95	1,000	✓	Paracetamol + Codeine (Relieve)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PETHIDINE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Tab 50 mg	8.68	10	✓	Noumed Pethidine
Inj 50 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	29.88	5	✓	DBL Pethidine Hydrochloride
Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	30.72	5	✓	DBL Pethidine Hydrochloride
TRAMADOL HYDROCHLORIDE				
Tab sustained-release 100 mg	1.95	20	✓	Tramal SR 100
Tab sustained-release 150 mg	2.95	20	✓	Tramal SR 150
Tab sustained-release 200 mg	3.80	20	✓	Tramal SR 200
Cap 50 mg	3.33	100	✓	Arrow-Tramadol

Antidepressants

Cyclic and Related Agents

AMITRIPTYLINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	2.99	100	✓	Arrow-Amitriptyline
Tab 25 mg	1.99	100	✓	Arrow-Amitriptyline
Tab 50 mg	3.14	100	✓	Arrow-Amitriptyline
CLOMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
Tab 25 mg	16.99	50	✓	APO Clomipramine
DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Subsidy by endorsement				
a) Safety medicine; prescriber may determine dispensing frequency				
b) Subsidy by endorsement – Subsidised for patients who were taking dosulepin [dothiepin] hydrochloride prior to 1 June 2019 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of dosulepin [dothiepin] hydrochloride.				
Tab 75 mg	3.85	30	✓	Dosulepin Viatris
Cap 25 mg	7.83	50	✓	Dosulepin Viatris §29
IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	5.48	50	✓	Tofranil
Tab 25 mg	10.96	100	✓	Tofranil
Tab 25 mg	4.93	28	✓	Imipramine Crescent §29
	8.80	50	✓	Tofranil
NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	2.24	50	✓	Allegron
Tab 25 mg	2.95	50	✓	Allegron

Monoamine-Oxidase Inhibitors (MAOIs) - Non Selective

TRANLYCPROMINE SULPHATE				
* Tab 10 mg	22.94	50	✓	Parnate

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Monoamine-Oxidase Type A Inhibitors

MOCLOBEMIDE

* Tab 150 mg	23.60	60	✓ Aurorix
* Tab 300 mg	38.50	60	✓ Aurorix

Selective Serotonin Reuptake Inhibitors

CITALOPRAM HYDROBROMIDE

* Tab 20 mg	3.55	84	✓ Celapram
-------------------	------	----	-------------------

ESCITALOPRAM

* Tab 10 mg	0.95	28	✓ Ipca-Escitalopram
	1.07		✓ Escitalopram (Ethics)
* Tab 20 mg	1.80	28	✓ Ipca-Escitalopram
<i>(Escitalopram (Ethics) Tab 10 mg to be delisted 1 February 2027)</i>			

FLUOXETINE HYDROCHLORIDE

* Tab dispersible 20 mg, scored – Subsidy by endorsement.....	2.37	28	✓ Fluox
Subsidised by endorsement			
1) When prescribed for a patient who cannot swallow whole tablets or capsules and the prescription is endorsed accordingly; or			
2) When prescribed in a daily dose that is not a multiple of 20 mg in which case the prescription is deemed to be endorsed. Note: Tablets should be combined with capsules to facilitate incremental 10 mg doses.			

* Cap 20 mg	3.50	90	✓ Arrow-Fluoxetine
-------------------	------	----	---------------------------

PAROXETINE

* Tab 20 mg	4.98	90	✓ Loxamine
-------------------	------	----	-------------------

SERTRALINE

* Tab 50 mg	1.24	30	✓ Setrona
* Tab 100 mg	2.00	30	✓ Setrona

Other Antidepressants

MIRTAZAPINE

Tab 30 mg	2.34	30	✓ Noumed
Tab 45 mg	3.10	30	✓ Noumed

VENLAFAXINE

* Cap 37.5 mg	8.29	84	✓ Enlafax XR
* Cap 75 mg	10.32	84	✓ Enlafax XR
* Cap 150 mg	13.95	84	✓ Enlafax XR

Antiepilepsy Drugs

Agents for Control of Status Epilepticus

DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency

Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorsement.....	27.92	5	✓ Hospira
a) Up to 5 inj available on a PSO			
b) Only on a PSO			
c) PSO must be endorsed "not for anaesthetic procedures".			
Rectal tubes 5 mg – Up to 5 tube available on a PSO	54.58	5	✓ Stesolid

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PHENYTOIN SODIUM				
* Inj 50 mg per ml, 5 ml ampoule – Up to 5 inj available on a PSO	154.01	5	✓	Hospira
Control of Epilepsy				
CARBAMAZEPINE				
* Tab 200 mg	14.53	100	✓	Tegretol
* Tab long-acting 200 mg.....	16.98	100	✓	Tegretol CR
	33.96	200	✓	Tegretol CR
* Tab 400 mg	34.58	100	✓	Tegretol
* Tab long-acting 400 mg.....	39.17	100	✓	Tegretol CR
* Oral liq 20 mg per ml	26.37	250 ml	✓	Tegretol
CLOBAZAM – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	9.12	50	✓	Frisium
CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency				
Oral drops 2.5 mg per ml.....	7.38	10 ml OP	✓	Rivotril
ETHOSUXIMIDE				
Cap 250 mg	140.88	100	✓	Zarontin
Oral liq 250 mg per 5 ml	56.35	200 ml	✓	Zarontin
GABAPENTIN				
Note: Not subsidised in combination with subsidised pregabalin				
* Cap 100 mg	6.45	100	✓	Nupentin
* Cap 300 mg	8.45	100	✓	Nupentin
* Cap 400 mg	10.26	100	✓	Nupentin
LACOSAMIDE – Special Authority see SA2267 below – Retail pharmacy				
▲ Tab 50 mg	25.04	14	✓	Vimpat
▲ Tab 100 mg	50.06	14	✓	Vimpat
	200.24	56	✓	Vimpat
▲ Tab 150 mg	75.10	14	✓	Vimpat
	300.40	56	✓	Vimpat
▲ Tab 200 mg	400.55	56	✓	Vimpat
►SA2267 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:				
1 Patient has focal epilepsy; and				
2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).				
Note: Those of childbearing potential are not required to trial sodium valproate, or topiramate. Those who can father children are not required to trial sodium valproate.				
Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment.				
LAMOTRIGINE				
▲ Tab dispersible 2 mg	55.00	30	✓	Lamictal
▲ Tab dispersible 5 mg	50.00	30	✓	Lamictal
* Tab dispersible 25 mg	4.20	56	✓	Logem
* Tab dispersible 50 mg	5.11	56	✓	Logem
* Tab dispersible 100 mg	6.75	56	✓	Logem

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LEVETIRACETAM				
Tab 250 mg	5.84	60	✓	Everet
Tab 500 mg	10.51	60	✓	Everet
Tab 750 mg	16.71	60	✓	Everet
Tab 1,000 mg	21.82	60	✓	Everet
Oral liq 100 mg per ml	44.78	300 ml OP	✓	Levetiracetam-AFT
Inj 100 mg per ml, 5 ml vial	38.95	10	✓	Levetiracetam-AFT
PHENOBARBITONE				
For phenobarbitone oral liquid refer Standard Formulae, page 287				
Tab 15 mg	248.50	500	✓	Noumed Phenobarbitone
Tab 30 mg	398.50	500	✓	Noumed Phenobarbitone
PHENYTOIN SODIUM				
* Tab 50 mg	75.00	200	✓	Dilantin Infatab
Cap 30 mg	74.00	200	✓	Dilantin
Cap 100 mg	37.00	200	✓	Dilantin
* Oral liq 30 mg per 5 ml	22.03	500 ml	✓	Dilantin Paediatric
PREGABALIN				
Note: Not subsidised in combination with subsidised gabapentin				
* Cap 25 mg	2.25	56	✓	Lyrica
			✓	Pregabalin Pfizer
* Cap 75 mg	2.65	56	✓	Lyrica
			✓	Pregabalin Pfizer
* Cap 150 mg	4.01	56	✓	Lyrica
			✓	Pregabalin Pfizer
* Cap 300 mg	7.38	56	✓	Lyrica
			✓	Pregabalin Pfizer
PRIMIDONE				
* Tab 250 mg	37.35	100	✓	Primidone Clinect
SODIUM VALPROATE				
Tab 100 mg	13.65	100	✓	Epilim Crushable
Tab 200 mg EC	27.44	100	✓	Epilim
Tab 500 mg EC	52.24	100	✓	Epilim
* Oral liq 200 mg per 5 ml	20.48	300 ml	✓	Epilim S/F Liquid
			✓	Epilim Syrup
* Inj 100 mg per ml, 4 ml	9.98	1	✓	Epilim IV
STIRIPENTOL – Special Authority see SA2268 below – Retail pharmacy				
Cap 250 mg	509.29	60	✓	Diacomit
Powder for oral liq 250 mg sachet	509.29	60	✓	Diacomit

➔ [SA2268](#) Special Authority for Subsidy

Initial application only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has confirmed diagnosis of Dravet syndrome; and
- 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
continued...			
Note: Those of childbearing potential are not required to trial sodium valproate or topiramate. Those who can father children are not required to trial sodium valproate.			
Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.			
TOPIRAMATE			
▲ Tab 25 mg	11.07	60	✓ Arrow-Topiramate
	26.04		✓ Topiramate Actavis
▲ Tab 50 mg	18.81	60	✓ Topamax
	44.26		✓ Arrow-Topiramate
▲ Tab 100 mg	31.99	60	✓ Topiramate Actavis
	75.25		✓ Topamax
▲ Tab 200 mg	55.19	60	✓ Arrow-Topiramate
	129.85		✓ Topiramate Actavis
▲ Sprinkle cap 15 mg	20.84	60	✓ Topamax
▲ Sprinkle cap 25 mg	26.04	60	✓ Topamax
VIGABATRIN – Special Authority see SA2088 below – Retail pharmacy			
▲ Tab 500 mg	119.30	100	✓ Sabril

► **SA2088** **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:
Both:

- 1 Any of the following:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; or
 - 1.3 Patient has tuberous sclerosis complex; and
- 2 Either:
 - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields..

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Both:
- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
 - 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields..

Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, [page 121](#)

Acute Migraine Treatment

RIZATRIPTAN

Tab orodispersible 10 mg	2.46	18	✓ Rizatriptan Rising ^{\$29}
	4.10	30	✓ Rizamelt ✓ Rizatriptan Viatrix ^{\$29}

Rizamelt to be Principal Supply on 1 December 2026

SUMATRIPTAN

Tab 50 mg	14.41	90	✓ Sumagran
Tab 100 mg	22.68	90	✓ Sumagran
Inj 12 mg per ml, 0.5 ml prefilled pen – Maximum of 10 inj per prescription	29.80	2 OP	✓ Clustran

Prophylaxis of Migraine

For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYSTEM, [page 50](#)

PIZOTIFEN

* Tab 500 mcg.....	23.21	100	✓ Sandomigran
--------------------	-------	-----	----------------------

Antinausea and Vertigo Agents

For Antispasmodics refer to ALIMENTARY TRACT, [page 9](#)

APREPITANT – Special Authority see [SA0987 below](#) – Retail pharmacy

Cap 2 x 80 mg and 1 x 125 mg.....	21.90	3 OP	✓ Emend Tri-Pack
-----------------------------------	-------	------	-------------------------

►SA0987 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

BETAHISTINE DIHYDROCHLORIDE

* Tab 16 mg	6.55	100	✓ Serc
-------------------	------	-----	---------------

CYCLIZINE HYDROCHLORIDE

Tab 50 mg	0.66	10	✓ Nausicalm
-----------------	------	----	--------------------

CYCLIZINE LACTATE

Inj 50 mg per ml, 1 ml ampoule – Up to 10 inj available on a PSO	6.98	5	✓ Cyclizine lactate Medsurge
	17.86	10	✓ Hameln

(Hameln Inj 50 mg per ml, 1 ml ampoule to be delisted 1 February 2027)

DOMPERIDONE

* Tab 10 mg	3.80	100	✓ Domperidone Viatrix
-------------------	------	-----	--

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DROPERIDOL – Subsidy by endorsement				
a) Up to 10 inj available on a PSO				
b) Only on a PSO				
c) Subsidised only for use within a Primary Response in Medical Emergencies (PRIME) service and the PSO is endorsed accordingly.				
Inj 2.5 mg per ml, 1 ml ampoule	28.68	10	✓	Droperidol Medsurge
	43.85		✓	Droperidol Panpharma
<i>(Droperidol Panpharma Inj 2.5 mg per ml, 1 ml ampoule to be delisted 1 December 2026)</i>				
HYOSCINE HYDROBROMIDE				
* Inj 400 mcg per ml, 1 ml ampoule	93.00	10	✓	Martindale S29
Patch 1 mg per 72 hours – Special Authority see SA1998 below – Retail pharmacy	88.50	10	✓	Scopolamine Transdermal System Viatrix
►SA1998 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:				
1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or				
2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective.				
Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.				
METOCLOPRAMIDE HYDROCHLORIDE				
* Tab 10 mg – Up to 30 tab available on a PSO	1.57	100	✓	Metoclopramide Actavis 10
* Inj 5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	5.48	10	✓	Medsurge
ONDANSETRON				
* Tab 4 mg	1.95	50	✓	Periset
Tab disp 4 mg – Up to 10 tab available on a PSO	0.56	10	✓	Periset ODT
* Tab 8 mg	3.50	50	✓	Periset
Tab disp 8 mg – Up to 10 tab available on a PSO	0.90	10	✓	Periset ODT
PROCHLORPERAZINE				
* Tab 3 mg buccal	5.97 (30.00)	50		Prochlorperazine maleate (Brown & Burk)
* Tab 5 mg – Up to 30 tab available on a PSO	25.00	250	✓	Nausafix
* Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO	25.81	10	✓	Stemetil

Antipsychotics

General

AMISULPRIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 100 mg	5.84	30	✓	Sulprix
Tab 200 mg	14.47	60	✓	Sulprix
Tab 400 mg	35.06	60	✓	Sulprix

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ARIPRAZOLE – Safety medicine; prescriber may determine dispensing frequency				
Tab 5 mg	10.50	30	✓	Aripiprazole Sandoz
Tab 10 mg	10.50	30	✓	Aripiprazole Sandoz
Tab 15 mg	10.50	30	✓	Aripiprazole Sandoz
Tab 20 mg	10.50	30	✓	Aripiprazole Sandoz
Tab 30 mg	10.50	30	✓	Aripiprazole Sandoz
CHLORPROMAZINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
Tab 25 mg – Up to 30 tab available on a PSO	15.62	100	✓	Largactil
Tab 100 mg – Up to 30 tab available on a PSO	36.73	100	✓	Largactil
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO	30.79	10	✓	Largactil
CLOZAPINE – Hospital pharmacy [HP4]				
Safety medicine; prescriber may determine dispensing frequency				
Tab 25 mg	6.69	50	✓	Clopine
	13.37	100	✓	Clozaril
			✓	Clopine
			✓	Clozaril
Tab 50 mg	8.67	50	✓	Clopine
	17.33	100	✓	Clopine
Tab 100 mg	17.33	50	✓	Clopine
			✓	Clozaril
	34.65	100	✓	Clopine
			✓	Clozaril
Tab 200 mg	34.65	50	✓	Clopine
	69.30	100	✓	Clopine
Suspension 50 mg per ml	173.30	100 ml	✓	Versacloz
HALOPERIDOL – Safety medicine; prescriber may determine dispensing frequency				
Tab 500 mcg – Up to 30 tab available on a PSO	6.23	100	✓	Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO	9.43	100	✓	Serenace
Tab 5 mg – Up to 30 tab available on a PSO	14.86	50	✓	Serenace
	29.72	100	✓	Serenace
Oral liq 2 mg per ml – Up to 200 ml available on a PSO	23.84	100 ml	✓	Serenace
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	12.93	10	✓	Serenace
LEVOMEPROMAZINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 25 mg (33.8 mg as a maleate)	16.10	100	✓	Nozinan (Swiss)
Tab 25 mg as a maleate	16.10	100	✓	Nozinan
Tab 100 mg (135 mg as a maleate)	41.75	100	✓	Nozinan (Swiss)
Tab 100 mg as a maleate	41.75	100	✓	Nozinan
LEVOMEPROMAZINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
Inj 25 mg per ml, 1 ml ampoule	23.26	10	✓	Wockhardt
LITHIUM CARBONATE – Safety medicine; prescriber may determine dispensing frequency				
Tab long-acting 400 mg	82.80	100	✓	Priadel
Cap 250 mg	35.78	100	✓	Douglas

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
OLANZAPINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 2.5 mg	1.40	30	✓ Zypine	
	1.96	28	✓ APO-	
			Olanzapine	S29
Tab 5 mg	1.93	30	✓ Zypine	
	2.90	28	✓ APO-	
			Olanzapine	S29
Tab orodispersible 5 mg	2.42	28	✓ Zypine ODT	
	3.93		✓ APO-	
			Olanzapine	S29
	8.64	100	✓ Olanzapine ODT	
			Viatris	S29
Tab 10 mg	1.80	28	✓ Zypine	
	1.93	30	✓ Zypine	
	2.97	28	✓ APO-	
			Olanzapine	S29
Tab orodispersible 10 mg	2.89	28	✓ Olanzapina	
			Mylan	S29
			✓ Olanzapina Mylan	
			Pharma	S29
	4.49		✓ Zypine ODT	
			✓ APO-	
			Olanzapine	S29
	10.32	100	✓ Olanzapine ODT	
			Viatris	S29
PERICAZINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 2.5 mg	13.61	100	✓ Neulactil	
Tab 10 mg	48.45	100	✓ Neulactil	
QUETIAPINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 25 mg	0.79	30	✓ Quetiapine	
			Viatris	S29
	2.14	90	✓ Quetapel	
	13.11	500	✓ Quetiapine	
			Viatris	S29
Quetapel to be Principal Supply on 1 December 2026				
Tab 100 mg	5.91	90	✓ Quetapel	
Quetapel to be Principal Supply on 1 December 2026				
Tab 200 mg	9.93	90	✓ Quetapel	
Quetapel to be Principal Supply on 1 December 2026				
Tab 300 mg	14.48	90	✓ Quetapel	
Quetapel to be Principal Supply on 1 December 2026				

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
RISPERIDONE – Safety medicine; prescriber may determine dispensing frequency				
Tab 0.5 mg	2.17 4.01	60	✓	Risperidone (Teva) ✓ Risperidone Sandoz ^{S29}
Tab 1 mg	2.44	60	✓	Risperidone (Teva)
Tab 2 mg	2.72 5.38	60	✓	Risperidone (Teva) ✓ Risperidone Sandoz ^{S29}
Tab 3 mg	4.50	60	✓	Risperidone (Teva)
Tab 4 mg	6.25	60	✓	Risperdal ✓ Risperidone (Teva)
Oral liq 1 mg per ml	10.29 34.30	30 ml 100 ml	✓	Risperon ✓ Risperon
ZIPRASIDONE – Safety medicine; prescriber may determine dispensing frequency				
Cap 20 mg	17.90	60	✓	Zusdone
Cap 40 mg	27.41	60	✓	Zusdone
Cap 60 mg	38.39	60	✓	Zusdone
Cap 80 mg	46.55	60	✓	Zusdone
ZUCLOPENTHIXOL HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	31.45	100	✓	Clopixol

Depot Injections

ARIPIRAZOLE – Special Authority see [SA2395 below](#) – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 300 mg vial	273.56	1	✓	Abilify Maintena
Inj 400 mg vial	341.96	1	✓	Abilify Maintena

► [SA2395](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Either:
 - 1.1 The patient has had an initial Special Authority approval for risperidone depot injection, paliperidone depot injection or olanzapine depot injection; or
 - 1.2 All of the following:
 - 1.2.1 The patient has schizophrenia or other psychotic disorder; and
 - 1.2.2 The patient has received treatment with oral atypical antipsychotic agents but has been unable to adhere; and
 - 1.2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months; or
- 2 Patient has been unable to access olanzapine depot injection due to supply issues with olanzapine depot injection, or otherwise would have been started on olanzapine depot injection but has been unable to due to supply issues with olanzapine depot injection.

Notes: The Olanzapine depot injection Special Authority criteria that apply to criterion 2 in this Aripiprazole Special Authority application are as follows:

- The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
- All of the following:
 - The patient has schizophrenia; and
 - The patient has not been able to adhere with treatment using oral atypical antipsychotic agents; and
 - The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
FLUPENTHIXOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency				
Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO	13.14	5	✓	Fluanxol
Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO	20.90	5	✓	Fluanxol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	40.87	5	✓	Fluanxol
HALOPERIDOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency				
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO	28.39	5	✓	Haldol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	55.90	5	✓	Haldol Concentrate
			✓	Haldol
				Decanoas \$29
OLANZAPINE – Special Authority see SA2586 below – Retail pharmacy				
Safety medicine; prescriber may determine dispensing frequency				
Inj 210 mg vial	252.00	1	✓	Zyprexa Relprevv
Inj 300 mg vial	414.00	1	✓	Zyprexa Relprevv
Inj 405 mg vial	504.00	1	✓	Zyprexa Relprevv

► **SA2586** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
 - 1.2 All of the following:
 - 1.2.1 The patient has schizophrenia or other psychotic disorder; and
 - 1.2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 1.2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months; and
- 2 The patient has trialled other funded depot antipsychotics (aripiprazole, risperidone, and paliperidone) unless it is considered clinically inappropriate to use these; and
- 3 The patient continues to have difficulties with adherence on oral antipsychotic treatments; and
- 4 Prescribing clinician has relevant Clinical Director (Mental Health and Addiction services) approval.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE – Special Authority see [SA2396 below](#) – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency				
Inj 25 mg syringe	194.25	1	✓	Invega Sustenna
Inj 50 mg syringe	271.95	1	✓	Invega Sustenna
Inj 75 mg syringe	357.42	1	✓	Invega Sustenna
Inj 100 mg syringe	435.12	1	✓	Invega Sustenna
Inj 150 mg syringe	435.12	1	✓	Invega Sustenna

► **SA2396** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection or aripiprazole depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has been unable to adhere to treatment using oral atypical antipsychotic agents; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE PALMITATE – Special Authority see [SA2167 below](#) – Retail pharmacy

Inj 175 mg syringe	815.85	1	✓ Invega Trinza
Inj 263 mg syringe	1,072.26	1	✓ Invega Trinza
Inj 350 mg syringe	1,305.36	1	✓ Invega Trinza
Inj 525 mg syringe	1,305.36	1	✓ Invega Trinza

➔ [SA2167](#) **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Both:

- 1 The patient has schizophrenia; and
- 2 The patient has had an initial Special Authority approval for paliperidone once-monthly depot injection.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

RISPERIDONE – Special Authority see [SA2397 below](#) – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 25 mg vial	135.98	1	✓ Risperdal Consta
Inj 37.5 mg vial	178.71	1	✓ Risperdal Consta
Inj 50 mg vial	217.56	1	✓ Risperdal Consta

➔ [SA2397](#) **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection or aripiprazole depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has not been able to adhere with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

ZUCLOPENTHIXOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency

Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO	19.80	5	✓ Clopixol
--	-------	---	------------

Anxiolytics

BUSPIRONE HYDROCHLORIDE

* Tab 5 mg	13.95	100	✓ Buspirone Viatris
* Tab 10 mg	12.50	100	✓ Buspirone Viatris

CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency

Tab 500 mcg	5.64	100	✓ Paxam
Tab 2 mg	10.78	100	✓ Paxam

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency				
Tab 2 mg	95.00	500	✓	Arrow-Diazepam
Tab 5 mg	115.00	500	✓	Arrow-Diazepam
LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency				
Tab 1 mg	10.20	250	✓	Ativan
Tab 2.5 mg	13.13	100	✓	Ativan

Multiple Sclerosis Treatments

►SA2274 Special Authority for Subsidy

Initial application — (Multiple Sclerosis - dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab and teriflunomide) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1 All of the following:

- 1.1 Diagnosis of multiple sclerosis (MS) meets the McDonald 2017 diagnostic criteria for MS and has been confirmed by a neurologist; and
- 1.2 Patient has an EDSS score between 0 – 6.0; and
- 1.3 Patient has had at least one significant attack of MS in the previous 12 months or two significant attacks in the past 24 months; and
- 1.4 All of the following:
 - 1.4.1 Each significant attack must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the attack, but the neurologist/physician must be satisfied that the clinical features were characteristic); and
 - 1.4.2 Each significant attack is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s); and
 - 1.4.3 Each significant attack has lasted at least one week and has started at least one month after the onset of a previous attack (where relevant); and
 - 1.4.4 Each significant attack can be distinguished from the effects of general fatigue; and is not associated with a fever ($T > 37.5^{\circ}\text{C}$); and
 - 1.4.5 Either:
 - 1.4.5.1 Each significant attack is severe enough to change either the EDSS or at least one of the Kurtz Functional System scores by at least 1 point; or
 - 1.4.5.2 Each significant attack is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom); and

1.5 Evidence of new inflammatory activity on an MRI scan within the past 24 months; and

1.6 Any of the following:

- 1.6.1 A sign of that new inflammatory activity on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing lesion; or
- 1.6.2 A sign of that new inflammatory activity is a lesion showing diffusion restriction; or
- 1.6.3 A sign of that new inflammatory is a T2 lesion with associated local swelling; or
- 1.6.4 A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent attack that occurred within the last 2 years; or
- 1.6.5 A sign of that new inflammatory activity is new T2 lesions compared with a previous MRI scan; or

2 Patient has an active approval for ocrelizumab and does not have primary progressive MS.

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

Renewal — (Multiple Sclerosis - dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
beta-1-beta, natalizumab and teriflunomide) from any relevant practitioner. Approvals valid for 12 months where patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use of unilateral or bilateral aids at any time in the last six months (ie the patient has walked 100 metres or more with or without aids in the last six months).				
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
DIMETHYL FUMARATE – Special Authority see SA2274 on the previous page – Retail pharmacy				
a) Wastage claimable				
b) Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Cap 120 mg.....	520.00	14	✓	Tecfidera
Cap 240 mg.....	2,000.00	56	✓	Tecfidera
FINGOLIMOD – Special Authority see SA2274 on the previous page – Retail pharmacy				
a) Wastage claimable				
b) Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Cap 0.5 mg.....	2,200.00	28	✓	Gilenya
GLATIRAMER ACETATE – Special Authority see SA2274 on the previous page – Retail pharmacy				
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Inj 40 mg prefilled syringe.....	1,500.00	12	✓	Copaxone
INTERFERON BETA-1-ALPHA – Special Authority see SA2274 on the previous page – Retail pharmacy				
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Inj 6 million iu prefilled syringe.....	1,170.00	4	✓	Avonex
INTERFERON BETA-1-BETA – Special Authority see SA2274 on the previous page – Retail pharmacy				
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Inj 8 million iu per 1 ml.....	1,322.89	15	✓	Betaferon
NATALIZUMAB – Special Authority see SA2274 on the previous page – Retail pharmacy				
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Inj 20 mg per ml, 15 ml vial.....	1,750.00	1	✓	Tysabri
TERIFLUNOMIDE – Special Authority see SA2274 on the previous page – Retail pharmacy				
a) Wastage claimable				
b) Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Tab 14 mg	263.96	28	✓	Teriflunomide Sandoz
	282.81	30	✓	Teriflunomide Aurobindo \$29

Multiple Sclerosis Treatments - Other

OCRELIZUMAB – Special Authority see SA2273 below – Retail pharmacy				
Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.				
Inj 30 mg per ml, 10 ml vial.....	8,450.00	1	✓	Ocrevus
Inj 40 mg per ml, 23 ml vial.....	16,900.00	1	✓	Ocrevus SC
►SA2273 Special Authority for Subsidy				
Initial application — (Multiple Sclerosis - ocrelizumab) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:				
Either:				

1 All of the following:

1.1 Diagnosis of multiple sclerosis (MS) meets the McDonald 2017 diagnostic criteria for MS and has been confirmed

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- by a neurologist; and
- 1.2 Patient has an EDSS score between 0 – 6.0; and
- 1.3 Patient has had at least one significant attack of MS in the previous 12 months or two significant attacks in the past 24 months; and
- 1.4 All of the following:
 - 1.4.1 Each significant attack must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the attack, but the neurologist/physician must be satisfied that the clinical features were characteristic); and
 - 1.4.2 Each significant attack is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s); and
 - 1.4.3 Each significant attack has lasted at least one week and has started at least one month after the onset of a previous attack (where relevant); and
 - 1.4.4 Each significant attack can be distinguished from the effects of general fatigue; and is not associated with a fever ($T > 37.5^{\circ}\text{C}$); and
 - 1.4.5 Either:
 - 1.4.5.1 Each significant attack is severe enough to change either the EDSS or at least one of the Kurtz Functional System scores by at least 1 point; or
 - 1.4.5.2 Each significant attack is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom); and
- 1.5 Evidence of new inflammatory activity on an MRI scan within the past 24 months; and
- 1.6 Any of the following:
 - 1.6.1 A sign of that new inflammatory activity on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing lesion; or
 - 1.6.2 A sign of that new inflammatory activity is a lesion showing diffusion restriction; or
 - 1.6.3 A sign of that new inflammatory is a T2 lesion with associated local swelling; or
 - 1.6.4 A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent attack that occurred within the last 2 years; or
 - 1.6.5 A sign of that new inflammatory activity is new T2 lesions compared with a previous MRI scan; or
- 2 Patient has an active Special Authority approval for either dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1-alpha, interferon beta-1-beta, natalizumab or teriflunomide.

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

Renewal — (Multiple Sclerosis - ocrelizumab) from any relevant practitioner. Approvals valid for 12 months where patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use of unilateral or bilateral aids at any time in the last six months (ie the patient has walked 100 metres or more with or without aids in the last six months).

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

Initial application — (Primary Progressive Multiple Sclerosis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Diagnosis of primary progressive multiple sclerosis (PPMS) meets the 2017 McDonald criteria and has been confirmed by a neurologist; and
- 2 Patient has an EDSS 2.0 (score equal to or greater than 2 on pyramidal functions) to EDSS 6.5; and
- 3 Patient has no history of relapsing remitting multiple sclerosis.

Renewal — (Primary Progressive Multiple Sclerosis) from any relevant practitioner. Approvals valid for 12 months where patient has had an EDSS score of less than or equal to 6.5 at any time in the last six months (ie patient has walked 20 metres with bilateral assistance/aids, without rest in the last six months).

Sedatives and Hypnotics

MELATONIN – Special Authority see [SA2523 on the next page](#) – Retail pharmacy

Tab modified-release 2 mg – No more than 5 tab per day.....5.80

30

✓ **Vigisom**

Restricted to patients aged 18 years or under.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

►SA2523 Special Authority for Subsidy

Initial application only from a psychiatrist, paediatrician, neurologist, respiratory specialist or any relevant practitioner on the recommendation of a psychiatrist, paediatrician, neurologist or respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder)*; and
- 2 Behavioural and environmental approaches have been tried and were unsuccessful, or are inappropriate; and
- 3 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and
- 4 Patient is aged 18 years or under*.

Renewal only from a psychiatrist, paediatrician, neurologist, respiratory specialist or any relevant practitioner on the recommendation of a psychiatrist, paediatrician, neurologist or respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is aged 18 years or under*;
- 2 Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined); and
- 3 Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia; and
- 4 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day.

Note: Indications marked with * are unapproved indications.

MIDAZOLAM – Safety medicine; prescriber may determine dispensing frequency

Inj 1 mg per ml, 5 ml ampoule	7.80	10	✓ Midazolam-Baxter
Inj 1 mg per ml, 5 ml plastic ampoule – Up to 10 inj available on a PSO	46.65	10	✓ Midazolam-Pfizer
On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only.			
Inj 5 mg per ml, 1 ml plastic ampoule – Up to 10 inj available on a PSO	22.50	10	✓ Midazolam-Pfizer
On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only.			
Inj 5 mg per ml, 3 ml ampoule	4.75	5	✓ Midazolam-Baxter
Inj 5 mg per ml, 3 ml plastic ampoule – Up to 5 inj available on a PSO	35.10	5	✓ Midazolam-Pfizer
On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only.			

PHENOBARBITONE SODIUM – Special Authority see [SA1386 below](#) – Retail pharmacy

Inj 200 mg per ml, 1 ml ampoule	113.37	10	✓ Max Health ^{§29}
---------------------------------------	--------	----	-----------------------------

►SA1386 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 For the treatment of terminal agitation that is unresponsive to other agents; and
- 2 The applicant is part of a multidisciplinary team working in palliative care.

TEMAZEPAM – Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg	1.47	25	✓ Normison
-----------------	------	----	------------

ZOPICLONE – Safety medicine; prescriber may determine dispensing frequency

Tab 7.5 mg	21.85	500	✓ Zopiclone Actavis
------------------	-------	-----	---------------------

Spinal Muscular Atrophy

NUSINERSEN – PCT only – Special Authority see [SA2174 on the next page](#)

Inj 12 mg per 5 ml vial	120,000.00	1	✓ Spinraza
-------------------------------	------------	---	------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2174 Special Authority for Subsidy

Initial application — (spinal muscular atrophy (SMA)) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation; and
- 2 Patient is 18 years of age or under; and
- 3 Either:
 - 3.1 Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age; or
 - 3.2 Both:
 - 3.2.1 Patient is pre-symptomatic; and
 - 3.2.2 Patient has three or less copies of SMN2.

Renewal — (spinal muscular atrophy (SMA)) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 There has been demonstrated maintenance of motor milestone function since treatment initiation; and
- 2 Patient does not require invasive permanent ventilation (at least 16 hours per day) in the absence of a potentially reversible cause while being treated with nusinersen; and
- 3 Nusinersen not to be administered in combination other SMA disease modifying treatments or gene therapy.

RISDIPLAM – [Xpharm] – Special Authority see [SA2203 below](#)

Note: the supply of risdiplam is via Pharmac's approved direct distribution supply. Further details can be found on Pharmac's website <https://pharmac.govt.nz/risdiplam>

Powder for oral soln 750 mcg per ml, 60 mg per bottle..... 14,100.00 80 ml OP ✓ Evrysdi

►SA2203 Special Authority for Subsidy

Initial application — (spinal muscular atrophy (SMA)) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation; and
- 2 Patient is 18 years of age or under; and
- 3 Either:
 - 3.1 Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age; or
 - 3.2 Both:
 - 3.2.1 Patient is pre-symptomatic; and
 - 3.2.2 Patient has three or less copies of SMN2.

Renewal — (spinal muscular atrophy (SMA)) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 There has been demonstrated maintenance of motor milestone function since treatment initiation; and
- 2 Patient does not require invasive permanent ventilation (at least 16 hours per day) in the absence of a potentially reversible cause while being treated with risdiplam; and
- 3 Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy.

Stimulants/ADHD Treatments

ATOMOXETINE

Cap 10 mg	43.02	28	✓ APO-Atomoxetine
Cap 18 mg	45.57	28	✓ APO-Atomoxetine
Cap 25 mg	44.30	28	✓ APO-Atomoxetine
Cap 40 mg	46.21	28	✓ APO-Atomoxetine
Cap 60 mg	51.31	28	✓ APO-Atomoxetine
Cap 80 mg	65.20	28	✓ APO-Atomoxetine
Cap 100 mg	65.71	28	✓ APO-Atomoxetine

DEXAMFETAMINE SULFATE – Special Authority see [SA2587 below](#) – Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

Tab 5 mg	29.80	100	✓ Dexamfetamine Aspen
			✓ Noured Dexamfetamine

➔SA2587 Special Authority for Subsidy

Initial application — (ADHD in patients aged 5 years or over) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) in patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Applicant is a health practitioner authorised to prescribe treatment consistent with the approval notice gazetted for dexamfetamine (see note).

Note: Prescribing practitioner detail is in the relevant approval notice published in the New Zealand Gazette. Approval notices are located through the 'Medicines (controlled drugs) with restrictions under regulation 22 of the Misuse of Drugs Regulations 1977' section of the Medsafe 'Restrictions on the Supply, Prescribing or Administration of Medicines under the Medicines Act 1981 and Misuse of Drugs Regulations 1977' webpage (<https://www.medsafe.govt.nz/profs/riss/restrict.asp#MedicinesReg22> as of April 2025).

Initial application — (ADHD in patients aged under 5 years) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) in patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Applicant is a health practitioner authorised to prescribe treatment consistent with the approval notice gazetted for dexamfetamine (see note).

Note: Prescribing practitioner detail is in the relevant approval notice published in the New Zealand Gazette. Approval notices are located through the 'Medicines (controlled drugs) with restrictions under regulation 22 of the Misuse of Drugs Regulations 1977' section of the Medsafe 'Restrictions on the Supply, Prescribing or Administration of Medicines under the Medicines Act 1981 and Misuse of Drugs Regulations 1977' webpage (<https://www.medsafe.govt.nz/profs/riss/restrict.asp#MedicinesReg22> as of April 2025).

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid without further renewal unless notified where the patient suffers from narcolepsy.

LISDEXAMFETAMINE DIMESILATE – Special Authority see [SA2588 on the next page](#) – Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

Cap 30 mg – No more than 1 cap per day	60.00	30	✓ Vyvanse
Cap 50 mg	60.00	30	✓ Vyvanse
Cap 70 mg	60.00	30	✓ Vyvanse

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2588 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with lisdexamfetamine dimesilate and met all the following criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 ADHD (Attention Deficit and Hyperactivity Disorder); and
 - 2.2 Diagnosed according to DSM-5 or ICD 11 criteria; and
 - 2.3 Applicant is a health practitioner authorised to prescribe treatment consistent with the approval notice gazetted for lisdexamfetamine (see note); and
 - 2.4 Any of the following:
 - 2.4.1 Patient is taking a currently subsidised formulation of atomoxetine or methylphenidate hydrochloride (extended-release) for ADHD and has not received sufficient clinical benefit or has experienced intolerable side effects; or
 - 2.4.2 Patient is taking a currently subsidised formulation of dexamfetamine sulfate (immediate-release) which has not been effective due to significant administration and/or treatment adherence difficulties; or
 - 2.4.3 There is significant concern regarding the risk of diversion or abuse of immediate release dexamfetamine sulfate; or
 - 2.4.4 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained release) which has not been effective due to significant administration and/or treatment adherence difficulties; or
 - 2.4.5 There is significant concern regarding the risk of diversion or abuse of immediate release methylphenidate hydrochloride; or
 - 2.4.6 Both:
 - 2.4.6.1 Patient would have been prescribed a subsidised formulation of methylphenidate hydrochloride (extended-release) but has been unable to access due to supply issues with methylphenidate hydrochloride (extended-release); and
 - 2.4.6.2 Other alternative stimulant presentations (methylphenidate or dexamfetamine) are not appropriate; and
- 2.5 Lisdexamfetamine dimesilate is not to be used in combination with another funded methylphenidate presentation.

Note: Prescribing practitioner detail is in the relevant approval notice published in the New Zealand Gazette. Approval notices are located through the 'Medicines (controlled drugs) with restrictions under regulation 22 of the Misuse of Drugs Regulations 1977' section of the Medsafe 'Restrictions on the Supply, Prescribing or Administration of Medicines under the Medicines Act 1981 and Misuse of Drugs Regulations 1977' webpage (<https://www.medsafe.govt.nz/profs/riss/restrict.asp#MedicinesReg22> as of April 2025).

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
METHYLPHENIDATE HYDROCHLORIDE – Special Authority see SA2590 below – Retail pharmacy				
a) Only on a controlled drug form				
b) Safety medicine; prescriber may determine dispensing frequency				
Tab modified-release 18 mg.....	15.25	30	✓	Methylphenidate Sandoz XR
Tab modified-release 27 mg.....	16.25	30	✓	Methylphenidate Sandoz XR
Tab modified-release 36 mg.....	21.25	30	✓	Methylphenidate Sandoz XR
Tab modified-release 54 mg.....	24.25	30	✓	Methylphenidate Sandoz XR
Tab immediate-release 5 mg.....	3.20	30	✓	Rubifen
Tab immediate-release 10 mg.....	3.00	30	✓	Rubifen
	4.00		✓	Ritalin
Tab extended-release 18 mg.....	15.25	30	✓	Methylphenidate ER - Teva
Tab immediate-release 20 mg.....	7.85	30	✓	Rubifen
Tab sustained-release 20 mg.....	10.95	30	✓	Rubifen SR
Tab extended-release 27 mg.....	16.25	30	✓	Methylphenidate ER - Teva
Tab extended-release 36 mg.....	21.25	30	✓	Methylphenidate ER - Teva
Tab extended-release 54 mg.....	24.25	30	✓	Methylphenidate ER - Teva

➤ [SA2590](#) Special Authority for Subsidy

Initial application — (ADHD in patients aged 5 years or over) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) in patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Applicant is a health practitioner authorised to prescribe treatment consistent with the approval notice gazetted for methylphenidate (see note).

Note: Prescribing practitioner detail is in the relevant approval notice published in the New Zealand Gazette. Approval notices are located through the 'Medicines (controlled drugs) with restrictions under regulation 22 of the Misuse of Drugs Regulations 1977' section of the Medsafe 'Restrictions on the Supply, Prescribing or Administration of Medicines under the Medicines Act 1981 and Misuse of Drugs Regulations 1977' webpage (<https://www.medsafe.govt.nz/profs/riss/restrict.asp#MedicinesReg22> as of April 2025).

Initial application — (ADHD in patients aged under 5 years) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) in patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Applicant is a health practitioner authorised to prescribe treatment consistent with the approval notice gazetted for methylphenidate (see note).

Note: Prescribing practitioner detail is in the relevant approval notice published in the New Zealand Gazette. Approval notices are located through the 'Medicines (controlled drugs) with restrictions under regulation 22 of the Misuse of Drugs Regulations 1977' section of the Medsafe 'Restrictions on the Supply, Prescribing or Administration of Medicines under the Medicines Act 1981 and Misuse of Drugs Regulations 1977' webpage (<https://www.medsafe.govt.nz/profs/riss/restrict.asp#MedicinesReg22> as of April 2025).

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

of April 2025).

Initial application — (Narcolepsy*) only from a neurologist or respiratory specialist. Approvals valid without further renewal unless notified where the patient suffers from narcolepsy.

Note: *narcolepsy is not a registered indication for Methylphenidate ER – Teva or Methylphenidate Sandoz XR.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE – Special Authority see [SA2591 below](#) – Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

Tab extended-release 18 mg.....	58.96	30	✓ Concerta
Tab extended-release 27 mg.....	65.44	30	✓ Concerta
Tab extended-release 36 mg.....	71.93	30	✓ Concerta
Tab extended-release 54 mg.....	86.24	30	✓ Concerta
Cap modified-release 10 mg.....	19.41	30	✓ Ritalin LA
Cap modified-release 20 mg.....	27.72	30	✓ Ritalin LA
Cap modified-release 30 mg.....	34.39	30	✓ Ritalin LA
Cap modified-release 40 mg.....	38.67	30	✓ Ritalin LA

➔ **SA2591** Special Authority for Subsidy

Initial application — (ADHD) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 All of the following:

1.1 ADHD (Attention Deficit and Hyperactivity Disorder); and

1.2 Diagnosed according to DSM-IV or ICD 10 criteria; and

1.3 Applicant is a health practitioner authorised to prescribe treatment consistent with the approval notice gazetted for methylphenidate (see note); and

1.4 Either:

1.4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or difficulties with adherence; or

1.4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride; or

2 Both:

2.1 Patient meets the Special Authority criteria for SA2590 methylphenidate hydrochloride; and

2.2 Patient is unable to access other methylphenidate hydrochloride presentations under Special Authority criteria SA2590 due to an out of stock (see note).

Notes: Criterion 2 is to permit short-term funding to cover an out-of-stock on tab extended-release Methylphenidate ER – Teva and tab sustained-release 20 mg Rubifen SR subsidised under SA2590 (<https://schedule.pharmac.govt.nz/latest/SA2590.pdf>). Prescribing practitioner detail is in the relevant approval notice published in the New Zealand Gazette. Approval notices are located through the 'Medicines (controlled drugs) with restrictions under regulation 22 of the Misuse of Drugs Regulations 1977' section of the Medsafe 'Restrictions on the Supply, Prescribing or Administration of Medicines under the Medicines Act 1981 and Misuse of Drugs Regulations 1977' webpage (<https://www.medsafe.govt.nz/profs/riss/restrict.asp#MedicinesReg22> as of April 2025).

Initial application — (Narcolepsy*) only from a neurologist or respiratory specialist. Approvals valid without further renewal unless notified where the patient suffers from narcolepsy.

Note: *narcolepsy is not a registered indication for Concerta or Ritalin LA.

MODAFINIL – Special Authority see [SA2451 on the next page](#) – Retail pharmacy

Tab 100 mg.....	14.27	30	✓ Modafinil Max Health
-----------------	-------	----	-------------------------------

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

►SA2451 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
 - 1.2 Either:
 - 1.2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
 - 1.2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
 - 1.3 Either:
 - 1.3.1 An effective dose of a subsidised formulation of methylphenidate or dexamfetamine has been trialled and discontinued because of intolerable side effects; or
 - 1.3.2 Methylphenidate and dexamfetamine are contraindicated; or
- 2 Both:
 - 2.1 Patient meets the Special Authority criteria for methylphenidate hydrochloride or methylphenidate hydrochloride extended-release for narcolepsy; and
 - 2.2 Patient is unable to access methylphenidate hydrochloride presentations due to an out of stock (see note).

Note: Criterion 2 is to permit short-term funding to cover an out-of-stock of methylphenidate hydrochloride or methylphenidate hydrochloride extended release.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

* Tab 5 mg	3.85	84	✓ Ipca-Donepezil
* Tab 10 mg	5.90	84	✓ Ipca-Donepezil
RIVASTIGMINE – Special Authority see SA2524 below – Retail pharmacy			
Patch 4.6 mg per 24 hour	49.40	30	✓ Rivastigmine Patch BNM 5
Patch 9.5 mg per 24 hour	49.40	30	✓ Rivastigmine Patch BNM 10

►SA2524 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient has been diagnosed with dementia; and
- 2 The patient is contraindicated to or has experienced intolerable side effects from donepezil tablets.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Treatments for Substance Dependence

BUPRENORPHINE WITH NALOXONE – Special Authority see [SA2592 below](#) – Retail pharmacy

a) No patient co-payment payable

b) Safety medicine; prescriber may determine dispensing frequency

Tab sublingual 2 mg with naloxone 0.5 mg	11.76	28	✓ <u>Buprenorphine</u> <u>Naloxone BNM</u>
Tab sublingual 8 mg with naloxone 2 mg	26.86	28	✓ <u>Buprenorphine</u> <u>Naloxone BNM</u>

►SA2592 Special Authority for Subsidy

Initial application — (Detoxification) from any medical practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health..

Initial application — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Detoxification) from any medical practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and
- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient received but failed detoxification with buprenorphine with naloxone; and
- 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
- 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE

Tab modified-release 150 mg	15.00	30	✓ Zyban
-----------------------------------	-------	----	----------------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DISULFIRAM				
Tab 200 mg	236.40	100	✓	Antabuse
NALTREXONE HYDROCHLORIDE – Special Authority see SA1408 below – Retail pharmacy				
Tab 50 mg	83.33	30	✓	Naltrexond
	106.45		✓	Naltrexone-GH \$29

►SA1408 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to Health NZ or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

NICOTINE

- a) Nicotine will not be funded in amounts less than 4 weeks of treatment.
 - b) Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.
- | | | | | |
|---|-------|-----|---|-----------------|
| Patch 7 mg – Up to 28 patch available on a PSO | 19.62 | 28 | ✓ | Habitrol |
| Patch 14 mg – Up to 28 patch available on a PSO | 21.57 | 28 | ✓ | Habitrol |
| Patch 14 mg for direct distribution only – [Xpharm]..... | 12.49 | 7 | ✓ | Habitrol |
| Patch 21 mg – Up to 28 patch available on a PSO | 24.72 | 28 | ✓ | Habitrol |
| Patch 21 mg for direct distribution only – [Xpharm]..... | 13.19 | 7 | ✓ | Habitrol |
| Lozenge 1 mg – Up to 216 loz available on a PSO | 22.53 | 216 | ✓ | Habitrol |
| Lozenge 1 mg for direct distribution only – [Xpharm]..... | 12.89 | 36 | ✓ | Habitrol |
| Lozenge 2 mg – Up to 216 loz available on a PSO | 24.68 | 216 | ✓ | Habitrol |
| Lozenge 2 mg for direct distribution only – [Xpharm]..... | 13.25 | 36 | ✓ | Habitrol |
| Gum 2 mg (Fruit) – Up to 204 piece available on a PSO | 23.02 | 204 | ✓ | Habitrol |
| Gum 2 mg (Fruit) for direct distribution only – [Xpharm]..... | 17.57 | 96 | ✓ | Habitrol |
| Gum 2 mg (Mint) – Up to 204 piece available on a PSO..... | 23.02 | 204 | ✓ | Habitrol |
| Gum 2 mg (Mint) for direct distribution only – [Xpharm]..... | 17.57 | 96 | ✓ | Habitrol |
| Gum 4 mg (Fruit) – Up to 204 piece available on a PSO | 25.98 | 204 | ✓ | Habitrol |
| Gum 4 mg (Fruit) for direct distribution only – [Xpharm]..... | 23.87 | 96 | ✓ | Habitrol |
| Gum 4 mg (Mint) – Up to 204 piece available on a PSO..... | 25.98 | 204 | ✓ | Habitrol |
| Gum 4 mg (Mint) for direct distribution only – [Xpharm]..... | 23.87 | 96 | ✓ | Habitrol |

VARENICLINE TARTRATE – Special Authority see [SA1845 on the next page](#) – Retail pharmacy

- a) A maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval, including the starter pack
- b) Varenicline will not be funded in amounts less than 4 weeks of treatment.
- c) The 6-month time period in which a patient can receive a funded 12-week course of varenicline tartrate starts from the date the Special Authority is approved.

Tab 0.5 mg x 11 and 1 mg x 42	15.99	53 OP	✓	Pharmacor Varenicline
Tab 1 mg	10.99	56	✓	Pharmacor Varenicline

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1845 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not had a Special Authority for varenicline approved in the last 6 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 12 weeks' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 It has been 6 months since the patient's previous Special Authority was approved; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 12 weeks' funded varenicline (see note).

The patient must not have had an approval in the past 6 months.

Notes: a maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval.

This includes the 4-week 'starter' pack.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Chemotherapeutic Agents

Alkylating Agents

BENDAMUSTINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see [SA2398](#) below

Inj 25 mg vial	50.05	1	✓	Bendamustine Sandoz
	77.00		✓	Ribomustin
Inj 100 mg vial	200.20	1	✓	Bendamustine Sandoz
	308.00		✓	Ribomustin
Inj 1 mg for ECP	2.11	1 mg	✓	Baxter

► [SA2398](#) Special Authority for Subsidy

Initial application — (CLL*) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has chronic lymphocytic leukaemia requiring treatment; and
- 2 Patient has ECOG performance status of 0-2; and
- 3 Bendamustine is to be administered at a maximum dose of 100 mg/m² on days 1 and 2 every 4 weeks for a maximum of 6 cycles.

Note: Indication marked with a * includes indications that are unapproved. 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL).

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has indolent low grade NHL requiring treatment; and
- 2 The patient has ECOG performance status of 0-2; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient is treatment naive; and
 - 3.1.2 Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+); or
 - 3.2 Both:
 - 3.2.1 Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen; and
 - 3.2.2 Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles; or
 - 3.3 All of the following:
 - 3.3.1 The patient has not received prior bendamustine therapy; and
 - 3.3.2 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
 - 3.3.3 Patient has had a rituximab treatment-free interval of 12 months or more; or
 - 3.4 Bendamustine is to be administered as monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient is refractory to or has relapsed within 12 months of rituximab in combination with bendamustine; and

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
continued...			
1.2 Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles; or			
2 Both:			
2.1 Patients have not received a bendamustine regimen within the last 12 months; and			
2.2 Either:			
2.2.1 Both:			
2.2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and			
2.2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or			
2.2.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.			
Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenstrom's macroglobulinaemia.			
Initial application — (Hodgkin's lymphoma*) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:			
All of the following:			
1 Patient has Hodgkin's lymphoma requiring treatment; and			
2 Patient has a ECOG performance status of 0-2; and			
3 Patient has received one prior line of chemotherapy; and			
4 Patient's disease relapsed or was refractory following prior chemotherapy; and			
5 Bendamustine is to be administered in combination with gemcitabine and vinorelbine (BeGeV) at a maximum dose of no greater than 90 mg/m ² twice per cycle, for a maximum of four cycles.			
Note: Indications marked with * are unapproved indications.			
BUSULFAN – PCT – Retail pharmacy-Specialist			
Tab 2 mg	89.25	100	✓ Myleran
CARBOPLATIN – PCT only – Specialist			
Inj 10 mg per ml, 45 ml vial.....	25.73	1	✓ Carboplatin Accord
	32.59		✓ DBL Carboplatin
	48.50		✓ Carbaccord
Inj 1 mg for ECP	0.06	1 mg	✓ Baxter
CARMUSTINE – PCT only – Specialist			
Inj 100 mg vial	710.00	1	✓ BICNU
Inj 100 mg for ECP	710.00	100 mg OP	✓ Baxter
CHLORAMBUCIL – PCT – Retail pharmacy-Specialist			
Tab 2 mg	29.06	25	✓ Leukeran FC
CISPLATIN – PCT only – Specialist			
Inj 1 mg per ml, 50 ml vial.....	9.45	1	✓ Cisplatin Accord
	15.00		✓ Cisplatin Ebewe
Inj 1 mg per ml, 100 ml vial.....	18.90	1	✓ Cisplatin Accord
	21.00		✓ Cisplatin Ebewe
	29.66		✓ DBL Cisplatin
Inj 1 mg for ECP	0.19	1 mg	✓ Baxter
CYCLOPHOSPHAMIDE			
Tab 50 mg – PCT – Retail pharmacy-Specialist.....	145.00	50	✓ Cyclonex
Inj 1 g vial – PCT – Retail pharmacy-Specialist.....	47.46	1	✓ Endoxan
	127.80	6	✓ Cytoxan
Inj 2 g vial – PCT only – Specialist	95.06	1	✓ Cyclophosphamide
			Seacross
			✓ Endoxan
Inj 1 mg for ECP – PCT only – Specialist.....	0.05	1 mg	✓ Baxter

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
IFOSFAMIDE – PCT only – Specialist				
Inj 1 g.....	96.00	1	✓	Holoxan
Inj 2 g.....	180.00	1	✓	Holoxan
Inj 1 mg for ECP.....	0.10	1 mg	✓	Baxter
IFOSFAMIDE WITH MESNA – PCT only – Specialist				
Inj 2 g vial with mesna 3 x 100 mg per ml, 4 ml ampoule	62.00	1 OP	✓	Ifomid - M
LOMUSTINE – PCT – Retail pharmacy-Specialist				
Cap 40 mg.....	880.00	20	✓	Medac S29
MELPHALAN				
Tab 2 mg – PCT – Retail pharmacy-Specialist.....	40.70	25	✓	Alkeran
Inj 50 mg – PCT only – Specialist.....	46.80	1	✓	Melpha
	67.80		✓	Alkeran
OXALIPLATIN – PCT only – Specialist				
Inj 100 mg vial	25.01	1	✓	Oxaliplatin Actavis 100
	110.00		✓	Oxaliplatin Ebewe
Inj 5 mg per ml, 20 ml vial.....	33.35	1	✓	Alchemy Oxaliplatin
	46.32		✓	Oxaliplatin Accord
Inj 1 mg for ECP.....	0.35	1 mg	✓	Baxter
THIOTEPA – PCT only – Specialist				
Inj 15 mg vial	CBS	1	✓	Bedford S29
			✓	Max Health S29
			✓	THIO-TEPA S29
	398.00		✓	Tepadina
Inj 100 mg vial	CBS	1	✓	Max Health S29
	1,800.00		✓	Tepadina
			✓	Thiotepa-Reach

Antimetabolites

AZACITIDINE – PCT only – Specialist – Special Authority see [SA2479 below](#)

Inj 100 mg vial	50.00	1	✓	Azacitidine Dr Reddy's
Inj 1 mg for ECP.....	0.54	1 mg	✓	Baxter

►SA2479 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- Any of the following:
 - The individual has intermediate or high risk MDS based on an internationally recognised scoring system; or
 - The individual has chronic myelomonocytic leukaemia (based on an intermediate or high risk score from an internationally recognised scoring system or 10%-29% marrow blasts without myeloproliferative disorder); or
 - The individual has acute myeloid leukaemia according to World Health Organisation Classification (WHO); and
- The individual has an estimated life expectancy of at least 3 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where there is no evidence of disease progression.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CALCIUM FOLINATE				
Tab 15 mg – PCT – Retail pharmacy-Specialist.....	135.33	10	✓	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist.....	17.10	5	✓	Hospira
Inj 10 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist.....	112.20	5	✓	Eurofolic
Inj 50 mg – PCT – Retail pharmacy-Specialist.....	72.80	10	✓	Leucovorin Pharmacia ^{S29}
Inj 10 mg per ml, 10 ml vial – PCT only – Specialist	163.35	5	✓	Eurofolic
Inj 100 mg – PCT only – Specialist.....	94.90	10	✓	Leucovorin Pharmacia ^{S29}
Inj 300 mg – PCT only – Specialist.....	21.55	1	✓	Leucovorin DBL ^{S29}
Inj 10 mg per ml, 100 ml vial – PCT only – Specialist	139.48	1	✓	Eurofolic
Inj 1 mg for ECP – PCT only – Specialist.....	0.14	1 mg	✓	Baxter
CAPECITABINE – Retail pharmacy-Specialist				
Tab 150 mg	10.92	60	✓	Capecitabine Viatris
Tab 500 mg	50.96	120	✓	Capecitabine Viatris
CLADRIBINE – PCT only – Specialist				
Inj 1 mg per ml, 10 ml.....	749.96	1	✓	Leustatin
Inj 10 mg for ECP	749.96	10 mg OP	✓	Baxter
CYTARABINE				
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist.....	472.00	5	✓	Pfizer
Inj 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist	48.80	1	✓	Cytarabine DBL
Inj 1 mg for ECP – PCT only – Specialist.....	0.29	10 mg	✓	Pfizer
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist.....	94.40	100 mg OP	✓	Baxter
FLUDARABINE PHOSPHATE				
Tab 10 mg – PCT – Retail pharmacy-Specialist.....	412.00	20	✓	Fludara Oral
Inj 50 mg vial – PCT only – Specialist	744.95	5	✓	Fludarabine Ebewe
Inj 50 mg for ECP – PCT only – Specialist.....	148.99	50 mg OP	✓	Baxter
FLUOROURACIL				
Inj 50 mg per ml, 20 ml vial – PCT only – Specialist	10.51	1	✓	Fluorouracil Accord
Inj 50 mg per ml, 50 ml vial – PCT only – Specialist	14.72	1	✓	Fluorouracil Accord
Inj 50 mg per ml, 100 ml vial – PCT only – Specialist	19.36	1	✓	Fluorouracil Accord
Inj 1 mg for ECP – PCT only – Specialist.....	0.41	100 mg	✓	Baxter
GEMCITABINE HYDROCHLORIDE – PCT only – Specialist				
Inj 43.3 mg per ml (equivalent to 38 mg per ml gemcitabine), 26.3 ml vial	18.94	1	✓	DBL Gemcitabine
Inj 1 g.....	15.89	1	✓	Gemcitabine Ebewe
Inj 1 mg for ECP	0.02	1 mg	✓	Baxter
IRINOTECAN HYDROCHLORIDE – PCT only – Specialist				
Inj 20 mg per ml, 5 ml vial.....	52.57	1	✓	Accord
	71.44		✓	Irinotecan Actavis 100
	100.00		✓	Irinotecan-Rex
Inj 20 mg per ml, 25 ml vial.....	262.85	1	✓	Accord ^{S29}
Inj 1 mg for ECP	0.54	1 mg	✓	Baxter

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MERCAPTOPURINE				
Tab 50 mg – PCT – Retail pharmacy-Specialist.....	19.50	25	✓	Puri-nethol
Oral suspension 20 mg per ml – Retail pharmacy-Specialist – Special Authority see SA1725 below	428.00	100 ml OP	✓	Allmercap Xaluprine ^{S29}
►SA1725 Special Authority for Subsidy				
Initial application only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where the patient requires a total dose of less than one full 50 mg tablet per day.				
Renewal only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where patient still requires a total dose of less than one full 50 mg tablet per day.				
METHOTREXATE				
* Tab 2.5 mg – PCT	7.80	90	✓	Trexate
* Tab 10 mg – PCT	26.40	90	✓	Trexate
* Inj 2.5 mg per ml, 2 ml – PCT.....	95.29	5	✓	Methotrexate DBL
* Inj 7.5 mg prefilled syringe.....	29.17	1	✓	Methotrexate Pharmascience ^{S29}
			✓	Methotrexate Sandoz
* Inj 10 mg prefilled syringe.....	19.09	1	✓	Methotrexate Sandoz
* Inj 15 mg prefilled syringe.....	24.53	1	✓	Methotrexate Sandoz
* Inj 20 mg prefilled syringe.....	16.64	1	✓	Methotrexate Sandoz
* Inj 25 mg prefilled syringe.....	20.72	1	✓	Methotrexate Sandoz
* Inj 30 mg prefilled syringe.....	55.00	1	✓	Methotrexate Sandoz
* Inj 25 mg per ml, 2 ml vial – PCT	30.00	5	✓	Methotrexate DBL Onco-Vial
* Inj 25 mg per ml, 20 ml vial – PCT	45.00	1	✓	DBL Methotrexate Onco-Vial
* Inj 100 mg per ml, 10 ml – PCT.....	25.00	1	✓	Methotrexate Ebewe
* Inj 100 mg per ml, 50 ml vial – PCT	67.99	1	✓	Methotrexate Ebewe
* Inj 1 mg for ECP – PCT only – Specialist.....	0.06	1 mg	✓	Baxter
* Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist.....	19.06	5 mg OP	✓	Baxter
PEMETREXED – PCT only – Specialist				
Inj 100 mg vial	8.99	1	✓	Pemetrexed-AFT
	60.89		✓	Juno Pemetrexed
Inj 500 mg vial	29.99	1	✓	Pemetrexed-AFT
	217.77		✓	Juno Pemetrexed
Inj 1 mg for ECP	0.11	1 mg	✓	Baxter
THIOGUANINE – PCT – Retail pharmacy-Specialist				
Tab 40 mg	126.31	25	✓	Lanvis

Other Cytotoxic Agents

AMSACRINE – PCT only – Specialist

Inj 50 mg per ml, 1.5 ml ampoule	4,736.00	6	✓	Amsidine ^{S29}
Inj 75 mg.....	6,218.00	5	✓	AmsaLyo ^{S29}

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ANAGRELIDE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist				
Cap 0.5 mg.....	1,175.87	100	✓	Agrylin
ARSENIC TRIOXIDE – PCT only – Specialist				
Inj 1 mg per ml, 10 ml vial.....	4,817.00	10	✓	Phenasen
Inj 10 mg for ECP.....	481.70	10 mg OP	✓	Baxter
BLEOMYCIN SULPHATE – PCT only – Specialist				
Inj 15,000 iu, vial.....	185.16	1	✓	DBL Bleomycin Sulfate
Inj 1,000 iu for ECP.....	14.32	1,000 iu	✓	Baxter
BORTEZOMIB – PCT only – Specialist – Special Authority see SA2593 below				
Inj 3.5 mg vial.....	23.99	1	✓	Bortezomib Eugia
	74.93		✓	DBL Bortezomib
Inj 1 mg for ECP.....	7.13	1 mg	✓	Baxter
►SA2593 Special Authority for Subsidy				
Initial application — (plasma cell dyscrasia) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment.				
Initial application — (Waldenström Macroglobulinaemia) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:				
Both:				
1 The patient has Waldenström Macroglobulinaemia/Lymphoplasmacytic Lymphoma requiring treatment; and				
2 The patient has not received prior bortezomib treatment.				
Renewal — (Waldenström Macroglobulinaemia) from any relevant practitioner. Approvals valid for 12 months where there is no evidence of clinical disease progression during bortezomib use.				
DACARBAZINE – PCT only – Specialist				
Inj 200 mg vial.....	72.11	1	✓	DBL Dacarbazine
Inj 200 mg for ECP.....	72.11	200 mg OP	✓	Baxter
DACTINOMYCIN [ACTINOMYCIN D] – PCT only – Specialist				
Inj 0.5 mg vial.....	255.00	1	✓	Cosmegen
Inj 0.5 mg for ECP.....	255.00	0.5 mg OP	✓	Baxter
DAUNORUBICIN – PCT only – Specialist				
Inj 20 mg vial.....	171.93	1	✓	Cerubidine
Inj 18.7 mg for ECP.....	160.75	18.7 mg OP	✓	Baxter
Inj 20 mg for ECP.....	171.93	20 mg OP	✓	Baxter
Inj 18.7 mg vial.....	160.75	1	✓	Pfizer
DOCETAXEL – PCT only – Specialist				
Inj 20 mg.....	48.75	1	✓	Docetaxel Sandoz
Inj 10 mg per ml, 8 ml vial.....	24.91	1	✓	DBL Docetaxel
Inj 20 mg per ml, 4 ml vial.....	26.95	1	✓	Docetaxel
				Accord S29
Inj 80 mg.....	195.00	1	✓	Docetaxel Sandoz
Inj 1 mg for ECP.....	0.35	1 mg	✓	Baxter
DOXORUBICIN HYDROCHLORIDE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml vial.....	10.00	1	✓	Doxorubicin Ebewe
Inj 2 mg per ml, 25 ml vial.....	17.00	1	✓	Arrow-Doxorubicin
	75.55		✓	Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial.....	65.00	1	✓	Arrow-Doxorubicin
	164.50		✓	Adriamycin
			✓	Doxorubicin Ebewe
Inj 1 mg for ECP.....	0.84	1 mg	✓	Baxter

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
EPIRUBICIN HYDROCHLORIDE – PCT only – Specialist				
Inj 2 mg per ml, 25 ml vial.....	284.36	1	✓	Epirubicin Ebewe
Inj 2 mg per ml, 100 ml vial.....	284.36	1	✓	Epirubicin Ebewe
Inj 1 mg for ECP.....	1.42	1 mg	✓	Baxter
ETOPOSIDE				
Cap 50 mg – PCT – Retail pharmacy-Specialist.....	340.73	20	✓	Vepesid
Wastage claimable				
Cap 100 mg – PCT – Retail pharmacy-Specialist.....	340.73	10	✓	Vepesid
Wastage claimable				
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist.....	7.90	1	✓	Rex Medical
Inj 1 mg for ECP – PCT only – Specialist.....	0.09	1 mg	✓	Baxter
ETOPOSIDE PHOSPHATE – PCT only – Specialist				
Inj 100 mg (of etoposide base).....	40.00	1	✓	Etopophos
Inj 1 mg (of etoposide base) for ECP.....	0.47	1 mg	✓	Baxter
HYDROXYUREA [HYDROXYCARBAMIDE] – PCT – Retail pharmacy-Specialist				
Cap 500 mg.....	25.98	100	✓	Devatis
IBRUTINIB – Special Authority see SA2637 below – Retail pharmacy				
Tab 140 mg.....	3,217.00	30	✓	Imbruvica
Tab 420 mg.....	9,652.00	30	✓	Imbruvica
►SA2637 Special Authority for Subsidy				
Initial application — (previously untreated chronic lymphocytic leukaemia in combination with venetoclax) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:				
Either:				
1 Individual is currently on treatment with ibrutinib and/or venetoclax and met all of the following criteria prior to commencing treatment; or				
2 Both:				
2.1 Individual has previously untreated CLL; and				
2.2 Ibrutinib is to be administered at a maximum dose of 420 mg daily for 3 (28 day) cycles as monotherapy, followed by a maximum of 12 (28 day) cycles in combination with venetoclax.				
Initial application — (chronic lymphocytic leukaemia (CLL)) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:				
All of the following:				
1 Individual has chronic lymphocytic leukaemia (CLL) requiring therapy; and				
2 Ibrutinib is to be used as monotherapy; and				
3 Individual has experienced intolerable side effects, or their disease has relapsed or is refractory following at least one prior line of therapy; and				
4 Individual has not received ibrutinib monotherapy previously.				
Renewal — (chronic lymphocytic leukaemia (CLL)) from any relevant practitioner. Approvals valid for 12 months where there is no evidence of disease progression.				
Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL) and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.				
IDARUBICIN HYDROCHLORIDE				
Inj 5 mg vial – PCT only – Specialist.....	109.74	1	✓	Zavedos
Inj 10 mg vial – PCT only – Specialist.....	233.64	1	✓	Zavedos
Inj 1 mg for ECP – PCT only – Specialist.....	25.77	1 mg	✓	Baxter

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LENALIDOMIDE (VIATRIS) – Special Authority see SA2353 below – Retail pharmacy				
Cap 5 mg.....	76.92	21	✓	Lenalidomide Viatris
Cap 10 mg.....	50.30	21	✓	Lenalidomide Viatris
Cap 15 mg.....	62.13	21	✓	Lenalidomide Viatris
Cap 25 mg.....	65.09	21	✓	Lenalidomide Viatris
►SA2353 Special Authority for Subsidy				
Initial application — (Plasma cell dyscrasia) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:				
Both:				
1 Patient has plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment; and				
2 Patient is not refractory to prior lenalidomide use.				
Initial application — (Myelodysplastic syndrome) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:				
Both:				
1 Patient has low or intermediate-1 risk myelodysplastic syndrome (based on IPSS or an IPSS-R score of less than 3.5) associated with a deletion 5q cytogenetic abnormality; and				
2 Patient has transfusion-dependent anaemia.				
Renewal — (Myelodysplastic syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:				
Both:				
1 Patient has not needed a transfusion in the last 4 months; and				
2 No evidence of disease progression.				
MESNA				
Tab 400 mg – PCT – Retail pharmacy-Specialist.....	314.00	50	✓	Uromitexan
Tab 600 mg – PCT – Retail pharmacy-Specialist.....	448.50	50	✓	Uromitexan
Inj 100 mg per ml, 4 ml ampoule – PCT only – Specialist.....	177.45	15	✓	Uromitexan
Inj 100 mg per ml, 10 ml ampoule – PCT only – Specialist.....	407.40	15	✓	Uromitexan
Inj 1 mg for ECP – PCT only – Specialist.....	2.96	100 mg	✓	Baxter
MITOMYCIN C – PCT only – Specialist				
Inj 5 mg vial	517.65	1	✓	Accord §29
			✓	Mitomycin (Fresenius Kabi) §29
	526.00		✓	Mitomycin (Sagent) §29
Inj 20 mg vial	1,129.94	1	✓	Teva
Inj 1 mg for ECP	119.67	1 mg	✓	Baxter
MITOZANTRONE – PCT only – Specialist				
Inj 2 mg per ml, 10 ml vial.....	170.63	1	✓	Mitozantrone Ebewe
Inj 1 mg for ECP	9.64	1 mg	✓	Baxter
NIRAPARIB – Special Authority see SA2325 on the next page – Retail pharmacy				
Wastage claimable				
Tab 100 mg	8,929.84	56	✓	Zejula
	13,393.50	84	✓	Zejula
Cap 100 mg.....	8,929.84	56	✓	Zejula

(Zejula Cap 100 mg to be delisted 1 October 2026)

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

➤SA2325 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has advanced high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 Patient has received at least one line** of treatment with platinum-based chemotherapy; and
- 3 Patient has experienced a partial or complete response to the preceding treatment with platinum-based chemotherapy; and
- 4 Patient has not previously received funded treatment with a PARP inhibitor; and
- 5 Either:
 - 5.1 Treatment will be commenced within 12 weeks of the patient's last dose of the preceding platinum-based regimen; or
 - 5.2 Patient commenced treatment with niraparib prior to 1 May 2024; and
- 6 Treatment to be administered as maintenance treatment; and
- 7 Treatment not to be administered in combination with other chemotherapy.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 No evidence of progressive disease; and
- 2 Treatment to be administered as maintenance treatment; and
- 3 Treatment not to be administered in combination with other chemotherapy; and
- 4 Either:
 - 4.1 Treatment with niraparib to cease after a total duration of 36 months from commencement; or
 - 4.2 Treatment with niraparib is being used in the second-line or later maintenance setting.

Notes: * "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

**A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments

OLAPARIB – Retail pharmacy-Specialist – Special Authority see [SA2163 below](#)

Tab 100 mg	3,701.00	56	✓ Lynparza
Tab 150 mg	3,701.00	56	✓ Lynparza

➤SA2163 Special Authority for Subsidy

Initial application — (Ovarian cancer) only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and
- 3 Either:
 - 3.1 All of the following:
 - 3.1.1 Patient has newly diagnosed, advanced disease; and
 - 3.1.2 Patient has received one line** of previous treatment with platinum-based chemotherapy; and
 - 3.1.3 Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen; or
 - 3.2 All of the following:
 - 3.2.1 Patient has received at least two lines** of previous treatment with platinum-based chemotherapy; and
 - 3.2.2 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy; and
 - 3.2.3 Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen; and
 - 3.2.4 Patient has not previously received funded olaparib treatment; and

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 4 Treatment will be commenced within 12 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and
- 5 Treatment to be administered as maintenance treatment; and
- 6 Treatment not to be administered in combination with other chemotherapy.

Renewal — (Ovarian cancer) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from treatment; and
- 2 Either:
 - 2.1 No evidence of progressive disease; or
 - 2.2 Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinician's opinion; and
- 3 Treatment to be administered as maintenance treatment; and
- 4 Treatment not to be administered in combination with other chemotherapy; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 Patient has received one line** of previous treatment with platinum-based chemotherapy; and
 - 5.1.2 Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years; or
 - 5.2 Patient has received at least two lines** of previous treatment with platinum-based chemotherapy.

Notes: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

**A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

PACLITAXEL – PCT only – Specialist

Inj 30 mg.....	47.30	5	✓ Paclitaxel Ebewe
Inj 6 mg per ml, 16.7 ml vial.....	19.59	1	✓ Anzatax
	24.00		✓ Paclitaxel Ebewe
	91.67		✓ Paclitaxel Actavis
Inj 150 mg.....	26.69	1	✓ Paclitaxel Ebewe
	137.50		✓ Anzatax
			✓ Paclitaxel Actavis
Inj 6 mg per ml, 50 ml vial.....	37.89	1	✓ Anzatax
	44.00		✓ Paclitaxel Ebewe
	275.00		✓ Paclitaxel Actavis
Inj 1 mg for ECP	0.17	1 mg	✓ Baxter

PEGASPARGASE – PCT only – Special Authority see SA2618 below

Inj 750 iu per ml, 5 ml vial.....	3,973.25	1	✓ Oncaspar LYO
-----------------------------------	----------	---	----------------

► **SA2618** Special Authority for Subsidy

Initial application — (Acute lymphoblastic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria:
Both:

- 1 The patient has newly diagnosed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol.

Initial application — (Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where the patient has lymphoma requiring L-asparaginase containing protocols (e.g.

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
SMILE).				
Renewal — (Acute lymphoblastic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:				
Both:				
1 The patient has relapsed acute lymphoblastic leukaemia; and				
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol.				
PENTOSTATIN [DEOXYCOFORMYCIN] – PCT only – Specialist				
Inj 10 mg.....	CBS	1	✓	Nipent ^{\$29}
POMALIDOMIDE – Special Authority see SA2354 below – Retail pharmacy				
Cap 1 mg.....	47.45	14	✓	Pomalide
	71.18	21	✓	Pomalide
Cap 2 mg.....	94.90	14	✓	Pomalide
	142.35	21	✓	Pomalide
Cap 3 mg.....	142.35	14	✓	Pomalide
	213.53	21	✓	Pomalide
Cap 4 mg.....	189.81	14	✓	Pomalide
	284.71	21	✓	Pomalide
SA2354 Special Authority for Subsidy				
Initial application — (Relapsed/refractory plasma cell dyscrasia) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:				
Both:				
1 Patient has relapsed or refractory plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment; and				
2 Patient has not received prior funded pomalidomide.				
Renewal — (Relapsed/refractory plasma cell dyscrasia) from any relevant practitioner. Approvals valid for 12 months where there is no evidence of disease progression.				
PROCARBAZINE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist				
Cap 50 mg.....	980.00	50	✓	Natulan ^{\$29}
TEMOZOLOMIDE – Special Authority see SA2686 below – Retail pharmacy				
Cap 5 mg.....	9.13	5	✓	Temaccord
			✓	Temozolomide-Taro ^{\$29}
	12.70		✓	Temozolomide (Devatis) ^{\$29}
Cap 20 mg.....	16.38	5	✓	Temaccord
	18.30		✓	Apo-Temozolomide
Cap 100 mg.....	35.98	5	✓	Temaccord
	40.20		✓	Apo-Temozolomide
Cap 140 mg.....	50.12	5	✓	Temaccord
Cap 250 mg.....	86.34	5	✓	Temaccord
SA2686 Special Authority for Subsidy				
Initial application — (gliomas) only from a relevant specialist. Approvals valid for 12 months where the patient has a glioma.				
Renewal — (gliomas) only from a relevant specialist. Approvals valid for 12 months where treatment remains appropriate and patient is benefitting from treatment.				

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

Initial application — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour; and
- 2 Temozolomide is to be given in combination with capecitabine; and
- 3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
- 4 Temozolomide to be discontinued at disease progression.

Renewal — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Initial application — (ewing's sarcoma) only from a relevant specialist. Approvals valid for 9 months where the patient has relapsed/refractory Ewing's sarcoma.

Renewal — (ewing's sarcoma) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Initial application — (Neuroblastoma) from any relevant practitioner. Approvals valid for 12 months where the patient has neuroblastoma.

Renewal — (Neuroblastoma) from any relevant practitioner. Approvals valid for 12 months where there is no evidence of disease progression.

THALIDOMIDE – Retail pharmacy-Specialist – Special Authority see [SA2356 below](#)

Cap 50 mg	378.00	28	✓ Thalomid
Cap 100 mg	756.00	28	✓ Thalomid

►SA2356 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months where the patient has plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

TRETINOIN

Cap 10 mg – PCT – Retail pharmacy-Specialist	479.50	100	✓ Vesanoïd
Wastage claimable			

VENETOCLAX – Retail pharmacy-Specialist – Special Authority see [SA2678 below](#)

Tab 14 x 10 mg, 7 x 50 mg, 21 x 100 mg	1,771.86	42 OP	✓ Venclexta
Tab 10 mg	13.68	2 OP	✓ Venclexta
Tab 50 mg	239.44	7 OP	✓ Venclexta
Tab 100 mg – Wastage claimable	8,209.41	120	✓ Venclexta

►SA2678 Special Authority for Subsidy

Initial application — (previously untreated chronic lymphocytic leukaemia in combination with obinutuzumab) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Either:

- 1 Individual is currently on treatment with venetoclax and obinutuzumab and met all of the following criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Individual has previously untreated chronic lymphocytic leukaemia; and
 - 2.2 Venetoclax is to be administered with obinutuzumab; and
 - 2.3 Venetoclax is to be used to a maximum dose of 400 mg and for a total of 12 (28 day) cycles.

Initial application — (previously untreated chronic lymphocytic leukaemia in combination with ibrutinib) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Either:

- 1 Individual is currently on treatment with venetoclax and/or ibrutinib and met all of the following criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Individual has previously untreated chronic lymphocytic leukaemia; and
 - 2.2 Venetoclax is to be administered in combination with ibrutinib; and
 - 2.3 Venetoclax is to be used to a maximum dose of 400 mg and for a total of 12 (28 day) cycles.

Initial application — (relapsed/refractory chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 8 months for applications meeting the following criteria:

All of the following:

- 1 Individual has chronic lymphocytic leukaemia requiring treatment; and
- 2 Individual has received at least one prior therapy for chronic lymphocytic leukaemia; and
- 3 The individual's disease has relapsed; and
- 4 Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax; and
- 5 Individual has an ECOG performance status of 0-2.

Renewal — (relapsed/refractory chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Treatment remains clinically appropriate and the individual is benefitting from and tolerating treatment; and
- 2 Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL) and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.

Initial application — (previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Individual has previously untreated chronic lymphocytic leukaemia; and
- 2 There is documentation confirming that individual has 17p deletion by FISH testing or TP53 mutation by sequencing; and
- 3 Individual has an ECOG performance status of 0-2.

Renewal — (previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*) from any relevant practitioner. Approvals valid for 6 months where the treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL)* and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications

Initial application — (previously untreated acute myeloid leukaemia) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

continued...

- 1 The individual is currently on treatment with venetoclax and met all remaining special authority criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Individual has previously untreated acute myeloid leukaemia (see note a), according to World Health Organization (WHO) Classification; and
 - 2.2 Venetoclax not to be used in combination with standard intensive remission induction chemotherapy; and
 - 2.3 Venetoclax to be used in combination with azacitidine or low dose cytarabine.

Renewal — (previously untreated acute myeloid leukaemia) from any relevant practitioner. Approvals valid for 6 months where there is no evidence of disease progression.

Notes:

- a) 'Acute myeloid leukaemia' includes myeloid sarcoma*
- b) Indications marked with * are Unapproved indications

VINBLASTINE SULPHATE

Inj 1 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist.....	270.37	5	✓ Hospira
Inj 1 mg for ECP – PCT only – Specialist.....	6.00	1 mg	✓ Baxter

VINCISTINE SULPHATE

Inj 1 mg per ml, 1 ml vial – PCT – Retail pharmacy-Specialist.....	74.52	5	✓ DBL Vincristine Sulfate
Inj 1 mg per ml, 2 ml vial – PCT – Retail pharmacy-Specialist.....	102.73	5	✓ DBL Vincristine Sulfate
Inj 1 mg for ECP – PCT only – Specialist.....	12.60	1 mg	✓ Baxter

VINORELBINE

Cap 20 mg.....	32.10	1	✓ Vinorelbine Te Arai
Cap 30 mg.....	42.80	1	✓ Vinorelbine Te Arai
Cap 80 mg.....	80.00	1	✓ Vinorelbine Te Arai
Inj 10 mg per ml, 5 ml vial – PCT only – Specialist	155.00	1	✓ Vinorelbine Ebewe
	168.00		✓ Navelbine S29 S29
Inj 1 mg for ECP – PCT only – Specialist.....	3.51	1 mg	✓ Baxter

Protein-tyrosine Kinase Inhibitors

ALECTINIB – Retail pharmacy-Specialist – Special Authority see [SA1870 below](#)

Wastage claimable			
Cap 150 mg.....	7,935.00	224	✓ Alecensa

►SA1870 Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-small cell lung cancer; and
- 2 There is documentation confirming that the patient has an ALK tyrosine kinase gene rearrangement using an appropriate ALK test; and
- 3 Patient has an ECOG performance score of 0-2.

Renewal only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of progressive disease according to RECIST criteria; and
- 2 The patient is benefitting from and tolerating treatment.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

AXITINIB – Special Authority see [SA2458 below](#) – Retail pharmacy

Wastage claimable

Tab 1 mg	536.40	28	✓	Inlyta
----------------	--------	----	---	--------

Tab 5 mg	2,682.00	28	✓	Inlyta
----------------	----------	----	---	--------

►SA2458 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 The disease is of predominant clear cell histology; and
- 3 The patient has documented disease progression following one previous line of treatment; and
- 4 The patient has ECOG performance status of 0-2.

Renewal from any relevant practitioner. Approvals valid for 4 months where there is no evidence of disease progression..

CRIZOTINIB – Special Authority see [SA2547 below](#) – Retail pharmacy

Cap 200 mg	7,250.00	60	✓	Xalkori
------------------	----------	----	---	---------

Cap 250 mg	7,250.00	60	✓	Xalkori
------------------	----------	----	---	---------

►SA2547 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Individual has locally advanced or metastatic, unresectable, non-squamous non-small cell lung cancer; and
- 2 Either:
 - 2.1 The individual has not received entrectinib; or
 - 2.2 Both:
 - 2.2.1 The individual has received an initial Special Authority approval for entrectinib and has discontinued entrectinib due to intolerance; and
 - 2.2.2 The cancer did not progress while the individual was on entrectinib; and
- 3 There is documentation confirming that the patient has a ROS1 rearrangement using an appropriate ROS1 test; and
- 4 Individual has ECOG performance score of 0-3; and
- 5 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Response to treatment has been determined by comparable radiological assessment following the most recent treatment period; and
- 2 No evidence of disease progression.

DABRAFENIB – Special Authority see [SA2548 below](#) – Retail pharmacy

Cap 50 mg	6,320.86	120	✓	Tafinlar
-----------------	----------	-----	---	----------

Cap 75 mg	9,481.29	120	✓	Tafinlar
-----------------	----------	-----	---	----------

►SA2548 Special Authority for Subsidy

Initial application – (stage III or IV resected melanoma - adjuvant) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The individual has resected stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note a); or
 - 1.2 Both:
 - 1.2.1 The individual has received neoadjuvant treatment with a PD-1/PD-L1 inhibitor; and
 - 1.2.2 Adjuvant treatment with dabrafenib is required; and
- 2 The individual has not received prior funded systemic treatment in the adjuvant setting for stage IIIB, IIIC, IIID or IV

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- melanoma; and
- 3 Treatment must be adjuvant to complete surgical resection; and
- 4 Treatment must be initiated within 13 weeks of surgical resection, unless delay is necessary due to post-surgery recovery (see note b); and
- 5 The individual has a confirmed BRAF mutation; and
- 6 Dabrafenib must be administered in combination with trametinib; and
- 7 The individual has ECOG performance score 0-2.

Notes:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition
- b) Initiating treatment within 13 weeks of complete surgical resection means 13 weeks after resection (primary or lymphadenectomy)

Renewal — (stage III or IV resected melanoma - adjuvant) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 All of the following:
 - 1.1 No evidence of disease recurrence; and
 - 1.2 Dabrafenib must be administered in combination with trametinib; and
 - 1.3 Treatment to be discontinued at signs of disease recurrence or at completion of 12 months' total treatment course, including any systemic neoadjuvant treatment; or
- 2 All of the following:
 - 2.1 The individual has received adjuvant treatment with a BRAF/MEK inhibitor; and
 - 2.2 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
 - 2.3 The individual meets initial application criteria for dabrafenib for unresectable or metastatic melanoma; or
- 3 All of the following:
 - 3.1 The individual has received adjuvant treatment with a BRAF/MEK inhibitor; and
 - 3.2 The individual has received a BRAF/MEK inhibitor for unresectable or metastatic melanoma; and
 - 3.3 The individual meets renewal criteria for dabrafenib for unresectable or metastatic melanoma.

Initial application — (unresectable or metastatic melanoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
- 3 The individual has ECOG performance score 0-2; and
- 4 The individual has confirmed BRAF mutation; and
- 5 Dabrafenib must be administered in combination with trametinib; and
- 6 Any of the following:
 - 6.1 The individual has been diagnosed in the metastatic or unresectable stage III or IV setting; or
 - 6.2 The individual did not receive treatment in the adjuvant setting with a BRAF/MEK inhibitor; or
 - 6.3 All of the following:
 - 6.3.1 The individual received treatment in the adjuvant setting with a BRAF/MEK inhibitor; and
 - 6.3.2 The individual did not experience disease recurrence while on treatment with that BRAF/MEK inhibitor; and
 - 6.3.3 The individual did not experience disease recurrence within six months of completing adjuvant treatment with a BRAF/MEK inhibitor.

Renewal — (unresectable or metastatic melanoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 Any of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1.1 The individual's disease has had a complete response to treatment; or
- 1.2 The individual's disease has had a partial response to treatment; or
- 1.3 The individual has stable disease with treatment; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period.

DASATINIB – Special Authority see [SA2385 below](#) – Retail pharmacy

Wastage claimable

Tab 20 mg	132.88	60	✓	Dasatinib-Teva
Tab 50 mg	304.13	60	✓	Dasatinib-Teva
Tab 70 mg	415.75	60	✓	Dasatinib-Teva

► **SA2385** Special Authority for Subsidy

Initial application only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; or
- 2 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); or
- 3 Both:
 - 3.1 The patient has a diagnosis of CML in chronic phase; and
 - 3.2 Any of the following:
 - 3.2.1 Patient has documented treatment failure* with imatinib; or
 - 3.2.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
 - 3.2.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system.

Renewal only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Lack of treatment failure while on dasatinib*; and
- 2 Dasatinib treatment remains appropriate and the patient is benefiting from treatment.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines.

ENTRECTINIB – Special Authority see [SA2532 below](#) – Retail pharmacy

Cap 200 mg	9,610.00	90	✓	Rozlytrek
------------------	----------	----	---	------------------

► **SA2532** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Individual has locally advanced or metastatic, unresectable, non-squamous non-small cell lung cancer; and
- 2 Either:
 - 2.1 The individual has not received crizotinib; or
 - 2.2 Both:
 - 2.2.1 The individual has received an initial Special Authority approval for crizotinib and has discontinued crizotinib due to intolerance; and
 - 2.2.2 The cancer did not progress while the individual was on crizotinib; and
- 3 There is documentation confirming that the patient has a ROS1 rearrangement using an appropriate ROS1 test; and
- 4 Individual has ECOG performance score of 0-3; and
- 5 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Response to treatment has been determined by comparable radiological assessment following the most recent treatment period; and
- 2 No evidence of disease progression.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ERLOTINIB – Retail pharmacy-Specialist – Special Authority see SA2422 below				
Tab 100 mg	280.84	30	✓	Alchemy
Tab 150 mg	484.24	30	✓	Alchemy

► **SA2422** **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:
All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 There is documentation confirming that the disease expresses activating mutations of EGFR; and
- 3 Any of the following:
 - 3.1 Patient is treatment naive; or
 - 3.2 Patient has received prior treatment in the adjuvant setting and/or while awaiting EGFR results; or
 - 3.3 Both:
 - 3.3.1 The patient has discontinued osimertinib or gefitinib due to intolerance; and
 - 3.3.2 The cancer did not progress while on osimertinib or gefitinib.

Renewal from any relevant practitioner. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB – Retail pharmacy-Specialist – Special Authority see [SA2423 below](#)

Tab 250 mg	918.00	30	✓	Iressa
------------------	--------	----	---	---------------

► **SA2423** **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:
All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 Any of the following:
 - 2.1 Patient is treatment naive; or
 - 2.2 Patient has received prior treatment in the adjuvant setting and/or while awaiting EGFR results; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued osimertinib or erlotinib due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on osimertinib or erlotinib; and
- 3 There is documentation confirming that disease expresses activating mutations of EGFR.

Renewal from any relevant practitioner. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESILATE

* Cap 100 mg	44.93	60	✓	Imatinib-Rex
* Cap 400 mg	69.76	30	✓	Imatinib-Rex

LENVATINIB – Special Authority see [SA2442 below](#) – Retail pharmacy

Wastage claimable				
Cap 4 mg	3,407.40	30	✓	Lenvima
Cap 10 mg	3,407.40	30	✓	Lenvima

► **SA2442** **Special Authority for Subsidy**

Initial application — (thyroid cancer) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with lenvatinib and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 The patient has locally advanced or metastatic differentiated thyroid cancer; and
 - 2.2 Either:

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 2.2.1 Patient must have symptomatic progressive disease prior to treatment; or
- 2.2.2 Patient must progressive disease at critical anatomical sites with a high risk of morbidity or mortality where local control cannot be achieved by other measures; and
- 2.3 Any of the following:
 - 2.3.1 A lesion without iodine uptake in a RAI scan; or
 - 2.3.2 Receiving cumulative RAI greater than or equal to 600 mCi; or
 - 2.3.3 Experiencing disease progression after a RAI treatment within 12 months; or
 - 2.3.4 Experiencing disease progression after two RAI treatments administered within 12 months of each other; and
- 2.4 Patient has thyroid stimulating hormone (TSH) adequately suppressed; and
- 2.5 Patient is not a candidate for radiotherapy with curative intent; and
- 2.6 Surgery is clinically inappropriate; and
- 2.7 Patient has an ECOG performance status of 0-2.

Renewal — (thyroid cancer) from any relevant practitioner. Approvals valid for 6 months where there is no evidence of disease progression.

Initial application — (unresectable hepatocellular carcinoma) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has unresectable hepatocellular carcinoma; and
- 2 Patient has preserved liver function (Childs-Pugh A); and
- 3 Transarterial chemoembolisation (TACE) is unsuitable; and
- 4 Patient has an ECOG performance status of 0-2; and
- 5 Either:
 - 5.1 Patient has not received prior systemic therapy for their disease in the palliative setting; or
 - 5.2 Both:
 - 5.2.1 Patient has experienced treatment-limiting toxicity from treatment with atezolizumab with bevacizumab; and
 - 5.2.2 No disease progression since initiation of atezolizumab with bevacizumab.

Renewal — (unresectable hepatocellular carcinoma) from any relevant practitioner. Approvals valid for 6 months where there is no evidence of disease progression.

Initial application — (renal cell carcinoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic renal cell carcinoma; and
 - 1.2 The disease is of predominant clear-cell histology; and
 - 1.3 The patient has documented disease progression following one previous line of treatment; and
 - 1.4 The patient has an ECOG performance status of 0-2; and
 - 1.5 Lenvatinib is to be used in combination with everolimus; or
- 2 All of the following:
 - 2.1 Patient has received funded treatment with nivolumab for the second line treatment of metastatic renal cell carcinoma; and
 - 2.2 Patient has experienced treatment limiting toxicity from treatment with nivolumab; and
 - 2.3 Lenvatinib is to be used in combination with everolimus; and
 - 2.4 There is no evidence of disease progression.

Renewal — (renal cell carcinoma) from any relevant practitioner. Approvals valid for 4 months where there is no evidence of disease progression.

MIDOSTAURIN – PCT only – Special Authority see [SA2342 on the next page](#)

Cap 25 mg	10,981.00	56	✓ Rydapt
-----------------	-----------	----	----------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA2342 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:
All of the following:

- 1 Patient has a diagnosis of acute myeloid leukaemia; and
- 2 Condition must be FMS tyrosine kinase 3 (FLT3) mutation positive; and
- 3 Patient must not have received a prior line of intensive chemotherapy for acute myeloid leukaemia; and
- 4 Patient is to receive standard intensive chemotherapy in combination with midostaurin only; and
- 5 Midostaurin to be funded for a maximum of 4 cycles.

NILOTINIB – Special Authority see SA2301 below – Retail pharmacy

Wastage claimable

Cap 150 mg	4,680.00	120	✓ Tasigna
Cap 200 mg	6,532.00	120	✓ Tasigna

►SA2301 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:

- 1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, high risk chronic phase, or in chronic phase; and
- 2 Either:
 - 2.1 Patient has documented CML treatment failure* with a tyrosine kinase inhibitor (TKI); or
 - 2.2 Patient has experienced treatment limiting toxicity with a tyrosine kinase inhibitor (TKI) precluding further treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

Renewal only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:

- 1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
- 2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

OSIMERTINIB – Special Authority see SA2418 below – Retail pharmacy

Tab 40 mg	9,310.00	30	✓ Tagrisso
Tab 80 mg	9,310.00	30	✓ Tagrisso

►SA2418 Special Authority for Subsidy

Initial application — (NSCLC – first line) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:
Either:

- 1 Patient is currently on treatment with osimertinib and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has locally advanced or metastatic, incurable, non-squamous non-small cell lung cancer (NSCLC); and
 - 2.2 Any of the following:
 - 2.2.1 Patient is treatment naïve; or
 - 2.2.2 Patient has received prior chemotherapy in the adjuvant setting and/or while awaiting EGFR results; or
 - 2.2.3 Both:
 - 2.2.3.1 The patient has discontinued gefitinib or erlotinib due to intolerance; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

2.2.3.2 The cancer did not progress while on gefitinib or erlotinib; and

2.3 There is documentation confirming that the cancer expresses activating mutations of EGFR; and

2.4 Patient has an ECOG performance status 0-3; and

2.5 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal — (NSCLC – first line) from any relevant practitioner. Approvals valid for 6 months where response to or stable disease with treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period.

Initial application — (NSCLC – second line) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with osimertinib and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has locally advanced or metastatic, incurable, non-squamous non-small cell lung cancer (NSCLC); and
 - 2.2 Patient has an ECOG performance status 0-3; and
 - 2.3 The patient must have received previous treatment with erlotinib or gefitinib; and
 - 2.4 There is documentation confirming that the cancer expresses T790M mutation of EGFR following progression on or after erlotinib or gefitinib; and
 - 2.5 The treatment must be given as monotherapy; and
 - 2.6 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal — (NSCLC – second line) from any relevant practitioner. Approvals valid for 6 months where response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period.

PALBOCICLIB – Special Authority see [SA2345 below](#) – Retail pharmacy

Wastage claimable

Tab 75 mg	1,200.00	21	✓ Palbociclib Pfizer
Tab 100 mg	1,200.00	21	✓ Palbociclib Pfizer
Tab 125 mg	1,200.00	21	✓ Palbociclib Pfizer

► [SA2345](#) **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has unresectable locally advanced or metastatic breast cancer; and
 - 1.2 There is documentation confirming disease is hormone-receptor positive and HER2-negative; and
 - 1.3 Patient has an ECOG performance score of 0-2; and
 - 1.4 Either:
 - 1.4.1 Disease has relapsed or progressed during prior endocrine therapy; or
 - 1.4.2 Both:
 - 1.4.2.1 Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal or without menstrual-potential state; and
 - 1.4.2.2 Patient has not received prior systemic treatment for metastatic disease; and
 - 1.5 Treatment must be used in combination with an endocrine partner; and
 - 1.6 Patient has not received prior funded treatment with a CDK4/6 inhibitor; or
- 2 All of the following:
 - 2.1 Patient has an active Special Authority approval for ribociclib; and
 - 2.2 Patient has experienced a grade 3 or 4 adverse reaction to ribociclib that cannot be managed by dose reductions and requires treatment discontinuation; and
 - 2.3 Treatment must be used in combination with an endocrine partner; and

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

continued...

2.4 There is no evidence of progressive disease since initiation of ribociclib.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Treatment must be used in combination with an endocrine partner; and
- 2 There is no evidence of progressive disease since initiation of palbociclib.

PAZOPANIB – Special Authority see [SA2596 below](#) – Retail pharmacy

Tab 200 mg	172.88	30	✓ Pazopanib ADVZ S29
Tab 400 mg	464.00	30	✓ Pazopanib Teva ✓ Pazopanib Teva

➤ **SA2596** **Special Authority for Subsidy**

Initial application only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist.

Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic renal cell carcinoma of predominantly clear cell histology; and
 - 1.2 Either:
 - 1.2.1 The patient is treatment naive; or
 - 1.2.2 The patient has only received prior cytokine treatment; and
 - 1.3 The patient has an ECOG performance score of 0-2; and
The patient has intermediate or poor prognosis defined as:
 - 1.4 Any of the following:
 - 1.4.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 1.4.2 Haemoglobin level < lower limit of normal; or
 - 1.4.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 1.4.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 1.4.5 Karnofsky performance score of less than or equal to 70; or
 - 1.4.6 2 or more sites of organ metastasis; and
 - 1.5 Pazopanib to be used for a maximum of 3 months; or
- 2 All of the following:
 - 2.1 The patient has metastatic renal cell carcinoma; and
 - 2.2 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on sunitinib; and
 - 2.4 Pazopanib to be used for a maximum of 3 months.

Renewal only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months where there is no evidence of disease progression.

RIBOCICLIB – Special Authority see [SA2495 below](#) – Retail pharmacy

Wastage claimable			
Tab 200 mg	1,883.00	21	✓ Kisqali
	3,767.00	42	✓ Kisqali
	5,650.00	63	✓ Kisqali

➤ **SA2495** **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 All of the following:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1.1 Patient has unresectable locally advanced or metastatic breast cancer; and
- 1.2 There is documentation confirming disease is hormone-receptor positive and HER2-negative; and
- 1.3 Patient has an ECOG performance score of 0-2; and
- 1.4 Either:
 - 1.4.1 Disease has relapsed or progressed during prior endocrine therapy; or
 - 1.4.2 Both:
 - 1.4.2.1 Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal or without menstrual-potential state; and
 - 1.4.2.2 Patient has not received prior systemic endocrine treatment for metastatic disease; and
- 1.5 Treatment to be used in combination with an endocrine partner; and
- 1.6 Patient has not received prior funded treatment with a CDK4/6 inhibitor; or
- 2 All of the following:
 - 2.1 Patient has an active Special Authority approval for palbociclib; and
 - 2.2 Patient has experienced a grade 3 or 4 adverse reaction to palbociclib that cannot be managed by dose reductions and requires treatment discontinuation; and
 - 2.3 Treatment must be used in combination with an endocrine partner; and
 - 2.4 There is no evidence of progressive disease since initiation of palbociclib.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Treatment must be used in combination with an endocrine partner; and
- 2 There is no evidence of progressive disease since initiation of ribociclib.

RUXOLITINIB – Special Authority see [SA1890 below](#) – Retail pharmacy

Wastage claimable

Tab 5 mg	2,500.00	56	✓ Jakavi
Tab 10mg	5,000.00	56	✓ Jakavi
Tab 15 mg	5,000.00	56	✓ Jakavi
Tab 20 mg	5,000.00	56	✓ Jakavi

► **SA1890** Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
- 2 Either:
 - 2.1 A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; or
 - 2.2 Both:
 - 2.2.1 A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
 - 2.2.2 Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy; and
- 3 A maximum dose of 20 mg twice daily is to be given.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 A maximum dose of 20 mg twice daily is to be given.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SUNITINIB – Special Authority see SA2687 below – Retail pharmacy				
Cap 12.5 mg	103.11	28	✓	Sunitinib Rex
Cap 25 mg	203.15	28	✓	Sunitinib Rex
Cap 50 mg	343.19	28	✓	Sunitinib Rex

► **SA2687** Special Authority for Subsidy

Initial application — (RCC) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 The patient has not previously received funded sunitinib.

Renewal — (RCC) from any relevant practitioner. Approvals valid for 4 months where there is no evidence of disease progression.

Initial application — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Sunitinib is to be discontinued at disease progression.

Note: It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

TRAMETINIB – Special Authority see [SA2549 below](#) – Retail pharmacy

Tab 0.5 mg	2,370.32	30	✓	Mekinist
Tab 2 mg	9,481.29	30	✓	Mekinist

► **SA2549** Special Authority for Subsidy

Initial application — (stage III or IV resected melanoma - adjuvant) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The individual has resected stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note a); or
 - 1.2 Both:
 - 1.2.1 The individual has received neoadjuvant treatment with a PD-1/PD-L1 inhibitor; and
 - 1.2.2 Adjuvant treatment with trametinib is required; and
- 2 The individual has not received prior funded systemic treatment in the adjuvant setting for stage IIIB, IIIC, IIID or IV melanoma; and
- 3 Treatment must be adjuvant to complete surgical resection; and
- 4 Treatment must be initiated within 13 weeks of surgical resection, unless delay is necessary due to post-surgery recovery (see note b); and
- 5 The individual has a confirmed BRAF mutation; and
- 6 Trametinib must be administered in combination with dabrafenib; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

7 The individual has ECOG performance score 0-2.

Notes:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition
- b) Initiating treatment within 13 weeks of complete surgical resection means 13 weeks after resection (primary or lymphadenectomy)

Renewal — (stage III or IV resected melanoma - adjuvant) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 All of the following:
 - 1.1 No evidence of disease recurrence; and
 - 1.2 Trametinib must be administered in combination with dabrafenib; and
 - 1.3 Treatment to be discontinued at signs of disease recurrence or at completion of 12 months' total treatment course, including any systemic neoadjuvant treatment; or
- 2 All of the following:
 - 2.1 The individual has received adjuvant treatment with a BRAF/MEK inhibitor; and
 - 2.2 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
 - 2.3 The individual meets initial application criteria for trametinib for unresectable or metastatic melanoma; or
- 3 All of the following:
 - 3.1 The individual has received adjuvant treatment with a BRAF/MEK inhibitor; and
 - 3.2 The individual has received a BRAF/MEK inhibitor for unresectable or metastatic melanoma; and
 - 3.3 The individual meets renewal criteria for trametinib for unresectable or metastatic melanoma.

Initial application — (unresectable or metastatic melanoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The individual has metastatic or unresectable melanoma (excluding uveal melanoma) stage III or IV; and
- 2 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
- 3 The individual has ECOG performance score 0-2; and
- 4 The individual has confirmed BRAF mutation; and
- 5 Trametinib must be administered in combination with dabrafenib; and
- 6 Any of the following:
 - 6.1 The individual has been diagnosed in the metastatic or unresectable stage III or IV setting; or
 - 6.2 The individual did not receive treatment in the adjuvant setting with a BRAF/MEK inhibitor; or
 - 6.3 All of the following:
 - 6.3.1 The individual received treatment in the adjuvant setting with a BRAF/MEK inhibitor; and
 - 6.3.2 The individual did not experience disease recurrence while on treatment with that BRAF/MEK inhibitor; and
 - 6.3.3 The individual did not experience disease recurrence within six months of completing adjuvant treatment with a BRAF/MEK inhibitor.

Renewal — (unresectable or metastatic melanoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The individual's disease has had a complete response to treatment; or
 - 1.2 The individual's disease has had a partial response to treatment; or
 - 1.3 The individual has stable disease with treatment; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Endocrine Therapy

For GnRH ANALOGUES – refer to HORMONE PREPARATIONS, Tropic Hormones, [page 90](#)

ABIRATERONE ACETATE – Retail pharmacy-Specialist – Special Authority see [SA2118 below](#)

Wastage claimable

Tab 250 mg	4,276.19	120	✓ Zytiga
------------------	----------	-----	----------

►SA2118 Special Authority for Subsidy

Initial application only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has prostate cancer; and
- 2 Patient has metastases; and
- 3 Patient's disease is castration resistant; and
- 4 Either:
 - 4.1 All of the following:
 - 4.1.1 Patient is symptomatic; and
 - 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
 - 4.1.3 Patient has ECOG performance score of 0-1; and
 - 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
 - 4.2 All of the following:
 - 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
 - 4.2.2 Patient has ECOG performance score of 0-2; and
 - 4.2.3 Patient has not had prior treatment with abiraterone.

Renewal — (abiraterone acetate) only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Significant decrease in serum PSA from baseline; and
- 2 No evidence of clinical disease progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Abiraterone acetate to be discontinued at progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

BICALUTAMIDE

Tab 50 mg	4.18	28	✓ Binarex
-----------------	------	----	-----------

FLUTAMIDE

Tab 250 mg	107.55	90	✓ Prostaticur ^{\$29}
	119.50	100	✓ Flutamin

FULVESTRANT – Retail pharmacy-Specialist – Special Authority see [SA1895 on the next page](#)

Inj 50 mg per ml, 5 ml prefilled syringe.....	181.00	2	✓ Fulvestrant EVER Pharma
---	--------	---	----------------------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

►SA1895 Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has oestrogen-receptor positive locally advanced or metastatic breast cancer; and
- 2 Patient has disease progression following prior treatment with an aromatase inhibitor or tamoxifen for their locally advanced or metastatic disease; and
- 3 Treatment to be given at a dose of 500 mg monthly following loading doses; and
- 4 Treatment to be discontinued at disease progression.

Renewal only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains appropriate and patient is benefitting from treatment; and
- 2 Treatment to be given at a dose of 500 mg monthly; and
- 3 There is no evidence of disease progression.

OCTREOTIDE

Inj 100 mcg per ml, 1 ml ampoule	32.71	5	✓ Max Health
			✓ Octreotide GH \$29
			✓ Sun Pharma \$29
Inj 100 mcg per ml, 1 ml vial.....	48.50	5	✓ Omega \$29
Inj 50 mcg per ml, 1 ml vial.....	27.58	5	✓ Omega \$29
Inj 500 mcg per ml, 1 ml vial.....	113.10	5	✓ Omega \$29
Inj 50 mcg per ml, 1 ml ampoule	27.58	5	✓ Max Health
			✓ Octreotide GH \$29
Inj 500 mcg per ml, 1 ml ampoule	113.10	5	✓ Max Health
			✓ Octreotide GH \$29
			✓ Sun Pharma \$29

TAMOXIFEN CITRATE

* Tab 10 mg	15.00	60	✓ Tamoxifen Sandoz
Tamoxifen Sandoz to be Principal Supply on 1 December 2026			
* Tab 20 mg	5.32	60	✓ Tamoxifen Sandoz
Tamoxifen Sandoz to be Principal Supply on 1 December 2026			

Long-acting Somatostatin Analogues

►SA2445 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has not been successful; and
- 3 Treatment to be given for up to 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has acromegaly; and
- 2 Either:
 - 2.1 Treatment with surgery and radiotherapy is not suitable or was unsuccessful; or
 - 2.2 Treatment is for an interim period while awaiting the beneficial effects of radiotherapy; and
- 3 Treatment with a dopamine agonist has been unsuccessful.

Renewal — (Acromegaly) from any relevant practitioner. Approvals valid for 2 years where iGF1 levels have decreased since starting treatment.

Note: In patients with acromegaly, treatment should be discontinued if IGF1 levels have not decreased 3 months after treatment. In patients treated with radiotherapy treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following treatment withdrawal for at least 4 weeks

Initial application — (pre-operative acromegaly) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has acromegaly; and
- 2 Patient has a large pituitary tumour, greater than 10 mm at its widest; and
- 3 Patient is scheduled to undergo pituitary surgery in the next six months.

Initial application — (Other Indications) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Surgery has been unsuccessful; or
 - 2.2.2 Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful; or
- 3 Both:
 - 3.1 Insulinomas; and
 - 3.2 Surgery is contraindicated or has not been successful; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
 - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
 - 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded under Special Authority

Renewal — (Other Indications) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LANREOTIDE – Special Authority see SA2445 on page 184 – Retail pharmacy				
Inj 60 mg per 0.5 ml, 0.5 ml syringe	382.77	1	✓	Mytolac
	1,543.79		✓	Mytolac S29 \$29
Inj 90 mg per 0.5 ml, 0.5 ml syringe	562.92	1	✓	Somatuline Autogel
	2,054.40		✓	Mytolac
Inj 120 mg per 0.5 ml, 0.5 ml syringe	646.70	1	✓	Somatuline Autogel
	2,570.44		✓	Mytolac
			✓	Somatuline Autogel
OCTREOTIDE LONG-ACTING – Special Authority see SA2445 on page 184 – Retail pharmacy				
Inj depot 10 mg prefilled syringe.....	438.40	1	✓	Sandostatin LAR
Inj depot 20 mg prefilled syringe.....	583.70	1	✓	Sandostatin LAR
Inj depot 30 mg prefilled syringe.....	670.80	1	✓	Sandostatin LAR

Aromatase Inhibitors

ANASTROZOLE				
* Tab 1 mg	6.25	30	✓	Anatrole
EXEMESTANE				
* Tab 25 mg	9.86	30	✓	Pfizer Exemestane
LETROZOLE				
* Tab 2.5 mg	4.67	30	✓	Letrole

Immunosuppressants

Cytotoxic Immunosuppressants

AZATHIOPRINE				
* Tab 25 mg	10.15	60	✓	Azamun
* Tab 50 mg	10.34	100	✓	Azamun
MYCOPHENOLATE MOFETIL				
Tab 500 mg	35.90	50	✓	Cellcept
Cap 250 mg	35.90	100	✓	Cellcept
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement	187.25	165 ml OP	✓	Cellcept
Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.				

Fusion Proteins

ETANERCEPT – Special Authority see SA2619 below – Retail pharmacy				
Inj 25 mg	690.00	4	✓	Enbrel
Inj 25 mg autoinjector	690.00	4	✓	Enbrel
Inj 50 mg autoinjector	1,050.00	4	✓	Enbrel
Inj 50 mg prefilled syringe.....	1,050.00	4	✓	Enbrel

➔ [SA2619](#) Special Authority for Subsidy

Initial application — (Stills disease - adult-onset (AOSD)) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Both:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.1 Patient has had a Special Authority approval for adalimumab or tocilizumab for AOSD; and
- 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria from at least a 3-month trial of adalimumab or tocilizumab; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria; and
 - 2.2 Patient has tried and received insufficient benefit from at least 6 months of corticosteroids at a dose of at least 0.5 mg/kg prednisone-equivalents, NSAIDs and methotrexate, unless contraindicated; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initial application — (ankylosing spondylitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had a Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by radiologic imaging; and
 - 2.4 Disease has not responded adequately to treatment with two or more NSAIDs (unless contraindicated), while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following BASMI measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender; and
 - 2.6 BASDAI of at least 6 on a 10-point scale completed after 3-month exercise trial before ceasing any previous pharmacological treatment and not more than 1 month before the application.

Renewal — (ankylosing spondylitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 BASDAI has improved from pre-treatment baseline either by at least 4 points on a 10-point scale, or by at least 50%; and
- 2 Maximum dose 50 mg every 7 days.

Initial application — (arthritis - polyarticular course juvenile idiopathic) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Patient has had a Special Authority approval for adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for polyarticular course JIA; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2 At least 5 active joints and at least 3 joints with pain, tenderness or a limited range of motion, after a 3-month trial of methotrexate at the maximum tolerated dose, unless contraindicated; or
- 3 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate at the maximum tolerated dose, unless contraindicated; or
- 4 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Renewal — (arthritis - polyarticular course juvenile idiopathic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, at least a 50% decrease in active joint count from baseline; or
- 2 On subsequent reapplications, at least a continuing 30% improvement in active joint count from baseline.

Initial application — (arthritis - oligoarticular course juvenile idiopathic) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Patient has had a Special Authority approval for adalimumab for oligoarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for oligoarticular course JIA; or
- 2 At least 2 active joints with pain, tenderness or a limited range of motion, after a 3-month trial of methotrexate at the maximum tolerated dose, unless contraindicated; or
- 3 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate at the maximum tolerated dose, unless contraindicated.

Renewal — (arthritis - oligoarticular course juvenile idiopathic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, at least a 50% decrease in active joint count from baseline; or
- 2 On subsequent reapplications, at least a continuing 30% improvement in active joint count from baseline.

Initial application — (arthritis - psoriatic) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had a Special Authority approval for adalimumab or secukinumab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has received insufficient benefit from at least 3 months of methotrexate at maximum tolerated dose unless contraindicated; and
 - 2.2 Patient received insufficient benefit from at least 3 months of sulfasalazine or leflunomide at maximum tolerated dose unless contraindicated; and
 - 2.3 Either:
 - 2.3.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 joints; or
 - 2.3.2 Patient has persistent symptoms of poorly controlled and active disease in at least 4 joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.4 Any of the following:
 - 2.4.1 Patient has a CRP greater than 15 mg/L measured within one month before the application; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.4.2 Patient has an ESR greater than 25 mm per hour measured within one month before the application; or
- 2.4.3 ESR and CRP not measured as patient is receiving prednisone therapy greater than 5 mg per day received for more than 3 months.

Renewal — (arthritis - psoriatic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Following initial treatment, at least a 50% decrease in active joint count from baseline; or
 - 1.2 At least a continuing 30% improvement in active joint count from baseline; and
- 2 Maximum dose 50 mg every 7 days.

Initial application — (pyoderma gangrenosum*) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has received insufficient benefit from 3 months of conventional therapy including a minimum of 3 pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate). Where conventional pharmaceuticals are contraindicated, a 3 month trial has occurred of those that are not contraindicated; and
- 2 Maximum of 8 doses every 4 months.

Note: Indications marked with * are unapproved indications.

Initial application — (arthritis - rheumatoid) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had a Special Authority approval for adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had rheumatoid arthritis (either confirmed by radiologic imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive); and
 - 2.2 Patient has received insufficient benefit from at least 3 months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.3 Patient has received insufficient benefit from at least 3 months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses unless contraindicated); and
 - 2.4 Either:
 - 2.4.1 Patient has received insufficient benefit from at least 3 months of methotrexate in combination with the maximum tolerated dose of ciclosporin, unless contraindicated; or
 - 2.4.2 Patient has received insufficient benefit from at least 3 months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate, unless contraindicated; and
 - 2.5 Either:
 - 2.5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 joints; or
 - 2.5.2 Patient has persistent symptoms of poorly controlled and active disease in at least 4 joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

Renewal — (arthritis - rheumatoid) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Following initial treatment, at least a 50% decrease in active joint count from baseline; or

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.2 On subsequent reapplications, at least a continuing 30% improvement in active joint count from baseline; and
- 2 Maximum dose 50 mg every 7 days.

Initial application — (Plaque psoriasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had a Special Authority approval for adalimumab for plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for plaque psoriasis; or
- 2 All of the following:
 - 2.1 Any of the following:
 - 2.1.1 Patient has "whole body" plaque psoriasis with a PASI score of greater than 10; or
 - 2.1.2 Patient has plaque psoriasis of the face, or palm of a hand or sole of a foot; or
 - 2.1.3 Patient has localised genital or flexural plaque psoriasis with a DLQI score greater than 10; and
 - 2.2 Patient has received insufficient benefit from (see Note), or has experienced intolerable side effects from, at least 3 of the following at maximum tolerated doses (unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 2.3 A PASI assessment or DLQI assessment has been completed for the most recent prior treatment course within 1 month of stopping that treatment; and
 - 2.4 The most recent PASI or DLQI assessment is within 1 month before the application.

Note: "Insufficient benefit" is defined as: for whole body plaque psoriasis, a PASI score of greater than 10, for plaque psoriasis of the face, hand, foot, genital or flexural areas at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and for the face, palm of a hand or sole of a foot the skin area affected is 30% or more of the face, palm of a hand or sole of a foot. As assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (Plaque psoriasis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" plaque psoriasis at the start of treatment; and
 - 1.1.2 Either:
 - 1.1.2.1 Patient has a PASI score which is reduced by 75% or more, or is sustained at this level, compared with the pre-treatment baseline; or
 - 1.1.2.2 Patient has a DLQI improvement of 5 or more, compared with the pre-treatment baseline; or
 - 1.2 Both:
 - 1.2.1 Patient had plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, compared to the pre-treatment baseline; or
 - 1.2.2.2 Patient has a reduction of 75% or more in the skin area affected, or sustained at this level, compared to the pre-treatment baseline; or
 - 1.3 Both:
 - 1.3.1 Patient has localised genital or flexural plaque psoriasis at the start of treatment; and
 - 1.3.2 Either:

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

1.3.2.1 Patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, compared to the pre-treatment baseline; or

1.3.2.2 Patient has a DLQI improvement of 5 or more, compared to the pre-treatment baseline; and

2 Maximum dose 50 mg every 7 days.

Initial application — (undifferentiated spondyloarthritis*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis with active peripheral joint arthritis in at least 4 joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has received insufficient benefit from least 3 months of each of methotrexate, sulfasalazine, and leflunomide at maximum tolerated doses, unless contraindicated; and
- 3 Any of the following:
 - 3.1 Patient has a CRP level greater than 15 mg/L measured within one month before the application; or
 - 3.2 Patient has an ESR greater than 25 mm per hour measured within one month before the application; or
 - 3.3 ESR and CRP not measured as patient is currently receiving prednisone therapy greater than 5 mg per day received for more than 3 months.

Note: Indications marked with * are unapproved indications.

Renewal — (undifferentiated spondyloarthritis*) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Following initial treatment, the patient has experienced at least a 50% decrease in active joint count from baseline; or
 - 1.2 Patient has experienced at least a continuing 30% improvement in active joint count from baseline; and
- 2 Maximum dose 50 mg every 7 days.

Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist

Inj 50 mg per ml, 5 ml.....	4,439.17	5	✓ ATGAM
-----------------------------	----------	---	---------

BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Specialist

Subsidised only for bladder cancer.

Inj 2-8 x 100 million CFU.....	182.45	1	✓ OncoTICE
--------------------------------	--------	---	------------

Inj 40 mg per ml, vial	182.45	3	✓ SII-Onco-BCG \$29
------------------------------	--------	---	------------------------------------

Monoclonal Antibodies

ADALIMUMAB (AMGEVITA) – Special Authority see [SA2525 below](#) – Retail pharmacy

Inj 20 mg per 0.4 ml prefilled syringe.....	190.00	1	✓ Amgevita
---	--------	---	------------

Inj 40 mg per 0.8 ml prefilled pen	375.00	2	✓ Amgevita
--	--------	---	------------

Inj 40 mg per 0.8 ml prefilled syringe.....	375.00	2	✓ Amgevita
---	--------	---	------------

► **SA2525** Special Authority for Subsidy

Initial application — (Behcet's disease - severe) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has severe Behcet's disease* that is significantly impacting the patient's quality of life; and
- 2 Either:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.1 The patient has severe ocular, neurological, and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s); or
- 2.2 The patient has severe gastrointestinal, rheumatological, and/or mucocutaneous symptoms and has not responded adequately to two or more treatments appropriate for the particular symptom(s).

Note: Indications marked with * are unapproved indications.

Initial application — (Hidradenitis suppurativa) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
- 2 Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or has demonstrated intolerance to or has contraindications for systemic antibiotics; and
- 3 Patient has 3 or more active lesions; and
- 4 The patient has a DLQI of 10 or more and the assessment is no more than 1 month old at time of application.

Renewal — (Hidradenitis suppurativa) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a DLQI improvement of 4 or more from baseline.

Initial application — (Plaque psoriasis - severe chronic) only from a dermatologist or any relevant practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Any of the following:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a PASI score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.3 Patient has severe chronic localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis, and with a Dermatology Life Quality Index (DLQI) score greater than 10; and
 - 2.2 Patient has tried, but had an inadequate response to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 2.3 A PASI assessment or DLQI assessment has been completed for at least the most recent prior treatment course but no longer than 1 month following cessation of each prior treatment course and is no more than 1 month old at the time of application.

Renewal — (Plaque psoriasis - severe chronic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 Both:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
- 1.2 Either:
 - 1.2.1 The patient has experienced a 75% or more reduction in PASI score, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 1.2.2 The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value; or
- 2 Both:
 - 2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2 Either:
 - 2.2.1 The patient has experienced reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2 The patient has experienced reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre treatment baseline value; or
- 3 Both:
 - 3.1 Patient had severe chronic localised genital or flexural plaque psoriasis at the start of treatment; and
 - 3.2 Either:
 - 3.2.1 The patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; or
 - 3.2.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing adalimumab.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and has not received an adequate response.

Note: Indications marked with * are unapproved indications.

Initial application — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Renewal — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced by 3 points, from when the patient was initiated on adalimumab; or
- 2 CDAI score is 150 or less, or HBI is 4 or less; or
- 3 The patient has demonstrated an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Initial application — (Crohn's disease - children) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a PCDAI score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Renewal — (Crohn's disease - children) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
- 2 PCDAI score is 15 or less; or
- 3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed.

Initial application — (Crohn's disease - fistulising) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); or
 - 2.3 Patient has complex peri-anal fistula; and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application.

Renewal — (Crohn's disease - fistulising) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initial application — (Ocular inflammation - chronic) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Renewal — (Ocular inflammation - chronic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Any of the following:

- 1 The patient has had a good clinical response following 12 weeks' initial treatment; or
- 2 Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Initial application — (Ocular inflammation - severe) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Renewal — (Ocular inflammation - severe) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects; or
 - 1.2.2 The patient has received insufficient benefit to meet the renewal criteria for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by radiology imaging; and
 - 2.4 Patient has not responded adequately to treatment with two or more NSAIDs, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following BASMI measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender; and

2.6 A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment and is no more than 1 month old at the time of application.

Renewal — (ankylosing spondylitis) from any relevant practitioner. Approvals valid for 2 years where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less.

Initial application — (Arthritis - oligoarticular course juvenile idiopathic) only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for oligoarticular course juvenile idiopathic arthritis (JIA); and

1.2 Either:

1.2.1 Patient has experienced intolerable side effects; or

1.2.2 Patient has received insufficient benefit to meet the renewal criteria for oligoarticular course JIA; or

2 All of the following:

2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and

2.3 Either:

2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or

2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose).

Renewal — (Arthritis - oligoarticular course juvenile idiopathic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

1 Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (Arthritis - polyarticular course juvenile idiopathic) only from a named specialist or rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 Patient has had an initial Special Authority approval for etanercept for polyarticular course juvenile idiopathic arthritis (JIA); and

1.2 Either:

1.2.1 Patient has experienced intolerable side effects; or

1.2.2 Patient has received insufficient benefit to meet the renewal criteria for polyarticular course JIA; or

2 All of the following:

2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and

2.3 Any of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
- 2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
- 2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Renewal — (Arthritis - polyarticular course juvenile idiopathic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (Arthritis - psoriatic) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had an initial Special Authority approval for etanercept or secukinumab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects; or
 - 1.2.2 The patient has received insufficient benefit from to meet the renewal criteria for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine or leflunomide at maximum tolerated doses (unless contraindicated); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an ESR greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (Arthritis - psoriatic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in swollen joint count from baseline and a clinically significant response in the opinion of the physician; or
- 2 Patient demonstrates at least a continuing 30% improvement in swollen joint count from baseline and a clinically significant response in the opinion of the treating physician.

Initial application — (Arthritis - rheumatoid) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is CCP antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.4 Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated); and
 - 2.5 Either:
 - 2.5.1 Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin (unless contraindicated); or
 - 2.5.2 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide (unless contraindicated) alone or in combination with methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

Renewal — (Arthritis - rheumatoid) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Initial application — (Still's disease - adult-onset (AOSD)) only from a rheumatologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept and/or tocilizumab for AOSD; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 Patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria; and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, NSAIDs and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active ulcerative colitis; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

2 Either:

- 2.1 Patient's SCCAI score is greater than or equal to 4; or
- 2.2 Patient's PUCAI score is greater than or equal to 20; and

- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from prior therapy with immunomodulators and systemic corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on biologic therapy; or
- 2 The PUCAI score has reduced by 10 points or more from the PUCAI score when the patient was initiation on biologic therapy.

Initial application — (undifferentiated spondyloarthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has tried and not responded to at least three months of each of methotrexate, sulfasalazine and leflunomide, at maximum tolerated doses (unless contraindicated); and
- 3 Any of the following:
 - 3.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 3.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 3.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with * are unapproved indications

Renewal — (undifferentiated spondyloarthritis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response in the opinion of the treating physician.

Initial application — (inflammatory bowel arthritis – axial) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has axial inflammatory pain for six months or more; and
- 3 Patient is unable to take NSAIDs; and
- 4 Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI; and
- 5 Patient has not responded adequately to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist; and
- 6 A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment.

Renewal — (inflammatory bowel arthritis – axial) from any relevant practitioner. Approvals valid for 2 years where treatment

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less.

Initial application — (inflammatory bowel arthritis – peripheral) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular; and
- 3 Patient has tried and not experienced a response to at least three months of methotrexate, or azathioprine at a maximum tolerated dose (unless contraindicated); and
- 4 Patient has tried and not experienced a response to at least three months of sulfasalazine at a maximum tolerated dose (unless contraindicated); and
- 5 Any of the following:
 - 5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (inflammatory bowel arthritis – peripheral) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 Patient has experienced at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician.

ADALIMUMAB (HUMIRA - ALTERNATIVE BRAND) – Special Authority see [SA2157 below](#) – Retail pharmacy

Inj 20 mg per 0.2 ml prefilled syringe.....	595.50	2	✓ Humira
Inj 40 mg per 0.4 ml prefilled pen	595.50	2	✓ HumiraPen
Inj 40 mg per 0.4 ml prefilled syringe.....	595.50	2	✓ Humira

» [SA2157](#) Special Authority for Subsidy

Initial application — (Behcet's disease – severe) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Behcet's disease – severe) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient has had a good clinical response to treatment with measurably improved quality of life; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (Hidradenitis suppurativa) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 7 days. Fortnightly dosing has been considered.

Renewal — (Hidradenitis suppurativa) only from a dermatologist or Practitioner on the recommendation of a dermatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
- 3 Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

Initial application — (Psoriasis - severe chronic plaque) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Psoriasis - severe chronic plaque) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Either:
 - 1.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 1.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
 - 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

compared to the treatment course baseline values; or

- 1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and

- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Pyoderma gangrenosum) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 A maximum of 8 doses.

Renewal — (Pyoderma gangrenosum) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated clinical improvement and continues to require treatment; and
- 2 A maximum of 8 doses.

Initial application — (Crohn's disease - adult) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Crohn's disease - adult) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 1.2 CDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Crohn's disease - children) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
- 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
- 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Crohn's disease - children) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment, but PCDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Crohn's disease - fistulising) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Crohn's disease - fistulising) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
 - 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Ocular inflammation – chronic) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1.3 Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Ocular inflammation – chronic) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Ocular inflammation – severe) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Ocular inflammation – severe) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 3 initial doses; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita); and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Arthritis – oligoarticular course juvenile idiopathic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

Renewal — (Arthritis – oligoarticular course juvenile idiopathic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months where the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (Arthritis - polyarticular course juvenile idiopathic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

Renewal — (Arthritis - polyarticular course juvenile idiopathic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months where the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (Arthritis - psoriatic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (Arthritis - psoriatic) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Arthritis – rheumatoid) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- Either:
 - The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- Patient has received a maximum of 6 months treatment with Amgevita; and
- Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- Either:
 - Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Renewal — (Arthritis – rheumatoid) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- Either:
 - Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Initial application — (Still's disease – adult-onset (AOSD)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- Either:
 - The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- Patient has received a maximum of 6 months treatment with Amgevita; and
- Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

Renewal — (Still's disease – adult-onset (AOSD)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months where the patient has demonstrated a sustained improvement in inflammatory markers and functional status.

AFLIBERCEPT – Special Authority see [SA2550 on the next page](#) – Retail pharmacy

Inj 40 mg per ml, 0.1 ml vial.....1,250.00 1 ✓ Eylea

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

➤SA2550 Special Authority for Subsidy

Initial application — (diabetic macular oedema) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has centre involving diabetic macular oedema (DMO); and
- 2 Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
- 3 Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
- 4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
- 5 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
- 6 Patient has not previously been treated with faricimab for longer than 3 months.

Renewal — (diabetic macular oedema) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 There is stability or two lines of Snellen visual acuity gain; and
- 2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
- 3 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 4 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Initial application — (wet age related macular degeneration) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Wet age-related macular degeneration (wet AMD); or
 - 1.1.2 Polypoidal choroidal vasculopathy; or
 - 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
 - 1.2 Either:
 - 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
 - 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
 - 1.3 There is no structural damage to the central fovea of the treated eye; and
 - 1.4 Patient has not previously been treated with ranibizumab or faricimab for longer than 3 months; or
- 2 Either:
 - 2.1 Patient has current approval to use ranibizumab or faricimab for treatment of wAMD and was found to be intolerant within 3 months; or
 - 2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Renewal — (wet age related macular degeneration) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 3 There is no structural damage to the central fovea of the treated eye.

BENRALIZUMAB – Special Authority see [SA2151 on the next page](#) – Retail pharmacy

Inj 30 mg per ml, 1 ml prefilled pen3,539.00 1

✓ Fasenra

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA2151 Special Authority for Subsidy

Initial application — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than 0.5×10^9 cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long-acting beta-2 agonist, or budesonide/formoterol as part of the anti-inflammatory reliever therapy plus maintenance regimen, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
 - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
- 7 Treatment is not to be used in combination with subsidised mepolizumab; and
- 8 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment; and
- 9 Either:
 - 9.1 Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma; or
 - 9.2 Both:
 - 9.2.1 Patient was refractory or intolerant to previous anti-IL5 biological therapy; and
 - 9.2.2 Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment.

Renewal — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 Either:
 - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with benralizumab; or
 - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

BEVACIZUMAB – PCT only – Special Authority see [SA2453 below](#)

Inj 25 mg per ml, 4 ml vial.....	69.00	1	✓ Vegzelma
Inj 25 mg per ml, 16 ml vial.....	276.00	1	✓ Vegzelma
Inj 1 mg for ECP.....	0.71	1 mg	✓ Baxter

►SA2453 Special Authority for Subsidy

Initial application — (unresectable hepatocellular carcinoma) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with bevacizumab, and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.1 Patient has locally advanced or metastatic, unresectable hepatocellular carcinoma; and
- 2.2 Patient has preserved liver function (Child-Pugh A); and
- 2.3 Transarterial chemoembolisation (TACE) is unsuitable; and
- 2.4 Any of the following:
 - 2.4.1 Patient has not received prior systemic therapy for the treatment of hepatocellular carcinoma; or
 - 2.4.2 Patient received funded lenvatinib before 1 March 2025; or
 - 2.4.3 Both:
 - 2.4.3.1 Patient has experienced treatment-limiting toxicity from treatment with lenvatinib; and
 - 2.4.3.2 No disease progression since initiation of lenvatinib; and
- 2.5 Patient has an ECOG performance status of 0-2; and
- 2.6 To be given in combination with atezolizumab.

Renewal — (unresectable hepatocellular carcinoma) from any relevant practitioner. Approvals valid for 6 months where there is no evidence of disease progression.

Initial application — (advanced or metastatic ovarian cancer) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has FIGO Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer; or
 - 1.2 Both:
 - 1.2.1 The patient has previously untreated advanced (FIGO Stage IIIB or IIIC) epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
 - 1.2.2 Either:
 - 1.2.2.1 Debulking surgery is inappropriate; or
 - 1.2.2.2 The cancer is sub-optimally debulked (maximum diameter of any gross residual disease greater than 1cm); and
- 2 Bevacizumab to be administered at a maximum dose of 15 mg/kg every three weeks; and
- 3 18 weeks concurrent treatment with chemotherapy is planned.

Renewal — (advanced or metastatic ovarian cancer) from any relevant practitioner. Approvals valid for 4 months where there is no evidence of disease progression.

Initial application — (Recurrent Respiratory Papillomatosis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Maximum of 6 doses; and
- 2 The patient has recurrent respiratory papillomatosis; and
- 3 The treatment is for intra-lesional administration.

Renewal — (Recurrent Respiratory Papillomatosis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Maximum of 6 doses; and
- 2 The treatment is for intra-lesional administration; and
- 3 There has been a reduction in surgical treatments or disease regrowth as a result of treatment.

Initial application — (Ocular Conditions) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Ocular neovascularisation; or
- 2 Exudative ocular angiopathy.

BRENTUXIMAB VEDOTIN – PCT only – Special Authority see [SA2629 on the next page](#)

Inj 50 mg vial	5,275.18	1	✓ Adcetris
----------------------	----------	---	------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2629 Special Authority for Subsidy

Initial application — (CD30 positive systemic anaplastic large-cell lymphoma) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with brentuximab vedotin and met all the following criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has CD30 positive systemic anaplastic large-cell lymphoma; and
 - 2.2 Patient must have histological confirmation of CD30 expression; and
 - 2.3 Patient must not have received prior treatment with curative intent chemotherapy for this condition; and
 - 2.4 Treatment must be in combination with cyclophosphamide, anthracycline, and steroids for a maximum of 8 cycles; and
 - 2.5 Brentuximab vedotin is to be administered at doses no greater than 1.8 mg/kg every 3 weeks.

Initial application — (relapsed/refractory Hodgkin lymphoma) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient has relapsed/refractory CD30-positive Hodgkin lymphoma after two or more lines of chemotherapy; and
 - 1.1.2 Patient is ineligible for autologous stem cell transplant; or
 - 1.2 Both:
 - 1.2.1 Patient has relapsed/refractory CD30-positive Hodgkin lymphoma; and
 - 1.2.2 Patient has previously undergone autologous stem cell transplant; and
- 2 Patient has not previously received funded brentuximab vedotin; and
- 3 Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles; and
- 4 Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks.

Renewal — (relapsed/refractory Hodgkin lymphoma) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has achieved a partial or complete response to brentuximab vedotin after 6 treatment cycles; and
- 2 Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated; and
- 3 Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment.

Initial application — (relapsed/refractory anaplastic large cell lymphoma) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has relapsed/refractory CD30-positive systemic anaplastic large cell lymphoma; and
- 2 Patient has an ECOG performance status of 0-1; and
- 3 Patient has not previously received brentuximab vedotin; and
- 4 Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles; and
- 5 Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks.

Renewal — (relapsed/refractory anaplastic large cell lymphoma) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has experienced a partial or complete response to brentuximab vedotin after 6 treatment cycles; and
- 2 Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated; and
- 3 Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CETUXIMAB – PCT only – Specialist – Special Authority see SA2401 below				
Inj 5 mg per ml, 20 ml vial.....	364.00	1	✓	Erbitux
Inj 5 mg per ml, 100 ml vial.....	1,820.00	1	✓	Erbitux
Inj 1 mg for ECP	3.82	1 mg	✓	Baxter

► **SA2401** **Special Authority for Subsidy**

Initial application — (head and neck cancer, locally advanced) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck; and
- 2 Cisplatin is contraindicated or has resulted in intolerable side effects; and
- 3 Patient has an ECOG performance score of 0-2; and
- 4 To be administered in combination with radiation therapy.

Initial application — (colorectal cancer, metastatic) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has metastatic colorectal cancer located on the left side of the colon (see Note); and
- 2 There is documentation confirming disease is RAS and BRAF wild-type; and
- 3 Patient has an ECOG performance score of 0-2; and
- 4 Patient has not received prior funded treatment with cetuximab; and
- 5 Either:
 - 5.1 Cetuximab is to be used in combination with chemotherapy; or
 - 5.2 Chemotherapy is determined to not be in the best interest of the patient based on clinician assessment.

Renewal — (colorectal cancer, metastatic) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where there is no evidence of disease progression.

Note: Left-sided colorectal cancer comprises of the distal one-third of the transverse colon, the splenic flexure, the descending colon, the sigmoid colon, or the rectum.

FARICIMAB – Special Authority see SA2533 below – Retail pharmacy

Inj 120 mg per ml, 0.24 ml vial.....	1,565.00	1	✓	Vabysmo
--------------------------------------	----------	---	---	----------------

► **SA2533** **Special Authority for Subsidy**

Initial application — (diabetic macular oedema) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has centre involving diabetic macular oedema (DMO); and
- 2 Patient's disease is nonresponsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
- 3 Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
- 4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
- 5 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
- 6 Patient has not previously been treated with aflibercept for longer than 3 months.

Renewal — (diabetic macular oedema) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 There is stability or two lines of Snellen visual acuity gain; and
- 2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
- 3 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 4 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Initial application — (wet age related macular degeneration) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

All of the following:

1 Any of the following:

- 1.1 Wet age-related macular degeneration (wet AMD); or
- 1.2 Polypoidal choroidal vasculopathy; or
- 1.3 Choroidal neovascular membrane from causes other than wet AMD; and

2 Either:

- 2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
- 2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and

3 There is no structural damage to the central fovea of the treated eye; and

4 Patient has not previously been treated with ranibizumab or aflibercept for longer than 3 months.

Renewal — (wet age related macular degeneration) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 2 There is no structural damage to the central fovea of the treated eye.

GEMTUMAB OZOGAMICIN – PCT only – Specialist – Special Authority see [SA2269 below](#)

Inj 5 mg vial	12,973.00	1	✓ Mylotarg
---------------------	-----------	---	------------

➔ [SA2269](#) **Special Authority for Subsidy**

Initial application only from a haematologist, paediatric haematologist or paediatric oncologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has not received prior chemotherapy for this condition; and
- 2 Patient has de novo CD33-positive acute myeloid leukaemia; and
- 3 Patient does not have acute promyelocytic leukaemia; and
- 4 Gemtuzumab ozogamicin will be used in combination with standard anthracycline and cytarabine (AraC); and
- 5 Patient is being treated with curative intent; and
- 6 Patient's disease risk has been assessed by cytogenetic testing to be good or intermediate; and
- 7 Patient must be considered eligible for standard intensive remission induction chemotherapy with standard anthracycline and cytarabine (AraC); and
- 8 Gemtuzumab ozogamicin to be funded for one course only (one dose at 3 mg per m² body surface area or up to 2 vials of 5 mg as separate doses).

Note: Acute myeloid leukaemia excludes acute promyelocytic leukaemia and acute myeloid leukaemia that is secondary to another haematological disorder (eg myelodysplasia or myeloproliferative disorder).

INFLIXIMAB – PCT only – Special Authority see [SA2620 below](#)

Inj 100 mg	428.00	1	✓ Remicade
Inj 1 mg for ECP	4.40	1 mg	✓ Baxter

➔ [SA2620](#) **Special Authority for Subsidy**

Initial application — (Crohn's disease (adults)) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a CDAI score of greater than or equal to 300 or HBI score of greater than or equal to 10; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
- 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but has experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Renewal — (Crohn's disease (adults)) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced by 3 points, from when the patient was initiated on infliximab; or
 - 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score and/or HBI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (Crohn's disease (children)) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a PCDAI score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Renewal — (Crohn's disease (children)) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (Graft vs host disease) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has steroid-refractory acute graft vs. host disease of the gut.

Initial application — (Pulmonary sarcoidosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has life-threatening pulmonary sarcoidosis diagnosed by a multidisciplinary team that is refractory to other treatments.

Initial application — (acute fulminant ulcerative colitis) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient has acute, fulminant ulcerative colitis; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

Initial application — (ankylosing spondylitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has had a Special Authority approval for adalimumab or etanercept for ankylosing spondylitis; and
- 2 Either:
 - 2.1 Patient has experienced intolerable side effects; or
 - 2.2 Patient has received insufficient benefit to meet the renewal criteria for ankylosing spondylitis; and
- 3 Following initial induction doses, maximum dose 5mg/kg every 6-8 weeks.

Renewal — (ankylosing spondylitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 BASDAI has improved from pre-treatment baseline either by at least 4 points on a 10-point scale, or by at least 50%; and
- 2 Maximum dose 5 mg/kg every 6-8 weeks.

Initial application — (ocular inflammation - chronic*) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had a Special Authority approval for adalimumab for chronic ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for chronic ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe uveitis with a severe risk of vision loss uncontrolled by treatment with corticosteroids and other immunosuppressants; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has been ineffective or are contraindicated; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has been ineffective, is contraindicated or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with corticosteroids or methotrexate has been ineffective, is contraindicated or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Note: Indications marked with * are unapproved indications

Renewal — (ocular inflammation - chronic*) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 Patient has received a good clinical response following 3 initial doses; or
- 2 Following each 2 year treatment period, the patient has experienced a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, the patient has a sustained corticosteroid sparing effect, allowing reduction in prednisone to < 10mg daily, or corticosteroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn. Indications marked with * are unapproved indications

Initial application — (fistulising Crohn's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Both:

- 1 Patient has confirmed Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); or
 - 2.3 Patient has complex peri-anal fistula.

Renewal — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
 - 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (neurosarcoidosis) only from a neurologist or Practitioner on the recommendation of a neurologist.

Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with neurosarcoidosis by a multidisciplinary team; and
- 2 Patient has CNS involvement; and
- 3 Patient has steroid-refractory disease; and
- 4 Either:
 - 4.1 IV cyclophosphamide has been tried; or
 - 4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

Renewal — (neurosarcoidosis) only from a neurologist or Practitioner on the recommendation of a neurologist. Approvals valid for 18 months for applications meeting the following criteria:

Either:

- 1 A withdrawal period has been tried and the patient has relapsed; or
- 2 All of the following:
 - 2.1 A withdrawal period has been considered but would not be clinically appropriate; and
 - 2.2 There has been a marked reduction in prednisone dose; and
 - 2.3 Either:
 - 2.3.1 There has been an improvement in MRI appearances; or
 - 2.3.2 Marked improvement in other symptomology.

Initial application — (plaque psoriasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient had a Special Authority approval for adalimumab, etanercept or secukinumab for plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for plaque psoriasis; or
- 2 All of the following:
 - 2.1 Any of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.1.1 Patient has "whole body" plaque psoriasis with a PASI score of greater than 10; or
- 2.1.2 Patient has plaque psoriasis of the face, or palm of a hand or sole of a foot; or
- 2.1.3 Patient has localised genital or flexural plaque psoriasis with a DLQI score greater than 10; and
- 2.2 Patient has received insufficient benefit (see Note) or has experienced intolerable side effects from at least 3 of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 2.3 A PASI assessment has been completed for the most recent prior treatment course within 1 month of stopping that treatment; and
- 2.4 The most recent PASI assessment is within 1 month before the application.

Note: "Insufficient benefit" is defined as: for whole body plaque psoriasis, a PASI score of greater than 10; for plaque psoriasis of the face, hand, foot, genital or flexural areas at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and for the face, palm of a hand or sole of a foot the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (plaque psoriasis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" plaque psoriasis at the start of treatment; and
 - 1.1.2 Patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab baseline; or
 - 1.2 Both:
 - 1.2.1 Patient had plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-infliximab baseline; or
 - 1.2.2.2 Patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab baseline; or
 - 1.3 Both:
 - 1.3.1 Patient had localised genital or flexural plaque psoriasis at the start of treatment; and
 - 1.3.2 Either:
 - 1.3.2.1 Patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline; or
 - 1.3.2.2 Patient has a DLQI improvement of 5 or more, as compared to the pre-infliximab baseline; and
- 2 Maximum dose 5 mg/kg every 8 weeks.

Initial application — (previous use) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient was being treated with infliximab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 Rheumatoid arthritis; or
 - 2.2 Ankylosing spondylitis; or
 - 2.3 Psoriatic arthritis; or
 - 2.4 Severe ocular inflammation; or
 - 2.5 Chronic ocular inflammation; or
 - 2.6 Crohn's disease (adults); or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.7 Crohn's disease (children); or
- 2.8 Fistulising Crohn's disease; or
- 2.9 Severe fulminant ulcerative colitis; or
- 2.10 Severe ulcerative colitis; or
- 2.11 Plaque psoriasis; or
- 2.12 Neurosarcoidosis; or
- 2.13 Severe Behcet's disease.

Initial application — (arthritis - psoriatic) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has had a Special Authority approval for adalimumab or etanercept or secukinumab for psoriatic arthritis; and
- 2 Either:
 - 2.1 Patient has experienced intolerable side effects; or
 - 2.2 Patient has received insufficient benefit to meet the renewal criteria for psoriatic arthritis; and
- 3 Following initial induction doses, maximum dose 5mg/kg every 8 weeks.

Renewal — (arthritis - psoriatic) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Following initial treatment, at least a 50% decrease in active joint count from baseline; or
 - 1.2 At least a continuing 30% improvement in active joint count from baseline; and
- 2 Maximum dose 5 mg/kg every 8 weeks.

Initial application — (arthritis - rheumatoid) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has had a Special Authority approval for adalimumab or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 Patient has experienced intolerable side effects; or
 - 2.2 Patient has received insufficient benefit to meet the renewal criteria for rheumatoid arthritis; and
- 3 Following initial induction doses, maximum dose 3mg/kg every 8 weeks.

Renewal — (arthritis - rheumatoid) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Following initial treatment, the patient has experienced at least a 50% decrease in active joint count from baseline; or
 - 1.2 Patient has experienced at least a continuing 30% improvement in active joint count from baseline; and
- 2 Maximum dose 3 mg/kg every 8 weeks.

Initial application — (Behcet disease) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has severe Behcet disease which is significantly impacting their quality of life; and
- 2 Either:
 - 2.1 Patient has severe ocular, neurological and/or vasculitic symptoms and has received insufficient benefit from 1 or more treatment(s) appropriate for the particular symptom(s); or
 - 2.2 Patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has received insufficient benefit from 2 or more treatments appropriate for the particular symptom(s); and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

3 Following initial loading doses, maximum dose 5mg/kg every 8 weeks.

Renewal — (fulminant ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (ocular inflammation - severe*) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for severe ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose IV corticosteroids followed by high dose oral corticosteroids has been ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose corticosteroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral corticosteroids and other immunosuppressants has been ineffective at controlling symptoms; or
 - 2.2.4 High dose corticosteroids are contraindicated.

Note: Indications marked with * are unapproved indications.

Renewal — (ocular inflammation - severe*) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 Patient has received a good clinical response following 3 initial doses; or
- 2 Following each 2 year treatment period, the patient has experienced a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, patient has a sustained corticosteroid sparing effect, allowing reduction in prednisone to < 10mg daily, or corticosteroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn. Indications marked with * are unapproved indications

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Either:
 - 2.1 Patients SCCAI is greater than or equal to 4; or
 - 2.2 Patients PUCAI score is greater than or equal to 20; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 3 Patient has tried but has experienced an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and systemic corticosteroids.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
 - 1.2 The PUCAI score has reduced by 10 points or more from the PUCAI score when the patient was initiated on infliximab; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (pyoderma gangrenosum*) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has received insufficient benefit from 3 months of conventional therapy including a minimum of 3 pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate). Where conventional pharmaceuticals are contraindicated, a 3-month trial has occurred of those that are not contraindicated; and
- 2 Maximum of 8 doses every 4 months.

Note: Note: Indications marked with * are unapproved indications.

Initial application — (inflammatory bowel arthritis – axial) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has had axial inflammatory pain for six months or more; and
- 3 Patient is unable to take NSAIDs; and
- 4 Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI; and
- 5 Patient's disease has not responded adequately to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist; and
- 6 Patient has a BASDAI of at least 6 on a 0 - 10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment .

Renewal — (inflammatory bowel arthritis – axial) from any relevant practitioner. Approvals valid for 2 years where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10-point scale, or an improvement in BASDAI of 50%, whichever is less.

Initial application — (inflammatory bowel arthritis – peripheral) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular; and
- 3 Patient has tried and not experienced a response to at least three months of methotrexate or azathioprine at a maximum tolerated dose (unless contraindicated); and
- 4 Patient has tried and not experienced a response to at least three months of sulfasalazine at a maximum tolerated dose (unless contraindicated); and
- 5 Any of the following:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 5.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
- 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (inflammatory bowel arthritis – peripheral) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Following initial treatment, patient has experienced at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 Patient has experienced at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician.

Initial application — (immune checkpoint inhibitor toxicity in malignancy*) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The individual requires treatment for moderate to severe autoimmune toxicity following immune checkpoint inhibitor treatment for malignancy; and
- 2 The individual has received insufficient benefit from use of corticosteroids; and
- 3 Infliximab is to be administered at up to 5mg/kg for up to four doses.

Renewal — (immune checkpoint inhibitor toxicity in malignancy*) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 The individual has shown clinical improvement and ongoing treatment is required; and
- 2 Infliximab is to be administered at up to 5mg/kg for up to a total of 8 doses.

Note: Indications marked with * are unapproved indications.

INOTUZUMAB OZOGAMICIN – PCT only – Specialist – Special Authority see [SA2460 below](#)

Inj 1 mg vial	14,457.00	1	✓ Besponsa
Inj 1 mg for ECP	14,457.00	1 mg	✓ Baxter

► **SA2460** Special Authority for Subsidy

Initial application only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist.

Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia/lymphoma, including minimal residual disease; and
- 2 Patient has ECOG performance status of 0-2; and
- 3 Either:
 - 3.1 Both:
 - 3.1.1 Patient has Philadelphia chromosome positive B-Cell ALL; and
 - 3.1.2 Patient has previously received a tyrosine kinase inhibitor; or
 - 3.2 Patient has received one prior line of treatment involving intensive chemotherapy; and
- 4 Treatment is to be administered for a maximum of 3 cycles.

Renewal only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient is not proceeding to a stem cell transplant; and

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

2 Either:

- 2.1 Patient has experienced complete disease response; or
- 2.2 Patient has experienced complete remission with incomplete haematological recovery; and

3 Treatment with inotuzumab ozogamicin is to cease after a total duration of 6 cycles.

MEPOLIZUMAB – Special Authority see [SA2331 below](#) – Retail pharmacy

Inj 100 mg prefilled pen	1,638.00	1	✓ Nucala
--------------------------------	----------	---	----------

▶SA2331 Special Authority for Subsidy

Initial application — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than 0.5×10^9 cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the single maintenance and reliever therapy regimen, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
 - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
- 7 Treatment is not to be used in combination with subsidised benralizumab; and
- 8 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment; and
- 9 Either:
 - 9.1 Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma; or
 - 9.2 Both:
 - 9.2.1 Patient was refractory or intolerant to previous anti-IL5 biological therapy; and
 - 9.2.2 Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment.

Renewal — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 Either:
 - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with mepolizumab; or
 - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

Initial application — (eosinophilic granulomatosis with polyangiitis) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

All of the following:

- 1 The patient has eosinophilic granulomatosis with polyangiitis; and
- 2 The patient has trialled and not received adequate benefit from at least one of the following for at least three months (unless contraindicated to all): azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate, or rituximab; and
- 3 Either:
 - 3.1 The patient has trialled prednisone for a minimum of three months and is unable to maintain disease control at doses below 7.5 mg per day; or
 - 3.2 Corticosteroids are contraindicated.

Renewal — (eosinophilic granulomatosis with polyangiitis) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where patient has no evidence of clinical disease progression.

OBINUTUZUMAB – PCT only – Specialist – Special Authority see [SA2639 below](#)

Inj 25 mg per ml, 40 ml vial.....	5,910.00	1	✓ Gazyva
Inj 1 mg for ECP	6.21	1 mg	✓ Baxter

► [SA2639](#) Special Authority for Subsidy

Initial application — (previously untreated chronic lymphocytic leukaemia in combination with venetoclax) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Either:

- 1 Individual is currently on treatment with obinutuzumab and venetoclax and met all of the following criteria prior to commencing treatment; or
- 2 Both:
 - 2.1 Individual has previously untreated chronic lymphocytic leukaemia; and
 - 2.2 Obinutuzumab is to be administered at a maximum cumulative dose of 8,000 mg and in combination with venetoclax for a maximum of 6 (28-day) cycles of treatment.

Initial application — (chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is obinutuzumab treatment naive; and
- 3 The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
- 4 Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and
- 5 Patient has good performance status; and
- 6 Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* Neutrophil greater than or equal to $1.5 \times 10^9/L$ and platelets greater than or equal to $75 \times 10^9/L$.

Initial application — (follicular / marginal zone lymphoma) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has follicular lymphoma; or

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1.2 Patient has marginal zone lymphoma; and
- 2 Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen*; and
- 3 Patient has an ECOG performance status of 0-2; and
- 4 Patient has been previously treated with no more than four chemotherapy regimens; and
- 5 Obinutuzumab to be administered at a maximum dose of 1000 mg for a maximum of 6 cycles in combination with chemotherapy*.

Note: * includes unapproved indications

Renewal — (follicular / marginal zone lymphoma) from any relevant practitioner. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 Patient has no evidence of disease progression following obinutuzumab induction therapy; and
- 2 Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and
- 3 Obinutuzumab to be discontinued at disease progression.

OMALIZUMAB — Special Authority see [SA2597 below](#) – Retail pharmacy

Inj 150 mg prefilled syringe.....	450.00	1	✓ Xolair
Inj 150 mg vial	450.00	1	✓ Xolair AU ✓ Xolair

►SA2597 Special Authority for Subsidy

Initial application — (severe asthma) only from a respiratory specialist or clinical immunologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 6 years or older; and
- 2 Patient has a diagnosis of severe asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
- 5 Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
 - 6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less; and
- 8 Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Initial application — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 7 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
 - 2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.2 Patient has a Urticaria Control Test (UCT) of 8 or less; and
- 3 Any of the following:
 - 3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
 - 3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
 - 3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and
- 4 Either:
 - 4.1 Treatment to be stopped if inadequate response* following 4 doses; or
 - 4.2 Complete response* to 6 doses of omalizumab.

Renewal — (severe asthma) only from a clinical immunologist or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria:

- Both:
- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
 - 2 A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Renewal — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

- Either:
- 1 Patient has previously adequately responded* to 6 doses of omalizumab; or
 - 2 Both:

- 2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
- 2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PALIVIZUMAB – PCT only – Special Authority see [SA2640 below](#)

Inj 100 mg per ml, 1 ml vial.....	1,700.00	1	✓ Synagis
-----------------------------------	----------	---	-----------

➔SA2640 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

- Both:
- 1 Palivizumab to be administered during the annual RSV season; and
 - 2 Either:
 - 2.1 All of the following:
 - 2.1.1 Infant was born in the last 12 months; and
 - 2.1.2 Infant was born at less than 32 weeks zero days' gestation; and
 - 2.1.3 Infant is to be administered palivizumab within a single calendar year; or
 - 2.2 Both:
 - 2.2.1 Child was born in the last 24 months; and
 - 2.2.2 Any of the following:
 - 2.2.2.1 Child has severe lung, airway, neurological or neuromuscular disease that requires ongoing ventilatory/respiratory support (see Note A) in the community; or
 - 2.2.2.2 Both:
 - 2.2.2.2.1 Child has haemodynamically significant heart disease; and
 - 2.2.2.2.2 Any of the following:
 - 2.2.2.2.2.1 Child has unoperated simple congenital heart disease with significant left to right shunt

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

(see Note B); or

2.2.2.2.2 Child has unoperated or surgically palliated complex congenital heart disease; or

2.2.2.2.3 Child has severe pulmonary hypertension (see Note C); or

2.2.2.2.4 Child has moderate or severe left ventricular (LV) failure (see Note D); or

2.2.2.3 Child has severe combined immune deficiency, confirmed by an immunologist, but has not received a stem cell transplant; or

2.2.2.4 Child has inborn errors of immunity (see Note E) that increase susceptibility to life-threatening viral respiratory infections, confirmed by an immunologist.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Palivizumab to be administered during the annual RSV season; and

2 Child was born in the last 24 months; and

3 Any of the following:

3.1 Child has severe lung, airway, neurological or neuromuscular disease that requires ongoing ventilatory/respiratory support (see Note A) in the community; or

3.2 Both:

3.2.1 Child has haemodynamically significant heart disease; and

3.2.2 Any of the following:

3.2.2.1 Child has unoperated simple congenital heart disease with significant left to right shunt (see Note B); or

3.2.2.2 Child has unoperated or surgically palliated complex congenital heart disease; or

3.2.2.3 Child has severe pulmonary hypertension (see Note C); or

3.2.2.4 Child has moderate or severe left ventricular (LV) failure (see Note D); or

3.3 Child has severe combined immune deficiency, confirmed by an immunologist, but has not received a stem cell transplant; or

3.4 Child has inborn errors of immunity (see Note E) that increase susceptibility to life-threatening viral respiratory infections, confirmed by an immunologist.

Notes:

a) Ventilatory/respiratory support includes those on home oxygen, CPAP/VPAP and those with tracheostomies in situ managed at home

b) Child requires/will require heart failure medication, and/or child has significant pulmonary hypertension, and/or infant will require surgical palliation/definitive repair within the next 3 months

c) Mean pulmonary artery pressure more than 25 mmHg

d) LV Ejection Fraction less than 40%

e) Inborn errors of immunity include, but are not limited to, IFNAR deficiencies

PERTUZUMAB – PCT only – Specialist – Special Authority see [SA2276 below](#)

Inj 30 mg per ml, 14 ml vial.....	3,927.00	1	✓ Perjeta
Inj 420 mg for ECP	3,927.00	420 mg OP	✓ Baxter

➔SA2276 Special Authority for Subsidy

Initial application — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 Either:

2.1 Patient is chemotherapy treatment naïve; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
- 3 The patient has good performance status (ECOG grade 0-1); and
- 4 Pertuzumab to be administered in combination with trastuzumab; and
- 5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
- 6 Pertuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with pertuzumab and trastuzumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with pertuzumab and trastuzumab.

PERTUZUMAB WITH TRASTUZUMAB – PCT only – Special Authority see [SA2534 below](#)

Inj 600 mg with trastuzumab 600 mg, 10 ml vial	7,707.00	1	✓ Phesgo
Inj 1,200 mg with trastuzumab 600 mg, 15 ml vial	12,894.00	1	✓ Phesgo

» [SA2534](#) **Special Authority for Subsidy**

Initial application — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The individual has received an initial Special Authority approval for intravenous pertuzumab and trastuzumab for metastatic breast cancer; and
 - 1.2 Pertuzumab with trastuzumab to be administered subcutaneously at a maximum dose of 600 mg pertuzumab with 600 mg trastuzumab every three weeks (or equivalent); or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 Either:
 - 2.2.1 Patient is chemotherapy treatment naïve; or
 - 2.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 2.3 The patient has good performance status (ECOG grade 0-1); and
 - 2.4 Loading dose of pertuzumab with trastuzumab to be administered subcutaneously at a maximum dose of 1200 mg pertuzumab with 600 mg trastuzumab, respectively; and
 - 2.5 Maintenance doses of pertuzumab with trastuzumab to be administered subcutaneously at a maximum dose of 600 mg pertuzumab with 600 mg trastuzumab every three weeks (or equivalent); and
 - 2.6 Pertuzumab with trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

the following criteria:

Either:

- 1 Both:
 - 1.1 The individual has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab; or
- 2 All of the following:
 - 2.1 Individual has previously discontinued treatment with pertuzumab with trastuzumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Individual has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with pertuzumab with trastuzumab.

RITUXIMAB (MABTHERA) – PCT only – Specialist – Special Authority see [SA2622 below](#)

Inj 100 mg per 10 ml vial	1,075.50	2	✓ Mabthera
Inj 500 mg per 50 ml vial	2,688.30	1	✓ Mabthera
Inj 1 mg for ECP	5.64	1 mg	✓ Baxter (Mabthera)

►SA2622 Special Authority for Subsidy

Initial application — (arthritis - rheumatoid - TNF inhibitors contraindicated) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had rheumatoid arthritis (either confirmed by radiologic imaging, or the patient is CCP antibody positive); and
- 3 Disease has not responded to at least 3 months of methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose, unless contraindicated; and
- 4 Disease has not responded to at least 3 months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses), unless contraindicated; and
- 5 Either:
 - 5.1 Disease has not responded to at least 3 months of methotrexate in combination with the maximum tolerated dose of ciclosporin, unless contraindicated; or
 - 5.2 Disease has not responded to at least 3 months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate, unless contraindicated; and
- 6 Either:
 - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 joints; or
 - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least 4 joints from the following: wrist, elbow, knee, ankle, shoulder, or hip; and
- 7 Either:
 - 7.1 Patient has CRP greater than 15 mg/L measured within one month before the application; or
 - 7.2 CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day received for more than 3 months; and
- 8 Maximum of two 1000 mg infusions given two weeks apart.

Initial application — (arthritis - rheumatoid - prior TNF inhibitor use) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has had a Special Authority approval for etanercept or adalimumab for rheumatoid arthritis; and
- 2 Either:
 - 2.1 Patient has experienced intolerable side effects; or

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

2.2 Following at least a 4 month trial of adalimumab or etanercept, the renewal criteria for rheumatoid arthritis were not met; and

3 Maximum of two 1000 mg infusions given two weeks apart.

Renewal — (arthritis - rheumatoid - re-treatment for people who have experienced a partial response to rituximab) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 Any of the following:

- 1.1 Following the initial course of rituximab the patient experienced between a 30% and 50% decrease in active joint count from baseline; or
- 1.2 Following the second course of rituximab the patient experienced at least a 50% decrease in active joint count from baseline; or
- 1.3 Following the third and subsequent courses of rituximab, the patient experienced at least a continuing 30% improvement in active joint count from baseline; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Maximum of two 1000 mg infusions given two weeks apart.

Renewal — (arthritis - rheumatoid - re-treatment for people who experience a response to rituximab) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 Either:

- 1.1 Following the initial course of rituximab infusions the patient experienced at least a 50% decrease in active joint count from baseline; or
- 1.2 Following the second and subsequent courses of rituximab, the patient experienced at least a continuing 30% improvement in active joint count from baseline; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Maximum of two 1000 mg infusions per course given two weeks apart.

RITUXIMAB (RIXIMYO) – PCT only – Specialist – Special Authority see [SA2689 below](#)

Inj 100 mg per 10 ml vial	275.33	2	✓ Riximyo
Inj 500 mg per 50 ml vial	688.20	1	✓ Riximyo
Inj 1 mg for ECP	1.38	1 mg	✓ Baxter (Riximyo)

➔ [SA2689](#) **Special Authority for Subsidy**

Initial application — (ABO-incompatible organ transplant) from any relevant practitioner. Approvals valid without further renewal unless notified where patient is to undergo an ABO-incompatible solid organ transplant*.

Note: Indications marked with * are unapproved indications.

Initial application — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

1 Patient has been diagnosed with ANCA associated vasculitis*; and

2 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and

3 Any of the following:

- 3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
- 3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
- 3.3 Cyclophosphamide and methotrexate are contraindicated; or
- 3.4 Patient is a female of child-bearing potential; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

Renewal — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (Antibody-mediated organ transplant rejection) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has been diagnosed with antibody-mediated organ transplant rejection*.

Note: Indications marked with * are unapproved indications.

Initial application — (Chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 Any of the following:
 - 2.1 The patient is rituximab treatment naive; or
 - 2.2 Either:
 - 2.2.1 The patient is chemotherapy treatment naive; or
 - 2.2.2 Both:
 - 2.2.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
 - 2.2.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; or
 - 2.3 The patient's disease has relapsed and rituximab treatment is to be used in combination with funded venetoclax; and
- 3 The patient has good performance status; and
- 4 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles; and
- 5 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

Renewal — (Chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The patient's disease has relapsed and rituximab treatment is to be used in combination with funded venetoclax; or
 - 1.2 All of the following:
 - 1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
 - 1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

1.2.3 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and

2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initial application — (neuromyelitis optica spectrum disorder (NMOSD)*) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

1 Cumulative dose up to 1,500 mg/m² body surface area up to 2,000 mg total per cycle; and

2 Either:

2.1 Patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms with supporting clinical investigations); or

2.2 All of the following:

2.2.1 Patient has experienced a breakthrough attack of NMOSD; and

2.2.2 Patient is receiving treatment with mycophenolate unless contraindicated or not tolerated; and

2.2.3 Patient is receiving treatment with corticosteroids unless contraindicated or not tolerated; and

3 Each treatment cycle at least 6 months apart.

Note: Indications marked with * are unapproved indications.

Initial application — (Post-transplant) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1 The patient has B-cell post-transplant lymphoproliferative disorder*; and

2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are unapproved indications.

Renewal — (Post-transplant) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

1 The patient has had a rituximab treatment-free interval of 12 months or more; and

2 The patient has B-cell post-transplant lymphoproliferative disorder*; and

3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

Initial application — (refractory myasthenia gravis*) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 Cumulative dose up to 1,500 mg/m² body surface area up to 2,000 mg total per cycle; and

2 Either:

2.1 Treatment with corticosteroids and at least one other immunosuppressant for a minimum period of 12 months has been ineffective; or

2.2 Both:

2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and

2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Note: Indications marked with * are unapproved indications.

Renewal — (refractory myasthenia gravis*) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 Cumulative dose up to 1,500 mg/m² body surface area up to 2,000 mg total per cycle; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Either:
 - 3.1 Patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
 - 3.2 Both:
 - 3.2.1 Patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
 - 3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Note: Indications marked with * are unapproved indications.

Initial application — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient is a child with SDNS* or FRNS*; and
- 2 Treatment with corticosteroids, ciclosporin, and mycophenolate for at least 3 months for each agent has been ineffective, not tolerated, or is contraindicated; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (Steroid resistant nephrotic syndrome (SRNS)) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient is a child with SRNS* and treatment with corticosteroids, ciclosporin and tacrolimus for at least 3 months for each agent has been ineffective, not tolerated, or is contraindicated; and
- 2 Genetic causes of nephrotic syndrome have been excluded; and
- 3 The total rituximab dose per cycle would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Steroid resistant nephrotic syndrome (SRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or

2 Both:

- 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
- 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Renewal — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

Renewal — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist.

Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Initial application — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
 - 1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
- 2 Any of the following:
 - 2.1 Treatment with steroids and splenectomy have been ineffective; or
 - 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
 - 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy); and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Renewal — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Renewal — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Initial application — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

Renewal — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initial application — (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has cold haemagglutinin disease*; and
- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Note: Indications marked with * are unapproved indications.

Renewal — (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (thrombotic thrombocytopenic purpura (TTP*)) only from a haematologist or any relevant practitioner on the recommendation of a haematologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 The total rituximab dose per cycle would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks; and
- 2 Each treatment cycle at least 6 months apart; and
- 3 Any of the following:
 - 3.1 Patient has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
 - 3.2 Patient has acute idiopathic TTP* with neurological or cardiovascular pathology; or
 - 3.3 Patient has a history of immune-mediated thrombotic thrombocytopenic purpura, currently in clinical remission but has demonstrated a decline in ADAMTS13 levels or equivalent, consistent with high risk of relapse.

Note: Indications marked with * are unapproved indications.

Initial application — (treatment refractory systemic lupus erythematosus (SLE*)) only from a rheumatologist, nephrologist or any relevant practitioner on the recommendation of a rheumatologist or nephrologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has severe, immediately life- or organ-threatening SLE*; and
- 2 The condition has been refractory to treatment with corticosteroids at a dose of at least 1 mg/kg unless contraindicated; and
- 3 The condition has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Initial treatment maximum of four 1000 mg infusions; and
- 5 Treatment for relapse following initial partial response to rituximab up to a maximum of two 1000 mg infusions every 6 months.

Note: Indications marked with * are unapproved indications.

Initial application — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has warm autoimmune haemolytic anaemia*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Renewal — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (antisyndetase syndrome) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has severe, immediately life- or organ-threatening disease, including interstitial lung disease; and
- 2 Either:
 - 2.1 Treatment with at least 3 immunosuppressants (oral corticosteroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has been ineffective controlling active disease; or
 - 2.2 Rapid treatment is required for life threatening complications; and
- 3 Maximum of two 1000mg infusions every 6 months.

Initial application — (graft versus host disease) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has refractory graft versus host disease following transplant; and
- 2 Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not be effective at controlling active disease; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Initial application — (chronic inflammatory demyelinating polyneuropathy (CIPD)*) only from a neurologist or any relevant practitioner on the recommendation of a neurologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Treatment with corticosteroids and intravenous immunoglobulin and/or plasma exchange has been ineffective controlling active disease, is not tolerated, or is contraindicated; and
 - 1.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) is not tolerated or has been ineffective controlling active disease. If an immunosuppressant is contraindicated, a trial has occurred of one of those which is not contraindicated (unless all are contraindicated); or
 - 1.2 Rapid treatment is required for life threatening complications; and
- 2 Cumulative dose up to 1500 mg/m² body surface area up to 2000 mg total per cycle; and
- 3 Each treatment cycle at least 6 months apart.

Note: Indications marked with * are unapproved indications.

Initial application — (anti-NMDA receptor autoimmune encephalitis*) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Both:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.1.1 Treatment with corticosteroids and intravenous immunoglobulin and/or plasma exchange has been ineffective controlling active disease, is not tolerated or is contraindicated; and
- 1.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has been ineffective controlling active disease, is not tolerated or is contraindicated; or
- 1.2 Rapid treatment is required for life threatening complications; and
- 2 Cumulative dose up to 1500 mg/m² body surface area up to 2000 mg total per cycle; and
- 3 Each treatment cycle at least 6 months apart.

Note: Indications marked with * are unapproved indications.

Initial application — (CD20+ low grade or follicular B-cell NHL) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has CD20+ low grade or follicular B-cell NHL with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has CD20+ low grade or follicular B-cell NHL requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Renewal — (CD20+ low grade or follicular B-cell NHL) from any relevant practitioner. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy; and
- 2 Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m² every 8 weeks (maximum of 12 cycles).

Initial application — (Membranous nephropathy) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has biopsy-proven primary/idiopathic membranous nephropathy*; or
 - 1.2 Patient has PLA2 antibodies with no evidence of secondary cause, and an eGFR of > 60ml/min/1.73m²; and
- 2 Patient remains at high risk of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures that include (unless contraindicated or the patient has experienced intolerable side effects) renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents; and
- 3 The total rituximab dose per cycle would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks; and
- 4 Subsequent retreatment only for disease relapse or after partial response.

Note: Indications marked with * are unapproved indications.

Initial application — (B-cell acute lymphoblastic leukaemia/lymphoma*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has newly diagnosed B-cell acute lymphoblastic leukaemia/lymphoma*; and
- 2 Treatment must be in combination with an intensive chemotherapy protocol with curative intent; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² per dose for a maximum of 18 doses.

Note: Indications marked with * are unapproved indications.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (desensitisation prior to transplant) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires desensitisation prior to mismatched allogenic stem cell transplant*; and
- 2 Patient would receive no more than two doses at 375 mg/m² of body-surface area.

Note: Indications marked with * are unapproved indications.

Initial application — (pemphigus*) only from a dermatologist or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has severe rapidly progressive pemphigus; and
 - 1.2 Is used in combination with systemic corticosteroids (20 mg/day); and
 - 1.3 Any of the following:
 - 1.3.1 Skin involvement is at least 5% body surface area; or
 - 1.3.2 Significant mucosal involvement (10 or more mucosal erosions) or diffuse gingivitis or confluent large erosions; or
 - 1.3.3 Involvement of two or more mucosal sites; or
- 2 Both:
 - 2.1 Patient has pemphigus; and
 - 2.2 Patient has not experienced adequate clinical benefit from systemic corticosteroids (20 mg/day) in combination with a steroid sparing agent, unless contraindicated.

Note: Indications marked with * are unapproved indications.

Renewal — (pemphigus*) only from a dermatologist or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has experienced adequate clinical benefit from rituximab treatment, with improvement in symptoms and healing of skin ulceration and reduction in corticosteroid requirement; and
- 2 Patient has not received rituximab in the previous 6 months.

Note: Indications marked with * are unapproved indications.

Initial application — (immunoglobulin G4-related disease (IgG4-RD*)) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed diagnosis of IgG4-RD*; and
- 2 Either:
 - 2.1 Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs for at least 3 months has been ineffective in lowering corticosteroid dose below 5 mg per day (prednisone equivalent) without relapse; or
 - 2.2 Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs is contraindicated or associated with evidence of toxicity or intolerance; and
- 3 Total rituximab dose used should not exceed a maximum of two 1000 mg infusions of rituximab given two weeks apart.

Note: Indications marked with * are unapproved indications.

Renewal — (immunoglobulin G4-related disease (IgG4-RD*)) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Treatment with rituximab for IgG4-RD* was previously successful and patient's disease has demonstrated sustained response, but the condition has relapsed; or
 - 1.2 Patient is receiving maintenance treatment for IgG4-RD*; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2 Rituximab re-treatment not to be given within 6 months of previous course of treatment; and
- 3 Maximum of two 1000 mg infusions of rituximab given two weeks apart.

Note: Indications marked with * are unapproved indications.

SECUKINUMAB – Special Authority see [SA2624 below](#) – Retail pharmacy

Inj 150 mg per ml, 1 ml prefilled syringe.....	799.50	1	✓	Cosentyx
	1,599.00	2	✓	Cosentyx

➤SA2624 Special Authority for Subsidy

Initial application — (plaque psoriasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient has "whole body" plaque psoriasis with a PASI score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.1.2 Patient has plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; or
 - 1.1.3 Patient has localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis, and with a DLQI score greater than 10; and
 - 1.2 Patient has received insufficient benefit (see Note) or has experienced intolerable side effects from at least 3 of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 1.3 A PASI assessment or DLQI assessment has been completed for the most recent prior treatment course, within 1 month of stopping that treatment; and
 - 1.4 The most recent PASI or DLQI assessment is within 1 month before the application; or
- 2 All of the following:
 - 2.1 Patient has had a Special Authority approval for adalimumab, etanercept, or infliximab, for plaque psoriasis; and
 - 2.2 Either:
 - 2.2.1 Patient has experienced intolerable side effects; or
 - 2.2.2 Patient has received insufficient benefit to meet the renewal criteria for plaque psoriasis; and
 - 2.3 A PASI assessment or DLQI assessment has been completed for the most recent prior treatment within 1 month of stopping that treatment; and
 - 2.4 The most recent PASI or DLQI assessment is within 1 month before the application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Insufficient benefit" is defined as: for whole body plaque psoriasis, a PASI score of greater than 10; for plaque psoriasis of the face, hand, foot, genital or flexural areas, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and for the face, palm of a hand or sole of a foot the skin area affected is 30% or more of the face, palm of a hand or sole of a foot. As assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment

Renewal — (plaque psoriasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 Patient's PASI score has reduced by 75% or more compared to pre-secukinumab baseline; or
 - 1.2 Patient has a DLQI improvement of 5 or more, compared to pre-secukinumab baseline; or
 - 1.3 Both:
 - 1.3.1 Patient had localised genital or flexural plaque psoriasis at the start of treatment; and
 - 1.3.2 Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

1.3.2.1 Patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, compared to the pre-secukinumab baseline; or

1.3.2.2 Patient has a DLQI improvement of 5 or more, compared to pre-secukinumab baseline; and

2 Maximum dose 300 mg monthly.

Initial application — (ankylosing spondylitis – second-line biologic) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1 Patient has had a Special Authority approval for adalimumab or etanercept for ankylosing spondylitis; and

2 Either:

2.1 Patient has experienced intolerable side effects; or

2.2 Patient has received insufficient benefit to meet the renewal criteria for ankylosing spondylitis.

Renewal — (ankylosing spondylitis – second-line biologic) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 BASDAI has improved from the pre-secukinumab baseline either by at least 4 points on a 10-point scale, or by at least 50%, whichever is less; and

2 Maximum dose 300 mg monthly.

Initial application — (arthritis - psoriatic) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 Patient has had a Special Authority approval for adalimumab, etanercept or infliximab for psoriatic arthritis; and

1.2 Either:

1.2.1 Patient has experienced intolerable side effects; or

1.2.2 Patient has received insufficient benefit to meet the renewal criteria for psoriatic arthritis; or

2 All of the following:

2.1 Patient has received insufficient benefit from at least 3 months of methotrexate at a maximum tolerated dose unless contraindicated; and

2.2 Patient has received insufficient benefit from at least 3 months of sulfasalazine or leflunomide at maximum tolerated doses unless contraindicated; and

2.3 Either:

2.3.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 joints; or

2.3.2 Patient has persistent symptoms of poorly controlled and active disease in at least 4 joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.4 Any of the following:

2.4.1 CRP greater than 15 mg/L measured within one month before the application; or

2.4.2 ESR greater than 25 mm per hour measured within one month before the application; or

2.4.3 ESR and CRP not measured as patient is receiving prednisone therapy greater than 5 mg per day received for more than 3 months.

Renewal — (arthritis - psoriatic) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Either:

1.1 Following initial treatment, at least a 50% decrease in active joint count from baseline; or

1.2 At least a continuing 30% improvement in active joint count from baseline; and

2 Maximum dose 300 mg monthly.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

SILTUXIMAB – Special Authority see [SA1596 below](#) – Retail pharmacy

Note: Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Inj 100 mg vial	770.57	1	✓	Sylvant
Inj 400 mg vial	3,082.33	1	✓	Sylvant

► [SA1596](#) Special Authority for Subsidy

Initial application only from a haematologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Renewal only from a haematologist or rheumatologist. Approvals valid for 12 months where the treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

TOCILIZUMAB – PCT only – Special Authority see [SA2489 below](#)

Inj 20 mg per ml, 4 ml vial.....	220.00	1	✓	Actemra
Inj 20 mg per ml, 10 ml vial.....	550.00	1	✓	Actemra
Inj 20 mg per ml, 20 ml vial.....	1,100.00	1	✓	Actemra
Inj 1 mg for ECP	2.85	1 mg	✓	Baxter

► [SA2489](#) Special Authority for Subsidy

Initial application — (cytokine release syndrome) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
 - 1.2 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg); or
- 2 All of the following:
 - 2.1 The patient is enrolled in the Malaghan Institute of Medical Research ENABLE trial programme; and
 - 2.2 The patient has developed CRS or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) following CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
 - 2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS or ICANS for CAR T-cell therapy at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

Initial application — (previous use) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient was being treated with tocilizumab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 rheumatoid arthritis; or
 - 2.2 systemic juvenile idiopathic arthritis; or
 - 2.3 adult-onset Still's disease; or
 - 2.4 polyarticular juvenile idiopathic arthritis; or
 - 2.5 idiopathic multicentric Castleman's disease.

Initial application — (Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
 - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
 - 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a Health NZ Hospital; and
 - 3.2.2 Either:
 - 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
 - 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Initial application — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 2 Tocilizumab is to be used as monotherapy; and
- 3 Either:
 - 3.1 Treatment with methotrexate is contraindicated; or
 - 3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
- 4 Either:
 - 4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or
 - 4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
- 5 Either:
 - 5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
 - 5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 6 Either:
 - 6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (systemic juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Initial application — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a Health NZ Hospital; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initial application — (polyarticular juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and
 - 1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or
- 2 All of the following:
 - 2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
 - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
 - 2.3 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.4 Any of the following:
 - 2.4.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.4.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.4.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Initial application — (idiopathic multicentric Castleman's disease) only from a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

Initial application — (moderate to severe COVID-19) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed (or probable) COVID-19; and
- 2 Oxygen saturation of < 92% on room air, or requiring supplemental oxygen; and
- 3 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and
- 4 Tocilizumab is to be administered at doses no greater than 8mg/kg IV for a maximum of one dose; and
- 5 Tocilizumab is not to be administered in combination with baricitinib.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Renewal — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Renewal — (systemic juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months where the patient has a sustained improvement in inflammatory markers and functional status.

Renewal — (polyarticular juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (idiopathic multicentric Castleman's disease) only from a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist. Approvals valid for 12 months where the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

Initial application — (immune checkpoint inhibitor toxicity in malignancy*) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The individual requires treatment for moderate to severe autoimmune toxicity following immune checkpoint inhibitor treatment for malignancy; and
- 2 The individual has received insufficient benefit from use of corticosteroids; and
- 3 Tocilizumab is to be administered at a maximum dose of 8 mg/kg fortnightly.

Renewal — (immune checkpoint inhibitor toxicity in malignancy*) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 The individual has shown clinical improvement and ongoing treatment is required; and
- 2 Tocilizumab is to be administered at a maximum dose of 8 mg/kg fortnightly.

Note: Indications marked with * are unapproved indications.

TRASTUZUMAB (HERZUMA) – PCT only – Special Authority see [SA2293 on the next page](#)

Inj 150 mg vial	100.00	1	✓ Herzuma
Inj 440 mg vial	293.35	1	✓ Herzuma
Inj 1 mg for ECP	0.70	1 mg	✓ Baxter

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

►SA2293 Special Authority for Subsidy

Initial application — (early breast cancer) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Both:

- 1 The patient has early breast cancer expressing HER-2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment).

Renewal — (early breast cancer*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
 - 1.3 Any of the following:
 - 1.3.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 1.3.2 The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib; or
 - 1.3.3 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 1.4 Either:
 - 1.4.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 1.4.2 All of the following:
 - 1.4.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 1.4.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 1.4.2.3 The patient has good performance status (ECOG grade 0-1); and
 - 1.5 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with trastuzumab in the metastatic setting for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with trastuzumab.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer

Initial application — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 2.2 The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib; and
- 3 Either:
 - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 3.2 All of the following:
 - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and

3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1 All of the following:

- 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 1.2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 1.3 Trastuzumab to be discontinued at disease progression; or

2 All of the following:

- 2.1 Patient has previously discontinued treatment with trastuzumab for reasons other than severe toxicity or disease progression; and
- 2.2 Patient has signs of disease progression; and
- 2.3 Disease has not progressed during previous treatment with trastuzumab.

Initial application — (gastric, gastro-oesophageal junction and oesophageal cancer) from any relevant practitioner.

Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has locally advanced or metastatic gastric, gastro-oesophageal junction or oesophageal cancer expressing HER-2 IHC 2+ FISH+ or IHC3+ (or other current technology); and
- 2 Patient has an ECOG score of 0-2.

Renewal — (gastric, gastro-oesophageal junction and oesophageal cancer) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 2 Trastuzumab to be discontinued at disease progression.

TRASTUZUMAB DERUXTECAN – PCT only – Special Authority see [SA2420 below](#)

Inj 100 mg per ml, 1 ml vial.....	2,550.00	1	✓ Enhertu
Inj 1 mg for ECP	27.05	1 mg	✓ Baxter

► **SA2420 Special Authority for Subsidy**

Initial application only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist.

Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with trastuzumab deruxtecan and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has metastatic breast cancer expressing HER-2 IHC3+ or ISH+ (including FISH or other current technology); and
 - 2.2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
 - 2.3 Either:
 - 2.3.1 The patient has received prior therapy for metastatic disease; or
 - 2.3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy; and
 - 2.4 Patient has a good performance status (ECOG 0-1); and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

2.5 Patient has not received prior funded trastuzumab deruxtecan treatment; and

2.6 Treatment to be discontinued at disease progression.

Renewal only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab deruxtecan; and
- 2 Treatment to be discontinued at disease progression.

Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

TRASTUZUMAB EMTANSINE – PCT only – Specialist – Special Authority see [SA2424](#) below

Inj 100 mg vial	2,320.00	1	✓ Kadcyła
Inj 160 mg vial	3,712.00	1	✓ Kadcyła
Inj 1 mg for ECP	24.52	1 mg	✓ Baxter

► [SA2424](#) Special Authority for Subsidy

Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has early breast cancer expressing HER2 IHC3+ or ISH+; and
- 2 Documentation of pathological invasive residual disease in the breast and/or axillary lymph nodes following completion of surgery; and
- 3 Patient has completed systemic neoadjuvant therapy with trastuzumab and chemotherapy prior to surgery; and
- 4 Disease has not progressed during neoadjuvant therapy; and
- 5 Patient has left ventricular ejection fraction of 45% or greater; and
- 6 Adjuvant treatment with trastuzumab emtansine to be commenced within 12 weeks of surgery; and
- 7 Trastuzumab emtansine to be discontinued at disease progression; and
- 8 Total adjuvant treatment duration must not exceed 42 weeks (14 cycles).

Initial application — (metastatic breast cancer) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
- 3 Either:
 - 3.1 The patient has received prior therapy for metastatic disease*; or
 - 3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy*; and
- 4 Patient has a good performance status (ECOG 0-1); and
- 5 Either:
 - 5.1 Patient does not have symptomatic brain metastases; or
 - 5.2 Patient has brain metastases and has received prior local CNS therapy; and
- 6 Either:
 - 6.1 Patient has not received prior funded trastuzumab emtansine or trastuzumab deruxtecan treatment; or
 - 6.2 Both:
 - 6.2.1 Patient has discontinued trastuzumab deruxtecan due to intolerance; and
 - 6.2.2 The cancer did not progress while on trastuzumab deruxtecan; and
- 7 Treatment to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- Both:
- 1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab emtansine; and
 - 2 Treatment to be discontinued at disease progression.

Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

USTEKINUMAB – Special Authority see [SA2182 below](#) – Retail pharmacy

Inj 90 mg per ml, 1 ml pre-filled syringe.....4,162.00 1 ✓ **Stelara**

►SA2182 Special Authority for Subsidy

Initial application — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

- Either:
- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or
 - 2 Both:
 - 2.1 Patient has active Crohn's disease; and
 - 2.2 Either:
 - 2.2.1 Patient has had an initial approval for prior biologic therapy for Crohn's disease and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for Crohn's disease; and
 - 2.2.2.2 Other biologics for Crohn's disease are contraindicated.

Renewal — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

- Both:
- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy; or
 - 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
 - 1.3 The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed; and
 - 2 Ustekinumab to be administered at a dose no greater than 90 mg every 8 weeks.

Initial application — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

- Either:
- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or
 - 2 Both:
 - 2.1 Patient has active Crohn's disease; and
 - 2.2 Either:
 - 2.2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for Crohn's disease; and
 - 2.2.2.2 Other biologics for Crohn's disease are contraindicated.

Note: Indication marked with * is an unapproved indication.

Renewal — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 12 months for applications

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Ustekinumab to administered at a dose no greater than 90 mg every 8 weeks.

Note: Indication marked with * is an unapproved indication.

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or
- 2 Both:
 - 2.1 Patient has active ulcerative colitis; and
 - 2.2 Either:
 - 2.2.1 Patient has had an initial approval for prior biologic therapy for ulcerative colitis and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for ulcerative colitis; and
 - 2.2.2.2 Other biologics for ulcerative colitis are contraindicated.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy; or
 - 1.2 PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy*; and
- 2 Ustekinumab will be used at a dose no greater than 90 mg intravenously every 8 weeks.

Note: Criterion marked with * is for an unapproved indication.

VEDOLIZUMAB – PCT only – Special Authority see [SA2183 below](#)

Inj 300 mg vial	3,313.00	1	✓ Entyvio
-----------------------	----------	---	-----------

► **SA2183** Special Authority for Subsidy

Initial application — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
 - 2.2 Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10; or
 - 2.3 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.4 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.5 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Any of the following:
 - 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- response) from prior therapy with immunomodulators and corticosteroids; or
- 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
- 3.3 Immunomodulators and corticosteroids are contraindicated.

Renewal — (Crohn's disease - adults) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy; or
 - 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
 - 1.3 The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed; and
- 2 Vedolizumab to administered at a dose no greater than 300 mg every 8 weeks.

Initial application — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
 - 2.2 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.3 Patient has extensive small intestine disease; and
- 3 Any of the following:
 - 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
 - 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
 - 3.3 Immunomodulators and corticosteroids are contraindicated.

Note: Indication marked with * is an unapproved indication.

Renewal — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Vedolizumab to administered at a dose no greater than 300mg every 8 weeks.

Note: Indication marked with * is an unapproved indication.

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Any of the following:
 - 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
 - 2.2 Patient has a SCCAI score is greater than or equal to 4; or
 - 2.3 Patient's PUCAI score is greater than or equal to 20*; and
- 3 Any of the following:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
- 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
- 3.3 Immunomodulators and corticosteroids are contraindicated.

Note: Indication marked with * is an unapproved indication.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 Either:

- 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy; or
- 1.2 The PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy *; and
- 2 Vedolizumab will be used at a dose no greater than 300 mg intravenously every 8 weeks.

Note: Indication marked with * is an unapproved indication.

Programmed Cell Death-1 (PD-1) Inhibitors

ATEZOLIZUMAB – PCT only – Specialist – Special Authority see [SA2630 below](#)

Inj 60 mg per ml, 20 ml vial.....	9,503.00	1	✓ Tecentriq
Inj 1 mg for ECP.....	8.08	1 mg	✓ Baxter

► [SA2630](#) Special Authority for Subsidy

Initial application — (non-small cell lung cancer second line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced or metastatic non-small cell lung cancer; and
- 2 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 3 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR, ROS-1 or ALK tyrosine kinase unless not possible to ascertain; and
- 4 Patient has an ECOG 0-2; and
- 5 Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy; and
- 6 Atezolizumab is to be used as monotherapy at a dose of 1200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and
- 7 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal — (non-small cell lung cancer second line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Atezolizumab to be used at a maximum dose of 1200 mg every three weeks (or equivalent); and
- 6 Treatment with atezolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

dosed every 3 weeks).

Initial application — (unresectable hepatocellular carcinoma) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with atezolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has locally advanced or metastatic, unresectable hepatocellular carcinoma; and
 - 2.2 Patient has preserved liver function (Child-Pugh A); and
 - 2.3 Transarterial chemoembolisation (TACE) is unsuitable; and
 - 2.4 Any of the following:
 - 2.4.1 Patient has not received prior systemic therapy for the treatment of hepatocellular carcinoma; or
 - 2.4.2 Patient received funded lenvatinib before 1 March 2025; or
 - 2.4.3 Both:
 - 2.4.3.1 Patient has experienced treatment-limiting toxicity from treatment with lenvatinib; and
 - 2.4.3.2 No disease progression since initiation of lenvatinib; and
 - 2.5 Patient has an ECOG performance status of 0-2; and
 - 2.6 To be given in combination with bevacizumab.

Renewal — (unresectable hepatocellular carcinoma) from any relevant practitioner. Approvals valid for 6 months where there is no evidence of disease progression.

DURVALUMAB – PCT only – Specialist – Special Authority see [SA2425 below](#)

Inj 50 mg per ml, 10 ml vial.....	4,700.00	1	✓ Imfinzi
Inj 50 mg per ml, 2.4 ml vial.....	1,128.00	1	✓ Imfinzi
Inj 1 mg for ECP	9.59	1 mg	✓ Baxter

► **SA2425 Special Authority for Subsidy**

Initial application — (Non-small cell lung cancer) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC); or
 - 1.2 Patient has histologically or cytologically documented stage IIb (T1N2a only), locally advanced, unresectable non-small cell lung cancer (NSCLC); and
- 2 Patient has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy; and
- 3 Patient has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation therapy treatment; and
- 4 Patient has a ECOG performance status of 0 or 1; and
- 5 Patient has completed last radiation dose within 8 weeks of starting treatment with durvalumab; and
- 6 Patient must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition; and
- 7 Either:
 - 7.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or
 - 7.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and
- 8 Treatment with durvalumab to cease upon signs of disease progression.

Renewal — (Non-small cell lung cancer) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1 The treatment remains clinically appropriate and the patient is benefitting from treatment; and
- 2 Either:
 - 2.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or
 - 2.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and
- 3 Treatment with durvalumab to cease upon signs of disease progression; and
- 4 Total continuous treatment duration must not exceed 12 months.

IPILIMUMAB – PCT only – Specialist – Special Authority see [SA2642 below](#)

Inj 5 mg per ml, 10 ml vial.....	5,000.00	1	✓	Yervoy
Inj 5 mg per ml, 40 ml vial.....	20,000.00	1	✓	Yervoy
Inj 1 mg for ECP.....	106.00	1 mg	✓	Baxter

► [SA2642](#) Special Authority for Subsidy

Initial application — (stage III or IV resectable melanoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

- Either:
- 1 The individual is currently on treatment with ipilimumab for neoadjuvant treatment of resectable stage IIIB, IIIC, IIID or IV melanoma and met all remaining criteria prior to commencing treatment; or
 - 2 All of the following:
 - 2.1 The individual has resectable stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note); and
 - 2.2 The individual has not received prior funded systemic treatment in the perioperative setting for their stage IIIB, IIIC, IIID or IV melanoma; and
 - 2.3 The individual has ECOG performance score 0-2; and
 - 2.4 Treatment must be prior to complete surgical resection; and
 - 2.5 Neoadjuvant ipilimumab must be administered in combination with nivolumab; and
 - 2.6 Ipilimumab to be administered for maximum of two cycles prior to surgical resection.

Notes:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition.
- b) Disease must be completely resectable and amenable to curative intent surgery, including stage IV disease.

Initial application — (renal cell carcinoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

- Either:
- 1 The patient is currently on treatment with ipilimumab and met all remaining criteria prior to commencing treatment; or
 - 2 All of the following:
 - 2.1 The patient has metastatic renal cell carcinoma; and
 - 2.2 The patient is treatment naive; and
 - 2.3 The patient has ECOG performance status 0-2; and
 - 2.4 The disease is predominantly of clear cell histology; and
 - 2.5 Any of the following:
 - 2.5.1 The patient has sarcomatoid histology; or
 - 2.5.2 Haemoglobin levels less than the lower limit of normal; or
 - 2.5.3 Corrected serum calcium level greater than 10 mg/dL (2.5 mmol/L); or
 - 2.5.4 Neutrophils greater than the upper limit of normal; or
 - 2.5.5 Platelets greater than the upper limit of normal; or
 - 2.5.6 Interval of less than 1 year from original diagnosis to the start of systemic therapy; or
 - 2.5.7 Karnofsky performance score of less than or equal to 70; and
 - 2.6 Ipilimumab is to be used at a maximum dose of 1 mg/kg for up to four cycles in combination with nivolumab..

NIVOLUMAB – PCT only – Specialist – Special Authority see [SA2643 on the next page](#)

Inj 10 mg per ml, 4 ml vial.....	1,051.98	1	✓	Opdivo
Inj 10 mg per ml, 10 ml vial.....	2,629.96	1	✓	Opdivo
Inj 1 mg for ECP.....	27.22	1 mg	✓	Baxter

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2643 Special Authority for Subsidy

Initial application — (stage III or IV resectable melanoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 The individual is currently on treatment with nivolumab for neoadjuvant treatment of resectable stage IIIB, IIIC, IIID or IV melanoma and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 The individual has resectable stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note); and
 - 2.2 The individual has not received prior funded systemic treatment in the perioperative setting for their stage IIIB, IIIC, IIID or IV melanoma; and
 - 2.3 The individual has ECOG performance score 0-2; and
 - 2.4 Treatment must be initiated prior to complete surgical resection; and
 - 2.5 Neoadjuvant nivolumab must be administered in combination with ipilimumab; and
 - 2.6 Nivolumab to be administered for maximum of two cycles prior to surgical resection.

Renewal — (stage III or IV resectable melanoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 All of the following:
 - 1.1 The individual has received funded neoadjuvant treatment with nivolumab in combination with ipilimumab; and
 - 1.2 Adjuvant treatment with nivolumab is required; and
 - 1.3 Treatment must be initiated within 13 weeks of complete surgical resection, unless delay is necessary due to post-surgery recovery; and
 - 1.4 Nivolumab must be administered as monotherapy; and
 - 1.5 Nivolumab to be discontinued at signs of disease recurrence or at completion of 12 months total treatment duration including any systemic neoadjuvant treatment (equivalent to 11 adjuvant cycles at 480 mg every 4 weeks plus initial 2 neoadjuvant treatment cycles); or
- 2 All of the following:
 - 2.1 The individual has received neoadjuvant treatment with nivolumab and ipilimumab; and
 - 2.2 The individual has unresectable or metastatic melanoma (excluding uveal) stage III or IV; and
 - 2.3 The individual meets initial application criteria for nivolumab for unresectable or metastatic melanoma; or
- 3 All of the following:
 - 3.1 The individual has received neoadjuvant treatment with nivolumab and ipilimumab; and
 - 3.2 The individual has received treatment with nivolumab for unresectable or metastatic melanoma; and
 - 3.3 The individual meets the renewal criteria for nivolumab for unresectable or metastatic melanoma.

Notes:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition.
- b) Disease must be completely resectable and amenable to curative intent surgery, including stage IV disease.

Initial application — (unresectable or metastatic melanoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
- 3 The individual has ECOG performance 0-2; and
- 4 Either:
 - 4.1 The individual has not received funded pembrolizumab; or
 - 4.2 Both:
 - 4.2.1 The individual has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

4.2.2 The cancer did not progress while the individual was on pembrolizumab; and

5 Any of the following:

- 5.1 The individual has been diagnosed in the metastatic or unresectable stage III or IV setting; or
- 5.2 The individual did not receive treatment in the perioperative setting with a PD-1/PD-L1 inhibitor; or
- 5.3 All of the following:
 - 5.3.1 The individual received treatment in the perioperative setting with a PD-1/PD-L1 inhibitor; and
 - 5.3.2 The individual did not experience disease recurrence while on treatment with that PD-1/PD-L1 inhibitor; and
 - 5.3.3 The individual did not experience disease recurrence within six months of completing perioperative treatment with a PD-1/PD-L1 inhibitor.

Renewal — (unresectable or metastatic melanoma, less than 24 months on treatment) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 Any of the following:
 - 1.1.1 The individual's disease has had a complete response to treatment; or
 - 1.1.2 The individual's disease has had a partial response to treatment; or
 - 1.1.3 The individual has stable disease; and
- 1.2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; or

2 All of the following:

- 2.1 The individual has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and
- 2.2 The individual has signs of disease progression; and
- 2.3 Disease has not progressed during previous treatment with nivolumab.

Renewal — (unresectable or metastatic melanoma, more than 24 months on treatment) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Both:

1 The individual has been on treatment for more than 24 months; and

2 Either:

2.1 Both:

2.1.1 Any of the following:

- 2.1.1.1 The individual's disease has had a complete response to treatment; or
- 2.1.1.2 The individual's disease has had a partial response to treatment; or
- 2.1.1.3 The individual has stable disease; and

2.1.2 Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period; or

2.2 All of the following:

- 2.2.1 The individual has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and
- 2.2.2 The individual has signs of disease progression; and
- 2.2.3 Disease has not progressed during previous treatment with nivolumab.

Initial application — (renal cell carcinoma, first line) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 Patient is currently on treatment with nivolumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 The patient has metastatic renal cell carcinoma; and
 - 2.2 The patient is treatment naive; and
 - 2.3 The patient has ECOG performance status 0-2; and
 - 2.4 The disease is predominantly of clear cell histology; and
 - 2.5 Any of the following:
 - 2.5.1 The patient has sarcomatoid histology; or
 - 2.5.2 Haemoglobin levels less than the lower limit of normal; or
 - 2.5.3 Corrected serum calcium level greater than 10 mg/dL (2.5 mmol/L); or
 - 2.5.4 Neutrophils greater than the upper limit of normal; or
 - 2.5.5 Platelets greater than the upper limit of normal; or
 - 2.5.6 Interval of less than 1 year from original diagnosis to the start of systemic therapy; or
 - 2.5.7 Karnofsky performance score of less than or equal to 70; and
 - 2.6 Nivolumab is to be used in combination with ipilimumab for the first four treatment cycles at a maximum dose of 3 mg/kg; and
 - 2.7 Nivolumab is to be used as monotherapy at a maximum maintenance dose of 240 mg every 2 weeks (or equivalent).

Initial application — (Renal cell carcinoma, second line) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has metastatic renal-cell carcinoma; and
- 2 The disease is of predominant clear-cell histology; and
- 3 Patient has ECOG performance status 0-2; and
- 4 Patient has documented disease progression following one or two previous regimens of antiangiogenic therapy; and
- 5 Patient has not previously received a funded immune checkpoint inhibitor; and
- 6 Nivolumab is to be used as monotherapy at a maximum dose of 240 mg every 2 weeks (or equivalent) and discontinued at disease progression.

Renewal — (Renal cell carcinoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 No evidence of disease progression; and
- 3 Nivolumab is to be used as monotherapy at a maximum dose of 240 mg every 2 weeks (or equivalent) and discontinued at disease progression.

PEMBROLIZUMAB – PCT only – Specialist – Special Authority see [SA2631](#) below

Inj 25 mg per ml, 4 ml vial.....	4,680.00	1	✓ Keytruda
Inj 1 mg for ECP	47.74	1 mg	✓ Baxter

► **SA2631** Special Authority for Subsidy

Initial application — (stage III or IV resectable melanoma - neoadjuvant) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1 The individual has resectable stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note); and
- 2 The individual has not received prior funded systemic treatment in the perioperative setting for their stage IIIB, IIIC, IIID or IV melanoma; and
- 3 Treatment must be prior to complete surgical resection; and
- 4 Pembrolizumab must be administered as monotherapy; and
- 5 The individual has ECOG performance score 0-2; and
- 6 Pembrolizumab to be administered at a fixed dose of 200 mg every 3 weeks (or equivalent).

Renewal — (stage III or IV resectable melanoma - neoadjuvant) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 The individual has received neoadjuvant treatment with an immune checkpoint inhibitor; and
 - 1.2 The individual meets initial application criteria for pembrolizumab for stage III or IV resected melanoma – adjuvant; or
- 2 Both:
 - 2.1 The individual has received neoadjuvant and adjuvant treatment with an immune checkpoint inhibitor; and
 - 2.2 The individual meets renewal criteria for pembrolizumab for stage III or IV resected melanoma – adjuvant; or
- 3 All of the following:
 - 3.1 The individual has received neoadjuvant and adjuvant treatment with an immune checkpoint inhibitor; and
 - 3.2 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
 - 3.3 The individual meets initial application criteria for pembrolizumab for unresectable or metastatic melanoma; or
- 4 All of the following:
 - 4.1 The individual has received neoadjuvant and adjuvant treatment with an immune checkpoint inhibitor; and
 - 4.2 The individual has received treatment with an immune checkpoint inhibitor for unresectable or metastatic melanoma; and
 - 4.3 The individual meets renewal criteria for pembrolizumab for unresectable or metastatic melanoma.

Notes:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition
- b) Initiating treatment within 13 weeks of complete surgical resection means either 13 weeks after resection (primary or lymphadenectomy) or 13 weeks prior to the scheduled date of the resection (primary or lymphadenectomy)

Initial application — (stage III or IV resected melanoma - adjuvant) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The individual has resected stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note a); and
- 2 Adjuvant treatment with pembrolizumab is required; and
- 3 The individual has not received prior funded systemic treatment in the adjuvant setting for stage IIIB, IIIC, IIID or IV melanoma; and
- 4 Treatment must be in addition to complete surgical resection; and
- 5 Treatment must be initiated within 13 weeks of complete surgical resection, unless delay is necessary due to post-surgery recovery (see note b); and
- 6 Pembrolizumab must be administered as monotherapy; and
- 7 The individual has ECOG performance score 0-2; and
- 8 Pembrolizumab to be administered at a fixed dose of 200 mg every 3 weeks (or equivalent).

Notes:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition
- b) Initiating treatment within 13 weeks of complete surgical resection means 13 weeks after resection (primary or lymphadenectomy)

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Renewal — (stage III or IV resected melanoma - adjuvant) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 All of the following:
 - 1.1 No evidence of disease recurrence; and
 - 1.2 Pembrolizumab must be administered as monotherapy; and
 - 1.3 Pembrolizumab to be administered at a fixed dose of 200 mg every three weeks (or equivalent) for a maximum of 12 months total treatment course, including any systemic neoadjuvant treatment; and
 - 1.4 Treatment to be discontinued at signs of disease recurrence or at completion of 12 months total treatment course (equivalent to 18 cycles at a dose of 200 mg every 3 weeks), including any systemic neoadjuvant treatment; or
- 2 All of the following:
 - 2.1 The individual has received adjuvant treatment with an immune checkpoint inhibitor; and
 - 2.2 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
 - 2.3 The individual meets initial application criteria for pembrolizumab for unresectable or metastatic melanoma; or
- 3 All of the following:
 - 3.1 The individual has received adjuvant treatment with an immune checkpoint inhibitor; and
 - 3.2 The individual has received treatment with an immune checkpoint inhibitor for unresectable or metastatic melanoma; and
 - 3.3 The individual meets renewal criteria for pembrolizumab for unresectable or metastatic melanoma.

Initial application — (unresectable or metastatic melanoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
- 3 The individual has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 The individual has not received funded nivolumab; or
 - 4.2 Both:
 - 4.2.1 The individual has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
 - 4.2.2 The cancer did not progress while the individual was on nivolumab; and
- 5 Any of the following:
 - 5.1 The individual has been diagnosed in the metastatic or unresectable stage III or IV setting; or
 - 5.2 The individual did not receive treatment in the perioperative setting with a PD-1/PD-L1 inhibitor; or
 - 5.3 All of the following:
 - 5.3.1 The individual received treatment in the perioperative setting with a PD-1/PD-L1 inhibitor; and
 - 5.3.2 The individual did not experience disease recurrence while on treatment with that PD-1/PD-L1 inhibitor; and
 - 5.3.3 The individual did not experience disease recurrence within six months of completing perioperative treatment with a PD-1/PD-L1 inhibitor.

Renewal — (unresectable or metastatic melanoma, less than 24 months on treatment) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Any of the following:
 - 1.1.1 The individual's disease has had a complete response to treatment; or
 - 1.1.2 The individual's disease has had a partial response to treatment; or

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1.1.3 The individual has stable disease; and
- 1.2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; or
- 2 All of the following:
 - 2.1 The individual has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and
 - 2.2 The individual has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with pembrolizumab.

Renewal — (unresectable or metastatic melanoma, more than 24 months on treatment) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 The individual has been on treatment for more than 24 months; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Any of the following:
 - 2.1.1.1 The individual's disease has had a complete response to treatment; or
 - 2.1.1.2 The individual's disease has had a partial response to treatment; or
 - 2.1.1.3 The individual has stable disease; and
 - 2.1.2 Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period; or
 - 2.2 All of the following:
 - 2.2.1 The individual has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and
 - 2.2.2 The individual has signs of disease progression; and
 - 2.2.3 Disease has not progressed during previous treatment with pembrolizumab.

Initial application — (non-small cell lung cancer first-line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
- 2 Patient has not had chemotherapy for their disease in the palliative setting; and
- 3 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 4 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR, ROS-1 or ALK tyrosine kinase unless not possible to ascertain; and
- 5 Pembrolizumab to be used as monotherapy; and
- 6 Either:
 - 6.1 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 50% as determined by a validated test unless not possible to ascertain; or
 - 6.2 Both:
 - 6.2.1 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 1% as determined by a validated test unless not possible to ascertain; and
 - 6.2.2 Chemotherapy is determined to be not in the best interest of the patient based on clinician assessment; and
- 7 Patient has an ECOG 0-2; and
- 8 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and
- 9 Baseline measurement of overall tumour burden is documented clinically and radiologically.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Renewal — (non-small cell lung cancer first line monotherapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 6 Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (non-small cell lung cancer first-line combination therapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
- 2 The patient has not had chemotherapy for their disease in the palliative setting; and
- 3 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 4 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR, ROS-1 or ALK tyrosine kinase unless not possible to ascertain; and
- 5 Pembrolizumab to be used in combination with platinum-based chemotherapy; and
- 6 Patient has an ECOG 0-2; and
- 7 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and
- 8 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Renewal — (non-small cell lung cancer first line combination therapy) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 6 Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (breast cancer, advanced) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

2 All of the following:

2.1 Either:

- 2.1.1 Patient has recurrent or de novo unresectable, inoperable locally advanced triple-negative breast cancer (that does not express ER, PR or HER2 IHC3+ or ISH+ [including FISH or other technology]); or
- 2.1.2 Patient has recurrent or de novo metastatic triple-negative breast cancer (that does not express ER, PR or HER2 IHC3+ or ISH+ [including FISH or other technology]); and

2.2 Patient is treated with palliative intent; and

2.3 Patient's cancer has confirmed PD-L1 Combined Positive Score (CPS) is greater than or equal to 10; and

2.4 Patient has received no prior systemic therapy in the palliative setting; and

2.5 Patient has an ECOG score of 0-2; and

2.6 Pembrolizumab is to be used in combination with chemotherapy; and

2.7 Baseline measurement of overall tumour burden is documented clinically and radiologically; and

2.8 Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks.

Renewal — (breast cancer, advanced) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Any of the following:

- 1.1 Patient's disease has had a complete response to treatment; or
- 1.2 Patient's disease has had a partial response to treatment; or
- 1.3 Patient has stable disease; and

2 No evidence of disease progression; and

3 Response to treatment in target lesions has been determined by a comparable radiologic assessment following the most recent treatment period; and

4 Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent); and

5 Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (head and neck squamous cell carcinoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or

2 All of the following:

2.1 Patient has recurrent or metastatic head and neck squamous cell carcinoma of mucosal origin (excluding nasopharyngeal carcinoma) that is incurable by local therapies; and

2.2 Patient has not received prior systemic therapy in the recurrent or metastatic setting; and

2.3 Patient has a positive PD-L1 combined positive score (CPS) of greater than or equal to 1; and

2.4 Patient has an ECOG performance score of 0-2; and

2.5 Either:

2.5.1 Pembrolizumab to be used in combination with platinum-based chemotherapy; or

2.5.2 Pembrolizumab to be used as monotherapy; and

2.6 Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks.

Renewal — (head and neck squamous cell carcinoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 Any of the following:

- 1.1 Patient's disease has had a complete response to treatment; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.2 Patient's disease has had a partial response to treatment; or
- 1.3 Patient has stable disease; and
- 2 No evidence of disease progression; and
- 3 Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 4 Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (MSI-H/dMMR advanced colorectal cancer) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Individual is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Individual has deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer; or
 - 2.1.2 Individual has deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) unresectable colorectal cancer; and
 - 2.2 Individual is treated with palliative intent; and
 - 2.3 Individual has not previously received funded treatment with pembrolizumab for MSI-H/dMMR advanced colorectal cancer; and
 - 2.4 Individual has an ECOG performance score of 0-2; and
 - 2.5 Baseline measurement of overall tumour burden is documented clinically and radiologically; and
 - 2.6 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks.

Renewal — (MSI-H/dMMR advanced colorectal cancer) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 No evidence of disease progression; and
- 2 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 3 Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (Urothelial carcinoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Patient has inoperable locally advanced (T4) or metastatic urothelial carcinoma; and
 - 2.2 Patient has an ECOG performance score of 0-2; and
 - 2.3 Patient has documented disease progression following treatment with chemotherapy; and
 - 2.4 Pembrolizumab to be used as monotherapy at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks.

Renewal — (Urothelial carcinoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2 No evidence of disease progression; and
- 3 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 4 Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initial application — (relapsed/refractory Hodgkin lymphoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Individual is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Both:
 - 2.1.1.1 Individual has relapsed/refractory Hodgkin lymphoma after two or more lines of chemotherapy; and
 - 2.1.1.2 Individual is ineligible for autologous stem cell transplant; or
 - 2.1.2 Individual has relapsed/refractory Hodgkin lymphoma and has previously undergone an autologous stem cell transplant; and
 - 2.2 Individual has not previously received funded pembrolizumab for relapsed/refractory Hodgkin lymphoma; and
 - 2.3 Pembrolizumab to be administered at doses no greater than 200 mg once every 3 weeks.

Renewal — (relapsed/refractory Hodgkin lymphoma) only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has received a partial or complete response to pembrolizumab; and
- 2 Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Other Immunosuppressants

CICLOSPORIN

Cap 25 mg	44.63	50	✓ Neoral
Cap 50 mg	88.91	50	✓ Neoral
Cap 100 mg	177.81	50	✓ Neoral
Oral liq 100 mg per ml	198.13	50 ml OP	✓ Neoral

EVEROLIMUS – Special Authority see [SA2598 below](#) – Retail pharmacy

Wastage claimable			
Tab 10 mg	6,512.29	30	✓ Afinitor
Tab 5 mg	4,555.76	30	✓ Afinitor

► [SA2598](#) Special Authority for Subsidy

Initial application only from a neurologist or oncologist. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 Patient has tuberous sclerosis; and
- 2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

Renewal only from a neurologist or oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Everolimus to be discontinued at progression of SEGAs.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (renal cell carcinoma) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic renal cell carcinoma; and
 - 1.2 The disease is of predominant clear-cell histology; and
 - 1.3 The patient has documented disease progression following one previous line of treatment; and
 - 1.4 The patient has an ECOG performance status of 0-2; and
 - 1.5 Everolimus is to be used in combination with lenvatinib; or
- 2 All of the following:
 - 2.1 Patient has received funded treatment with nivolumab for the second line treatment of metastatic renal cell carcinoma; and
 - 2.2 Patient has experienced treatment limiting toxicity from treatment with nivolumab; and
 - 2.3 Everolimus is to be used in combination with lenvatinib; and
 - 2.4 There is no evidence of disease progression.

Renewal — (renal cell carcinoma) from any relevant practitioner. Approvals valid for 4 months where there is no evidence of disease progression.

SIROLIMUS – Special Authority see [SA2270 below](#) – Retail pharmacy

Tab 1 mg	749.99	100	✓ Rapamune
Tab 2 mg	1,499.99	100	✓ Rapamune
Oral liq 1 mg per ml	449.99	60 ml OP	✓ Rapamune

► **SA2270 Special Authority for Subsidy**

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR< 30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease

Initial application — (severe non-malignant lymphovascular malformations*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe non-malignant lymphovascular malformation*; and
- 2 Any of the following:
 - 2.1 Malformations are not adequately controlled by sclerotherapy and surgery; or
 - 2.2 Malformations are widespread/extensive and sclerotherapy and surgery are not considered clinically appropriate; or
 - 2.3 Sirolimus is to be used to reduce malformation prior to consideration of surgery; and
- 3 Patient is being treated by a specialist lymphovascular malformation multi-disciplinary team; and
- 4 Patient has measurable disease as defined by RECIST version 1.1 (see Note).

Renewal — (severe non-malignant lymphovascular malformations*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Either:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 1.1 Patient's disease has had either a complete response or a partial response to treatment, or patient has stable disease according to RECIST version 1.1 (see Note); or
- 1.2 Patient's disease has stabilised or responded clinically and disease response to treatment has been clearly documents in patient notes; and
- 2 No evidence of progressive disease; and
- 3 The treatment remains clinically appropriate and the patient is benefitting from the treatment.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer et al. Eur J Cancer 2009;45:228-47)

Indications marked with * are unapproved indications

Initial application — (renal angiomyolipoma(s) associated with tuberous sclerosis complex*) only from a nephrologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has tuberous sclerosis complex*; and
- 2 Evidence of renal angiomyolipoma(s) measuring 3 cm or greater and that have shown interval growth.

Renewal — (renal angiomyolipoma(s) associated with tuberous sclerosis complex*) from any relevant practitioner.

Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Documented evidence of renal angiomyolipoma reduction or stability by magnetic resonance imaging (MRI) or ultrasound; and
- 2 Demonstrated stabilisation or improvement in renal function; and
- 3 The patient has not experienced angiomyolipoma haemorrhage or significant adverse effects to sirolimus treatment; and
- 4 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indications marked with * are unapproved indications

Initial application — (refractory seizures associated with tuberous sclerosis complex*) only from a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has epilepsy with a background of documented tuberous sclerosis complex; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Vigabatrin has been trialled and has not adequately controlled seizures; and
 - 2.1.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least two of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); or
 - 2.2 Both:
 - 2.2.1 Vigabatrin is contraindicated; and
 - 2.2.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least three of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); and
- 3 Seizures have a significant impact on quality of life; and
- 4 Patient has been assessed and surgery is considered inappropriate for this patient, or the patient has been assessed and would benefit from mTOR inhibitor treatment prior to surgery.

Note: Those of childbearing age potential are not required to trial phenytoin sodium, sodium valproate, or topiramate. Those who can father children are not required to trial sodium valproate.

Renewal — (refractory seizures associated with tuberous sclerosis complex*) only from a neurologist. Approvals valid for 12 months where demonstrated significant and sustained improvement in seizure rate (e.g. 50% reduction in seizure frequency) or severity and/or patient quality of life compared with baseline prior to starting sirolimus treatment.

Note: Indications marked with * are unapproved indications

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TACROLIMUS – Special Authority see SA2455 below – Retail pharmacy				
Cap 0.5 mg.....	49.60	100	✓	Tacrolimus Sandoz
Cap 0.75 mg.....	99.30	100	✓	Tacrolimus Sandoz
Cap 1 mg.....	84.30	100	✓	Tacrolimus Sandoz
Cap 5 mg.....	248.20	50	✓	Tacrolimus Sandoz

► **SA2455** Special Authority for Subsidy

Initial application — (organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 The individual is an organ transplant recipient; or
- 2 The individual is receiving induction therapy for an organ transplant.

Note: Subsidy applies for either primary or rescue therapy.

Initial application — (non-transplant indications*) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient requires long-term systemic immunosuppression; and
- 2 Either:
 - 2.1 Ciclosporin has been trialed and discontinued treatment because of unacceptable side effects or inadequate clinical response; or
 - 2.2 Patient is a child with nephrotic syndrome*.

Note: Indications marked with * are unapproved indications

JAK inhibitors

UPADACITINIB – Special Authority see [SA2599 below](#) – Retail pharmacy

Tab modified-release 15 mg.....	1,271.00	28	✓	Rinvoq
Tab modified-release 30 mg.....	2,033.00	28	✓	Rinvoq
Tab modified-release 45 mg.....	3,049.00	28	✓	Rinvoq

► **SA2599** Special Authority for Subsidy

Initial application — (Rheumatoid Arthritis (previously treated with adalimumab or etanercept)) from any relevant practitioner. Approvals valid for 7 months for applications meeting the following criteria:

All of the following:

- 1 The individual has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The individual has experienced intolerable side effects with adalimumab and/or etanercept; or
 - 2.2 The individual has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Any of the following:
 - 3.1 Rituximab is not clinically appropriate; or
 - 3.2 The individual is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
 - 3.3 Both:
 - 3.3.1 The individual has been started on rituximab for rheumatoid arthritis in a Health NZ Hospital; and
 - 3.3.2 Either:
 - 3.3.2.1 The individual has experienced intolerable side effects with rituximab; or
 - 3.3.2.2 At four months following the initial course of rituximab the individual has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Renewal — (Rheumatoid Arthritis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Either:

- 1 Following 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline; or
- 2 On subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from baseline.

Initial application — (atopic dermatitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Individual is currently on treatment with upadacitinib for atopic dermatitis and met all remaining criteria prior to commencing treatment; or
- 2 All of the following:
 - 2.1 Individual has moderate to severe atopic dermatitis, severity as defined by an Eczema Area and Severity Index (EASI) score of greater than or equal to 16 or a Dermatology Life Quality Index (DLQI) score of greater than or equal to 10; and
 - 2.2 Individual has received insufficient benefit from topical therapy (including topical corticosteroids or topical calcineurin inhibitors) for a 28-day trial within the last 6 months, unless contraindicated to all; and
 - 2.3 Individual has trialled and received insufficient benefit from at least one systemic therapy for a minimum of three months (eg ciclosporin, azathioprine, methotrexate or mycophenolate mofetil), unless contraindicated to all; and
 - 2.4 An EASI assessment or DLQI assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.5 The most recent EASI or DLQI assessment is no more than 1 month old at the time of application.

Renewal — (atopic dermatitis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 Individual has received a 75% or greater reduction in EASI score (EASI 75) as compared to baseline EASI prior to commencing upadacitinib; or
- 2 Individual has received a DLQI improvement of 4 or more as compared to baseline DLQI prior to commencing upadacitinib.

Initial application — (Crohn's disease - adult) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Individual is currently on treatment with upadacitinib for Crohn's disease and met all remaining criteria prior to commencing treatment; or
- 2 Both:
 - 2.1 Individual has active Crohn's disease; and
 - 2.2 Either:
 - 2.2.1 Individual has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Individual meets the initiation criteria for prior biologic therapies for Crohn's disease; and
 - 2.2.2.2 Other biologic therapies for Crohn's disease are contraindicated.

Renewal — (Crohn's disease - adult) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 CDAI score has reduced by 100 points from the CDAI score when the individual was initiated on biologic therapy; or
- 2 HBI score has reduced by 3 points from when individual was initiated on biologic therapy; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 3 CDAI score is 150 or less; or
- 4 HBI score is 4 or less; or
- 5 The individual has experienced an adequate response to treatment, but CDAI score cannot be assessed.

Initial application — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Individual is currently on treatment with upadacitinib for Crohn's disease and met all remaining criteria prior to commencing treatment; or
- 2 Both:
 - 2.1 Child has active Crohn's disease; and
 - 2.2 Either:
 - 2.2.1 Child has had an initial approval for prior biologic therapy for Crohn's disease and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Child meets the initiation criteria for prior biologic therapies for Crohn's disease; and
 - 2.2.2.2 Other biologic therapies for Crohn's disease are contraindicated.

Renewal — (Crohn's disease - children*) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 PCDAI score has reduced by 10 points from the child was initiated on treatment; or
- 2 PCDAI score is 15 or less; or
- 3 The child has experienced an adequate response to treatment, but PCDAI score cannot be assessed.

Note: Indications marked with * are unapproved indications.

Initial application — (ulcerative colitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Individual is currently on treatment with upadacitinib for ulcerative colitis and met all remaining criteria prior to commencing treatment; or
- 2 Both:
 - 2.1 Individual has active ulcerative colitis; and
 - 2.2 Either:
 - 2.2.1 Individual has had an initial approval for prior biologic therapy for ulcerative colitis and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Individual meets the initiation criteria for prior biologic therapies for ulcerative colitis; and
 - 2.2.2.2 Other biologic therapies for ulcerative colitis are contraindicated.

Renewal — (ulcerative colitis) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The SCCAI score has reduced by 2 points or more from the SCCAI score when the individual was initiated on treatment; or
- 2 PUCAI score has reduced by 10 points or more from the PUCAI score when the individual was initiated on treatment.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

Antiallergy Preparations

Allergic Emergencies

ADRENALINE – Special Authority see [SA2185 below](#) – Retail pharmacy

- Maximum of 2 inj per prescription
- Additional prescriptions limited to replacement of up to two devices prior to expiry, or replacement of used device for treatment of anaphylaxis.

Inj 0.15 mg per 0.3 ml auto-injector.....	85.50	1 OP	✓ Epipen Jr
Inj 0.3 mg per 0.3 ml auto-injector	85.50	1 OP	✓ Epipen

► [SA2185](#) Special Authority for Subsidy

Initial application — (anaphylaxis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- Either:
 - Patient has experienced an anaphylactic reaction which has resulted in presentation to a hospital or emergency department; or
 - Patient has been assessed to be at significant risk of anaphylaxis by a relevant practitioner; and
- Patient is not to be prescribed more than two devices in initial prescription.

ICATIBANT – Special Authority see [SA1558 below](#) – Retail pharmacy

Inj 10 mg per ml, 3 ml prefilled syringe.....	479.00	1	✓ Icatibant Lupin
	2,668.00		✓ Firazyr

Icatibant Lupin to be Principal Supply on 1 October 2026

(Firazyr Inj 10 mg per ml, 3 ml prefilled syringe to be delisted 1 October 2026)

► [SA1558](#) Special Authority for Subsidy

Initial application only from a clinical immunologist or relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and
- The patient has undergone product training and has agreed upon an action plan for self-administration.

Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Allergy Desensitisation

► [SA1367](#) Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- RAST or skin test positive; and
- Patient has had severe generalised reaction to the sensitising agent.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
BEE VENOM ALLERGY TREATMENT – Special Authority see SA1367 on the previous page – Retail pharmacy				
Initiation kit - 1 vial freeze dried venom with diluent	305.00	1 OP	✓	VENOX ^{\$29}
Maintenance kit - 1 vial freeze dried venom with diluent	305.00	1 OP	✓	VENOX ^{\$29}
Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent	285.00	1 OP	✓	Venomil ^{\$29}
Treatment kit - 1 vial 550 mcg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml	334.39	1 OP	✓	Albey
Treatment kit - 1 vial 550 mcg freeze dried venom, with diluent	305.00	1 OP	✓	Hymenoptera ^{\$29}
WASP VENOM ALLERGY TREATMENT – Special Authority see SA1367 on the previous page – Retail pharmacy				
Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze dried polistes venom, 1 diluent 9 ml, 3 diluent 1.8 ml	382.23	1 OP	✓	Albey
Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze dried venom, with diluent	305.00	1 OP	✓	Hymenoptera ^{\$29}
Treatment kit (Paper wasp venom) - 6 vials 120 mcg freeze dried venom, with diluent	305.00	1 OP	✓	Venomil ^{\$29}
Treatment kit (Yellow Jacket venom) - 1 vial 550 mcg freeze dried venom, with diluent	305.00	1 OP	✓	Hymenoptera ^{\$29}
Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze dried vespula venom, 1 diluent 9 ml, 3 diluent 1.8 ml	431.24	1 OP	✓	Albey
Treatment kit (Yellow jacket venom) - 6 vials 120 mcg freeze dried venom, with diluent	305.00	1 OP	✓	Venomil ^{\$29}

Antihistamines

CETIRIZINE HYDROCHLORIDE				
* Tab 10 mg	1.71	100	✓	Zista
* Oral liq 1 mg per ml	5.75	200 ml	✓	Histaclear
DEXTROCHLORPHENIRAMINE MALEATE				
* Tab 2 mg	2.02 (8.40)	40		Polaramine
	1.01 (5.99)	20		Polaramine
* Oral liq 2 mg per 5 ml	1.77 (10.29)	100 ml		Polaramine
FEXOFENADINE HYDROCHLORIDE				
* Tab 60 mg	4.34 (8.23)	20		Telfast
* Tab 120 mg	3.49	30	✓	Fexaclear
* Tab 180 mg	4.10	30	✓	Fexaclear
LORATADINE				
* Tab 10 mg	1.59	100	✓	Loratadine Noumed
* Oral liq 1 mg per ml	1.43	100 ml	✓	Haylor syrup
PROMETHAZINE HYDROCHLORIDE				
* Tab 10 mg	2.19	100	✓	Allersoothe
* Tab 25 mg	2.69	100	✓	Allersoothe
* Oral liq 1 mg per 1 ml	3.39	100 ml	✓	Allersoothe
* Inj 25 mg per ml, 1 ml ampoule – Up to 10 inj available on a PSO	52.73	25	✓	XGen ^{\$29}
* Inj 25 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	21.09	5	✓	DBL Promethazine Hydrochloride

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Inhaled Corticosteroids				
BECLOMETHASONE DIPROPIONATE				
Aerosol inhaler, 50 mcg per dose.....	14.01	200 dose OP	✓	Qvar
Aerosol inhaler, 50 mcg per dose CFC-free.....	8.54	200 dose OP	✓	Beclazone 50
Aerosol inhaler, 100 mcg per dose.....	17.52	200 dose OP	✓	Qvar
Aerosol inhaler, 100 mcg per dose CFC-free.....	12.50	200 dose OP	✓	Beclazone 100
Aerosol inhaler, 250 mcg per dose CFC-free.....	22.67	200 dose OP	✓	Beclazone 250
BUDESONIDE				
Powder for inhalation, 100 mcg per dose.....	17.00	200 dose OP	✓	Pulmicort Turbuhaler
Powder for inhalation, 200 mcg per dose.....	19.00	200 dose OP	✓	Pulmicort Turbuhaler
Powder for inhalation, 400 mcg per dose.....	32.00	200 dose OP	✓	Pulmicort Turbuhaler
FLUTICASONE				
Aerosol inhaler, 50 mcg per dose.....	7.19	120 dose OP	✓	Flixotide
Powder for inhalation, 50 mcg per dose.....	8.61	60 dose OP	✓	Flixotide Accuhaler
Powder for inhalation, 100 mcg per dose.....	7.81	60 dose OP	✓	Flixotide Accuhaler
Aerosol inhaler, 125 mcg per dose.....	13.60	120 dose OP	✓	Flixotide
Aerosol inhaler, 250 mcg per dose.....	24.62	120 dose OP	✓	Flixotide
Powder for inhalation, 250 mcg per dose.....	11.93	60 dose OP	✓	Flixotide Accuhaler
Inhaled Long-acting Beta-adrenoceptor Agonists				
EFORMOTEROL FUMARATE DIHYDRATE				
Powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose).....	10.32 (16.90)	60 dose OP		Oxis Turbuhaler
INDACATEROL				
Powder for inhalation 150 mcg.....	61.00	30 dose OP	✓	Onbrez Breezhaler
Powder for inhalation 300 mcg.....	61.00	30 dose OP	✓	Onbrez Breezhaler
SALMETEROL				
Aerosol inhaler CFC-free, 25 mcg per dose.....	26.25	120 dose OP	✓	Serevent
Powder for inhalation, 50 mcg per dose, breath activated.....	26.25	60 dose OP	✓	Serevent Accuhaler

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

BUDESONIDE WITH EFORMOTEROL

* Powder for inhalation 160 mcg with 4.5 mcg eformoterol fumarate per dose (equivalent to 200 mcg budesonide with 6 mcg eformoterol fumarate metered dose) – Up to 120 dose available on a PSO	41.50	120 dose OP	✓ DuoResp Spiromax
Powder for inhalation 320 mcg with 9 mcg eformoterol fumarate per dose (equivalent to 400 mcg budesonide with 12 mcg eformoterol fumarate metered dose) – No more than 2 dose per day	82.50	120 dose OP	✓ DuoResp Spiromax
* Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg – Up to 120 dose available on a PSO	18.23	120 dose OP	✓ Vannair
* Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg – Up to 120 dose available on a PSO	33.74	120 dose OP	✓ Symbicort Turbuhaler 100/6
* Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg – Up to 120 dose available on a PSO	21.40	120 dose OP	✓ Vannair
* Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg – Up to 120 dose available on a PSO	33.74	120 dose OP	✓ Symbicort Turbuhaler 200/6
Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg – No more than 2 dose per day	33.74	60 dose OP	✓ Symbicort Turbuhaler 400/12

FLUTICASONE FUROATE WITH VILANTEROL

Powder for inhalation 100 mcg with vilanterol 25 mcg	44.08	30 dose OP	✓ Breo Ellipta
--	-------	------------	----------------

FLUTICASONE WITH SALMETEROL

Aerosol inhaler 50 mcg with salmeterol 25 mcg	25.79	120 dose OP	✓ Seretide
Aerosol inhaler 125 mcg with salmeterol 25 mcg	32.60	120 dose OP	✓ Seretide
Powder for inhalation 100 mcg with salmeterol 50 mcg – No more than 2 dose per day	33.74	60 dose OP	✓ Seretide Accuhaler
Powder for inhalation 250 mcg with salmeterol 50 mcg – No more than 2 dose per day	44.08	60 dose OP	✓ Seretide Accuhaler

Beta-Adrenoceptor Agonists

SALBUTAMOL

Oral liq 400 mcg per ml	50.00	150 ml	✓ Ventolin
Infusion 1 mg per ml, 5 ml	130.00	10	✓ Ventolin
Inj 500 mcg per ml, 1 ml – Up to 5 inj available on a PSO	130.00	5	✓ Ventolin

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Inhaled Beta-Adrenoceptor Agonists				
SALBUTAMOL				
Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000 dose available on a PSO	4.18 (7.45)	200 dose OP	✓	SalAir Ventolin
Nebuliser soln, 1 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO	8.96	20	✓	Asthalin
			✓	UK Cipla ^{\$29}
Nebuliser soln, 2 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO	9.43	20	✓	Asthalin
			✓	UK Cipla ^{\$29}
TERBUTALINE SULPHATE				
Powder for inhalation, 200 mcg per dose (equivalent to 250 mcg metered dose), breath activated	22.20	120 dose OP	✓	Bricanyl Turbuhaler

Anticholinergic Agents

IPRATROPIUM BROMIDE				
Aerosol inhaler, 20 mcg per dose CFC-free – Up to 400 dose available on a PSO	16.20	200 dose OP	✓	Atrovent
Nebuliser soln, 250 mcg per ml, 2 ml ampoule – Up to 40 neb available on a PSO	8.11	10	✓	Ipratropium Viatris ^{\$29}
	11.73	20	✓	Accord ^{\$29}
			✓	Univent

Inhaled Beta-Adrenoceptor Agonists with Anticholinergic Agents

SALBUTAMOL WITH IPRATROPIUM BROMIDE				
Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg per dose CFC-free	12.19	200 dose OP	✓	Duolin HFA
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 3 ml vial	16.56	30	✓	Cipla ^{\$29}
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule – Up to 20 neb available on a PSO	11.04	20	✓	Duolin
	96.50	60	✓	Combiprasal ^{\$29}

Long-Acting Muscarinic Antagonists

GLYCOPYRRONIUM – Subsidy by endorsement				
a) Inhaled glycopyrronium treatment will not be subsidised if patient is also receiving treatment with subsidised tiotropium or umeclidinium.				
b) Glycopyrronium powder for inhalation 50 mcg per dose is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly.				
Powder for inhalation 50 mcg per dose	61.00	30 dose OP	✓	Seebri Breezhaler

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

TIOTROPIUM BROMIDE – Subsidy by endorsement

- Tiotropium treatment will not be subsidised if patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.
- Tiotropium bromide is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly. Patients who had tiotropium dispensed before 1 October 2018 with a valid Special Authority are deemed endorsed.

Powder for inhalation, 18 mcg per dose	50.37	30 dose	✓ Spiriva
Soln for inhalation 2.5 mcg per dose	50.37	60 dose OP	✓ Spiriva Respimat

UMECLIDINIUM – Subsidy by endorsement

- Umeclidinium will not be subsidised if patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.
- Umeclidinium powder for inhalation 62.5 mcg per dose is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly.

Powder for inhalation 62.5 mcg per dose	61.50	30 dose OP	✓ Incruse Ellipta
---	-------	------------	--------------------------

Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

Combination long acting muscarinic antagonist and long acting beta-2 agonist will not be subsidised if patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

►SA2554 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has been stabilised on a long acting muscarinic antagonist; and
- 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

GLYCOPYRRONIUM WITH INDACATEROL – Special Authority see SA2554 above – Retail pharmacy

Powder for Inhalation 50 mcg with indacaterol 110 mcg	81.00	30 dose OP	✓ Ultibro Breezhaler
---	-------	------------	-----------------------------

TIOTROPIUM BROMIDE WITH OLODATEROL – Special Authority see SA2554 above – Retail pharmacy

Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg	81.00	60 dose OP	✓ Spolto Respimat
---	-------	------------	--------------------------

UMECLIDINIUM WITH VILANTEROL – Special Authority see SA2554 above – Retail pharmacy

Powder for inhalation 62.5 mcg with vilanterol 25 mcg	77.00	30 dose OP	✓ Anoro Ellipta
---	-------	------------	------------------------

Inhaled Corticosteroid with Long-Acting Muscarinic Antagonist and Beta Agonist

BUDESONIDE WITH GLYCOPYRRONIUM AND EFORMOTEROL – Special Authority see SA2421 below – Retail pharmacy

Aerosol inhaler budesonide 160 mcg with glycopyrronium 7.2 mcg and formoterol 5 mcg per dose	79.15	120 dose OP	✓ Breztri Aerosphere
---	-------	-------------	-----------------------------

►SA2421 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has a diagnosis of COPD confirmed by spirometry or spirometry has been attempted and technically acceptable results are not possible; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient is currently receiving an inhaled corticosteroid with long acting beta-2 agonist (ICS/LABA) or a long

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

acting muscarinic antagonist with long acting beta-2 agonist (LAMA/LABA); and

2.1.2 Any of the following:

Clinical criteria:

- 2.1.2.1 Patient has a COPD Assessment Test (CAT) score greater than 10; or
- 2.1.2.2 Patient has had 2 or more exacerbations in the previous 12 months; or
- 2.1.2.3 Patient has had one exacerbation requiring hospitalisation in the previous 12 months; or
- 2.1.2.4 Patient has had an eosinophil count greater than or equal to 0.3×10^9 cells/L in the previous 12 months; or

- 2.2 Patient is currently receiving multiple inhaler triple therapy (inhaled corticosteroid with long-acting muscarinic antagonist and long-acting beta-2 agonist – ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to commencing multiple inhaler therapy.

FLUTICASONE FUROATE WITH UMECLIDINIUM AND VILANTEROL – Special Authority see [SA2326 below](#) – Retail pharmacy

Powder for inhalation fluticasone furoate 100 mcg with
umeclidinium 62.5 mcg and vilanterol 25 mcg..... 104.24 30 dose OP ✓ **Trelegy Ellipta**

►SA2326 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has a diagnosis of COPD confirmed by spirometry or spirometry has been attempted and technically acceptable results are not possible; and

2 Either:

2.1 Both:

- 2.1.1 Patient is currently receiving an inhaled corticosteroid with long acting beta-2 agonist (ICS/LABA) or a long acting muscarinic antagonist with long acting beta-2 agonist (LAMA/LABA); and

2.1.2 Any of the following:

Clinical criteria:

- 2.1.2.1 Patient has a COPD Assessment Test (CAT) score greater than 10; or
- 2.1.2.2 Patient has had 2 or more exacerbations in the previous 12 months; or
- 2.1.2.3 Patient has had one exacerbation requiring hospitalisation in the previous 12 months; or
- 2.1.2.4 Patient has had an eosinophil count greater than or equal to 0.3×10^9 cells/L in the previous 12 months; or

- 2.2 Patient is currently receiving multiple inhaler triple therapy (inhaled corticosteroid with long acting muscarinic antagonist and long acting beta-2 agonist – ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to commencing multiple inhaler triple therapy.

Antifibrotics

NINTEDANIB – Special Authority see [SA2012 below](#) – Retail pharmacy

Note: Nintedanib not subsidised in combination with subsidised pirfenidone.

Cap 100 mg.....2,554.00 60 OP ✓ **Ofev**
Cap 150 mg.....3,870.00 60 OP ✓ **Ofev**

►SA2012 Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Nintedanib is to be discontinued at disease progression (See Note); and
- 4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with pirfenidone; or
 - 5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

Renewal — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

PIRFENIDONE – Retail pharmacy-Specialist – Special Authority see [SA2013 below](#)

Note: Pirfenidone is not subsidised in combination with subsidised nintedanib.

Tab 801 mg	437.40	90	✓ Pirfenidone Sandoz
	3,645.00	90 OP	✓ Esbriet
Pirfenidone Sandoz to be Principal Supply on 1 October 2026			
Tab 267 mg	145.80	90	✓ Pirfenidone Sandoz
	1,215.00		✓ Esbriet

Pirfenidone Sandoz to be Principal Supply on 1 October 2026

(Esbriet Tab 801 mg to be delisted 1 October 2026)

(Esbriet Tab 267 mg to be delisted 1 October 2026)

► **SA2013** Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note); and
- 4 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with nintedanib; or
 - 5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

Renewal — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Leukotriene Receptor Antagonists

MONTELUKAST

* Tab 4 mg	3.10	28	✓	Montelukast (Sandoz) ^{\$29}
* Tab 5 mg	3.10	28	✓	Montelukast Viatris Montelukast Paediatric (Relonchem) ^{\$29}
* Tab 10 mg	2.45	28	✓	Montelukast Viatris Montelukast Viatris

Methylxanthines

AMINOPHYLLINE

* Inj 25 mg per ml, 10 ml ampoule – Up to 5 inj available on a PSO	180.00	5	✓	DBL Aminophylline
---	--------	---	---	-------------------

THEOPHYLLINE

* Tab long-acting 250 mg	25.65	100	✓	Nuelin-SR
* Oral liq 80 mg per 15 ml	18.49	500 ml	✓	Nuelin

Mucolytics

DORNASE ALFA – Special Authority see [SA1978 below](#) – Retail pharmacy

Nebuliser soln, 2.5 mg per 2.5 ml ampoule	250.00	6	✓	Pulmozyme
---	--------	---	---	-----------

►SA1978 Special Authority for Subsidy

Initial application — (cystic fibrosis) only from a respiratory physician or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of cystic fibrosis; and
- 2 Patient has previously undergone a trial with, or is currently being treated with, hypertonic saline; and
- 3 Any of the following:
 - 3.1 Patient has required one or more hospital inpatient respiratory admissions in the previous 12 month period; or
 - 3.2 Patient has had 3 exacerbations due to CF, requiring oral or intravenous (IV) antibiotics in the previous 12 month period; or
 - 3.3 Patient has had 1 exacerbation due to CF, requiring oral or IV antibiotics in the previous 12 month period and a Brasfield score of < 22/25; or
 - 3.4 Patient has a diagnosis of allergic bronchopulmonary aspergillosis (ABPA).

Renewal — (cystic fibrosis) only from a respiratory physician or paediatrician. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient continues to benefit from treatment.

ELEXACAFTOR WITH TEZACAFTOR, IVACAFTOR AND IVACAFTOR – PCT only – Special Authority see [SA2652 on the next page](#)

Tab elexacافت 50 mg with tezacافت 25 mg, ivacافت 37.5 mg (56) and ivacافت 75 mg (28)	27,647.39	84 OP	✓	Trikafta
Tab elexacافت 100 mg with tezacافت 50 mg, ivacافت 75 mg (56) and ivacافت 150 mg (28)	27,647.39	84 OP	✓	Trikafta
Oral granules elexacافت 80 mg with tezacافت 40 mg, ivacافت 60 mg (28) and ivacافت 59.5mg (28), sachets	27,647.39	56 OP	✓	Trikafta
Oral granules elexacافت 100 mg with tezacافت 50 mg, ivacافت 75 mg (28) and ivacافت 75 mg (28), sachets	27,647.39	56 OP	✓	Trikafta

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA2652 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with cystic fibrosis; and
- 2 Either:
 - 2.1 Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele); or
 - 2.2 Patient has a sweat chloride value of at least 60 mmol/L; and
- 3 Either:
 - 3.1 Patient has a heterozygous or homozygous F508del mutation; or
 - 3.2 Patient has a mutation responsive to elexacaftor/tezacaftor/ivacaftor (see note); and
- 4 The treatment must be the sole funded CFTR modulator therapy for this condition; and
- 5 Treatment with elexacaftor/tezacaftor/ivacaftor must be given concomitantly with standard therapy for this condition.

Note: Eligible mutations are listed in the Food and Drug Administration (FDA) Trikafta prescribing information

https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212273s014lbl.pdf

IVACAFTOR – PCT only – Specialist – Special Authority see SA2650 below

Tab 150 mg	29,386.00	56	✓ Kalydeco
Oral granules 13.4 mg, sachet	29,386.00	56	✓ Kalydeco
Oral granules 25 mg, sachet	29,386.00	56	✓ Kalydeco
Oral granules 50 mg, sachet	29,386.00	56	✓ Kalydeco
Oral granules 75 mg, sachet	29,386.00	56	✓ Kalydeco

►SA2650 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with cystic fibrosis; and
- 2 Either:
 - 2.1 Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele); or
 - 2.2 Patients must have a sweat chloride value of at least 60 mmol/L; and
- 3 Patient has a mutation responsive to ivacaftor (see note); and
- 4 Treatment with ivacaftor must be given concomitantly with standard therapy for this condition; and
- 5 The dose of ivacaftor will not exceed one tablet or one sachet twice daily.

Note: Mutations listed in Table 3 of the Food and Drug Administration (FDA) Ivacaftor prescribing information

https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203188s038lbl.pdf

SODIUM CHLORIDE

Not funded for use as a nasal drop.			
Soln 7%	25.73	90 ml OP	✓ Biomed

VANZACAFTOR WITH TEZACAFTOR AND DEUTIVACAFTOR – PCT only – Special Authority see SA2648 on the next page

Tab vanzacaftor 4 mg with tezacaftor 20 mg and deutivacaftor			
50 mg.....	29,029.76	84 OP	✓ Alyftrek
Tab vanzacaftor 10 mg with tezacaftor 50 mg and deutivacaftor			
125 mg.....	29,029.76	56 OP	✓ Alyftrek

►SA2648 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with cystic fibrosis; and
- 2 Either:
 - 2.1 Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele); or
 - 2.2 Patient has a sweat chloride value of at least 60 mmol/L; and
- 3 Either:
 - 3.1 Patient has a heterozygous or homozygous F508del mutation; or
 - 3.2 Patient has a mutation responsive to vanzacaftor/tezacaftor/deutivacaftor (see note); and
- 4 The treatment must be the sole funded CFTR modulator therapy for this condition; and
- 5 Treatment with vanzacaftor/tezacaftor/deutivacaftor must be given concomitantly with standard therapy for this condition.

Note: Eligible mutations are listed in the in the Food and Drug Administration (FDA) Alyftrek prescribing information

https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218730s0011bl.pdf

Nasal Preparations

Allergy Prophylactics

BUDESONIDE

Metered aqueous nasal spray, 50 mcg per dose	2.59	200 dose OP	✓ SteroClear
Metered aqueous nasal spray, 100 mcg per dose	2.89	200 dose OP	✓ SteroClear

FLUTICASONE PROPIONATE

Metered aqueous nasal spray, 50 mcg per dose	2.57	120 dose OP	✓ Flixonase Hayfever & Allergy
--	------	-------------	---

IPRATROPIUM BROMIDE

Aqueous nasal spray, 0.03%.....	5.23	15 ml OP	✓ Univent
---------------------------------	------	----------	------------------

Respiratory Devices

MASK FOR SPACER DEVICE

a) Up to 50 dev available on a PSO			
b) Only on a PSO			
c) Only for children aged six years and under			
Small.....	2.70	1	✓ e-chamber Mask

PEAK FLOW METER

a) Up to 25 dev available on a PSO			
b) Only on a PSO			
Low range.....	9.54	1	✓ Mini-Wright AFS Low Range
Normal range.....	9.54	1	✓ Mini-Wright Standard

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

SPACER DEVICE

a) Up to 50 dev available on a PSO				
b) Only on a PSO				
220 ml (single patient)	3.65	1	✓	e-chamber Turbo
510 ml (single patient)	5.95	1	✓	e-chamber La Grande
800 ml.....	6.50	1	✓	Volumatic

Respiratory Stimulants

CAFFEINE CITRATE

Oral liq 20 mg per ml (10 mg base per ml)	16.91	25 ml OP	✓	Biomed
---	-------	----------	---	--------

Ear Preparations

FLUMETASONE PIVALATE

Ear drops 0.02% with clioquinol 1%	4.46	7.5 ml OP	✓ Locacorten-Viaform ED's ✓ Locorten-Vioform
--	------	-----------	---

TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN

Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g	5.16	7.5 ml OP	✓ Kenacomb
--	------	-----------	-------------------

Ear/Eye Preparations

DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN

Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml	4.50 (9.27)	8 ml OP	Sofradex
---	----------------	---------	----------

FRAMYCETIN SULPHATE

Ear/Eye drops 0.5%	4.13 (8.65)	8 ml OP	Soframycin
--------------------------	----------------	---------	------------

Eye Preparations

Eye preparations are only funded for use in the eye, unless explicitly stated otherwise in the Pharmaceutical Schedule.

Anti-Infective Preparations

ACICLOVIR

* Eye oint 3%	15.89	4.5 g OP	✓ ViruPOS
---------------------	-------	----------	------------------

CHLORAMPHENICOL

Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A in accordance with the Integrated Community Pharmacy Services Agreement (ICPSA) – Extended Pharmacy Services.

Eye oint 1%	1.55	5 g OP	✓ Devatis
Eye drops 0.5%	1.84	10 ml OP	✓ Chlorafast

Funded for use in the ear*. Indications marked with * are unapproved indications.

CIPROFLOXACIN

Eye drops 0.3% – Subsidy by endorsement	10.85	5 ml OP	✓ Ciprofloxacin Teva
---	-------	---------	-----------------------------

When prescribed for the treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol; or for the second line treatment of chronic suppurative otitis media (CSOM)*; and the prescription is endorsed accordingly.

Note: Indication marked with a * is an unapproved indication.

SODIUM FUSIDATE [FUSIDIC ACID]

Eye drops 1%	5.29	5 g OP	✓ Fucithalmic ✓ Fucithalmic Canada (ON) ^{S29} ✓ Fucithalmic Spain ^{S29}
--------------------	------	--------	--

TOBRAMYCIN

Eye oint 0.3%	10.45	3.5 g OP	✓ Tobrex
Eye drops 0.3%	11.48	5 ml OP	✓ Tobrex

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
Corticosteroids and Other Anti-Inflammatory Preparations			
DEXAMETHASONE			
* Eye oint 0.1%	5.86	3.5 g OP	✓ Maxidex
* Eye drops 0.1%	4.50	5 ml OP	✓ Maxidex
Ocular implant 700 mcg – Special Authority see SA1680 below			
– Retail pharmacy.....	1,444.50	1	✓ Ozurdex
» SA1680 Special Authority for Subsidy			
Initial application — (Diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:			
All of the following:			
1 Patient has diabetic macular oedema with pseudophakic lens; and			
2 Patient has reduced visual acuity of between 6/9 - 6/48 with functional awareness of reduction in vision; and			
3 Either:			
3.1 Patient's disease has progressed despite 3 injections with bevacizumab; or			
3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and			
4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.			
Renewal — (Diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:			
Both:			
1 Patient's vision is stable or has improved (prescriber determined); and			
2 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.			
Initial application — (Women of child bearing age with diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:			
All of the following:			
1 Patient has diabetic macular oedema; and			
2 Patient has reduced visual acuity of between 6/9 - 6/48 with functional awareness of reduction in vision; and			
3 Patient is of child bearing potential and has not yet completed a family; and			
4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.			
Renewal — (Women of child bearing age with diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:			
All of the following:			
1 Patient's vision is stable or has improved (prescriber determined); and			
2 Patient is of child bearing potential and has not yet completed a family; and			
3 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.			
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE			
* Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g.....	5.39	3.5 g OP	✓ Maxitrol
* Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml.....	4.50	5 ml OP	✓ Maxitrol
DICLOFENAC SODIUM			
Eye drops 0.1%, single dose.....	1.85	10 dose	✓ Diclofenac Devatis
	5.54	30 dose	✓ Diclofenac Devatis
FLUOROMETHOLONE			
* Eye drops 0.1%.....	3.09	5 ml OP	✓ FML
	5.20		✓ Flucon

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

SENSORY ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LEVOCABASTINE				
Eye drops 0.5 mg per ml	8.71 (10.34)	4 ml OP		Livostin
LODOXAMIDE				
Eye drops 0.1%	8.71	10 ml OP	✓	Lomide
PREDNISOLONE ACETATE				
Eye drops 1%	6.92 7.00	10 ml OP 5 ml OP	✓	Prednisolone-AFT Pred Forte
PREDNISOLONE SODIUM PHOSPHATE – Special Authority see SA1715 below – Retail pharmacy				
Eye drops 0.5%, single dose (preservative free).....	43.26	20 dose	✓	Minims Prednisolone

► [SA1715](#) Special Authority for Subsidy

Initial application only from an ophthalmologist or optometrist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has severe inflammation; and
- 2 Patient has a confirmed allergic reaction to preservative in eye drops.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

SODIUM CROMOGLICATE

Eye drops 2%	2.91	10 ml OP	✓	Allerfix
--------------------	------	----------	---	----------

Glaucoma Preparations - Beta Blockers

TIMOLOL

* Eye drops 0.25%	2.42	5 ml OP	✓	Arrow-Timolol
* Eye drops 0.5%	2.50	5 ml OP	✓	Arrow-Timolol

Glaucoma Preparations - Carbonic Anhydrase Inhibitors

ACETAZOLAMIDE

* Tab 250 mg	13.96	100	✓	Medsurge
--------------------	-------	-----	---	----------

BRINZOLAMIDE

* Eye drops 1%	5.11	5 ml OP	✓	Azopt
----------------------	------	---------	---	-------

DORZOLAMIDE WITH TIMOLOL

* Eye drops 2% with timolol 0.5%	3.58	5 ml OP	✓	Dortimopt
--	------	---------	---	-----------

Glaucoma Preparations - Prostaglandin Analogues

BIMATOPROST

* Eye drops 0.03%	5.15	3 ml OP	✓	Lumigan
-------------------------	------	---------	---	---------

LATANOPROST

* Eye drops 0.005%	2.08	2.5 ml OP	✓	Teva
--------------------------	------	-----------	---	------

TRAVOPROST

* Eye drops 0.004%	6.80	2.5 ml OP	✓	Travatan
--------------------------	------	-----------	---	----------

Glaucoma Preparations - Other

BRIMONIDINE TARTRATE

* Eye drops 0.2%	5.16	5 ml OP	✓	Arrow-Brimonidine
------------------------	------	---------	---	-------------------

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE			
* Eye drops 0.2% with timolol maleate 0.5%	7.13	5 ml OP	✓ Combigan
LATANOPROST WITH TIMOLOL			
* Eye drops 0.005% with timolol 0.5%	4.95	2.5 ml OP	✓ Arrow - Lattim
PILOCARPINE HYDROCHLORIDE			
* Eye drops 1%	4.26	15 ml OP	✓ Isopto Carpine
* Eye drops 2%	5.35	15 ml OP	✓ Isopto Carpine
* Eye drops 4%	7.99	15 ml OP	✓ Isopto Carpine
Subsidised for oral use pursuant to the Standard Formulae.			
PILOCARPINE NITRATE			
* Eye drops 2% single dose – Special Authority see SA2644 below – Retail pharmacy	35.90	20 dose	✓ Minims Pilocarpine

► **SA2644** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:
Either:

- 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or
- 2 Patient wears soft contact lenses.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics

ATROPINE SULPHATE			
* Eye drops 1%	19.18	15 ml OP	✓ Atropt
CYCLOPENTOLATE HYDROCHLORIDE			
* Eye drops 1%	68.52	15 ml OP	✓ Cyclogyl
TROPICAMIDE			
* Eye drops 0.5%	33.89	15 ml OP	✓ Mydriacyl
* Eye drops 1%	54.17	15 ml OP	✓ Mydriacyl

Preparations for Tear Deficiency

For acetylcysteine eye drops refer Standard Formulae, [page 287](#)

HYPROMELLOSE			
* Eye drops 0.5%	19.50	15 ml OP	✓ Methopt
HYPROMELLOSE WITH DEXTRAN			
* Eye drops 0.3% with dextran 0.1%	2.30	15 ml OP	✓ Poly-Tears

Preservative Free Ocular Lubricants

► **SA2431** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Confirmed diagnosis by slit lamp or Schirmer test of severe secretory dry eye; and
- 2 Either:
 - 2.1 Patient is using eye drops more than four times daily on a regular basis; or
 - 2.2 Patient has had a confirmed allergic reaction to preservative in eye drop.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL – Special Authority see SA2431 on the previous page – Retail pharmacy				
Eye drops 0.4% and propylene glycol 0.3%, 0.8 ml	10.06	28	✓	Systane Unit Dose
SODIUM HYALURONATE [HYALURONIC ACID] – Special Authority see SA2431 on the previous page – Retail pharmacy				
Eye drops 1 mg per ml	13.58	10 ml OP	✓	Hylo-Fresh
Hylo-Fresh has a 6 month expiry after opening. The Pharmacy Procedures Manual restriction allowing one bottle per month is not relevant and therefore only the prescribed dosage to the nearest OP may be claimed.				

Other Eye Preparations

NAPHAZOLINE HYDROCHLORIDE				
* Eye drops 0.1%	5.65	15 ml OP	✓	Albalon
OLOPATADINE				
Eye drops 0.1%	3.39	5 ml OP	✓	Olopatadine Teva
PARAFFIN LIQUID WITH WOOL FAT				
* Eye oint 3% with wool fat 3%	3.63	3.5 g OP	✓	Poly-Visc
RETINOL PALMITATE				
Eye oint 138 mcg per g	3.80	5 g OP	✓	VitA-POS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Various

PHARMACY SERVICES

* Brand switch fee	4.50	1 fee	✓ BSF AutoSoft 90
a) May only be claimed once per patient.			
b) The Pharmacode for BSF AutoSoft 90 is 2733498 - see also page 21			
(BSF AutoSoft 90 Brand switch fee to be delisted 1 October 2026)			

Agents Used in the Treatment of Poisonings

Antidotes

ACETYL CYSTEINE

Inj 200 mg per ml, 10 ml ampoule	42.99	10	✓ DBL Acetylcysteine
Inj 200 mg per ml, 10 ml vial	42.99	10	✓ Hikma
			Acetylcysteine ^{S29}

NALOXONE HYDROCHLORIDE

a) Up to 10 inj available on a PSO			
b) Only on a PSO			
* Inj 400 mcg per ml, 1 ml ampoule	13.29	5	✓ DBL Naloxone Hydrochloride

Removal and Elimination

CHARCOAL

* Oral liq 50 g per 250 ml	59.85	250 ml OP	✓ Carbosorb-X
a) Up to 250 ml available on a PSO			
b) Only on a PSO			

DEFERASIROX – Special Authority see [SA1492 below](#) – Retail pharmacy

Wastage claimable			
Tab 125 mg dispersible	276.00	28	✓ Exjade
Tab 250 mg dispersible	552.00	28	✓ Exjade
Tab 500 mg dispersible	1,105.00	28	✓ Exjade

► [SA1492](#) Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
- 2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
- 3 Any of the following:
 - 3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or
 - 3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
 - 3.3 Treatment with deferiprone has resulted in arthritis; or
 - 3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per μ L) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per μ L).

Renewal only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed at one time

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

Either:

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
- 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

DEFERIPRONE – Special Authority see [SA1480 below](#) – Retail pharmacy

Tab 500 mg	533.17	100	✓ Feriprox
Oral liq 100 mg per 1 ml	266.59	250 ml OP	✓ Feriprox

►SA1480 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; or
- 2 The patient has been diagnosed with chronic iron overload due to acquired red cell aplasia.

DEFERRIOXAMINE MESILATE

* Inj 500 mg vial	332.88	10	✓ DBL Desferrioxamine Mesylate for Inj BP
-------------------------	--------	----	--

SODIUM CALCIUM EDETATE

* Inj 200 mg per ml, 5 ml	53.31 (156.71)	6	Calcium Disodium Versenate
---------------------------------	-------------------	---	-------------------------------

Standard Formulae

ACETYLCYSTEINE EYE DROPS

Acetylcysteine inj 200 mg per ml, 10 ml	qs
Suitable eye drop base	qs

CODEINE LINCTUS (3 mg per 5 ml)

Codeine phosphate	60 mg
Glycerol	40 ml
Preservative	qs
Water	to 100 ml

CODEINE LINCTUS (15 mg per 5 ml)

Codeine phosphate	300 mg
Glycerol	40 ml
Preservative	qs
Water	to 100 ml

FOLINIC MOUTHWASH

Calcium folinate 15 mg tab	1 tab
Preservative	qs
Water	to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

METHYL HYDROXYBENZOATE 10% SOLUTION

Methyl hydroxybenzoate	10 g
Propylene glycol	to 100 ml

(Use 1 ml of the 10% solution per 100 ml of oral liquid mixture)

OMEPRAZOLE SUSPENSION

Omeprazole capsules or powder	qs
Sodium bicarbonate powder BP	8.4 g
Water	to 100 ml

PHENOBARBITONE ORAL LIQUID

Phenobarbitone Sodium	1 g
Glycerol BP	70 ml
Water	to 100 ml

PHENOBARBITONE SODIUM PAEDIATRIC ORAL LIQUID (10 mg per ml)

Phenobarbitone Sodium	400 mg
Glycerol BP	4 ml
Water	to 40 ml

PILOCARPINE ORAL LIQUID

Pilocarpine 4% eye drops	qs
Preservative	qs
Water	to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days.)

SALIVA SUBSTITUTE FORMULA

Methylcellulose	5 g
Preservative	qs
Water	to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

SODIUM CHLORIDE ORAL LIQUID

Sodium chloride inj 23.4%, 20 ml	qs
Water	qs

(Only funded if prescribed for treatment of hyponatraemia)

VANCOMYCIN ORAL SOLUTION (25 mg per ml)

Vancomycin 500 mg injection	5 vials
Glycerin with sucrose suspension	37.5 ml
Water	to 100 ml

(Only funded if prescribed for treatment of Clostridium difficile following metronidazole failure)

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Extemporaneously Compounded Preparations and Galenicals				
COLLODION FLEXIBLE				
Note: This product is no longer being manufactured by the supplier and will be delisted from the Schedule at a date to be determined.				
Collodion flexible	19.30	100 ml	✓	PSM
COMPOUND HYDROXYBENZOATE – Only in combination				
Only in extemporaneously compounded oral mixtures.				
Soln	36.00	100 ml	✓	Midwest
GLYCERIN WITH SODIUM SACCHARIN – Only in combination				
Suspension.....	38.00	473 ml	✓	Ora-Sweet SF
GLYCERIN WITH SUCROSE – Only in combination				
Suspension.....	38.00	473 ml	✓	Ora-Sweet
GLYCEROL				
* Liquid – Only in combination	3.23	500 ml	✓	healthE Glycerol BP
Only in extemporaneously compounded oral liquid preparations.				
METHYL HYDROXYBENZOATE				
Powder	11.00	25 g	✓	Midwest
METHYLCELLULOSE				
Powder	44.00	100 g	✓	MidWest
Suspension – Only in combination	38.00	473 ml	✓	Ora-Plus
<i>(MidWest Powder to be delisted 1 February 2028)</i>				
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN – Only in combination				
Suspension.....	38.00	473 ml	✓	Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE – Only in combination				
Suspension.....	38.00	473 ml	✓	Ora-Blend
PHENOBARBITONE SODIUM				
Powder – Only in combination.....	125.00	10 g	✓	MidWest
Only in children up to 12 years				
PROPYLENE GLYCOL				
Only in extemporaneously compounded methyl hydroxybenzoate 10% solution.				
Liq.....	16.00	500 ml	✓	Midwest
SODIUM BICARBONATE				
Powder BP – Only in combination	13.50	500 g	✓	Midwest
Only in extemporaneously compounded omeprazole and lansoprazole suspension.				
SYRUP (PHARMACEUTICAL GRADE) – Only in combination				
Only in extemporaneously compounded oral liquid preparations.				
Liq.....	25.00	500 ml	✓	Midwest
WATER				
Tap – Only in combination.....	0.00	1 ml	✓	Tap water

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Nutrient Modules

Carbohydrate

►SA1930 Special Authority for Subsidy

Initial application — (Cystic fibrosis or kidney disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Either:

- 1 cystic fibrosis; or
- 2 chronic kidney disease.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 cancer in children; or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 faltering growth in an infant/child; or
- 4 bronchopulmonary dysplasia; or
- 5 premature and post premature infant; or
- 6 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified where the patient has inborn errors of metabolism.

Renewal — (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT – Special Authority see SA1930 above – Hospital pharmacy [HP3]

Powder 6.72 400 g OP ✓ Polycal

Carbohydrate And Fat

►SA1376 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1 Infant or child aged four years or under; and
- 2 cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 faltering growth; or
 - 2.3 bronchopulmonary dysplasia; or
 - 2.4 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND FAT SUPPLEMENT – Special Authority see [SA1376 on the previous page](#) – Hospital pharmacy [HP3]

Powder (neutral)	71.77	400 g OP	✓ Duocal Super Soluble Powder
------------------------	-------	----------	----------------------------------

Fat

»SA2204 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified where the patient has an inborn error of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 faltering growth in an infant/child; or
- 2 bronchopulmonary dysplasia; or
- 3 fat malabsorption; or
- 4 lymphangiectasia; or
- 5 short bowel syndrome; or
- 6 infants with necrotising enterocolitis; or
- 7 biliary atresia; or
- 8 for use in a ketogenic diet; or
- 9 chyle leak; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

- 10 ascites; or
- 11 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT – Special Authority see [SA2204 on the previous page](#) – Hospital pharmacy [HP3]

Emulsion (neutral)	15.38	200 ml OP	✓ Calogen
Emulsion (strawberry).....	15.38	200 ml OP	✓ Calogen
Oil	37.50	500 ml OP	✓ MCT oil (Nutricia)
MCT Emulsion, 250 ml	143.65	4 OP	✓ Liquigen

Protein

►SA1524 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 protein losing enteropathy; or
- 2 high protein needs; or
- 3 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEMENT – Special Authority see [SA1524 above](#) – Hospital pharmacy [HP3]

Powder	13.82	225 g OP	✓ Protifar
	17.90	227 g OP	✓ Resource Beneprotein

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

Oral and Enteral Feeds

Diabetic Products

»SA1095 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is a type I or II diabetic who is suffering weight loss and malnutrition that requires nutritional support.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1095 above – Hospital pharmacy [HP3]			
Liquid, 500 ml bottle	4.65	1 OP	✓ Glucerna Select
DIABETIC ORAL FEED 1KCAL/ML – Special Authority see SA1095 above – Hospital pharmacy [HP3]			
Liquid (strawberry), 200 ml bottle	2.25	1 OP	✓ Diasip
Liquid (vanilla), 200 ml bottle	2.25	1 OP	✓ Diasip
	8.99	4	✓ Nutren Diabetes

Fat Modified Products

»SA2205 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified where the patient has an inborn error of metabolism.

Initial application — (Indications other than errors of inborn metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Either:
- 1 Patient has a chyle leak; or
 - 2 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED – Special Authority see SA2205 above – Hospital pharmacy [HP3]			
Powder	62.90	400 g OP	✓ Monogen

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Paediatric Products For Children Awaiting Liver Transplant

►SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see [SA1098 above](#) – Hospital pharmacy [HP3]

Powder (unflavoured)93.97 400 g OP ✓ Heparon Junior

Paediatric Products For Children With Chronic Renal Failure

►SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see [SA1099 above](#) – Hospital pharmacy [HP3]

Powder64.26 400 g OP ✓ Kindergen

Paediatric Products

►SA1379 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 any condition causing malabsorption; or
 - 2.3 faltering growth in an infant/child; or
 - 2.4 increased nutritional requirements; or
 - 2.5 the child is being transitioned from TPN or tube feeding to oral feeding.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for

continued...

SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
applications meeting the following criteria:				
Both:				
1 The treatment remains appropriate and the patient is benefiting from treatment; and				
2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.				
PAEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid, 500 ml bottle	7.46	1 OP	✓	Nutrini Energy RTH
PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid, 500 ml bottle	3.32	1 OP	✓	Pediasure RTH
	4.69		✓	Nutrini RTH
PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid, 500 ml bottle	7.14	1 OP	✓	Nutrini Energy Multi Fibre
PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid (strawberry), 200 ml bottle	1.90	1 OP	✓	Fortini
Liquid (vanilla), 200 ml bottle	1.90	1 OP	✓	Fortini
Liquid (vanilla), 500 ml bottle	8.67	1 OP	✓	Pediasure Plus
PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid (chocolate), 200 ml bottle	1.33	1 OP	✓	Pediasure
Liquid (strawberry), 200 ml bottle	1.33	1 OP	✓	Pediasure
Liquid (vanilla), 200 ml bottle	1.33	1 OP	✓	Pediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Liquid (chocolate), 200 ml bottle	1.90	1 OP	✓	Fortini Multi Fibre
Liquid (strawberry), 200 ml bottle	1.90	1 OP	✓	Fortini Multi Fibre
Liquid (unflavoured), 200 ml bottle	1.90	1 OP	✓	Fortini Multi Fibre
Liquid (vanilla), 200 ml bottle	1.90	1 OP	✓	Fortini Multi Fibre
PEPTIDE-BASED ORAL FEED – Special Authority see SA1379 on the previous page – Hospital pharmacy [HP3]				
Powder	46.65	400 g OP	✓	Peptamen Junior

Renal Products

►SA1101 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

RENAL ORAL FEED 1.8 KCAL/ML – Special Authority see [SA1101 above](#) – Hospital pharmacy [HP3]

Liquid, 220 ml bottle	3.31	1 OP	✓	Nepro HP (strawberry)
			✓	Nepro HP (vanilla)

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
RENAL ORAL FEED 2 KCAL/ML – Special Authority see SA1101 on the previous page – Hospital pharmacy [HP3]			
Liquid, 200 ml bottle	14.17	4 OP	✓ NovaSource Renal
Liquid (apricot) 125 ml	13.72	4 OP	✓ Renilon 7.5
Liquid (caramel) 125 ml	13.72	4 OP	✓ Renilon 7.5

Specialised And Elemental Products

►SA1377 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 malabsorption; or
- 2 short bowel syndrome; or
- 3 enterocutaneous fistulas; or
- 4 eosinophilic oesophagitis; or
- 5 inflammatory bowel disease; or
- 6 patients with multiple food allergies requiring enteral feeding.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL SEMI-ELEMENTAL FEED 1.5KCAL/ML – Special Authority see [SA1377 above](#) – Hospital pharmacy [HP3]

Liquid, 1,000 ml bottle	22.39	1 OP	✓ Vital
-------------------------------	-------	------	---------

ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see [SA1377 above](#) – Hospital pharmacy [HP3]

Liquid (grapefruit), 250 ml carton.....	179.46	18 OP	✓ Elemental 028 Extra
Liquid (pineapple & orange), 250 ml carton.....	179.46	18 OP	✓ Elemental 028 Extra
Liquid (summer fruits), 250 ml carton.....	179.46	18 OP	✓ Elemental 028 Extra

ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see [SA1377 above](#) – Hospital pharmacy [HP3]

Powder (unflavoured), 80 g sachet.....	48.15	10	✓ Vivonex TEN
--	-------	----	---------------

SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Authority see [SA1377 above](#) – Hospital pharmacy [HP3]

Liquid, 500 ml bottle	7.47	1 OP	✓ Nutrison Advanced Peptisorb
-----------------------------	------	------	----------------------------------

Paediatric Products For Children With Low Energy Requirements

►SA1196 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1 Child aged one to eight years; and
- 2 The child has a low energy requirement but normal protein and micronutrient requirements.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 KCAL/ML – Special Authority see [SA1196 on the previous page](#) – Hospital pharmacy [HP3]

Liquid, 500 ml bottle	6.27	1 OP	✓ Nutrini Low Energy Multi Fibre
-----------------------------	------	------	-------------------------------------

Standard Supplements

►SA1859 Special Authority for Subsidy

Initial application — (Children - indications other than exclusive enteral nutrition for Crohn's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
 - 2.1 The patient has a condition causing malabsorption; or
 - 2.2 The patient has failure to thrive; or
 - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal — (Children - indications other than exclusive enteral nutrition for Crohn's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Children - exclusive enteral nutrition for Crohn's disease) only from a gastroenterologist or dietitian on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 Dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

Renewal — (Children - exclusive enteral nutrition for Crohn's disease) from any relevant practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 General Practitioners and dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (Adults) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1 Any of the following:

Patient is Malnourished

- 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m²; or
- 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
- 1.3 Patient has a BMI of less than 20 kg/m² and unintentional weight loss greater than 5% within the last 3-6 months; and

2 Any of the following:

Patient has not responded to first-line dietary measures over a 4 week period by:

- 2.1 Increasing their food intake frequency (eg snacks between meals); or
- 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
- 2.3 Using over the counter supplements (e.g. Complan); and

3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 A nutrition goal has been set (eg reach a specific weight or BMI); and

2 Any of the following:

Patient is Malnourished

- 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m²; or
- 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
- 2.3 Patient has a BMI of less than 20 kg/m² and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Short-term medical condition) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

1 Is being fed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or

2 Malignancy and is considered likely to develop malnutrition as a result; or

3 Is undergoing a bone marrow transplant; or

4 Tempomandibular surgery or glossectomy; or

5 Both:

5.1 Pregnant; and

5.2 Any of the following:

- 5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or
- 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
- 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Renewal — (Short-term medical condition) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

1 Is being fed via a nasogastric tube; or

2 Malignancy and is considered likely to develop malnutrition as a result; or

3 Has undergone a bone marrow transplant; or

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

4 Tempomandibular surgery or glossectomy; or

5 Both:

5.1 Pregnant; and

5.2 Any of the following:

5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or

5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or

5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Initial application — (Long-term medical condition) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or

2 Cystic Fibrosis; or

3 Liver disease; or

4 Chronic Renal failure; or

5 Inflammatory bowel disease; or

6 Chronic obstructive pulmonary disease with hypercapnia; or

7 Short bowel syndrome; or

8 Bowel fistula; or

9 Severe chronic neurological conditions; or

10 Epidermolysis bullosa; or

11 AIDS (CD4 count < 200 cells/mm³); or

12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or

2 Cystic Fibrosis; or

3 Liver disease; or

4 Chronic Renal failure; or

5 Inflammatory bowel disease; or

6 Chronic obstructive pulmonary disease with hypercapnia; or

7 Short bowel syndrome; or

8 Bowel fistula; or

9 Severe chronic neurological conditions.

ENTERAL FEED 1.5KCAL/ML – Special Authority see [SA1859 on page 296](#) – Hospital pharmacy [HP3]

Liquid, 1,000 ml bottle	8.68	1 OP	✓ Ensure Plus HN RTH
	9.00		✓ Nutrison Energy

ENTERAL FEED 1KCAL/ML – Special Authority see [SA1859 on page 296](#) – Hospital pharmacy [HP3]

Liquid, 1,000 ml bottle	6.56	1 OP	✓ Osmolite RTH
	6.90		✓ Nutrison RTH

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Special Authority see SA1859 on page 296 – Hospital pharmacy [HP3]			
Liquid, 1,000 ml bottle	9.05	1 OP	✓ Nutrison 800 Complete Multi Fibre
ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA1859 on page 296 – Hospital pharmacy [HP3]			
Liquid, 1,000 ml bottle	6.56 7.21	1 OP	✓ Jevity RTH Nutrison Multi Fibre
ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1859 on page 296 – Hospital pharmacy [HP3]			
Liquid, 1,000 ml bottle	8.68	1 OP	✓ Jevity HiCal RTH Nutrison Energy Multi Fibre
ORAL FEED (POWDER) – Special Authority see SA1859 on page 296 – Hospital pharmacy [HP3]			
Powder (chocolate).....	19.08	840 g OP	✓ Sustagen Hospital Formula
	40.00	800 g OP	✓ Ensure
		850 g OP	✓ Ensure
Powder (vanilla).....	19.08	840 g OP	✓ Sustagen Hospital Formula
	40.00	800 g OP	✓ Ensure
		850 g OP	✓ Ensure
ORAL FEED 1.5KCAL/ML – Special Authority see SA1859 on page 296 – Hospital pharmacy [HP3]			
Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, who have severe epidermolysis bullosa, or as exclusive enteral nutrition for the treatment of Crohn's disease, or for patients with COPD and hypercapnia, defined as CO ₂ value exceeding 55mmHg. The prescription must be endorsed accordingly.			
Liquid (banana), 200 ml bottle – Higher subsidy of up to \$1.76 per 1 btl with Endorsement.....	0.72 (1.56) (1.76)	1 OP	Ensure Plus Fortisip
Liquid (chocolate), 200 ml bottle – Higher subsidy of up to \$1.76 per 1 btl with Endorsement.....	0.72 (1.56) (1.76)	1 OP	Ensure Plus Fortisip
Liquid (fruit of the forest), 200 ml bottle – Higher subsidy of \$1.56 per 1 btl with Endorsement.....	0.72 (1.56)	1 OP	Ensure Plus
Liquid (strawberry), 200 ml bottle – Higher subsidy of \$1.76 per 1 btl with Endorsement.....	0.72 (1.76)	1 OP	Fortisip
Liquid (vanilla), 200 ml bottle – Higher subsidy of up to \$1.76 per 1 btl with Endorsement.....	0.72 (1.56) (1.76)	1 OP	Ensure Plus Fortisip

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA1859 on page 296 – Hospital pharmacy [HP3]				
Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.				
Liquid (chocolate), 200 ml bottle – Higher subsidy of \$1.76 per				
1 btl with Endorsement.....	0.72 (1.76)	1 OP		Fortisip Multi Fibre
Liquid (strawberry), 200 ml bottle – Higher subsidy of \$1.76 per				
1 btl with Endorsement.....	0.72 (1.76)	1 OP		Fortisip Multi Fibre
Liquid (vanilla), 200 ml bottle – Higher subsidy of \$1.76 per				
1 btl with Endorsement.....	0.72 (1.76)	1 OP		Fortisip Multi Fibre

High Calorie Products

►SA1195 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner.

Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 faltering growth in an infant/child; or
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
ENTERAL FEED 2 KCAL/ML – Special Authority see SA1195 on the previous page – Hospital pharmacy [HP3]			
Liquid, 1,000 ml bottle	13.64	1 OP	✓ Ensure Two Cal HN RTH
Liquid, 500 ml bottle	6.82	1 OP	✓ Nutrison Concentrated
ORAL FEED 2 KCAL/ML – Special Authority see SA1195 on the previous page – Hospital pharmacy [HP3]			
Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.			
Liquid (vanilla), 200 ml bottle – Higher subsidy of \$2.34 per			
1 btl with Endorsement	0.96 (2.34)	1 OP	Two Cal HN

Food Thickeners

►SA1106 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has motor neurone disease with swallowing disorder.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FOOD THICKENER – Special Authority see [SA1106 above](#) – Hospital pharmacy [HP3]

Powder	8.29	300 g OP	✓ Nutrilis
	24.00	380 g OP	✓ Aptamil Feed Thickener

Gluten Free Foods

The funding of gluten free foods is no longer being actively managed by Pharmac from 1 April 2011. This means that we are no longer considering the listing of new products, or making subsidy, or other changes to the existing listings. As a result we anticipate that the range of funded items will reduce over time. Management of Coeliac disease with a gluten free diet is necessary for good outcomes. A range of gluten free options are available through retail outlets.

►SA1729 Special Authority for Subsidy

Initial application — (all patients) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Gluten enteropathy has been diagnosed by biopsy; or
- 2 Patient suffers from dermatitis herpetiformis.

Initial application — (paediatric patients diagnosed by ESPGHAN criteria) only from a paediatric gastroenterologist. Approvals valid without further renewal unless notified where the paediatric patient fulfils ESPGHAN criteria for biopsy free diagnosis of coeliac disease.

GLUTEN FREE BAKING MIX – Special Authority see [SA1729 above](#) – Hospital pharmacy [HP3]

Powder	2.81 (5.15)	1,000 g OP	Healtheries Simple Baking Mix
--------------	----------------	------------	-------------------------------

SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
GLUTEN FREE BREAD MIX – Special Authority see SA1729 on the previous page – Hospital pharmacy [HP3]				
Powder	3.93 (7.32)	1,000 g OP		NZB Low Gluten Bread Mix
	3.51 (10.87)			Horleys Bread Mix
GLUTEN FREE FLOUR – Special Authority see SA1729 on the previous page – Hospital pharmacy [HP3]				
Powder	5.62 (18.10)	2,000 g OP		Horleys Flour

Foods And Supplements For Inherited Metabolic Disease

► [SA2357](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where patient requires dietary management of inherited metabolic disorders.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE – Special Authority see SA2357 above – Hospital pharmacy [HP3]				
Powder (neutral), 36 g sachets.....	750.30	30	✓	HCU Anamix Junior
Powder, 12.5 g sachets	349.65	30	✓	HCU Explore 5
Powder, 25 g sachets	1,048.95	30	✓	HCU Express 15
Powder (neutral), can	480.42	500 g OP	✓	XMET Maxamum
Powder (unflavoured), can	260.00	400 g OP	✓	HCU Anamix Infant
Liquid (juicy berries), 125 ml bottle.....	1,684.80	30	✓	HCU Lophlex LQ
Liquid (orange), 125 ml bottle.....	941.40	36	✓	HCU Anamix Junior LQ

Supplements For MSUD and short chain enoyl coA hydratase deficiency

AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE – Special Authority see SA2357 above – Hospital pharmacy [HP3]				
Powder (neutral) 36 g sachets.....	750.00	30	✓	MSUD Anamix Junior
Powder, 12.5 g sachets	349.65	30	✓	MSUD Explore 5
Powder, 25 g sachets	1,048.95	30	✓	MSUD Express 15
Powder (neutral), can	454.71	500 g OP	✓	MSUD Maxamum
Powder (orange), can	454.71	500 g OP	✓	MSUD Maxamum
Powder (unflavoured), can	260.00	400 g OP	✓	MSUD Anamix Infant
Liquid (orange) 125 ml bottles.....	941.40	36	✓	MSUD Anamix Junior LQ
Liquid (juicy berries) 125 ml pouches	1,684.80	30	✓	MSUD Lophlex LQ 20

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Supplements For PKU

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see [SA2357 on the previous page](#) – Hospital pharmacy [HP3]

Tabs.....	99.00	75 OP	✓ Phlexy 10
Powder (Lemon), 34 g sachets.....	883.50	30	✓ PKU Express 20
Powder (Neutral), 12.5 g sachets.....	220.88	30	✓ PKU Explore 5
Powder (Neutral), 34 g sachets.....	883.50	30	✓ PKU Express 20
Powder (Orange), 25 g sachets.....	441.75	30	✓ PKU Explore 10
Powder (Orange), 34 g sachets.....	883.50	30	✓ PKU Express 20
Powder (Raspberry), 25 g sachets.....	441.75	30	✓ PKU Explore 10
Powder (Tropical), 34 g sachets.....	883.50	30	✓ PKU Express 20
Powder (berry) 28 g sachets	936.00	30	✓ PKU Lophlex Powder
Powder (chocolate) 36 g sachet	393.00	30	✓ PKU Anamix Junior Chocolate
Powder (neutral) 28 g sachets.....	936.00	30	✓ PKU Lophlex Powder
Powder (neutral) 36 g sachets.....	393.00	30	✓ PKU Anamix Junior
Powder (orange) 28 g sachets	936.00	30	✓ PKU Lophlex Powder
Powder (orange) 36 g sachet	393.00	30	✓ PKU Anamix Junior Orange
Powder (unflavoured) 12.5 g sachets.....	234.00	30	✓ PKU First Spoon
Powder (vanilla) 36 g sachet	393.00	30	✓ PKU Anamix Junior Vanilla
Infant formula.....	174.72	400 g OP	✓ PKU Anamix Infant
Powder (neutral), 4 x 400 g can	715.16	1,600 g OP	✓ Pku Start
Powder (orange).....	320.00	500 g OP	✓ XP Maxamum
Powder (unflavoured)	320.00	500 g OP	✓ XP Maxamum
Liquid (berry), 125 ml bottle.....	13.10	1 OP	✓ PKU Anamix Junior LQ
Liquid (orange), 125 ml bottle.....	13.10	1 OP	✓ PKU Anamix Junior LQ
Liquid (forest berries), 250 ml carton.....	540.00	18 OP	✓ Easiphen Liquid
Liquid (juicy tropical) 125 ml.....	936.00	30 OP	✓ PKU Lophlex LQ 20
Oral semi-solid (berries) 109 g	1,123.20	36 OP	✓ PKU Lophlex Sensation 20
Liquid (juicy berries) 62.5 ml.....	939.00	60 OP	✓ PKU Lophlex LQ 10
Liquid (juicy berries) 125 ml.....	936.00	30 OP	✓ PKU Lophlex LQ 20
Liquid (juicy orange) 125 ml	936.00	30 OP	✓ PKU Lophlex LQ 20

SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE – Special Authority see SA2357 on page 302 – Hospital pharmacy [HP3]				
Powder (Banana) 35 g sachets	930.00	30	✓	PKU sphere20 Banana
Powder (Berry), 20 g sachets	449.28	60	✓	PKU Restore Powder
Powder (Chocolate) 32 g sachets	898.56	30	✓	PKU Build 20 Chocolate
Powder (Chocolate) 35 g sachets	930.00	30	✓	PKU sphere20 Chocolate
Powder (Lemon) 35 g sachets	930.00	30	✓	PKU sphere20 Lemon
Powder (Lemonade) 33.4 g sachets	936.00	30	✓	PKU GMP Ultra Lemonade
Powder (Neutral), 15 g sachets	449.28	30	✓	PKU Build 10
Powder (Orange), 20 g sachets	449.28	60	✓	PKU Restore Powder
Powder (Raspberry Lemonade) 31 g sachets	898.56	30	✓	PKU Build 20 Raspberry Lemonade
Powder (Smooth) 31 g sachets	898.56	30	✓	PKU Build 20 Smooth
Powder (Vanilla) 33 g sachets	898.56	30	✓	PKU Build 20 Vanilla
Powder (neutral), 40 g sachets	673.92	30	✓	Glytactin Bettermilk
Powder (unflavoured) 12.5 g sachets	468.00	30	✓	PKU GMP Mix-In
Powder (vanilla) 33.4 g sachets	936.00	30	✓	PKU GMP Ultra Vanilla
Powder (Red Berry) 35 g sachets	930.00	30	✓	PKU sphere20 Red Berry
Powder (Vanilla) 35 g sachets	930.00	30	✓	PKU sphere20 Vanilla
Liquid (neutral), 250 ml carton	280.80	18	✓	PKU GMP LQ
Liquid (original), 250 ml carton	684.45	30 OP	✓	PKU Glytactin RTD 15
Liquid (Coffee Mocha), 250 ml carton	684.45	30 OP	✓	PKU Glytactin RTD 15 Lite
Liquid (chocolate), 250 ml carton	684.45	30 OP	✓	PKU Glytactin RTD 15
Liquid (vanilla), 250 ml carton	684.45	30 OP	✓	PKU Glytactin RTD 15 Lite

Foods

LOW PROTEIN BAKING MIX – Special Authority see [SA2357](#) on [page 302](#) – Hospital pharmacy [HP3]

Powder	8.55	500 g OP	✓	Loprofin Mix
--------------	------	----------	---	--------------

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
LOW PROTEIN PASTA – Special Authority see SA2357 on page 302 – Hospital pharmacy [HP3]			
Animal shapes	12.39	500 g OP	✓ Loprofin
Lasagne	6.19	250 g OP	✓ Loprofin
Low protein rice pasta	12.39	500 g OP	✓ Loprofin
Macaroni	6.19	250 g OP	✓ Loprofin
Penne	12.39	500 g OP	✓ Loprofin
Spaghetti	12.39	500 g OP	✓ Loprofin
Spirals	12.39	500 g OP	✓ Loprofin

Supplements for Tyrosinaemia

AMINOACID FORMULA WITHOUT PHENYLALANINE AND TYROSINE – Special Authority see [SA2357 on page 302](#) – Hospital pharmacy [HP3]

Powder (Neutral), 12.5 g sachets	349.65	30	✓ TYR Explore 5
Powder (neutral) 36 g sachets	471.00	30	✓ TYR Anamix Junior
Powder, can	260.00	400 g OP	✓ TYR Anamix Infant
Liquid (juicy berries) 125 ml pouches	1,684.80	30	✓ TYR Lophlex LQ 20
Liquid (orange) 125 ml bottle	941.40	36	✓ TYR Anamix Junior LQ

GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME TYROSINE AND PHENYLALANINE – Special Authority see [SA2357 on page 302](#) – Hospital pharmacy [HP3]

Powder (Red Berry), 35 g sachets	1,398.60	30	✓ TYR Sphere 20
Powder (Vanilla), 35 g sachets	1,398.60	30	✓ TYR Sphere 20

Supplements for Organic Acidaemias

AMINOACID FORMULA WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE – Special Authority see [SA2357 on page 302](#) – Hospital pharmacy [HP3]

Powder, can	260.00	400 g OP	✓ MMA/PA Anamix Infant
-------------------	--------	----------	-------------------------------

AMINOACID FORMULA WITHOUT METHIONINE, THREONINE AND VALINE – Special Authority see [SA2357 on page 302](#) – Hospital pharmacy [HP3]

Powder (neutral), 18 g sachets	750.30	30	✓ MMA/PA Anamix Junior
Powder, 12.5 g sachets	349.65	30	✓ MMA/PA Explore 5
Powder, 25 g sachets	1,048.95	30	✓ MMA/PA Express 15

Supplements for Glutaric Aciduria type 1

AMINOACID FORMULA WITHOUT LYSINE – Special Authority see [SA2357 on page 302](#) – Hospital pharmacy [HP3]

Powder (neutral), 18 g sachets	750.30	30	✓ GA1 Anamix Junior
Powder, 12.5 g sachets	349.65	30	✓ GA Explore 5
Powder, can	260.00	400 g OP	✓ GA1 Anamix Infant

Supplements for Glycogen Storage Disease

HIGH AMYLOPECTIN CORN-STARCH – Special Authority see [SA2357 on page 302](#) – Hospital pharmacy [HP3]

Powder, 60 g sachets	241.62	30	✓ Glycosade
----------------------------	--------	----	--------------------

Single dose amino acids

ARGININE – Special Authority see [SA2357 on page 302](#) – Hospital pharmacy [HP3]

Powder, 4 g sachets	211.45	30	✓ Arginine2000
---------------------------	--------	----	-----------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CITRULLINE – Special Authority see SA2357 on page 302 – Hospital pharmacy [HP3]				
Powder, 4 g sachets.....	211.45	30	✓	Citrulline1000
ISOLEUCINE – Special Authority see SA2357 on page 302 – Hospital pharmacy [HP3]				
Powder, 4 g sachets.....	141.05	30	✓	Isoleucine50
LEUCINE – Special Authority see SA2357 on page 302 – Hospital pharmacy [HP3]				
Powder, 4 g sachets.....	141.05	30	✓	Leucine100
PHENYLALANINE – Special Authority see SA2357 on page 302 – Hospital pharmacy [HP3]				
Powder, 4 g sachets.....	141.05	30	✓	Phenylalanine50
TYROSINE – Special Authority see SA2357 on page 302 – Hospital pharmacy [HP3]				
Powder, 4 g sachets.....	211.45	30	✓	Tyrosine1000
VALINE – Special Authority see SA2357 on page 302 – Hospital pharmacy [HP3]				
Powder, 4 g sachets.....	141.05	30	✓	Valine50

Other Fat Modified Products

ELEMENTAL FEED WITH HIGH MEDIUM CHAIN TRIGLYCERIDES – Special Authority see SA2357 on page 302 – Hospital pharmacy [HP3]				
Powder (neutral), 100 g sachets.....	47.01	10	✓	Emsogen

Carbohydrate and Fat with added vitamins and minerals

PROTEIN FREE SUPPLEMENT CONTAINING CARBOHYDRATE, FAT WITH ADDED VITAMINS AND MINERALS – Special Authority see SA2357 on page 302 – Hospital pharmacy [HP3]				
Powder (neutral), can	49.29	400 g OP	✓	Energivit

Essential Amino Acids

ESSENTIAL AMINOACID FORMULA – Special Authority see SA2357 on page 302 – Hospital pharmacy [HP3]				
Powder (neutral), can	313.73	200 g OP	✓	Essential Amino Acid Mix

Infant Formulae

For Williams Syndrome

►SA1110 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

LOW CALCIUM INFANT FORMULA – Special Authority see SA1110 above – Hospital pharmacy [HP3]				
Powder	46.18	400 g OP	✓	Locasol

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
Gastrointestinal and Other Malabsorptive Problems			
AMINO ACID FORMULA – Special Authority see SA2092 below – Hospital pharmacy [HP3]			
Powder	46.65	400 g OP	✓ Alfamino
			✓ Alfamino Junior
Powder (unflavoured)	55.61	400 g OP	✓ Neocate Gold
			✓ Neocate Junior
			Unflavoured
	65.72		✓ Neocate SYNEO
			✓ Elecare
			✓ Elecare LCP
Powder (vanilla).....	55.61	400 g OP	✓ Neocate Junior
			Vanilla
	65.72		✓ Elecare

► **SA2092** Special Authority for Subsidy

Initial application — (Infants under 12 months of age) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 History of anaphylaxis to cow's milk protein formula or dairy products; or
- 2 Eosinophilic oesophagitis; or
- 3 Ultra-short gut; or
- 4 Severe Immune deficiency; or
- 5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or
- 6 Both:
 - 6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and
 - 6.2 Either:
 - 6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or
 - 6.2.2 Patient has IgE mediated allergy.

Initial application — (Children 12 months of age and over) only from a paediatrician, paediatric gastroenterologist, paediatric immunologist or dietitian on the recommendation of a paediatrician, paediatric gastroenterologist or paediatric immunologist.

Approvals valid for 6 months for applications meeting the following criteria:

- Both:
- 1 Either:
 - 1.1 Applicant is a paediatrician, paediatric gastroenterologist or paediatric immunologist; or
 - 1.2 Applicant is a dietitian and confirms that a paediatrician, paediatric gastroenterologist or paediatric immunologist has been consulted within the last 12 months and has recommended treatment for the patient; and
 - 2 Any of the following:
 - 2.1 History of anaphylaxis to cow's milk protein formula or dairy products; or
 - 2.2 Eosinophilic oesophagitis; or
 - 2.3 Ultra-short gut; or
 - 2.4 Severe Immune deficiency; or
 - 2.5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or
 - 2.6 Both:
 - 2.6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and
 - 2.6.2 Either:
 - 2.6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

number; or

2.6.2.2 Patient has IgE mediated allergy.

Renewal — (Infants up to 12 months of age) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 Patient has IgE mediated allergy; and

1.2 All of the following:

1.2.1 Patient remains allergic to cow's milk; and

1.2.2 An assessment as to whether the infant can be transitioned to a cow's milk protein, soy or extensively hydrolysed infant formula has been undertaken; and

1.2.3 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and

1.2.4 Amino acid formula is required for a nutritional deficit; and

1.2.5 It has been more than three months from the previous approval; or

2 Both:

2.1 Patient has non IgE mediated severe gastrointestinal intolerance (including eosinophilic oesophagitis, ultra-short gut and severe immune deficiency); and

2.2 All of the following:

2.2.1 An assessment as to whether the infant can be transitioned to a cow's milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and

2.2.2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and

2.2.3 Amino acid formula is required for a nutritional deficit; and

2.2.4 It has been more than three months from the previous approval.

Renewal — (Children 12 months of age and over) only from a paediatrician, paediatric gastroenterologist, paediatric immunologist or dietitian on the recommendation of a paediatrician, paediatric gastroenterologist or paediatric immunologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Either:

1.1 Applicant is a paediatrician, paediatric gastroenterologist or paediatric immunologist; or

1.2 Applicant is a dietitian and confirms that a paediatrician, paediatric gastroenterologist or paediatric immunologist has been consulted within the last 12 months and has recommended treatment for the patient; and

2 Any of the following:

2.1 History of anaphylaxis to cow's milk protein formula or dairy products; or

2.2 Eosinophilic oesophagitis; or

2.3 Ultra-short gut; or

2.4 Severe Immune deficiency; or

2.5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or

2.6 Both:

2.6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and

2.6.2 Either:

2.6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or

2.6.2.2 Patient has IgE mediated allergy.

Initial application — (for patients who have a current funding under Special Authority form SA1557) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

All of the following:

- 1 Patient has a valid Special Authority approval for extensively hydrolysed formula (SA1557); and
- 2 Extensively hydrolysed formula (Aptamil Gold+ Pepti Junior, AllerPro SYNEO 1 and 2) is unable to be supplied at this time; and
- 3 The approval only applies to funded dispensings of Neocate Gold and Neocate Syneo.

Note: This criteria is short term funding to cover an out-of-stock situation on some extensively hydrolysed formula powder funded under Special Authority form SA1557. There is no renewal criteria under this restriction.

ENTERAL LIQUID PEPTIDE FORMULA – Special Authority see [SA1953 below](#) – Hospital pharmacy [HP3]

Liquid 1 kcal/ml, 500 ml bottle	12.44	1 OP	✓ Nutrini Peptisorb
Liquid 1.5 kcal/ml, 500 ml bottle	18.66	1 OP	✓ Nutrini Peptisorb Energy

► [SA1953](#) Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable; and
- 2 Any of the following:
 - 2.1 Severe malabsorption; or
 - 2.2 Short bowel syndrome; or
 - 2.3 Intractable diarrhoea; or
 - 2.4 Biliary atresia; or
 - 2.5 Cholestatic liver diseases causing malabsorption; or
 - 2.6 Cystic fibrosis; or
 - 2.7 Proven fat malabsorption; or
 - 2.8 Severe intestinal motility disorders causing significant malabsorption; or
 - 2.9 Intestinal failure; or
 - 2.10 Both:
 - 2.10.1 The patient is currently receiving funded amino acid formula; and
 - 2.10.2 The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula; and
- 3 Either:
 - 3.1 A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable; or
 - 3.2 For step down from intravenous nutrition.

Note: A reasonable trial is defined as a 2-4 week trial.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken; and
- 2 The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula; and
- 3 General practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

EXTENSIVELY HYDROLYSED FORMULA – Special Authority see [SA1557 on the next page](#) – Hospital pharmacy [HP3]

Powder	18.10	450 g OP	✓ Pepti-Junior
	36.20	900 g OP	✓ Allerpro Syneo 1
			✓ Allerpro Syneo 2

►SA1557 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malabsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure; or
- 11 All of the following:
 - 11.1 For step down from Amino Acid Formula; and
 - 11.2 The infant is currently receiving funded amino acid formula; and
 - 11.3 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
 - 11.4 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Fluid Restricted

PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML – Special Authority see [SA1698 below](#) – Hospital pharmacy [HP3]

Liquid, 125 ml bottle2.80 1 OP ✓ **Infatrin**

►SA1698 Special Authority for Subsidy

Initial application only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is fluid restricted or volume intolerant and has been diagnosed with faltering growth; and
- 2 Patient is under the care of a paediatrician or dietitian who has recommended treatment with a high energy infant formula; and
- 3 Patient is under 18 months of age or weighs less than 8 kg.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Renewal only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient continues to be fluid restricted or volume intolerant and has faltering growth; and
- 2 Patient is under the care of a hospital paediatrician or dietitian who has recommended treatment with a high energy infant formula; and
- 3 Patient is under 18 months of age or weighs less than 8 kg.

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Ketogenic Diet

►SA1197 Special Authority for Subsidy

Initial application only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

Renewal only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is benefiting from the diet.

HIGH FAT LOW CARBOHYDRATE FORMULA – Special Authority see SA1197 above – Hospital pharmacy [HP3]

Powder (unflavoured)	36.92	300 g OP	✓ KetoCal 4:1
Powder (vanilla).....	36.92	300 g OP	✓ Ketocal 3:1
			✓ KetoCal 4:1

SECTION E: AMBULANCE LIST

Read the [Ambulance List](https://pharmac.govt.nz/section-e) : <https://pharmac.govt.nz/section-e>.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Vaccinations

BACILLUS CALMETTE-GUERIN VACCINE – [Xpharm]

For infants at increased risk of tuberculosis. Increased risk is defined as:

- 1) living in a house or family with a person with current or past history of TB; or
- 2) having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; or
- 3) during their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000

Note a list of countries with high rates of TB are available at www.health.govt.nz/tuberculosis (search for downloads) or www.bcgatlas.org/index.php.

Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin),

Danish strain 1331, live attenuated, vial with diluent..... 0.00 10 ✓ **BCG Vaccine AJV**

COVID-19 VACCINE – [Xpharm]

Inj 3 mcg SARS-CoV-2 spike protein (mRNA) LP.8.1 per 0.3 ml,

0.48 ml multi-dose vial; infant vaccine, yellow cap..... 0.00 10 ✓ **Comirnaty (LP.8.1)**

Any of the following:

- 1) Up to three doses for previously unvaccinated children aged 6 months - 4 years at high risk of severe illness or highly immunocompromised; or
- 2) One additional dose with the most current variant-matched vaccine every 6 months for highly immunocompromised children aged 6 months to 4 years; or
- 3) One additional dose with the most current variant-matched vaccine every 12 months for children aged 6 months to 4 years old at high risk of severe illness.

Inj 10 mcg SARS-CoV-2 spike protein (mRNA) LP.8.1 per

0.3 ml, 0.48 ml single-dose vial; paediatric vaccine, light

blue cap..... 0.00 10 ✓ **Comirnaty (LP.8.1)**

Any of the following:

- 1) One dose for previously unvaccinated children aged 5–11 years old; or
- 2) Up to three doses for immunocompromised children aged 5–11 years old; or
- 3) One additional dose with the most current variant-matched vaccine every 6 months for highly immunocompromised children aged 5 to 11 years; or
- 4) One additional dose with the most current variant-matched vaccine up to every 12 months for children aged 5 to 11 years old at high risk of severe illness.

Inj 30 mcg SARS-CoV-2 spike protein (mRNA) LP.8.1 per

0.3 ml, pre-filled syringe; adult dose..... 0.00

10 ✓ **Comirnaty (LP.8.1)**

Any of the following:

- 1) One dose for previously unvaccinated people aged 12–15 years and over 30 years old; or
- 2) Two doses for previously unvaccinated people aged 16–29 years old; or
- 3) Up to three doses for previously unvaccinated immunocompromised people from 12 years old; or
- 4) Up to four doses for people at risk of severe illness aged from 12–29 years; or
- 5) One additional dose with the most current variant-matched vaccine every 6 months, any of the following criteria:
 - i) Previously vaccinated people aged 30 years and over; or
 - ii) Previously vaccinated immunocompromised people from 12 years; or
 - iii) Previously vaccinated people at high-risk from 12 years.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE				
a) Only on a prescription				
b) No patient co-payment payable				
c)				
A) Funded for any of the following criteria:				
1) A single dose for pregnant women in the second or third trimester of each pregnancy; or				
2) A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or				
3) A course of up to four doses is funded for children from age 7 up to the age of 18 years inclusive to complete full primary immunisation; or				
4) An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or				
5) A single dose for vaccination of patients aged from 65 years old; or				
6) A single dose for vaccination of patients aged from 45 years old who have not had 4 previous tetanus doses; or				
7) For vaccination of previously unimmunised or partially immunised patients; or				
8) For revaccination following immunosuppression; or				
9) For boosting of patients with tetanus-prone wounds.				
Notes: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.				
B) Contractors will be entitled to claim payment from the Funder for the supply of diphtheria, tetanus and pertussis vaccine to patients eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the diphtheria, tetanus and pertussis vaccine listed in the Pharmaceutical Schedule.				
C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs 1 – 9 above.				
Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml prefilled syringe	0.00	10	✓	<u>Boostrix</u>

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- c)
 - A) Funded for any of the following:
 - 1) A single dose for children up to the age of 7 who have completed primary immunisation; or
 - 2) A course of four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
 - 3) An additional four doses (as appropriate) are funded for (re-)immunisation for people post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
 - 4) Five doses will be funded for children requiring solid organ transplantation.
 - B) Contractors will be entitled to claim payment from the Funder for the supply of Diphtheria, tetanus, pertussis and polio vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Diphtheria, tetanus, pertussis and polio vaccine listed in the Pharmaceutical Schedule.
 - C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5ml syringe	0.00	10	✓ Infanrix IPV
---	------	----	-----------------------

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- c)
 - A) Funded for children meeting any of the following criteria
 - 1) Up to four doses for children under the age of 10 years for primary immunisation; or
 - 2) An additional four doses (as appropriate) for (re-)immunisation of children under the age of 18 years post haematopoietic stem cell transplantation; or
 - 3) An additional four doses (as appropriate) for (re-)immunisation of children under the age of 10 years who are post chemotherapy; pre or post splenectomy; undergoing renal dialysis and other severely immunosuppressive regimens; or
 - 4) Up to five doses for children under the age of 10 years receiving solid organ transplantation.
 - B) Contractors will be entitled to claim payment from the Funder for the supply of Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type b vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type b vaccine listed in the Pharmaceutical Schedule.
 - C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Inj 30IU diphtheria with 40IU tetanus and 25mcg pertussis toxoids, 25mcg pertussis filamentous haemagglutinin, 8mcg pertactin, 80D-AgU polio virus, 10mcg hepatitis B antigen, 10mcg H. influenzae type b with tetanus toxoid 20-40mcg in 0.5ml syringe	0.00	10	✓ Infanrix-hexa
--	------	----	------------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
HAEMOPHILUS INFLUENZAE TYPE B VACCINE				
a) Only on a prescription b) No patient co-payment payable c) A) One dose for people meeting any of the following: 1) For primary vaccination in children; or 2) An additional dose (as appropriate) is funded for (re-)immunisation for people post chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or 3) An additional 3 doses (as appropriate) funded for (re-)immunisation for people post haematopoietic stem cell transplantation; or 4) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician. B) Contractors will be entitled to claim payment from the Funder for the supply of Haemophilus influenzae type b vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Haemophilus influenzae type b vaccine listed in the Pharmaceutical Schedule. C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.				
Inj 10 mcg vial with diluent syringe	0.00	1	✓	Act-HIB
HEPATITIS A VACCINE – [Xpharm]				
Funded for patients meeting any of the following criteria:				
1) Two vaccinations for use in transplant patients; or 2) Two vaccinations for use in children with chronic liver disease; or 3) One dose of vaccine for close contacts of known hepatitis A cases.				
Inj 1440 ELISA units in 1 ml syringe	0.00	1	✓	Havrix 1440
Inj 720 ELISA units in 0.5 ml syringe	0.00	1	✓	Havrix Junior

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
HEPATITIS B RECOMBINANT VACCINE – [Xpharm]				
Inj 10 mcg per 0.5 ml prefilled syringe.....	0.00	1	✓	<u>Engerix-B</u>
Funded for patients meeting any of the following criteria:				
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or 2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or 3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or 4) for HIV positive patients; or 5) for hepatitis C positive patients; or 6) for patients following non-consensual sexual intercourse; or 7) for patients prior to planned immunosuppression for greater than 28 days; or 8) for patients following immunosuppression; or 9) for solid organ transplant patients; or 10) for post-haematopoietic stem cell transplant (HSCT) patients; or 11) following needle stick injury.				
Inj 20 mcg per 1 ml prefilled syringe.....	0.00	1	✓	<u>Engerix-B</u>
Funded for patients meeting any of the following criteria:				
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or 2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or 3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or 4) for HIV positive patients; or 5) for hepatitis C positive patients; or 6) for patients following non-consensual sexual intercourse; or 7) for patients prior to planned immunosuppression for greater than 28 days; or 8) for patients following immunosuppression; or 9) for solid organ transplant patients; or 10) for post-haematopoietic stem cell transplant (HSCT) patients; or 11) following needle stick injury; or 12) for chronic kidney disease (CKD) stage 4 or 5 patients; or 13) for liver or kidney transplant patients.				

NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV]				
a) Maximum of 1 inj per prescription b) Only on a prescription c) No patient co-payment payable d) a) A) Any of the following: 1) Maximum of two doses for children aged 14 years and under; or 2) Maximum of three doses for people meeting any of the following criteria: 1) People aged 15 to 26 years inclusive; or 2) Either: - People aged 9 to 26 years inclusive who have 1) Confirmed HIV infection; or 2) Received a transplant (including stem cell): or 3) Maximum of four doses for people aged 9 to 26 years inclusive post chemotherapy B) Contractors will be entitled to claim payment from the Funder for the supply of Human papillomavirus vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Human papillomavirus vaccine listed in the Pharmaceutical Schedule. C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A above.				
Inj 270 mcg in 0.5 ml syringe.....	0.00	10	✓	<u>Gardasil 9</u>

	Subsidy (Manufacturer's Price) \$	Fully Subsidised ✓ Per	Brand or Generic Manufacturer
INFLUENZA VACCINE			
Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine).....	120.00	10	✓ Influvac Tetra (2026 formulation)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
a) Maximum of 1 inj per prescription				
b) Only on a prescription				
c) No patient co-payment payable				
d)				
A) INFLUENZA VACCINE				
is available each year for patients who meet the following criteria, as set by Pharmac:				
a) all people 65 years of age and over; or				
b) people under 65 years of age who:				
i) have any of the following cardiovascular diseases:				
a) ischaemic heart disease, or				
b) congestive heart failure, or				
c) rheumatic heart disease, or				
d) congenital heart disease, or				
e) cerebo-vascular disease; or				
ii) have either of the following chronic respiratory diseases:				
a) asthma, if on a regular preventative therapy, or				
b) other chronic respiratory disease with impaired lung function; or				
iii) have diabetes; or				
iv) have chronic renal disease; or				
v) have any cancer, excluding basal and squamous skin cancers if not invasive; or				
vi) have any of the following other conditions:				
a) autoimmune disease, or				
b) immune suppression or immune deficiency, or				
c) HIV, or				
d) transplant recipients, or				
e) neuromuscular and CNS diseases/disorders, or				
f) haemoglobinopathies, or				
g) are children on long term aspirin, or				
h) have a cochlear implant, or				
i) errors of metabolism at risk of major metabolic decompensation, or				
j) pre and post splenectomy, or				
k) Down syndrome, or				
vii) are pregnant; or				
c) children 4 years of age and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or				
d) people under 65 years of age who:				
i) have any of the following serious mental health conditions:				
a) schizophrenia, or				
b) major depressive disorder, or				
c) bipolar disorder, or				
d) schizoaffective disorder, or				
ii) are currently accessing secondary or tertiary mental health and addiction services; or				
Unless meeting the criteria set out above, the following conditions are excluded from funding:				
a) asthma not requiring regular preventative therapy,				
b) hypertension and/or dyslipidaemia without evidence of end-organ disease.				
B) Contractors will be entitled to claim payment for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with Health NZ for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.				
C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
MEASLES, MUMPS AND RUBELLA VACCINE			
a) Only on a prescription			
b) No patient co-payment payable			
c)			
A) Measles, mumps and rubella vaccine			
A maximum of two doses for any patient meeting the following criteria:			
1) For primary vaccination in children; or			
2) For revaccination following immunosuppression; or			
3) For any individual susceptible to measles, mumps or rubella; or			
4) A maximum of three doses for children who have had their first dose prior to 12 months.			
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes. Although a price is listed for the vaccine, doctors can still order measles mumps and rubella vaccine free of charge, as with other Schedule vaccines.			
B) Contractors will be entitled to claim payment for the supply of measles, mumps and rubella vaccine to patients eligible under the above criteria pursuant to their contract with Health NZ for subsidised immunisation, and they may only do so in respect of the measles, mumps and rubella vaccine listed in the Pharmaceutical Schedule.			
C) Contractors can only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.			
Inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml	0.00	10	✓ Priorix

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MENINGOCOCCAL (GROUPS A, C, Y AND W-135) CONJUGATE VACCINE				
Inj 10 mcg of each meningococcal polysaccharide conjugated to a total of approximately 55 mcg of tetanus toxoid carrier per 0.5 ml vial	0.00	1	✓	MenQuadfi
a) Only on a prescription b) No patient co-payment payable c)				
A) Any of the following: - Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or - One dose for close contacts of meningococcal cases of any group; or - One dose for person who has previously had meningococcal disease of any group; or - A maximum of two doses for bone marrow transplant patients; or - A maximum of two doses for person pre- and post-immunosuppression*;				
B) Both: - Person is aged between 13 and 25 years, inclusive; and - Either: - One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, Youth Justice residences, or prisons; or - One dose for individuals who turn 13 years of age while living in boarding school hostels.				
C) Contractors will be entitled to claim payment from the Funder for the supply of Meningococcal A, C, Y and W-135 vaccine to patients eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Meningococcal A, C, Y and W-135 vaccine listed in the Pharmaceutical Schedule.				
D) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A-B above.				
Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly. *Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.				
Inj 5 mcg of each meningococcal polysaccharide conjugated to a total of approximately 44 mcg of tetanus toxoid carrier per 0.5 ml vial – [Xpharm].....	0.00	1	✓	Nimenrix
A) Both: - The child is under 12 months of age; and - Any of the following: - A maximum of three doses (dependant on age at first dose) for patients pre- and post- splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post- solid organ transplant; or - A maximum of three doses (dependant on age at first dose) for close contacts of meningococcal cases of any group; or - A maximum of three doses (dependant on age at first dose) for child who has previously had meningococcal disease of any group; or - A maximum of three doses (dependant on age at first dose) for bone marrow transplant patients; or - A maximum of three doses (dependant on age at first dose) for child pre- and post-immunosuppression*.				
Note: infants from 6 weeks to less than 6 months of age require a 2+1 schedule, infants from 6 months to less than 12 months of age require a 1+1 schedule. Refer to the Immunisation Handbook for recommended booster schedules with meningococcal ACWY vaccine. *Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
MENINGOCOCCAL B MULTICOMPONENT VACCINE			
a) Only on a prescription b) No patient co-payment payable c) Any of the following: A) A primary course of up to three doses for children up to the age of 59 months inclusive; or B) Both: 1) Person is 5 years of age or over; and 2) Any of the following: i) up to two doses and a booster every five years for patients pre- and post-splenectomy; or ii) up to two doses and a booster every five years for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited); or iii) up to two doses and a booster every five years pre- or post-solid organ transplant; or iv) up to two doses for close contacts of meningococcal cases of any group; or v) up to two doses for person who has previously had meningococcal disease of any group; or vi) up to two doses for bone marrow transplant patients; or vii) up to two doses for person pre- and post-immunosuppression*; or C) Both: 1) Person is aged between 13 and 25 years (inclusive); and 2) Either: i) Two doses for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, Youth Justice residences or prison; or ii) Two doses for individuals who turn 13 years of age while living in boarding school hostels. D) Contractors will be entitled to claim payment from the Funder for the supply of Meningococcal B multicomponent vaccine to patients eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Meningococcal B multicomponent vaccine listed in the Pharmaceutical Schedule. E) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A-C above. *Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.			
Inj 175 mcg per 0.5 ml prefilled syringe.....	0.00	1 10	✓ Bexsero ✓ Bexsero

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE				
a) Only on a prescription				
b) No patient co-payment payable				
c)				
A) Any of the following:				
1) A course of three doses for previously unvaccinated children up to the age of 59 months inclusive; or				
2) Two doses are funded for high risk individuals (over the age of 12 months and under 18 years) who have previously received two doses of the primary course of PCV10; or				
3) Up to an additional four doses (as appropriate) are funded for the (re)immunisation of high risk children aged under 5 years with any of the following:				
a) on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or				
b) primary immune deficiencies; or				
c) HIV infection; or				
d) renal failure, or nephrotic syndrome; or				
e) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or				
f) cochlear implants or intracranial shunts; or				
g) cerebrospinal fluid leaks; or				
h) receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or				
i) chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or				
j) pre term infants, born before 28 weeks gestation; or				
k) cardiac disease, with cyanosis or failure; or				
l) diabetes; or				
m) Down syndrome; or				
n) who are pre-or post-splenectomy, or with functional asplenia; or				
4) Up to an additional four doses (as appropriate) are funded for the (re-)immunisation of individuals 5 years and over with HIV, pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, intracranial shunts, cerebrospinal fluid leaks or primary immunodeficiency; or				
5) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.				
B) Contractors will be entitled to claim payment from the Funder for the supply of Pneumococcal (PCV13) conjugate vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Pneumococcal (PCV13) conjugate vaccine listed in the Pharmaceutical Schedule.				
C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.				
Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes				
Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5ml				
syringe	0.00	10	✓	Prevenar 13
		1	✓	Prevenar 13

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – [Xpharm]

Any of the following:

- 1) Up to three doses (as appropriate) for patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or
- 2) All of the following:
 - a) Patient is a child under 18 years for (re-)immunisation; and
 - b) Treatment is for a maximum of two doses; and
 - c) Any of the following:
 - i) on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
 - ii) with primary immune deficiencies; or
 - iii) with HIV infection; or
 - iv) with renal failure, or nephrotic syndrome; or
 - v) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
 - vi) with cochlear implants or intracranial shunts; or
 - vii) with cerebrospinal fluid leaks; or
 - viii) receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
 - ix) with chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
 - x) pre term infants, born before 28 weeks gestation; or
 - xi) with cardiac disease, with cyanosis or failure; or
 - xii) with diabetes; or
 - xiii) with Down syndrome; or
 - xiv) who are pre-or post-splenectomy, or with functional asplenia; or
- 3) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician

Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each

23 pneumococcal serotype) 0.00

1

✓ **Pneumovax 23**

POLIOMYELITIS VACCINE – [Xpharm]

Up to three doses for patients meeting either of the following:

- 1) For partially vaccinated or previously unvaccinated individuals; or
- 2) For revaccination following immunosuppression.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch-up programmes.

Inj 80D antigen units in 0.5 ml syringe..... 0.00

1

✓ **IPOL**

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ROTAVIRUS ORAL VACCINE				
a) Only on a prescription				
b) No patient co-payment payable				
c)				
A) Maximum of two doses for people meeting the following:				
1) first dose to be administered in infants aged under 14 weeks of age; and				
2) no vaccination being administered to children aged 24 weeks or over.				
B) Contractors will be entitled to claim payment from the Funder for the supply of Rotavirus oral vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Rotavirus oral vaccine listed in the Pharmaceutical Schedule.				
C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.				
Oral susp live attenuated human rotavirus				
1,000,000 CCID50 per dose, squeezable tube (PVC free)	0.00	10	✓	Rotarix
Oral susp live attenuated human rotavirus				
1,000,000 CCID50 per dose, prefilled oral applicator.....	0.00	10	✓	Rotarix

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
VARICELLA VACCINE [CHICKENPOX VACCINE]			
a) Only on a prescription b) No patient co-payment payable c)			
A) Either: 1) Maximum of one dose for primary vaccination for either: a) Any infant born on or after 1 April 2016; or b) For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox), or 2) Maximum of two doses for any of the following: a) Any of the following for non-immune individuals: i) with chronic liver disease who may in future be candidates for transplantation; or ii) with deteriorating renal function before transplantation; or iii) prior to solid organ transplant; or iv) prior to any elective immunosuppression*; or v) for post exposure prophylaxis who are immune competent inpatients; or b) For individuals at least 2 years after bone marrow transplantation, on advice of their specialist; or c) For individuals at least 6 months after completion of chemotherapy, on advice of their specialist; or d) For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or e) For individuals with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or f) For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or g) For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.			
B) Contractors will be entitled to claim payment from the Funder for the supply of Varicella vaccine [Chickenpox vaccine] vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Varicella vaccine [Chickenpox vaccine] listed in the Pharmaceutical Schedule.			
C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A above.			
* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days			
Inj 2000 PFU prefilled syringe plus vial	0.00	10	✓ Varilrix

NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
VARICELLA ZOSTER VACCINE [SHINGLES VACCINE]				
a) Only on a prescription				
b) No patient co-payment payable				
c)				
A) Funded for patients meeting the following criteria:				
1) Either:				
1) Two doses for all people aged 65 years, or				
2) Two doses for people 18 years of age or older with any of the following:				
a) pre- and post-haematopoietic stem cell transplant or cellular therapy; or				
b) pre- or post-solid organ transplant; or				
c) haematological malignancies; or				
d) people living with poorly controlled HIV infection; or				
e) planned or receiving disease modifying anti-rheumatic drugs (DMARDs – targeted synthetic, biologic, or conventional synthetic) for polymyalgia rheumatica, systemic lupus erythematosus or rheumatoid arthritis; or				
f) end stage kidney disease (CKD 4 or 5); or				
g) primary immunodeficiency				
B) Contractors will be entitled to claim payment from the Funder for the supply of Varicella zoster vaccine (Shingles vaccine) to patients eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Varicella zoster vaccine [Shingles vaccine] listed in the Pharmaceutical Schedule.				
C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.				
Inj 50 mcg per 0.5 ml vial plus vial.....	0.00	1 10	✓ ✓	Shingrix Shingrix

Diagnostic Agents

TUBERCULIN PPD [MANTOUX] TEST – [Xpharm]				
Inj 5 TU per 0.1 ml, 1 ml vial.....	0.00	1	✓	<u>Tubersol</u>

- Symbols -		
3TC.....	116	
- A -		
A-Scabies.....	75	
Abacavir sulphate.....	116	
Abacavir sulphate with lamivudine.....	116	
Abacavir/Lamivudine Viatris.....	116	
Abilify Maintena.....	142	
Abiraterone acetate.....	183	
Acarbose.....	12	
Accarb.....	12	
Acetazolamide.....	282	
Acetic acid with hydroxyquinoline and ricinoleic acid.....	82	
Acetylcysteine.....	285	
Aci-Jel.....	82	
Aciclovir.....		
Infection.....	109	
Sensory.....	280	
Acidex.....	6	
Acipimox.....	55	
Acitretin.....	75	
Act-HIB.....	316	
Actemra.....	240	
Actinomycin D.....	163	
Actrapid.....	11	
Actrapid Penfill.....	11	
Acupan.....	129	
Adalimumab (Amgevita).....	191	
Adalimumab (Humira - Alternative brand).....	200	
Adapalene.....	69	
Adcetris.....	209	
ADR Cartridge 1.8.....	21	
Adrenaline.....		
Cardiovascular.....	57	
Respiratory.....	268	
Adriamycin.....	163	
Advantan.....	72	
Advate.....	39	
Adynovate.....	39	
Afinitor.....	262	
Aflibercept.....	206	
AFT-Pyrazinamide.....	108	
Agents Affecting the Renin-Angiotensin System.....	47	
Agents for Parkinsonism and Related Disorders.....	126	
Agents Used in the Treatment of Poisonings.....	285	
Agrylin.....	163	
Albalon.....	284	
Albendazole.....	96	
Albey.....	269	
Albustix.....	84	
Alchemy Oxaliplatin.....	160	
Alchemy Oxybutynin.....	83	
Aldara.....	78	
Aldurazyme.....	27	
Alecensa.....	171	
Alectinib.....	171	
Alendronate sodium.....	122	
Alendronate sodium with colecalciferol.....	122	
Alfacalcidol.....	32	
Alfamino.....	307	
Alfamino Junior.....	307	
Alginic acid.....	6	
Alglucosidase alfa.....	25	
Alkeran.....	160	
Allegron.....	133	
Allerfix.....	282	
Allergoval.....	8	
Allerpro Syneo 1.....	309	
Allerpro Syneo 2.....	309	
Allersoothe.....	269	
Allmercap.....	162	
Allopurinol.....	124	
Almarytm.....	50	
Alpha-Adrenoceptor Blockers.....	47	
Alpha-Keri Lotion.....	74	
Alphamox 125.....	99	
Alphamox 250.....	99	
Alprolix.....	37	
Alu-Tab.....	6	
Aluminium hydroxide.....	6	
Alyftrek.....	277	
Amantadine hydrochloride.....	126	
Ambrisentan.....	58	
Ambrisentan Viatris.....	58	
Amdipharm.....	98	
Amgevita.....	191	
Amiloride hydrochloride.....	53	
Amiloride hydrochloride with furosemide.....	53	
Amiloride hydrochloride with hydrochlorothiazide.....	53	
Aminophylline.....	276	
Amiodarone hydrochloride.....	49	
Amisulpride.....	139	
Amitriptyline.....	133	
Amlodipine.....	52	
Amorolfine.....	70	
Amoxicillin.....	99	
Amoxicillin with clavulanic acid.....	99	
Amoxiclav Devatis Forte.....	99	
Amoxycillin Sandoz.....	99	
Amphotericin B.....	31	
Amsacrine.....	162	
AmsaLyo.....	162	
Amsidine.....	162	
Amzoate.....	29	
Anaesthetics.....	127	
Anagrelide hydrochloride.....	163	
Analgescics.....	128	
Anastrozole.....	186	
Anatrole.....	186	
Anoro Ellipta.....	273	
Antabuse.....	156	
Antacids and Antiflatulents.....	6	
Anthelmintics.....	96	
Antiacne Preparations.....	69	
Antiallergy Preparations.....	268	
Antianaemics.....	36	
Antiandrogen Oral Contraceptives.....	82	
Antiarrhythmics.....	49	
Antibacterials.....	96	
Antibacterials Topical.....	70	
Anticholinergic Agents.....	272	
Anticholinesterases.....	121	
Antidepressants.....	133	
Antidiarrhoeals.....	6	
Antiepilepsy Drugs.....	134	
Antifibrinolytics, Haemostatics and Local Sclerosants.....	37	
Antifibrotics.....	274	
Antifungals.....	103	
Antifungals Topical.....	70	
Antihistamines.....	269	
Antihypotensives.....	50	
Antimalarials.....	106	
Antimigraine Preparations.....	138	
Antinausea and Vertigo Agents.....	138	
Antipruritic Preparations.....	71	
Antipsychotics.....	139	
Antiretrovirals.....	114	
Antirheumatoid Agents.....	122	
Antispasmodics and Other Agents Altering Gut Motility.....	9	
Antithrombotic Agents.....	40	
Antithymocyte globulin (equine).....	191	
Antitrichomonal Agents.....	107	
Antituberculosics and Antileprotics.....	107	
Antulcerants.....	9	
Antivirals.....	109	
Anxiolytics.....	144	
Anzatax.....	167	
Apidra.....	12	

Apidra SoloStar	12	Atenolol Viatris.....	50	Benzetacil	99
APO Clomipramine.....	133	Atezolizumab.....	250	Benztrop	126
APO-Atomoxetine.....	150	ATGAM.....	191	Benzydamine hydrochloride	31
Apo-Azithromycin	97	Ativan.....	145	Benzylpenicillin sodium [Penicillin G].....	99
Apo-Candesartan	48	Atnahs Olsalazine.....	8	Besponsa.....	220
APO-Candesartan HCTZ 16/12.5.....	48	Atomoxetine.....	150	Beta Cream	72
APO-Candesartan HCTZ 32/12.5.....	48	Atorvastatin.....	55	Beta Ointment.....	72
APO-Olanzapine.....	141	Atropine sulphate Cardiovascular	49	Beta Scalp	77
Apo-Temozolomide	168	Sensory.....	283	Beta-Adrenoceptor Agonists.....	271
APO-Ursodeoxycholic Acid	23	Atropt	283	Beta-Adrenoceptor Blockers.....	50
Apomorphine hydrochloride.....	126	Atrovent	272	Beta-hCG low sensitivity urine test kit.....	82
Apreritant	138	Augmentin	99	Betadine	74
Apresoline.....	57	Aurobindo Tamsulosin.....	83	Betadine Skin Prep	74
Aptamil Feed Thickener.....	301	Aurorix	134	Betaferon	146
Aqueous cream	73	AutoSoft 30.....	20	Betahistine dihydrochloride	138
Aratac	49	AutoSoft 90.....	21	Betaine	26
Arava	122	Avelox	101	Betamethasone dipropionate.....	72
Arginine	26	Avonex.....	146	Betamethasone dipropionate with calcipotriol.....	76
Arginine2000	305	Axitinib	172	Betamethasone sodium phosphate with betamethasone acetate.....	86
Aripiprazole.....	140, 142	Azacitidine	160	Betamethasone valerate.....	72, 77
Aripiprazole Sandoz	140	Azacitidine Dr Reddy's	160	Betamethasone valerate with sodium fusidate [fusidic acid]	73
Aristocort	72	Azacinun	186	Betnovate	72
Arrotex-Prazosin S29	47	Azathioprine.....	186	Bevacizumab	208
Arrow - Clopid.....	40	Azilect	126	Bexsero	323
Arrow - Lattim	283	Azithromycin	97	Bezafibrate	55
Arrow-Amritriptyline	133	Azopt	282	Bezalip	55
Arrow-Bendrofluazide	54	- B -		Bezalip Retard.....	55
Arrow-Brimonidine.....	282	B-D Micro-Fine	16	Bicalutamide	183
Arrow-Diazepam.....	145	B-D Ultra Fine.....	16	Bicillin LA.....	99
Arrow-Doxorubicin	163	B-D Ultra Fine II.....	16	BiCNU.....	159
Arrow-Fluoxetine	134	Bacillus Calmette-Guerin (BCG) vaccine	191	Bile and Liver Therapy.....	10
Arrow-Norfloxacin.....	120	Bacillus Calmette-Guerin vaccine	313	Bimatoprost	282
Arrow-Ornidazole.....	107	Baclofen.....	125	Binarex	183
Arrow-Quinapril 10.....	47	Bactroban	70	Binocrit.....	36
Arrow-Quinapril 20.....	47	Balance	28	Biocon	51
Arrow-Quinapril 5.....	47	Barrier Creams and Emollients.....	73	Biodone	131
Arrow-Roxithromycin	98	Bayshore	106	Biodone Extra Forte.....	131
Arrow-Timolol	282	BCG Vaccine AJV	313	Biodone Forte.....	131
Arrow-Topiramate.....	137	Beclazone 100.....	270	Bisacodyl	25
Arrow-Tramadol.....	133	Beclazone 250.....	270	Bisacodyl-AFT	25
Arsenic trioxide	163	Beclazone 50.....	270	Bisoprolol fumarate.....	50
Asacol.....	8	Beclomethasone dipropionate.....	270	BK Lotion	74
Asacol S29	8	Bedaquiline.....	107	Bleomycin sulphate	163
Ascend-Cefuroxime	97	Bee venom allergy treatment.....	269	Blood Colony-stimulating Factors.....	43
Ascorbic acid	32	Bendamustine hydrochloride	158	Blood glucose diagnostic test meter	15
Aspen Adrenaline	57	Bendamustine Sandoz	158	Blood glucose diagnostic test strip.....	15
Aspirin		Bendrofluazide.....	54	Blood glucose test strips (visually impaired).....	15
Blood.....	40	Bendroflumethiazide [Bendrofluazide].....	54		
Nervous.....	128	Benralizumab.....	207		
Asthalin.....	272	Benzathine benzylpenicillin	99		
Atazanavir sulphate	117	Benzatropine mesylate.....	126		
Atazanavir Viatris.....	117	Benzbromarone	124		
Atenolol.....	50				
Atenolol AFT.....	50				

Blood Ketone Diagnostic Test Strip.....	14	Camber.....	57	Cetomacrogol with glycerol.....	73
Boostrix.....	314	Candesartan cilexetil.....	48	Cetomacrogol-AFT.....	73
Bortezomib.....	163	Candesartan cilexetil with hydrochlorothiazide.....	48	Cetuximab.....	211
Bortezomib Eugia.....	163	Candesartan Mylan.....	48	Charcoal.....	285
Bosentan.....	60	Candesartan Sandoz S29 AU.....	48	CheckTop.....	82
Bosentan Dr Reddy's.....	60	Candesartan Viatris.....	48	Chemotherapeutic Agents.....	158
Bplex.....	32	Candesartan Viatris Sante.....	48	Chickenpox vaccine.....	327
Brentuximab Vedotin.....	209	Candestar.....	48	Chlorafast.....	280
Breo Ellipta.....	271	Canesten.....	71	Chlorambucil.....	159
Brevinor 1/28.....	81	Capecitabine.....	161	Chloramphenicol.....	280
Breztri Aerosphere.....	273	Capecitabine Viatris.....	161	Chlorothiazide.....	54
Bricanyl Turbuhaler.....	272	Capsaicin.....		Chlorpromazine hydrochloride.....	140
Brimonidine tartrate.....	282	Musculoskeletal.....	122	Chlortalidone [Chlorthalidone].....	54
Brimonidine tartrate with timolol maleate.....	283	Nervous.....	128	Chlorthalidone.....	54
Brinzolamide.....	282	Captopril.....	47	Chlorvescent.....	45
BSF AutoSoft 90.....	285	Carafate.....	10	Choice 380 7med Nsha Silver/copper Short.....	81
Budesonide.....		Carbaccord.....	159	Ciclosporin.....	262
Alimentary.....	6	Carbamazepine.....	135	Cidomycin P/Free.....	101
Respiratory.....	270, 278	Carbimazole.....	89	Cilicaine VK.....	100
Budesonide Te Arai.....	6	Carboplatin.....	159	Cinacalcet.....	85
Budesonide with eformoterol.....	271	Carboplatin Accord.....	159	Cinacalcet Devatis.....	85
Budesonide with glycopyrronium and eformoterol.....	273	Carbosorb-X.....	285	Cipla.....	272
Bumetanide.....	53	Cardinol LA.....	51	Ciprofloxacin.....	
Buprenorphine Naloxone BNM.....	155	Cardizem CD.....	52	Infection.....	101
Buprenorphine with naloxone.....	155	CareSens Dual.....	14	Sensory.....	280
Bupropion hydrochloride.....	155	CareSens N.....	15	Ciprofloxacin Teva.....	280
Burel.....	104	CareSens N POP.....	15	Cisplatin.....	159
Burinex.....	53	CareSens N Premier.....	15	Cisplatin Accord.....	159
Buspirone hydrochloride.....	144	CareSens PRO.....	15	Cisplatin Ebewe.....	159
Buspirone Viatris.....	144	Carmellose sodium with gelatin and pectin.....	31	Citalopram hydrobromide.....	134
Busulfan.....	159	Carmustine.....	159	Citrulline 1000.....	306
- C -		Carvedilol.....	50	Cladribine.....	161
Cabergoline.....	94	Carvedilol Sandoz.....	50	Clarithromycin.....	
Caffeine citrate.....	279	Catapres.....	53	Alimentary.....	9
Calamine.....	71	Cefaclor monohydrate.....	96	Infection.....	98
Calci-Tab 500.....	33	Cefalexin.....	96	Clexane.....	42
Calcipotriol.....	76	Cefalexin Lupin.....	96	Clexane Forte.....	42
Calcitonin.....	85	Cefalexin Sandoz.....	96	Clindamycin.....	101
Calcitriol.....	32	Cefazolin.....	96	Clinicians.....	26, 32
Calcitriol Devatis.....	32	Cefazolin-AFT.....	96	Clinicians Renal Vit.....	33
Calcitriol XL.....	32	Ceftriaxone.....	97	Clobazam.....	135
Calcitriol-AFT.....	32	Ceftriaxone-AFT.....	97	Clobetasol propionate.....	72, 77
Calcium 500 mg Hexal.....	33	Cefuroxime axetil.....	97	Clobetasone butyrate.....	72
Calcium carbonate.....	6, 33	Celapram.....	134	Clofazimine.....	107
Calcium carbonate PAI.....	6	Celebrex.....	121	Clomazol.....	
Calcium Channel Blockers.....	52	Celecoxib.....	121	Dermatological.....	71
Calcium Disodium Versenate.....	286	Celestone Chronodose.....	86	Genito-Urinary.....	82
Calcium folinate.....	161	Cellcept.....	186	Clomifene citrate.....	95
Calcium gluconate.....	33	Celosteia.....	121	Clomipramine hydrochloride.....	133
Calcium Homeostasis.....	85	Centrally-Acting Agents.....	52	Clonazepam.....	135, 144
Calcium polystyrene sulphonate.....	45	Cerazette.....	81	Clonidine.....	52
Calcium Resonium.....	45	Cerubidine.....	163	Clonidine hydrochloride.....	53
Calogen.....	291	Cetirizine hydrochloride.....	269	Clonidine Teva.....	53
		Cetomacrogol.....	73	Clopidogrel.....	40
				Clopine.....	140

Clopidol.....	142, 144	Coversyl 2.5.....	47	DBL Bortezomib.....	163
Clotrimazole		Coversyl 5.....	47	DBL Carboplatin.....	159
Dermatological.....	71	COVID-19 vaccine.....	313	DBL Cisplatin.....	159
Genito-Urinary.....	82	Creon 10000.....	23	DBL Dacarbazine.....	163
Clozapine.....	140	Creon 25000.....	23	DBL Desferrioxamine Mesylate for Inj	
Clozaril.....	140	Creon Micro.....	23	BP.....	286
Clustran.....	138	Crizotinib.....	172	DBL Docetaxel.....	163
Co-trimoxazole.....	103	Crotamiton.....	71	DBL Ergometrine.....	82
Coal tar.....	76	Crystaderm.....	70	DBL Gemcitabine.....	161
Coal tar with allantoin, menthol,		Cu 375 Standard.....	81	DBL Gentamicin.....	101
phenol and sulphur.....	76	Curam Duo 500/125.....	99	DBL Leucovorin Calcium.....	161
Coal tar with salicylic acid and		Cvite.....	32	DBL Methotrexate Onco-Vial.....	162
sulphur.....	76	Cyclizine hydrochloride.....	138	DBL Naloxone Hydrochloride.....	285
Coco-Scalp.....	76	Cyclizine lactate.....	138	DBL Pethidine Hydrochloride.....	133
Codeine phosphate.....	131	Cyclogyl.....	283	DBL Promethazine	
Coenzyme Q10.....	26	Cyclonex.....	159	Hydrochloride.....	269
Colchicine.....	124	Cyclopentolate hydrochloride.....	283	DBL Vincristine Sulfate.....	171
Colchicine Indoco.....	124	Cyclophosphamide.....	159	Decozol.....	31
Colecalciferol.....	32	Cyclophosphamide Seacross.....	159	Deferasirox.....	285
Colestyramine.....	55	Cyclorin.....	107	Deferiprone.....	286
Colestyramine - Mylan.....	55	Cycloserine.....	107	Denosumab.....	122
Colgout.....	124	Cyproterone acetate.....	87	Deolate.....	105
Colifoam.....	7	Cyproterone acetate with		Deoxycoformycin.....	168
Colistin sulphomethate.....	101	ethinyloestradiol.....	82	Depo-Medrol.....	87
Collodion flexible.....	288	Cystadane.....	26	Depo-Provera.....	81
Colloidal bismuth subcitrate.....	10	Cytarabine.....	161	Depo-Testosterone.....	87
Colofac.....	9	Cytotec.....	9	Deprim.....	103
Colomycin.....	101	Cytoxan.....	159	Dermol.....	72, 77
Coloxyl.....	24			Desferrioxamine mesilate.....	286
Combigan.....	283	- D -		Desmopressin.....	94
Combiprasal.....	272	D-Penamine.....	122	Desmopressin acetate.....	94
Comirnaty (LP.8.1).....	313	Dabigatran.....	43	Desmopressin-PH&T.....	94
Compound electrolytes.....	45	Dabrafenib.....	172	Desogestrel.....	81
Compound electrolytes with glucose		Dacarbazine.....	163	Detection of Substances in	
[Dextrose].....	45	Dactinomycin [Actinomycin D].....	163	Urine.....	84
Compound hydroxybenzoate.....	288	Daivobet.....	76	Dexamethasone	
Concerta.....	153	Daivonex.....	76	Hormone.....	86
Condoms.....	80	Daktarin.....	71	Sensory.....	281
Condyline.....	78	Dalacin C.....	101	Dexamethasone phosphate.....	86
Condyline S29.....	78	Dantrium.....	125	Dexamethasone with framycetin and	
Continuous glucose monitor		Dantrium S29.....	125	gramicidin.....	280
(interoperable).....	22	Dantrolene.....	125	Dexamethasone with neomycin	
Continuous glucose monitor		Daonil.....	12	sulphate and polymyxin B	
(standalone).....	22	Dapa-Tabs.....	54	sulphate.....	281
Contraceptives - Hormonal.....	81	Dapsone.....	107	Dexamfetamine sulfate.....	150
Contraceptives - Non-hormonal.....	79	Dapsone (Rising).....	107	Dexcom G6.....	22
Copaxone.....	146	Darunavir.....	117	Dexcom G7.....	22
Corticosteroids and Related Agents		Darunavir Viatrix.....	117	Dexcom ONE+.....	22
for Systemic Use.....	86	Dasatinib.....	174	Dexmethsone.....	86
Corticosteroids Topical.....	72	Dasatinib-Teva.....	174	Dextrochlorpheniramine	
Cosentyx.....	238	Daunorubicin.....	163	maleate.....	269
Cosmegen.....	163	David One Step Cassette Pregnancy		Dextrose	
Coumadin.....	43	Test.....	83	Alimentary.....	11
Country Life.....	28	DBL Acetylcysteine.....	285	Blood.....	44-45
Coversyl.....	47	DBL Adrenaline.....	57	DHC Continus.....	131
Coversyl 10.....	47	DBL Aminophylline.....	276	Diabetes.....	10
		DBL Bleomycin Sulfate.....	163		

Diabetes Management	14	Dosulepin [Dothiepin]	and ivacaftor	276
Diacomit	136	hydrochloride	Elidel	76
Diagnostic Agents	328	Dosulepin Viatrix	Elocon	72
Diamide Relief	6	Dothiepin	Elocon Alcohol Free	72
Diasip	292	Dovato	Eltrombopag	37
Diazepam	134, 145	Doxazosin	Eltroxin	89
Diazoxide	10	Doxazosin Clinect	EMB Fatol	108
Diclofenac Devatis	281	Doxine	Embecta Micro-Fine	16
Diclofenac Sandoz	121	Doxorubicin Ebewe	Embecta Ultra Fine	16
Diclofenac sodium		Doxorubicin hydrochloride	Emend Tri-Pack	138
Musculoskeletal	121	Doxycycline	Emicizumab	38
Sensory	281	DP Lotion	EMLA	128
Differin	69	DP Lotn HC	Empagliflozin	13
Diffiam	31	DP-Captopril	Empagliflozin with metformin	
Diffucan	103	Dr Reddy's Omeprazole	hydrochloride	13
Digestives Including Enzymes	23	Drofat	Emsogen	306
Digoxin	49	Droperidol	Emtricitabine	116
Dihydrocodeine tartrate	131	Droperidol Panpharma	Emtricitabine with tenofovir	
Dilantin	136	Drugs Affecting Bone	disoproxil	113
Dilantin Infatab	136	Metabolism	Emtriva	116
Dilantin Paediatric	136	Dual blood glucose and blood ketone	Emulsifying ointment	73
Diltiazem CD Clinect	52	diagnostic test meter	Enalapril maleate	47
Diltiazem hydrochloride	52	Dulaglutide	Enbrel	186
Dimethicone	73-74	Dulcolax SP Drop	Endocrine Therapy	183
Dimethyl fumarate	146	Duocal Super Soluble Powder	Endoxan	159
Dipentum	8	Duolin	Energivit	306
Diphtheria, tetanus and pertussis		Duolin HFA	Engerix-B	317
vaccine	314	DuoResp Spiromax	Enhertu	245
Diphtheria, tetanus, pertussis and		Duride	Enlaxaf XR	134
polio vaccine	315	Durvalumab	Enoxaparin sodium	42
Diphtheria, tetanus, pertussis, polio,		- E -	Enstilar	76
hepatitis B and haemophilus		e-chamber La Grande	Ensure	299
influenzae type B vaccine	315	e-chamber Mask	Ensure Plus	299
Diprosone	72	e-chamber Turbo	Ensure Plus HN RTH	298
Diprosone OV	72	E-Mycin	Ensure Two Cal HN RTH	301
Dipyridamole	40	e5 Pharma	Entacapone	126
Dipyridamole - Strides	40	Ear Preparations	Entacapone Viatrix	126
Disopyramide phosphate	49	Ear/Eye Preparations	Entecavir	109
Distoside	96	Easiphen Liquid	Entecavir (Rex)	109
Disulfiram	156	Econazole nitrate	Entrectinib	174
Diuretics	53	Efavirenz	Entresto 24/26	49
Docetaxel	163	Efavirenz Milpharm	Entresto 49/51	49
Docetaxel Accord	163	Efavirenz with emtricitabine and	Entresto 97/103	49
Docetaxel Sandoz	163	tenofovir disoproxil	Entyvio	248
Docusate sodium	24	Eformoterol fumarate dihydrate	Epilim	136
Docusate sodium with		Eftrenonacog alfa [Recombinant	Epilim Crushable	136
sennosides	24	factor IX]	Epilim IV	136
Dolutegravir	117	Efudix	Epilim S/F Liquid	136
Dolutegravir with lamivudine	117	Egopsoryl TA	Epilim Syrup	136
Domperidone	138	Elaprase	Epipen	268
Domperidone Viatrix	138	Elecare	Epipen Jr	268
Donepezil hydrochloride	154	Elecare LCP	Epirubicin Ebewe	164
Dornase alfa	276	Electral	Epirubicin hydrochloride	164
Dortimopt	282	Elelyso	Eplerenone	53
Dorzolamide with timolol	282	Elemental 028 Extra	Epoetin alfa	36
Dostinex	94	Elxacaftor with tezacaftor, ivacaftor	Epoprostenol	64

Eptacog alfa [Recombinant factor Vlla]	38	Famotidine.....	9	fluocortolone pivalate and cinchocaine.....	8
Erbitux.....	211	Famotidine Hovid.....	9	Fluorometholone.....	281
Ergometrine maleate.....	82	Famotidine Hovid MY.....	9	Fluorouracil.....	161
Eritrox.....	98	Fasenna.....	207	Fluorouracil Accord.....	161
Erlotinib.....	175	Fatty Emulsion Cream (Evara).....	73	Fluorouracil sodium.....	78
Erythrocin IV.....	98	Febuxostat.....	124	Fluox.....	134
Erythromycin (as lactobionate).....	98	Febuxostat (Teva).....	124	Fluoxetine hydrochloride.....	134
Erythromycin ethyl succinate.....	98	FEIBA NF.....	39	Flupenthixol decanoate.....	143
Esbriet.....	275	Felo 10 ER.....	52	Flutamide.....	183
Escitalopram.....	134	Felo 5 ER.....	52	Flutamin.....	183
Escitalopram (Ethics).....	134	Felodipine.....	52	Fluticasone.....	270
Eskazole.....	96	Fentanyl.....	131	Fluticasone furoate with umeclidinium and vilanterol.....	274
Essential Amino Acid Mix.....	306	Fentanyl Sandoz.....	131	Fluticasone furoate with vilanterol.....	271
Estradiol TDP Mylan.....	88	Ferinject.....	34	Fluticasone propionate.....	278
Estradot.....	88	Ferriprox.....	286	Fluticasone with salmeterol.....	271
Estrofem.....	88	Ferro-F-Tabs.....	34	Flynn.....	96
Estrogeol.....	88	Ferro-Liquid.....	34	FML.....	281
Etanercept.....	186	Ferro-tab.....	34	Foban.....	70
Ethambutol hydrochloride.....	108	Ferrosig.....	35	Folic acid.....	37
Ethics Aspirin.....	128	Ferrous fumarate.....	34	Folic Acid multichem.....	37
Ethics Aspirin EC.....	40	Ferrous fumarate with folic acid.....	34	Folic Acid Viatrix.....	37
Ethinylloestradiol with desogestrel.....	81	Ferrous sulfate.....	34	Food Thickeners.....	301
Ethinylloestradiol with levonorgestrel.....	81	Fexaclear.....	269	Foods And Supplements For Inherited Metabolic Disease.....	302
Ethinylloestradiol with norethisterone.....	81	Fexofenadine hydrochloride.....	269	Forteo.....	123
Ethosuximide.....	135	Fibro-vein.....	39	Fortini.....	294
Etopophos.....	164	Filgrastim.....	43	Fortini Multi Fibre.....	294
Etoposide.....	164	Finasteride.....	83	Fortisip.....	299
Etoposide phosphate.....	164	Fingolimod.....	146	Fortisip Multi Fibre.....	300
Etravirine.....	116	Firazyr.....	268	Fosamax.....	122
Eugia.....	57	Flagyl.....	107	Fosamax Plus.....	122
Eumovate.....	72	Flagyl-S.....	107	Fosfomycin.....	119
Eurofolic.....	161	Flamazine.....	70	Framycetin sulphate.....	280
Evara.....	73	Flecainide acetate.....	50	Freestyle Libre 2 Plus.....	22
Evara Emulsifying Ointment.....	73	Flecainide BNM.....	50	Freestyle Libre 3 Plus.....	22
EVARA Paraffin Ointment 50/50.....	73	Flecainide Controlled Release Teva.....	50	Frisium.....	135
EVARA White Soft Paraffin.....	74	Fleet Phosphate Enema.....	25	Frumil.....	53
Everet.....	136	Flixonase Hayfever & Allergy.....	278	Fruite.....	53
Everolimus.....	262	Flixotide.....	270	Fruite.....	53
Evrysdi.....	149	Flixotide Accuhaler.....	270	Fucicort.....	73
Exemestane.....	186	Florinef.....	86	Fucidin.....	102
Exjade.....	285	Fluanxol.....	143	Fucithalmic.....	280
Extemporaneously Compounded Preparations and Galentials.....	288	Flucazole.....	103	Fucithalmic Canada (ON).....	280
Eye Preparations.....	280	Flucloxacillin.....	100	Fucithalmic Spain.....	280
Eylea.....	206	Flucloxin.....	100	Fulvestrant.....	183
Ezetimibe.....	56	Flucon.....	281	Fulvestrant EVER Pharma.....	183
Ezetimibe Sandoz.....	56	Fluconazole.....	103	Fungilin.....	31
Ezetimibe with simvastatin.....	57	Fludara Oral.....	161	Furosemide [Frusemide].....	53
- F -		Fludarabine Ebewe.....	161	Furosemide-AFT.....	53
Factor eight inhibitor bypassing fraction.....	39	Fludarabine phosphate.....	161	fusidic acid Dermatological.....	70, 73
		Fludrocortisone acetate.....	86	Infection.....	102
		Fluids and Electrolytes.....	44	Sensory.....	280
		Flumetasone pivalate.....	280		
		Fluocortolone caproate with			

GA Explore 5.....	305	vaccine.....	316	Hydralazine hydrochloride.....	57
GA1 Anamix Infant.....	305	Haldol.....	143	Hydralock.....	73
GA1 Anamix Junior.....	305	Haldol Concentrate.....	143	Hydrapres.....	57
Gabapentin.....	135	Haldol Decanoas.....	143	Hydrocortisone	
Gacet.....	131	Haloperidol.....	140	Dermatological.....	72
Galsulfase.....	27	Haloperidol decanoate.....	143	Hormone.....	86
Galvumet.....	12	Harvoni.....	112	Hydrocortisone acetate.....	7
Galvus.....	12	Havrix 1440.....	316	Hydrocortisone acetate with	
Gardasil 9.....	318	Havrix Junior.....	316	pramoxine hydrochloride.....	7
Gastrodenol.....	10	Haylor syrup.....	269	Hydrocortisone and paraffin liquid	
Gaviscon Extra Strength.....	6	HCU Anamix Infant.....	302	and lanolin.....	72
Gaviscon Infant.....	6	HCU Anamix Junior.....	302	Hydrocortisone butyrate.....	72, 77
Gazyva.....	222	HCU Anamix Junior LQ.....	302	Hydrocortisone with cinchocaine.....	8
Gefitinib.....	175	HCU Explore 5.....	302	Hydrocortisone with miconazole.....	73
Gemcitabine Ebewe.....	161	HCU Express 15.....	302	Hydrocortisone with natamycin and	
Gemcitabine hydrochloride.....	161	HCU Lophlex LQ.....	302	neomycin.....	73
Gemtuzumab ozogamicin.....	212	healthE Calamine Aqueous.....	71	Hydrogen peroxide.....	70
Gentamicin sulphate.....	101	healthE Dimethicone 10%.....	73	Hydroxocobalamin.....	32
Gilenya.....	146	healthE Dimethicone 4% Lotion.....	74	Hydroxocobalamin Panpharma.....	32
Ginet.....	82	healthE Glycerol BP.....	288	hydroxycarbamide.....	164
Glatiramer acetate.....	146	healthE Urea Cream.....	73	Hydroxychloroquine sulphate.....	122
Glecaprevir with pibrentasvir.....	112	Healtheries Simple Baking Mix.....	301	Hydroxyurea	
Glibenclamide.....	12	Hemastix.....	84	[hydroxycarbamide].....	164
Gliclazide.....	12	Hemilibra.....	38	Hygroton.....	54
Glipizide.....	12	Heparin sodium.....	43	Hylo-Fresh.....	284
Glizide.....	12	Heparinised saline.....	43	Hymenoptera.....	269
Glucagen Hypokit.....	11	Heparon Junior.....	293	Hyoscine butylbromide.....	9
Glucagon hydrochloride.....	11	Hepatitis A vaccine.....	316	Hyoscine Butylbromide	
Glucerna Select.....	292	Hepatitis B recombinant		(Adiramedita).....	9
Glucose [Dextrose]		vaccine.....	317	Hyoscine hydrobromide.....	139
Alimentary.....	11	Herzuma.....	243	Hyperuricaemia and Antigout.....	124
Blood.....	44	Hikma.....	49	HypoPak Glucose.....	11
Gluten Free Foods.....	301	Hikma Acetylcysteine.....	285	Hypromellose.....	283
Glycerin with sodium saccharin.....	288	Hikma-Propranolol.....	51	Hypromellose with dextran.....	283
Glycerin with sucrose.....	288	Hiprex.....	120		
Glycerol		Histaclear.....	269	- I -	
Alimentary.....	24	Holoxan.....	160	Ibiamox.....	99
Extemporaneous.....	288	Horleys Bread Mix.....	302	Ibuprofen.....	121
Glyceryl trinitrate		Horleys Flour.....	302	Ibuprofen SR BNM.....	121
Alimentary.....	8	Hormone Replacement Therapy -		Icatibant.....	268
Cardiovascular.....	57	Systemic.....	88	Icatibant Lupin.....	268
Glycopyrronium.....	272	HPV.....	318	Idarubicin hydrochloride.....	164
Glycopyrronium bromide.....	9	Humalog.....	12	Idursulfase.....	27
Glycopyrronium with		Humalog Mix 25.....	11	Ifomid - M.....	160
indacaterol.....	273	Humalog Mix 50.....	11	Ifosfamide.....	160
Glycopyrronium-AFT.....	9	Human papillomavirus (6, 11, 16, 18,		Ifosfamide with Mesna.....	160
Glycosade.....	305	31, 33, 45, 52 and 58) vaccine		Iloprost.....	65
Glytactin Bettermilk.....	304	[HPV].....	318	Imatinib mesilate.....	175
Gold Knight.....	80	Humatin.....	102	Imatinib-Rex.....	175
Gold Knight XL.....	80	Humira.....	200	Imbruvica.....	164
Gonadron.....	88	HumiraPen.....	200	Imfinzi.....	251
Goserelin.....	94	Humulin 30/70.....	11	Imipramine Crescent.....	133
Gynaecological Anti-infectives.....	82	Humulin NPH.....	11	Imipramine hydrochloride.....	133
- H -		Humulin R.....	11	Imiquimod.....	78
Habitrol.....	156	Hyaluronic acid.....	284	Immune Modulators.....	117
Haemophilus influenzae type B		Hydralazine.....	57	Immunosuppressants.....	186

Incruse Ellipta.....	273	Insulin syringes, disposable with attached needle.....	16	Jaydess.....	81
Indacaterol.....	270	Intencele.....	116	Jevity HiCal RTH.....	299
Indapamide.....	54	Interferon beta-1-alpha.....	146	Jevity RTH.....	299
Infanrix IPV.....	315	Interferon beta-1-beta.....	146	Jinarc.....	54
Infanrix-hexa.....	315	Intra-uterine device.....	81	Juno Pemetrexed.....	162
Infant Formulae.....	306			- K -	
Infatrinl.....	310	Invega Sustenna.....	143	Kadcyla.....	246
Infliximab.....	212	Invega Trinza.....	144	Kalydeco.....	277
Influenza vaccine.....	319	Inza.....	121	Kemadrin.....	126
Influvac Tetra (2026 formulation).....	319	Ipca-Allopurinol.....	124	Kenacomb.....	280
Inhaled Corticosteroids.....	270	Ipca-Bisoprolol.....	50	Kenacort-A 10.....	87
Inhaled Long-acting Beta-adrenoceptor Agonists.....	270	Ipca-Ciprofloxacin.....	101	Kenacort-A 40.....	87
Inlyta.....	172	Ipca-Donepezil.....	154	Kenalog in Orabase.....	31
Inotuzumab ozogamicin.....	220	Ipca-Enalapril.....	47	Ketalar.....	128
Inresa.....	35	Ipca-Escitalopram.....	134	Ketamine.....	128
Inspira.....	53	IPCA-Frusemide.....	53	Ketocal 3:1.....	311
Instillagel Lido.....	127	Ipca-Hydroxychloroquine.....	122	KetoCal 4:1.....	311
Insulin aspart.....	11	IPCA-Metoprolol.....	51	Ketoconazole Dermatological.....	77
Insulin aspart with insulin aspart protamine.....	11	IPCA-Propranolol.....	51	Infection.....	104
Insulin degludec with insulin aspart.....	11	Ipilimumab.....	252	Ketogenic Diet.....	311
Insulin glargine.....	11	IPOLE.....	325	Ketoprofen.....	121
Insulin glulisine.....	12	Ipratropium bromide.....	272, 278	KetoProfen.....	14
Insulin isophane.....	11	Ipratropium Viatrix.....	272	KetoSens.....	255
Insulin isophane with insulin neutral.....	11	Iressa.....	175	Keytruda.....	293
Insulin lispro.....	12	Irinotecan Actavis 100.....	161	Kindergeren.....	179
Insulin lispro with insulin lispro protamine.....	11	Irinotecan hydrochloride.....	161	Kisqali.....	
Insulin neutral.....	11	Irinotecan-Rex.....	161	Klacid	
Insulin pen needles.....	16	Iron (as ferric carboxymaltose).....	34	Alimentary.....	9
Insulin pump cartridge.....	18	Iron polymaltose.....	35	Infection.....	98
Insulin pump infusion set (steel cannula).....	18	Isentress.....	117	Klaricid.....	98
Insulin pump infusion set (steel cannula, straight insertion).....	18	Isentress HD.....	117	Kliogest.....	89
Insulin pump infusion set (teflon cannula).....	19	Ismo 20.....	57	Kliovance.....	89
Insulin pump infusion set (teflon cannula, angle insertion with insertion device).....	20	Ismo 40 Retard.....	57	Kogenate FS.....	39
Insulin pump infusion set (teflon cannula, flexible insertion with insertion device).....	20	Isoleucine50.....	306	Konakion MM.....	40
Insulin pump infusion set (teflon cannula, flexible insertion).....	21	Isoniazid.....	108	Konakion MM Paediatric.....	40
Insulin pump infusion set (teflon cannula, straight insertion with insertion device).....	21	Isoniazid Teva.....	108	Konsyl-D.....	24
Insulin pump infusion set (teflon cannula, variable insertion).....	21	Isoniazid with rifampicin.....	108	Kuvan.....	29
Insulin pump reservoir.....	21	Isoptin.....	52	- L -	
Insulin pump with algorithm.....	17	Isoptin Retard.....	52	Labetalol.....	51
		Isoptin SR.....	52	Lacosamide.....	135
		Isopto Carpine.....	283	Lactulose.....	24
		Isosorbide mononitrate.....	57	Lacuna.....	28
		Isotretinoin.....	69	Laevolac.....	24
		Ispaghula (psyllium) husk.....	24	Lamictal.....	135
		Itch-Soothe.....	71	Lamivudine.....	109, 116
		Itraconazole.....	104	Lamivudine Viatrix.....	116
		Itraconazole Crescent.....	104	Lamivudine/Zidovudine Viatrix.....	117
		Itraconazole Kent.....	104	Lamotrigine.....	135
		Itrazole.....	104	Lamprene.....	107
		Ivacaftor.....	277	Lanoxin.....	49
		Ivermectin.....	74	Lanoxin PG.....	49
		- J -		Lanoxin S29.....	49
		Jadelle.....	81	Lanreotide.....	186
		Jakavi.....	180	Lansoprazole.....	9
		Jardiamet.....	13	Lansoprazole (Viatrix).....	9
		Jardiance.....	13	Lantus.....	11

Lantus SoloStar.....	11	Livostin.....	282	Maviret.....	112
Lanvis.....	162	LMX4.....	128	Maxidex.....	281
Lanzol Relief.....	9	Lo-Oralcon 20 ED.....	81	Maxitrol.....	281
Largactil.....	140	Locacorten-Viaform ED's.....	280	MCT oil (Nutricia).....	291
Laronidase.....	27	Local preparations for Anal and Rectal Disorders.....	8	Measles, mumps and rubella vaccine.....	321
Lasix.....	53	Locasol.....	306	Mebendazole.....	96
Latanoprost.....	282	Locoid.....	72, 77	Mebeverine hydrochloride.....	9
Latanoprost with timolol.....	283	Locoid Crelo.....	72	Med Adv Ext Infusion Set MDT-MMT-431AK.....	20
Lax-Suppositories.....	25	Locoid Lipocream.....	72	Med Adv Ext Infusion Set MDT-MMT-432AK.....	20
Lax-suppositories Glycerol.....	24	Locorten-Vioform.....	280	Med Adv Ext Infusion Set MDT-MMT-441AK.....	20
Laxatives.....	24	Lodoxamide.....	282	Med Adv Ext Infusion Set MDT-MMT-442AK.....	20
Ledipasvir with sofosbuvir.....	112	Logem.....	135	Medac.....	160
Leflunomide.....	122	Lomide.....	282	Medrol.....	86
Lenalidomide (Viatris).....	165	Lomustine.....	160	Medroxyprogesterone acetate Genito-Urinary.....	81
Lenalidomide Viatris.....	165	Loniten.....	58	Hormone.....	89
Lenvatinib.....	175	Loperamide hydrochloride.....	6	Mefenamic acid.....	121
Lenvima.....	175	Lopinavir with ritonavir.....	117	Mekinist.....	181
Letermovir.....	109	Lopinavir/Ritonavir Mylan.....	117	Melatonin.....	147
Letrole.....	186	Loprofin.....	305	Melpha.....	160
Letrozole.....	186	Loprofin Mix.....	304	Melphalan.....	160
Leucine100.....	306	Loratadine.....	269	Meningococcal (groups A, C, Y and W-135) conjugate vaccine.....	322
Leukeran FC.....	159	Lorazepam.....	145	Meningococcal B multicomponent vaccine.....	323
Leukotriene Receptor Antagonists.....	276	Lorstat.....	55	MenQuadfi.....	322
Leuprorelin.....	94	Losartan & Hydrochlorothiazide (Ipca).....	49	Menthol.....	71
Leustatin.....	161	Losartan Actavis.....	48	Mepolizumab.....	221
Levetiracetam.....	136	Losartan potassium.....	48	Mercaptopurine.....	162
Levetiracetam-AFT.....	136	Losartan potassium with hydrochlorothiazide.....	49	Mercion 28.....	81
Levocabastine.....	282	Lovir.....	109	Mesalazine.....	8
Levocarnitine.....	28	Loxamine.....	134	Mesna.....	165
Levodopa with benserazide.....	126	Lucrin Depot 1-month.....	94	Mestinon.....	121
Levodopa with carbidopa.....	126	Lucrin Depot 3-month.....	94	Metabolic Disorder Agents.....	25
Levodopa with carbidopa and entacapone.....	126	LumaCina.....	44	Metabolics.....	28
Levomopromazine.....	140	Lumigan.....	282	Metalyse.....	42
Levomopromazine hydrochloride.....	140	Lynparza.....	166	Metformin hydrochloride.....	12
Levonorgestrel.....	81-82	Lyrca.....	136	Metformin Viatris.....	12
Levonorgestrel -1 (Lupin).....	82	- M -			
Levothyroxine.....	89	m-Esion.....	132	Methadone BNM.....	131
Lidocaine [Lignocaine].....	127-128	Mabthera.....	227	Methadone hydrochloride.....	131
Lidocaine [Lignocaine] hydrochloride.....	128	Macrobid.....	120	Methenamine (hexamine) hippurate.....	120
Lidocaine [Lignocaine] with prilocaine.....	128	Macrogl 3350 with potassium chloride, sodium bicarbonate and sodium chloride.....	25	Methopt.....	283
Lidocaine-Baxter.....	128	Madopar 125.....	126	Methotrexate.....	162
Life Extension.....	30	Madopar 250.....	126	Methotrexate DBL Onco-Vial.....	162
Lignocaine.....	127-128	Madopar 62.5.....	126	Methotrexate Ebewe.....	162
Linezolid.....	108	Madopar HBS.....	126	Methotrexate Pharmascience.....	162
Lioresal Intrathecal.....	125	Madopar Rapid.....	126	Methotrexate Sandoz.....	162
Lipid-Modifying Agents.....	55	Magnesium hydroxide.....	35	Methoxyflurane.....	129
Liquigen.....	291	Magnesium sulphate.....	35	Methyl hydroxybenzoate.....	288
Liraglutide.....	13	Mantoux.....	328	Methylcellulose.....	288
Lisdexamfetamine dimesilate.....	150	Marevan.....	43		
Lisinopril.....	47	Marine Blue Lotion SPF 50+.....	77		
Lithium carbonate.....	140	Mask for spacer device.....	278		

Methylcellulose with glycerin and sodium saccharin.....	288	MiniMed Quick-Set MMT-397A	19	Moximed.....	101
Methylcellulose with glycerin and sucrose.....	288	MiniMed Quick-Set MMT-398A	19	MSUD Anamix Infant.....	302
Methyldopa.....	53	MiniMed Quick-Set MMT-399A	19	MSUD Anamix Junior.....	302
Methyldopa Viatris.....	53	MiniMed Silhouette MMT-377A	19	MSUD Anamix Junior LQ.....	302
Methylnaltrexone bromide	24	MiniMed Silhouette MMT-378A	19	MSUD Explore 5.....	302
Methylphenidate ER - Teva.....	152	MiniMed Silhouette MMT-381A	19	MSUD Express 15.....	302
Methylphenidate hydrochloride.....	152	MiniMed Sure-T MMT-864A	18	MSUD Lophlex LQ 20.....	302
Methylphenidate hydrochloride extended-release.....	153	MiniMed Sure-T MMT-866A	18	MSUD Maxamum.....	302
Methylphenidate Sandoz XR.....	152	MiniMed Sure-T MMT-874A	18	Mucolytics.....	276
Methylprednisolone.....	86	MiniMed Sure-T MMT-876A	18	Multiple Sclerosis Treatments.....	145
Methylprednisolone (as sodium succinate).....	87	Minims Pilocarpine	283	Multivitamin renal.....	33
Methylprednisolone aceponate.....	72	Minims Prednisolone.....	282	Multivitamins.....	33
Methylprednisolone acetate.....	87	Minipress.....	47	Mupirocin.....	70
Methylxanthines.....	276	Minirin.....	94	Muscle Relaxants.....	125
Metoclopramide Actavis 10.....	139	Minirin Melt.....	94	Mvite.....	33
Metoclopramide hydrochloride	139	Mino-tabs.....	100	Myambutol.....	108
Metolazone.....	54	Minocycline hydrochloride	100	Mycobutin.....	109
Metopirone.....	95	Minomycin.....	100	Mycosail.....	70
Metoprolol IV Mylan.....	51	Minor Skin Infections.....	74	Mycophenolate mofetil.....	186
Metoprolol IV Viatris.....	51	Minoxidil.....	58	Mydracyl.....	283
Metoprolol succinate.....	51	Minoxidil Roma.....	58	Mylan (24 hr release).....	52
Metoprolol tartrate.....	51	Mirena.....	81	Mylan Clomiphen.....	95
Metronidamed.....	107	Miro-Amoxicillin.....	99	Mylan Italy (24 hr release).....	52
Metronidazole.....	107	Mirtazapine.....	134	Myleran.....	159
Metyrapone.....	95	Misoprostol.....	9	mylife Inset soft.....	20
Mexiletine hydrochloride.....	50	Mitomycin (Fresenius Kabi).....	165	mylife Orbit micro.....	18
Miacalcic.....	85	Mitomycin (Sagent).....	165	mylife Orbit soft.....	21
Miacalcic S29.....	85	Mitomycin C.....	165	mylife YpsoPump Reservoir.....	21
Micolette.....	25	Mitozantrone.....	165	mylife YpsoPump with CamAPS FX.....	17
Miconazole.....	31	Mitozantrone Ebewe.....	165	Myloc CR.....	51
Miconazole nitrate.....		MMA/PA Anamix Infant.....	305	Mylotarg.....	212
Dermatological.....	71	MMA/PA Anamix Junior.....	305	Myometrial and Vaginal Hormone Preparations.....	82
Genito-Urinary.....	82	MMA/PA Explore 5.....	305	Myozyme.....	25
Micreme.....	82	MMA/PA Express 15.....	305	Mytolac.....	186
Micreme H.....	73	Moclobemide.....	134	Mytolac S29.....	186
Microlut.....	81	Modafinil.....	153		
Midazolam.....	148	Modafinil Max Health.....	153		
Midazolam-Baxter.....	148	Moduretic.....	53		
Midazolam-Pfizer.....	148	Molaxole.....	25		
Midodrine.....	50	Moments.....	80		
Midostaurin.....	176	Mometasone furoate.....	72		
Mifegyne.....	84	Monogen.....	292		
Mifepristone.....	84	Montelukast.....	276		
Minerals.....	33	Montelukast (Sandoz).....	276		
Mini-Wright AFS Low Range.....	278	Montelukast Paediatric (Relonchem).....	276		
Mini-Wright Standard.....	278	Montelukast Viatris.....	276		
Minidiab.....	12	Morocetocog alfa [Recombinant factor VIII].....	39		
MiniMed 3.0 Ext Reservoir.....		Morphine hydrochloride.....	132		
MDT-MMT-342G.....	21	Morphine sulphate.....	132		
MiniMed 3.0 Reservoir.....		Motetis.....	127		
MMT-332A.....	21	Mouth and Throat.....	31		
MiniMed Quick-Set MMT-396A	19	Movapo.....	126		
		Movicol.....	25		
		Moxifloxacin.....	101		

- N -

Navelbine S29.....	171	Noumed Dexamfetamine.....	150	Octreotide long-acting.....	186
Nefopam hydrochloride.....	129	Noumed Isoniazid.....	108	Oestradiol.....	88
Neo-Mercazole.....	89	Noumed Paracetamol.....	130	Oestradiol valerate.....	88
Neocate Gold.....	307	Noumed Pethidine.....	133	Oestradiol with norethisterone.....	89
Neocate Junior Unflavoured.....	307	Noumed Phenobarbitone.....	136	Oestriol	
Neocate Junior Vanilla.....	307	NovaSource Renal.....	295	Genito-Urinary.....	82
Neocate SYNEO.....	307	Novatretin.....	75	Hormone.....	89
Neoral.....	262	NovoMix 30 FlexPen.....	11	Oestrogens.....	88
Neostigmine metilsulfate.....	121	NovoRapid.....	11	Ofev.....	274
Nepro HP (strawberry).....	294	NovoRapid FlexPen.....	11	Oil in water emulsion.....	73
Nepro HP (vanilla).....	294	NovoRapid Penfill.....	11	Olanzapina Mylan.....	141
Neulactil.....	141	NovoSeven RT.....	38	Olanzapina Mylan Pharma.....	141
NeuroTabs.....	33	Nozinan.....	140	Olanzapine.....	141, 143
Nevirapine.....	116	Nozinan (Swiss).....	140	Olanzapine ODT Viatris.....	141
Nevirapine Viatris.....	116	Nucala.....	221	Olaparib.....	166
Nicorandil.....	58	Nuelin.....	276	Olbetam.....	55
Nicotine.....	156	Nuelin-SR.....	276	Olopatadine.....	284
Nifedipine.....	52	Nupentin.....	135	Olopatadine Teva.....	284
Nifuran.....	120	Nusinersen.....	148	Olsalazine.....	8
Nilotinib.....	177	Nutilis.....	301	Omalizumab.....	223
Nilstat		Nutren Diabetes.....	292	Omeprazole.....	10
Alimentary.....	31	Nutrient Modules.....	289	Omeprazole actavis 10.....	10
Genito-Urinary.....	82	Nutrini Energy Multi Fibre.....	294	Omeprazole actavis 20.....	10
Infection.....	104	Nutrini Energy RTH.....	294	Omeprazole actavis 40.....	10
Nimenrix.....	322	Nutrini Low Energy Multi Fibre.....	296	Omeprazole Teva.....	10
Nintedanib.....	274	Nutrini Peptisorb.....	309	Omnitrope.....	90
Nipent.....	168	Nutrini Peptisorb Energy.....	309	Omnitrope AU.....	90
Niraparib.....	165	Nutrini RTH.....	294	Onbrez Breezhaler.....	270
Nirmatrelvir with ritonavir.....	114	Nutrison 800 Complete Multi		Oncaspar LYO.....	167
Nitisinone.....	28	Fibre.....	299	OncoTICE.....	191
Nitisinone LogixX Pharma.....	28	Nutrison Advanced Peptisorb.....	295	Ondansetron.....	139
Nitrates.....	57	Nutrison Concentrated.....	301	One-Alpha.....	32
Nitroderm TTS.....	57	Nutrison Energy.....	298	Opdivo.....	252
Nitrofurantoin.....	120	Nutrison Energy Multi Fibre.....	299	Ora-Blend.....	288
Nitrofurantoin Clinect.....	120	Nutrison Multi Fibre.....	299	Ora-Blend SF.....	288
Nitrolingual Pump Spray.....	57	Nutrison RTH.....	298	Ora-Plus.....	288
Nivestim.....	43	Nyefax Retard.....	52	Ora-Sweet.....	288
Nivolumab.....	252	Nystatin		Ora-Sweet SF.....	288
Nodia.....	6	Alimentary.....	31	Oral and Enteral Feeds.....	292
Noflam 250.....	121	Genito-Urinary.....	82	Oralcon 30 ED.....	81
Noflam 500.....	121	Infection.....	104	Oramorph.....	132
Non-Steroidal Anti-Inflammatory		NZB Low Gluten Bread Mix.....	302	Oramorph CDC S29.....	132
Drugs.....	121	- O -		Oratane.....	69
Nonacog gamma, [Recombinant		Obinutuzumab.....	222	Ornidazole.....	107
Factor IX].....	39	Obstetric Preparations.....	84	Orphenadrine citrate.....	125
Norethisterone		Ocicure.....	10	Ortho-tolidine.....	84
Genito-Urinary.....	81	Ocrelizumab.....	146	Oruvail SR.....	121
Hormone.....	89	Ocrevus.....	146	Osimertinib.....	177
Norflex.....	125	Ocrevus SC.....	146	Osmolite RTH.....	298
Norfloxacina.....	120	Octasa.....	8	Other Endocrine Agents.....	94
Noriday.....	81	Octocog alfa [Recombinant factor		Other Oestrogen Preparations.....	89
Noriday 28.....	81	VIII] (Advate).....	39	Other Progestogen	
Norimin.....	81	Octocog alfa [Recombinant factor		Preparations.....	89
Normison.....	148	VIII] (Kogenate FS).....	39	Other Skin Preparations.....	78
Nortriptyline hydrochloride.....	133	Octreotide.....	184	Ovestin	
Norvir.....	117	Octreotide GH.....	184	Genito-Urinary.....	82

Hormone	89	Peak flow meter	278	Phytomenadione	40
Oxaliplatin	160	Pedialyte	45	Pilocarpine hydrochloride	283
Oxaliplatin Accord	160	Pediasure	294	Pilocarpine nitrate	283
Oxaliplatin Actavis 100	160	Pediasure Plus	294	Pimafucort	73
Oxaliplatin Ebewe	160	Pediasure RTH	294	Pimecrolimus	76
Oxis Turbuhaler	270	Pegaspargase	167	Pine tar with trolamine laurilsulfate and fluorescein	76
Oxpentifylline	58	Pegasys	117	Pinetarsol	76
Oxybutynin	83	Pegasys (S29)	117	Pioglitazone	12
Oxycodone Amneal	132	Pegasys S29	117	Pirfenidone	275
Oxycodone hydrochloride	132	Pegfilgrastim	44	Pirfenidone Sandoz	275
Oxycodone Sandoz	132	Pegylated interferon alfa-2a	117	Pizotifen	138
Oxytocin	82	Pembrolizumab	255	PKU Anamix Infant	303
Oxytocin BNM	82	Pemetrexed	162	PKU Anamix Junior	303
Oxytocin with ergometrine maleate	82	Pemetrexed-AFT	162	PKU Anamix Junior Chocolate	303
Ozurdex	281	Penicillamine	122	PKU Anamix Junior LQ	303
- P -					
Pacifen	125	Penicillin G	99	PKU Anamix Junior Orange	303
Pacimol	130	Pentasa	8	PKU Anamix Junior Vanilla	303
Paclitaxel	167	Penthrox	129	PKU Build 10	304
Paclitaxel Actavis	167	Pentostatin [Deoxycoformycin]	168	PKU Build 20 Chocolate	304
Paclitaxel Ebewe	167	Pentoxifylline [Oxpentifylline]	58	PKU Build 20 Raspberry Lemonade	304
Padagis		Peptamen Junior	294	PKU Build 20 Smooth	304
Cardiovascular	53	Pepti-Junior	309	PKU Build 20 Vanilla	304
Dermatological	78	Perhexiline maleate	52	PKU Explore 10	303
Paediatric Seravit	33	Pericyazine	141	PKU Explore 5	303
Palbociclib	178	Perindopril	47	PKU Express 20	303
Palbociclib Pfizer	178	Periset	139	PKU First Spoon	303
Paliperidone	143	Periset ODT	139	PKU Glytactin RTD 15	304
Paliperidone palmitate	144	Perjeta	225	PKU Glytactin RTD 15 Lite	304
Palivizumab	224	Permethrin	75	PKU GMPPro LQ	304
Pamidronate disodium	123	Perrigo	78	PKU GMPPro Mix-In	304
Pamisol	123	Pertuzumab	225	PKU GMPPro Ultra Lemonade	304
Pamol	130	Pertuzumab with trastuzumab	226	PKU GMPPro Ultra Vanilla	304
Pancreatic enzyme	23	Peteha	108	PKU Lophlex LQ 10	303
Pantoprazole	10	Pethidine hydrochloride	133	PKU Lophlex LQ 20	303
Panzop Relief	10	Pevaryl	71	PKU Lophlex Powder	303
Papaverine hydrochloride	58	Pexsig	52	PKU Lophlex Sensation 20	303
Para-amino salicylic acid	108	Pfizer Exemestane	186	PKU Restore Powder	304
Paracetamol	130	Pharmacor Varenicline	156	PKU sphere20 Banana	304
Paracetamol (Ethics)	130	Pharmacy Services	285	PKU sphere20 Chocolate	304
Paracetamol + Codeine (Relieve)	132	Pheburane	29	PKU sphere20 Lemon	304
Paracetamol with codeine	132	Phenacen	163	PKU sphere20 Red Berry	304
Paraffin	73–74	Phenobarbitone	136	PKU sphere20 Vanilla	304
Paraffin liquid with wool fat	284	Phenobarbitone sodium Extemporaneous	288	Pku Start	303
Parasiticial Preparations	74	Nervous	148	Plendil ER	52
Parnate	133	Phenoxybenzamine hydrochloride	47	Pneumococcal (PCV13) conjugate vaccine	324
Paromomycin	102	Phenoxymethylpenicillin (Penicillin V)	100	Pneumococcal (PPV23) polysaccharide vaccine	325
Paroxetine	134	Phenylalanine50	306	Pneumovax 23	325
Paser	108	Phenytoin sodium	135–136	Podophyllotoxin	78
Paxam	144	Phesgo	226	Polaramine	269
Paxlovid	114	Phillips Milk of Magnesia	35	Poliomyelitis vaccine	325
Pazopanib	179	Phlexy 10	303	Poloxamer	24
Pazopanib ADVZ	179	Phosphate Phebra	45	Poly-Tears	283
Pazopanib Teva	179	Phosphorus	45		

Poly-Visc.....	284	Promethazine hydrochloride.....	269	Resource Beneprotein.....	291
Polycal.....	289	Propafenone hydrochloride.....	50	Respiratory Devices.....	278
Polyethylene glycol 400 and propylene glycol.....	284	Propranolol.....	51	Respiratory Stimulants.....	279
Pomalidomide.....	168	Propranolol LA Lupin.....	51	Retinol palmitate.....	284
Pomolide.....	168	Propylene glycol.....	288	ReTrieve.....	70
Ponstan.....	121	Propylthiouracil.....	89	Retrovir.....	116
Posaconazole.....	104	Prostacur.....	183	Revolade.....	37
Posaconazole Juno.....	104	Protaphane.....	11	Ribociclib.....	179
Potassium chloride.....	44-45	Protaphane Penfill.....	11	Riboflavin.....	28
Potassium citrate.....	83	Protifar.....	291	Ribomustin.....	158
Potassium iodate.....	33	Protionamide.....	108	Ricit.....	83
Povidone iodine.....	74	Provera.....	89	Ricovir.....	109
Pradaxa.....	43	Provera HD.....	89	Rifabutin.....	109
Pramipexole hydrochloride.....	126	Psoriasis and Eczema Preparations.....	75	Rifadin.....	109
Pravastatin.....	55	PTU.....	89	Rifadin Sanofi.....	109
Praziquantel.....	96	Pulmicort Turbuhaler.....	270	Rifamizid.....	108
Prazosin.....	47	Pulmozyme.....	276	Rifampicin.....	109
Prazosin Mylan.....	47	Puri-nethol.....	162	Rifaximin.....	10
Pred Forte.....	282	Puritan's Pride Vitamin B-2 100 mg.....	28	Rifinah.....	108
Prednisolone.....	87	Pyrainamide.....	108	Rilutek.....	127
Prednisolone acetate.....	282	Pyridostigmine bromide.....	121	Riluzole.....	127
Prednisolone hexanoate with cinchocaine hydrochloride.....	8	Pyridoxine hydrochloride.....	32	Rinvoq.....	265
Prednisolone sodium phosphate.....	282	Pyridoxine multichem.....	32	Riodine.....	74
Prednisolone-AFT.....	282	- Q -		Risdiplam.....	149
Prednisone.....	87	Quantalan sugar free.....	55	Risedronate Sandoz.....	123
Prednisone Clinect.....	87	Questran Light (Neon).....	55	Risedronate sodium.....	123
Pregabalin.....	136	Quetapel.....	141	Risperdal.....	142
Pregabalin Pfizer.....	136	Quetiapine.....	141	Risperdal Consta.....	144
Pregnancy Tests - hCG Urine.....	82-83	Quetiapine Viatrix.....	141	Risperidone.....	142, 144
Premarin.....	88	Quinapril.....	47	Risperidone (Teva).....	142
Presolol.....	51	Qvar.....	270	Risperidone Sandoz.....	142
Prevenar 13.....	324	- R -		Risperon.....	142
Prevymis.....	109	RA-Morph.....	132	Ritalin.....	152
Priadel.....	140	Ralicrom.....	8	Ritalin LA.....	153
Primaquine.....	106	Raltegravir potassium.....	117	Ritonavir.....	117
Primidone.....	136	Ramipex.....	126	Rituximab (Mabthera).....	227
Primidone Clinect.....	136	Ramipril.....	48	Rituximab (Riximyo).....	228
Primolut N.....	89	Ramipril Mylan Generics.....	48	Rivaroxaban.....	43
Priorix.....	321	Ramipril Viatrix.....	48	Rivastigmine.....	154
Probenecid.....	124	Ranbaxy-Cefaclor.....	96	Rivastigmine Patch BNM 10.....	154
Probenecid-AFT.....	124	Rapamune.....	263	Rivastigmine Patch BNM 5.....	154
Procabazine hydrochloride.....	168	Rasagiline.....	126	Rivotril.....	135
Prochlorperazine.....	139	Reandron 1000.....	88	Riximyo.....	228
Prochlorperazine maleate (Brown & Burk).....	139	Recombinant factor IX.....	37, 39	RIXUBIS.....	39
Proctofoam.....	7	Recombinant factor VIIa.....	38	Rizamelt.....	138
Proctosedyl.....	8	Recombinant factor VIII.....	39	Rizatriptan.....	138
Procyclidine hydrochloride.....	126	Rectogesic.....	8	Rizatriptan Rising.....	138
Progesterone.....	89	Redipred.....	87	Rizatriptan Viatrix.....	138
Progicem.....	10	Relieve.....	121	Roma.....	45
Proglynova.....	88	Relistor.....	24	Ropin.....	126
Prolia.....	122	Remdesivir.....	114	Ropinirole hydrochloride.....	126
		Remicade.....	212	Rosemont.....	132
		Renilon 7.5.....	295	Rosuvastatin.....	55
		Resonium-A.....	46	Rosuvastatin - Sandoz.....	55
				Rosuvastatin Mylan.....	55
				Rosuvastatin Viatrix.....	55

Rotarix	326	Sildenafil	63	Span-K.....	45
Rotavirus oral vaccine	326	Sildenafil (Amarox)	63	Spazmol.....	9
Roxane-Propranolol.....	51	Siltuximab	240	Spinal Muscular Atrophy.....	148
Roxithromycin.....	98	Simvastatin	56	Spinraza	148
Rozlytrek	174	Simvastatin Mylan	56	Spiocto Respimat	273
Rubifen	152	Simvastatin Viatris	56	Spiractin.....	53
Rubifen SR	152	Sinemet	126	Spiriva.....	273
Rugby	35	Sinemet CR	126	Spiriva Respimat	273
Rurioctocog alfa pegol [Recombinant factor VIII]	39	Sintetica Baclofen Intrathecal	125	Spironolactone	53
Ruxolitinib.....	180	Sirolimus.....	263	Stalevo.....	126
Rydapt	176	Sirturo	107	Staphlex.....	100
Rythmodan - Cheplafarm	49	Siterone	87	Stelara	247
Rythmodan Neon	49	Slow-Lopresor	51	Stemetil.....	139
Rytmonorm.....	50	Sodibic.....	45	Steril-Gene	88
Ryzodeg 70/30 Penfill.....	11	Sodium acid phosphate.....	25	SteroClear	278
- S -		Sodium alginate.....	6	Stesolid.....	134
Sabril	137	Sodium benzoate.....	29	Stimulants/ADHD Treatments	150
Sacubitril with valsartan	49	Sodium bicarbonate		Stiripentol.....	136
SalAir.....	272	Blood.....	44-45	Stomahesive.....	31
Salazopyrin.....	8	Extemporaneous.....	288	Strides Shasun	104
Salazopyrin EN.....	8	Sodium calcium edetate	286	Stromectol	74
Salbutamol.....	271-272	Sodium chloride		Sucralfate	10
Salbutamol with ipratropium bromide.....	272	Blood.....	45	Sulfadiazin-Heyl.....	102
Salicylic acid	77	Respiratory.....	277	Sulfadiazine Silver.....	70
Salmeterol	270	Sodium citrate with sodium lauryl sulphoacetate	25	Sulfadiazine sodium	102
Sandomigran	138	Sodium citro-tartrate	84	Sulphur.....	77
Sandostatin LAR.....	186	Sodium cromoglicate		Sulprix.....	139
Sanofi Primaquine	106	Alimentary.....	8	Sumagran	138
Sapropterin dihydrochloride.....	29	Sensory.....	282	Sumatriptan	138
Scalp Preparations	77	Sodium Fusidate [fusidic acid] Dermatological	70	Sunitinib	181
Scheriproct	8	Infection	102	Sunitinib Rex	181
Scopolamine Transdermal System Viatri.....	139	Sensory.....	280	Sunscreens.....	77
Sebizole.....	77	Sodium hyaluronate [Hyaluronic acid]	284	Sunscreens, proprietary	77
Secukinumab.....	238	Sodium phenylbutyrate.....	29	Sustagen Hospital Formula	299
Sedatives and Hypnotics.....	147	Sodium picosulfate	25	Sustanon Ampoules	87
Seebri Breezhaler.....	272	Sodium polystyrene sulphonate	46	Sylvant.....	240
Senna	25	Sodium tetradecyl sulphate	39	Symbicort Turbuhaler 100/6	271
Senokot	25	Sodium valproate.....	136	Symbicort Turbuhaler 200/6	271
SensoCard.....	15	Sofradex	280	Symbicort Turbuhaler 400/12	271
Serc	138	Soframycin.....	280	Symmetrel	126
Serenace	140	Solax.....	24	Sympathomimetics	57
Seretide	271	Solgar	26, 28, 30	Synacthen.....	87
Seretide Accuhaler	271	Solifenacin succinate.....	84	Synacthen Depot	87
Serevent	270	Solifenacin succinate Max Health	84	Synacthene Retard	87
Serevent Accuhaler	270	Solu-Cortef	86	Synagis.....	224
Sertraline	134	Solu-Medrol	87	Synthroid	89
Setrona	134	Solu-Medrol-Act-O-Vial.....	87	Syntometrine	82
Sevredol	132	Somatropin (Omnitrope)	90	Syrup (pharmaceutical grade)	288
Sex Hormones Non Contraceptive	87	Somatuline Autogel	186	Systane Unit Dose.....	284
Shingles vaccine.....	328	Somex	8	- T -	
Shingrix.....	328	Sotalol.....	51	Tacrolimus	
SII-Onco-BCG	191	Spacer device.....	279	Dermatological	77
				Oncology.....	265
				Tacrolimus Sandoz	265
				Tafinlar.....	172

Tagrisso.....	177	Tetrabromophenol.....	84	Trastuzumab emtansine.....	246
Taliglucerase alfa.....	30	Tetracosactrin.....	87	Travatan.....	282
Tambocor.....	50	Tetracycline.....	100	Travoprost.....	282
Tambocor German.....	50	Tetracycline AA.....	100	Treatments for Dementia.....	154
Tamoxifen citrate.....	184	Teva Lisinopril.....	47	Treatments for Substance Dependence.....	155
Tamoxifen Sandoz.....	184	Teva-Ketoconazole.....	104	Trelegly Ellipta.....	274
Tamsulosin hydrochloride.....	83	Thalidomide.....	169	Trental 400.....	58
Tamsulosin-Rex.....	83	Thalomid.....	169	Tretinoin.....	
Tandem Cartridge.....	18	Theophylline.....	276	Dermatological.....	70
Tandem t:slim X2 with Basal-IQ.....	17	Thiamine hydrochloride.....	32	Oncology.....	169
Tandem t:slim X2 with Control-IQ+.....	17	Thiamine multichem.....	32	Trexate.....	162
Tap water.....	288	Thiamine-REX.....	32	Triamcinolone acetanide	
Taro.....	104	THIO-TEPA.....	160	Alimentary.....	31
Tasigna.....	177	Thioguanine.....	162	Dermatological.....	72
Tasmar.....	126	Thiotepa.....	160	Hormone.....	87
Taurine.....	30	Thiotepa-Reach.....	160	Triamcinolone acetanide with gramicidin, neomycin and nystatin	
TCu 380 Plus Normal.....	81	Thyroid and Antithyroid Agents.....	89	Dermatological.....	73
Tecentriq.....	250	Ticagrelor.....	40	Sensory.....	280
Tecfidera.....	146	Ticagrelor Mylan.....	40	Trientine.....	30
TEEVIR.....	116	Ticagrelor Sandoz.....	40	Trientine Waymade.....	30
TEEVIR (India).....	116	Ticagrelor Sandoz S29.....	40	Trikafta.....	276
Tegretol.....	135	Tilcotil.....	121	Trimethoprim.....	103
Tegretol CR.....	135	Timolol.....	282	Trimethoprim with sulphamethoxazole	
Telfast.....	269	Tiotropium bromide.....	273	[Co-trimoxazole].....	103
Temaccord.....	168	Tiotropium bromide with olodaterol.....	273	Trisequens.....	89
Temazepam.....	148	Tivicay.....	117	Trisul.....	103
Temozolomide.....	168	TMP.....	103	Trophic Hormones.....	90
Temozolomide (Devatis).....	168	Tobramycin.....		Tropicamide.....	283
Temozolomide-Taro.....	168	Infection.....	103	Trulicity.....	12
Tenecteplase.....	42	Sensory.....	280	TruSteel.....	18
Tenofovir disoproxil.....	109	Tobramycin (Viatris).....	103	Tryzan.....	48
Tenofovir Disoproxil Emtricitabine Mylan.....	113	Tobramycin BNM.....	103	Tuberculin PPD [Mantoux] test.....	328
Tenofovir Disoproxil Emtricitabine Viatr.....	113	Tobrex.....	280	Tubersol.....	328
Tenofovir Disoproxil Viatris.....	109	Tocilizumab.....	240	Two Cal HN.....	301
Tenofovir Efavirenz Emtricitabine(Mylan).....	116	Tofranil.....	133	TYR Anamix Infant.....	305
Tenoxicam.....	121	Tolcapone.....	126	TYR Anamix Junior.....	305
Tensipine MR10.....	52	Tolvaptan.....	54	TYR Anamix Junior LQ.....	305
Tepadina.....	160	Topamax.....	137	TYR Explore 5.....	305
Terbinafine.....	105	Topical Products for Joint and Muscular Pain.....	122	TYR Lophlex LQ 20.....	305
Terbutaline sulphate.....	272	Topiramate.....	137	TYR Sphere 20.....	305
Teriflunomide.....	146	Topiramate Actavis.....	137	Tyrosine1000.....	306
Teriflunomide Aurobindo.....	146	Total parenteral nutrition (TPN).....	45	Tysabri.....	146
Teriflunomide Sandoz.....	146	TPN.....	45		
Teriparatide.....	123	Tramadol hydrochloride.....	133		
Teriparatide - Teva.....	123	Tramal SR 100.....	133		
Teriparatide Teva S29.....	123	Tramal SR 150.....	133		
Testogel.....	87	Tramal SR 200.....	133		
Testosterone.....	87	Trametinin.....	181		
Testosterone cipionate.....	87	Trandate.....	51		
Testosterone esters.....	87	Tranexamic acid.....	40		
Testosterone undecanoate.....	88	Tranexamic-AFT.....	40		
Tetrabenazine.....	127	Tranycypromine sulphate.....	133		
		Trastuzumab (Herzuma).....	243		
		Trastuzumab deruxtecan.....	245		

- U -

UK Cipla.....	272
UK Synacthen.....	87
Ultibro Breezhaler.....	273
Ultraproct.....	8
Umeclidinium.....	273
Umeclidinium with vilanterol.....	273
Univent.....	272, 278
Upadacitinib.....	265
Ural.....	84
Urea.....	73

Urex Forte.....	53	Viaderm KC.....	73	Yervoy.....	252
Urinary Agents.....	83	Victoza.....	13	- Z -	
Urinary Tract Infections.....	119	Vigabatrin.....	137	Zarontin.....	135
UroFos.....	119	Vigisom.....	147	Zaroxolyn.....	54
Uromitexan.....	165	Vildagliptin.....	12	Zavedos.....	164
Ursodeoxycholic acid.....	23	Vildagliptin with metformin hydrochloride.....	12	Zeffix.....	109
Ursosan.....	23	Vimpat.....	135	Zejula.....	165
Ustekinumab.....	247	Vinblastine sulphate.....	171	Zematop.....	77
Utrogestan.....	89	Vincristine sulphate.....	171	Zetlam.....	109
- V -		Vinorelbine.....	171	Ziagen.....	116
Vabysmo.....	211	Vinorelbine Ebewe.....	171	Zidovudine.....	116
Vaccinations.....	313	Vinorelbine Te Arai.....	171	Zidovudine with lamivudine.....	117
Vaclovir.....	110	Viramune Suspension.....	116	Ziextenzo.....	44
Valaciclovir.....	110	ViruPOS.....	280	Zimybe.....	57
Valaciclovir Mylan.....	110	Vit.D3.....	32	Zinc and castor oil.....	73
Valaciclovir Viatris.....	110	VitA-POS.....	284	Zinc sulphate.....	35
Valganciclovir.....	110	Vitabdeck.....	33	Zincaps.....	35
Valganciclovir Viatris.....	110	Vital.....	295	Zincaps S29.....	35
Valine50.....	306	Vitamin B complex.....	32	Ziprasidone.....	142
Valni Retard.....	52	Vitamin B6 25.....	32	Zista.....	269
Vancomycin.....	103	Vitamins.....	32-33	Zithromax.....	97
Vancomycin Viatris.....	103	Vivonex TEN.....	295	Zo-Rub HP.....	128
Vannair.....	271	Voltaren.....	121	Zo-Rub Osteo.....	122
Vanzacaptor with Tezacaptor and Deutivacaptor.....	277	Voltaren D.....	121	Zoladex.....	94
Varenicline tartrate.....	156	Voltaren SR.....	121	Zoledronic acid Hormone.....	86
Varicella vaccine [Chickenpox vaccine].....	327	Volumatic.....	279	Musculoskeletal.....	124
Varicella zoster vaccine [Shingles vaccine].....	328	Voriconazole.....	105	Zoledronic acid Injection Mylan.....	86
Varilrix.....	327	Vttack.....	105	Zoledronic acid Viatris Hormone.....	86
Various.....	285	Vytorin.....	57	Musculoskeletal.....	124
VariSoft.....	21	Vyvanse.....	150	Zopiclone.....	148
Vasodilators.....	57	- W -		Zopiclone Actavis.....	148
Vasopressin Agonists.....	94	Warfarin sodium.....	43	Zostrix.....	122
Vasorex.....	52	Wart Preparations.....	78	Zostrix HP.....	128
Vebulis.....	65	Wasp venom allergy treatment.....	269	Zuclopenthixol decanoate.....	144
Vebulis S29.....	65	Water.....		Zuclopenthixol hydrochloride.....	142
Vedafil.....	63	Blood.....	45	Zusdone.....	142
Vedolizumab.....	248	Extemporaneous.....	288	Zyban.....	155
Vegzelma.....	208	Wool fat with mineral oil.....	74	Zypine.....	141
Veklury.....	114	- X -		Zypine ODT.....	141
Veletri.....	64	Xalkori.....	172	Zyprexa Relprevv.....	143
Venclexta.....	169	Xaluprine.....	162	Zytiga.....	183
Venetoclax.....	169	Xarelto.....	43	Zyvox.....	108
Venlafaxine.....	134	XGen.....	269		
Venomil.....	269	Xgeva.....	122		
VENOX.....	269	Xifaxan.....	10		
Ventolin.....	271-272	XMET Maxamum.....	302		
Vepesid.....	164	Xolair.....	223		
Verapamil hydrochloride.....	52	Xolair AU.....	223		
Vermox.....	96	XP Maxamum.....	303		
Versacloz.....	140	Xylocaine.....	128		
Vesanoid.....	169	Xylocaine 2% Jelly.....	127		
Vexazone.....	12	Xylocaine Viscous.....	128		
Vfend.....	105	Xylocard 500.....	128		
		Xyntha.....	39		
		- Y -			











